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ABSTRACT 
 
TARGET BASED DESIGN AND SYNTHESIS OF FUSED PYRIMIDINES IN THE 
POTENTIAL TREATMENT OF CANCER AND OPPORTUNISTIC INFECTION 
 
 
 
By 
Khushbu Shah 
December 2017 
 
Dissertation supervised by Dr. Aleem Gangjee 
This dissertation describes an introduction, background and research progress in 
the areas of agents designed as (a) selective Pneumocystis jirovecii dihydrofolate reductase 
(pjDHFR) inhibitors for pneumocystis pneumonia (PCP) infection; (b) inhibitors of 
microtubule polymerization and multiple receptor tyrosine kinase (RTK) for potential 
treatment of cancer; and (c) substrates for tumor-targeted therapy for cancer. 
PCP is a host species-specific infection. Most of the drugs, synthesized and 
evaluated so far, have been tested against Pneumocystis carinii dihydrofolate reductase 
(the causative organism in rats), which would not necessarily be effective against pjDHFR 
(the causative organism in humans). Trimethoprim-sulfamethoxazole (TMP-SMX) 
combination, which has been used for PCP for decades, has major limitations due to low 
inhibitory potency of TMP, side-effects of SMX and emergence of resistant strains 
  v 
expressing mutated dihydropteroate synthase enzyme (target of SMX). For patients 
unresponsive or resistant to this treatment, newer drugs are critically needed. The absence 
of an X-ray crystal structure of pjDHFR poses a large gap in drug discovery efforts. The 
status quo, as it pertains to designing selective inhibitors for an enzyme, is to exploit the 
amino acid differences between the active sites of the desired and undesired target enzyme. 
Structure based design, using a pjDHFR homology model and through identification of 
amino acid differences between pjDHFR and hDHFR active sites, has been presented in 
the text. Novel synthetic strategies were developed for efficient synthesis of 6- and 7-
substituted 5-methyl-pyrrolo[2,3-d]pyrimidine-2,4-diamines, N6-substituted pyrido[3,2-
d]pyrimidine-2,4,6-triamines, 6-(arylthio)pyrido[3,2-d]pyrimidine-2,4-diamines and 7-
(arylthio)pyrido[3,2-d]pyrimidine-2,4-diamines.  
In cancer chemotherapy, the two major limitations are the dose-limiting toxicities 
of clinically used agents and development of resistant to the treatment. Combination 
chemotherapy with antiangiogenic agents and microtubule targeting agents has shown an 
advantage against both these drawbacks. Single agents with both antiangiogenic activity 
and cytotoxicity would afford a therapy that circumvents pharmacokinetic problems of 
multiple agents, avoids drug-drug interactions, lowers the drug dose, decrease overlapping 
toxicities, and delays or prevents tumor cell resistance. The work in this dissertation 
discusses the development of fused pyrimidines, aimed to inhibit tubulin polymerization 
as well as act as antiangiogenic agents which inhibit one or more of the receptor tyrosine 
kinases (RTKs)- vascular endothelial growth factor receptor-2 (VEGFR2), platelet derived 
growth factor receptor-β (PDGFRβ) and epidermal growth factor receptor (EGFR), using 
molecular modeling studies. This work also reviews the synthesis pyrrolo[3,2-
  vi 
d]pyrimidines and thieno[3,2-d]pyrimidines and discusses novel synthetic strategies for 
substituted pyrrolo[3,2-d]pyrimidines and thieno[3,2-d]pyrimidines.  
Cancer cells transport folates through reduced folate carrier (RFC), Proton-Coupled 
Folate Transporter (PCFT) and/or Folate receptors (FR). Among several targeting 
strategies for cancer cells, selectively targeting through PCFT and FRs, over RFC have 
been successfully investigated. The next valid step in the field is to carry out a structure 
based design of agents to gain selectivity for PCFT and/or FRs transport over RFC and 
thus avoid dose-limiting toxicities. Absence of X-ray crystal structures for PCFT and RFC 
make this step impossible. The work in this dissertation discusses our efforts to fulfil this 
gap in the literature by developing a 3D QSAR pharmacophore for PCFT and RFC.  
PMX, the most widely used antifolate has three disadvantages: (i) transport by 
RFC; (ii) dependence on its polyglutamylation for potency; and (iii) development of 
resistance due to mutagenesis in the target enzyme (thymidylate synthase).  This 
dissertation focuses on development of substituted-pyrrolo[3,2-d]pyrimidines to combat 
the above-mentioned drawbacks of PMX, using the X-ray crystal structures of intracellular 
targets and transporters and using the basic principles of scaffold hopping and bioisosteric 
replacements. The work described herein discusses our efforts to obtain agents with 
inhibition of two or more intracellular targets to inhibit de novo purine biosynthesis. 
Synthetic efforts for the development of pyrrolo[3,2-d]pyrimidines with different linkers 
and aryl substitutions have been discussed.  
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I. BIOCHEMICAL REVIEW 
A.1. Selective pjDHFR inhibitors 
A.1.1. Pneumocystis jirovecii and pneumocystis pneumonia Infection  
Pneumocystis jirovecii (pj) is a fungus which is present in the lungs of a majority 
of the human population around the world.1 It is an atypical fungus, which differs from 
other fungi due to the presence of cholesterol, instead of ergosterol, in its cell membrane. 
The species affecting humans is very different than the species affecting other animals, 
such as rats and mice. The sepcies that infects rats does not proliferate when passaged into 
mice, whereas the infection from rats to other rats causes severe infection.2 The immune 
system in healthy individuals keeps the Pneumocystis jirovecii infection under control. In 
immunocompromised patients, Pneumocystis jirovecii infection causes Pneumocystis 
pneumonia (PCP).3 PCP can be fatal for patients with HIV/AIDS (most common), patients 
undergoing chemotherapy for cancer, patients on immunosuppressive medications, 
patients undergoing organ or bone-marrow transplantation or those that are malnourished.1, 
4 PCP presents itself when the patients’ CD4 count is below 200 cells/mm3.5 Although PCP 
prophylaxis and antiretroviral therapy (ART) has changed the face of the HIV/AIDS 
epidemic, the incidences of HIV cases persist due to non-adherence to the medication, 
toxicity to the medications, emergence of drug resistant HIV strains, late diagnosis of HIV 
and the rise of the number of cases in developing countries.6, 7 Thus, PCP continues to be 
a significant public health concern. In the US, 9% of the hospitalized HIV/AIDS and 1% 
of organ transplant patients develop PCP infection.8 In these patients, the mortality rate is 
from 5-40% while being treated for PCP and approaches 100% if left untreated.8 
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Figure 1. Clinical and non-clinical agents for the treatment for PCP  
Both the prophylaxis and treatment for PCP involves the combination of 
trimethoprim (TMP)-sulfamethoxazole (SMX) (co-trimoxazole).9, 10 TMP (Figure 1) is a 
selective, but weak inhibitor of dihydrofolate reductase (DHFR), the enzyme necessary for 
the reduction of dihydrofolate to tetrahydrofolate11, while SMX is an inhibitor of the 
dihydropteroate synthase (DHPS), the enzyme necessary for the synthesis of folates in 
fungi.12 The low activity of TMP against DHFR is augmented by SMX, in the treatment 
regimen. The efficacy, low cost and activity in variety of infections has propelled 
cotrimoxazole to be used indiscriminately. Due to the rampant use, mutations in the DHPS 
locus of Pneumocystis jirovecii encoding DHPS have been documented as the cause of 
TMP/SMX resistant strains of PCP.12-15 Various studies have also reported clinical and 
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non-clinical mutations discovered in DHFR after treatment or prophylaxis using DHFR 
inhibitors.16-20  Treatment failure and discontinuation of co-trimoxazole occurs in several 
cases due to such resistant strains or toxicity/allergy by SMX.21-25 In cases of treatment 
failure to TMP/SMX, the second-line treatment in mild to moderate PCP is TMP-dapsone 
or clindamycin-primaquine, which also leads to low efficacy and often lethal side-effects.9, 
26-28 Piritrexim (PTX) and trimetrexate (TMQ) are potent, but non-selective inhibitors of 
DHFR, which cause dose-limiting toxicities.9, 29, 30 These agents, combined with leucovorin 
(for rescue from myelosuppression) had high costs, drug toxicities, drug interactions and 
lack of efficacy.  For patients that do not respond to first line treatment as well the inevitable 
recurrence of resistance, new drugs for the treatment of PCP are critically needed.  
 
A.1.2. DHFR 
 
Figure 2. Reaction catalyzed by DHFR31 
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Dihydrofolate reductase (DHFR) is an important target for several human diseases- 
protozoal, bacterial, fungal infections, and autoimmune diseases.31, 32 Folate metabolism 
has been investigated and validated for decades as a target in chemotherapy. Eukaryotic 
organisms synthesize thymidine via thymidylate cycle, which consists of enzymes: (a) 
Serine hydroxymethyl transferase (SHMT); (b) DHFR; and (c) Thymidylate synthase (TS). 
DHFR catalyzes NADPH-dependent reduction of 7,8-dihydrofolate to the 5,6,7,8-
tetrahydrofolate (THF) (Figure 2). The THF then acts as a cofactor in the conversion of 
deoxyuridine monophosphate (dUMP) to deoxythymidine monophosphate (dTMP), 
catalyzed by TS. This inhibition causes disruption in DNA, RNA and protein synthesis of 
the organism and eventually leads to death. Thus, inhibition of TS or DHFR causes a 
“thymineless death” and this concept has been proven for several antimalarial, 
antiprotozoal and antimicrobial agents.11  
 
A.1.3. hDHFR, pcDHFR and pjDHFR 
Pneumocystis infection is host specific. Most of the drugs synthesized and 
evaluated thus far for PCP infections were tested against Pneumocystis carinii DHFR 
(pcDHFR), which was presumed to be the causative species of PCP infection in humans.11, 
33 Pneumocystis carinii (pc) however is a distinct species that infects rats, different from 
Pneumocystis jirovecii, responsible for human infections. The amino acid sequence of the 
DHFR of Pneumocystis carinii (pcDHFR) differs by 38% when compared to the DHFR of 
Pneumocystis jirovecii (pjDHFR).34 Hence, drugs evaluated against the surrogate pcDHFR 
in vitro, may not translate into activity in the treatment of PCP infection in humans.35 
Rational design of pjDHFR inhibitors is hampered due to a lack of crystal structure 
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information for pjDHFR. Another significant impediment in the drug discovery of 
inhibitors of pjDHFR is the inability to grow the organism outside the human lung and 
hence to develop a tissue culture for in vitro studies or an animal model for in vivo 
evaluation of the synthesized compounds.  
 
Table 1. Inhibitory Concentrations (IC50, in nM) against Recombinant DHFR from 
pjDHFR and human DHFR (hDHFR) and Selectivity Ratios35 
 
 pjDHFR (IC50, in nM) hDHFR (IC50, in nM) h/pj 
1 2.4 52 21 
2 2.5 5.6 2 
3 4.2 150 35 
TMP 120 32200 268 
PTX 1.6 3.0 2 
TMQ 2.1 2.6 1 
aThese assays were carried out at 37 °C under 18 μM dihydrofolic acid concentration. The 
standard error of the means for these values is 12% or less than the mean value. 
 
Gangjee and coworkers35 reported pyrido[2,3-d]pyrimidines as selective and potent 
pjDHFR inhibitors (Table 1). To illustrate the interactions that defines the enhanced 
selectivity and potency, Cody et al.36 reported the X-ray co-crystal structures of 3 with 
pcDHFR and hDHFR (PDB: 4IXE and 4QJC, respectively).  
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Figure 3. Superimposition of X-ray co-crystal structures of active sites of hDHFR (PDB: 
4QJC, 1.62 Å) and pcDHFR (PDB: 4IXE, 1.54 Å).36 The hDHFR amino acid residues are 
displayed in pink, ligand N6-methyl-N6-(3,4,5-trifluorophenyl)pyrido[2,3-d]pyrimidine-
2,4,6-triamine is displayed in cyan and the NADPH in yellow. The pcDHFR amino acid 
residues are displayed in grey, ligand N6-methyl-N6-(3,4,5-trifluorophenyl)pyrido[2,3-
d]pyrimidine-2,4,6-triamine is displayed in magenta and the NADPH in tan color. The 
visualization was performed using MOE 2016.0837 
 
The crystal structures of 1-3 were reported as ternary complexes with either human 
or native pcDHFR.36 Analysis of crystal structures of hDHFR-3-NADPH ternary complex 
with superimposition of pcDHFR-3-NADPH ternary complex (Figure 3) reveals the 
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differences in the binding geometry of 3 in pcDHFR and hDHFR.36 In hDHFR co-crystal 
structure (PDB:4QJC) with ligand (cyan), the scaffold pyrido[2,3-d]pyrimidine is 
stabilized by a π-π stacking interaction with Phe34. The protonated N1 and 2-NH2 form an 
ionic bond with Glu30. The 4-NH2 forms hydrogen bonding interaction between the 
backbone carbonyls of Ile7 and Val115. The side chain trifluorophenyl ring is oriented in 
pocket formed by Asp21, Ser59, Pro61 and Asn64. The N6-CH3 group is oriented towards 
Val115 side chain. The pcDHFR co-crystal structure (PDB:4IXE) with ligand (magenta), 
the scaffold pyrido[2,3-d]pyrimidine is stabilized by a π-π stacking interaction with Phe36. 
The protonated N1 and 2-NH2 form an ionic bond with Glu32. The 4-NH2 forms hydrogen 
bonding interaction between the backbone carbonyls of Ile10 and Ile123. The side chain 
trifluorophenyl ring is oriented in pocket formed by Ser24, Ser64, Pro66 and Phe69. The 
N6-CH3 group is oriented towards Ile123 side chain. The amino acids that are different 
between the active sites of pcDHFR and hDHFR are pointed out in Figure 3.  
The variability in pcDHFR, pjDHFR and hDHFR enzyme sequences have been 
investigated by Cody et al.20 The particular residues which seem to influence the active site 
(as seen in Figure 4) are at positions 35 and 64 (hDHFR numbering). In hDHFR enzyme, 
these residues are Gln and Asn; in pcDHFR enzyme, these are Lys and Phe and in pjDHFR 
enzyme are Ser and Ser. Structural data for inhibitor binding to hDHFR and pcDHFR reveal 
that these residues interact with inhibitors and that inhibitors have been designed in the 
past to specifically target these residues.19, 32, 38  
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 Figure 4. Sequence alignment of hDHFR (186 residues), pcDHFR and pjDHFR (both 206 
residues). Mutational sites are underlined and in red while key active site residues are 
numbered and colored cyan Reproduced with permission of the International Union of 
Crystallography from ref. 36. Copyright 2015 International Union of Crystallography.  
 
TMP is a moderate pcDHFR and pjDHFR inhibitor. The reason for its safety in PCP 
infection is its inactivity against hDHFR (Table 1). The importance of the positions 35 and 
64 in hDHFR was illustrated by evaluating the Ki of TMP against wild type and mutants 
of hDHFR (Table 2). The Q35S mutant hDHFR displays a 3-fold reduction in Ki for TMP, 
compared to hDHFR. The N64S mutant displays a 31-fold reduction in Ki compared to 
hDHFR. The Q35S/N64S double mutant displays a 4-fold reduction in Ki compared to 
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hDHFR. Thus, selectivity of agents can be achieved for pjDHFR over hDHFR by rational 
design of compounds targeting the amino acid residues that are different in hDHFR and 
pjDHFR enzymes.    
 
Table 2. Kinetic constants (Ki) of TMP against pjDHFR, pcDHFR, and wild type and 
mutant hDHFR.39 
Enzyme Ki (nM) 
hDHFR 5200 ± 700 (n = 4) 
pcDHFR 800 ± 300 (n = 7) 
pjDHFR 43 ± 5 (n = 14) 
hDHFR Q35S 1800 ± 100 (n = 3) 
hDHFR N64S 170 ± 0.5 (n = 2) 
hDHFR Q35S/N64S 1200 ± 100 (n = 4) 
 
 
A.2. Single agents with combination chemotherapy and multiple RTK inhibitory 
potential 
A.2.1. Microtubules 
A.2.1.1 Structure of microtubules 
Microtubules are long and hollow cylinders created by tubulin dimers. It is a 
globular protein containing a family of monomers: alpha (α), beta (β), gamma (γ), delta 
(δ), epsilon (ε) and zeta (ζ).40 The α and β tubulin form the microtubule. These dimers 
polymerize from end to end it to form a protofilament and 13 such protofilaments associate 
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laterally to form a single microtubule (Figure 5).  
 
Figure 5. (a) Structure of microtubule; (b) polymerization and depolymerization of 
microtubule40 Reproduced from Ramandeep Kaur; Gurneet Kaur; Rupinder Kaur Gill; 
Richard Soni; Jitender Bariwal, Recent developments in tubulin polymerization inhibitors: 
An overview 2014, 87, 89-124. Copyright © 2014 Elsevier Masson SAS. All rights 
reserved. 
The protofilament has a distinctive polarity: one end has (-) polarity, which has exposed α 
tubulin and the other end has (+) polarity, which has exposed β tubulin. GTP molecules 
bind on each end of the microtubule. At the site of (-) polarity, GTP molecule binds 
irreversibly and at the (+) end, GTP molecules bind reversibly. Microtubules undergo 
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dynamic growth and shrinkage. During growth (polymerization), α and β monomer ends 
are bound by GTP. During shrinkage (depolymerization), the GTP bound at β tubulin end 
is hydrolyzed to GDP. The GDP-bound β tubulin at the tip causes disassembly of 
microtubule. The switch from growth to shrinkage is called catastrophe. On the contrary, 
the switch from shrinkage to growth is called rescue.  
 
A.2.1.2 Microtubule Targeting Agents 
Microtubule Targeting Agents (MTAs) constitute the class of anticancer drugs 
which inhibit cell proliferation by suppressing microtubule dynamics.41  
(a) Classification of MTAs:  
Based on their effects on microtubule stability they are classified as follows. 42 
1) Microtubule-destabilizing agents: These agents inhibit microtubule polymerization and 
promote microtubule disassembly. These include natural products such as the vinca 
alkaloids, cryptophycins, halichondrins, estramustine, colchicine and its analogs and 
combretastatin.  
2) Microtubule-stabilizing agents: These agents induce microtubule polymerization and 
promote microtubule assembly. These include paclitaxel, docetaxel, epothilones and 
discodermolide.  
 
Distinct classes of microtubule binding agents classified by their binding sites on 
tubulin are as shown in Figure 6: 42, 43 
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Figure 6. Tubulin binding sites and representative agents of microtubule-targeted drugs.43 
Reprinted from Molecules, 21, Current Advances of Tubulin Inhibitors in Nanoparticle 
Drug Delivery and Vascular Disruption/Angiogenesis. Copyright 2016 by Souvik 
Banerjee, Dong-Jin Hwang, Wei Li and Duane D. Miller.  
 
1) The Vinca alkaloids:  
 
Figure 7. Representative structure of Vinca alkaloids 
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 The Vinca alkaloids, including vinblastine, vincristine, vindesine, and vinorelbine 
have been widely used in cancer chemotherapy for leukemia, lymphomas and non-small-
cell lung cancer (Figure 7).36 The effect of such alkaloids can be concentration dependent. 
At low concentrations, vinblastine inhibits microtubule assembly and depolymerization of 
microtubules, whereas at higher concentrations, vinblastine causes tubulin assembly. 
The Vinca alkaloids bind to the β-subunit of soluble tubulin heterodimers at a 
region commonly referred to as the Vinca-binding domain (Figure 6).44 Other MTAs such 
as the cryptophycins, halichondrins and dolastatins also bind at the same site. 
2) Taxanes and Epothilones: 
 
Figure 8. Representative taxanes 
The binding site for paclitaxel and its derivatives (Figure 8) is in the β-subunit on 
the internal surface of the microtubule (Figure 6).44, 45 Paclitaxel is suggested to bind by 
diffusing through pores in the microtubule lattice. Binding of paclitaxel stabilizes the 
microtubule by inducing a conformational change in β-tubulin that increases its affinity for 
adjacent tubulin molecules. Most MTAs that increase microtubule polymerization, such as 
the epothilones, discodermolide, eleutherobin, and sarcodictyins, bind to the Taxol-binding 
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site.45 Ixabepilone, which belongs to the Epothilone class of paclitaxel-site binders, was 
approved for the treatment of drug-refractory metastatic breast cancer in 2007.45  
3) Colchicine binding site agents: 
 
 Figure 9. Colchicine and combretastatins  
Colchicine binding site agents include podophyllotoxin, combretastatin and 
flavonols (Figure 9). Colchicine is not used clinically in cancer treatment due to its toxicity 
at doses that produce antimitotic effects.46 Colchicine binds to soluble tubulin at a distinct 
site referred to as the colchicine binding site. CA4P (Fosbretabulin) is under extensive 
investigation for platinum-resistant ovarian cancer, neuroendocrine tumors (NETs), 
hepatocellular carcinoma, and gastric cancer.47-49 The colchicine binding site is on β-
tubulin at the interface between α- and β- tubulins (Figure 6).44  
4. Laulimalide binding site agents:50 
 Laulimalide and peloruside (Figure 10) bind to a novel site on β-tubulin (Figure 
6).43 The binding causes the bridging of two adjacent β-tubulin across the protofilaments. 
Both laulimalide and peloruside allosterically stabilize the taxane site.  
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Figure 10. Structure of Laulimalide and Peloruside A. 
 
(b) Resistance to MTAs: 
Resistance to MTAs can occur at several stages of pharmacodynamics of the 
microtubule inhibition. Efflux through the membrane efflux pump of the ATP binding 
cassette (ABC) family is the primary mechanism of resistance towards MTAs.51, 52 P-
glycoprotein (Pgp), a product of multidrug resistant gene (MDR1 or ABCB1) is responsible 
for the efflux of MTAs.53 In Pgp-overexpressing SK-OV-3 MDR-1-6/6 cell line, the 
potency of paclitaxel was reduced 800-fold versus parental cell lines.54 Substrates of Pgp, 
in addition to drug efflux, cannot enter the CNS, when drugs are administered orally.51 
Thus, agents which are less susceptible to efflux by Pgp could possess novel 
pharmacodynamic and pharmacokinetic profile.51  
Microtubules are assembled with more than 13 diverse isotypes of α and β tubulins. 
Among them, increased levels of βIII-tubulin are associated with reduced rate of responses 
to taxanes in tumors of lung, breast and ovary.55, 56 On the contrary to the effect of βIII-
tubulin with taxanes, epithilones are indifferent to expression of βIII-tubulin.51 
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A.2.1.3 Function of microtubules 
The biological functions of MTAs are due to their role in polymerization dynamics.  
(a) Targeting mitosis:42  
MTAs have been long called “anti-mitotic agents”, because they can block the 
process of mitosis. At varied concentrations, MTAs can either increase or decrease 
polymerization. The mitotic arrest is due to an aberrant spindle formation. At the cellular 
level, both these effects cause cell-cycle arrest and cause cell death through apoptosis.  
Table 3. Tumor doubling time in days: comparison of preclinical in vivo models and patient 
data57 
 Preclinical models Patient data 
Breast cancer 5.6 152 
Colon cancer 3.4 391 
Lung cancer 4.4 114 
Prostate cancer 3.4 219 
Melanoma 5.4 147 
 
Based on the success of MTAs as anti-mitotic agents, inhibitors targeting several 
mitotic kinases (Polo-like kinase, Aurora Kinase A and Aurora Kinase B) have been 
developed, with the idea that these agents would exhibit similar cytotoxicity as MTAs.57 
However, they did not show success in clinical trials. The hypothesis that MTAs target only 
mitosis has since been questioned, which has since been supported by the findings that 
human tumors (sensitive to MTAs) do not divide as fast as in vitro tumor cells (Table 3). 
Thus, in addition to mitosis, other effects of MTAs in tumors are being investigated. 
  17 
(b) Targeting interphase:58  
 The interphase microtubule network is responsible for multitude of functions 
(Figure 11), namely: 
 
Figure 11. Diverse anticancer interphase activities of MTAs.58 Reprinted from Drug 
discovery today, 19, Ogden A, Rida PCG, Reid MD, Aneja R, Interphase microtubules: 
chief casualties in the war on cancer? 824-829, Copyright (2013), with permission from 
Elsevier.  
(a) centrosome clustering; (b) induction of voltage-dependent anion channel opening with 
release of Ca2+ and cytochrome c; (c) disruption of delivery of mRNA along interphase 
microtubule tracks; (d) induction of mRNA release from polysomes; (e) improvement of 
major histocompatibility complex (MHC) class I expression; increased activation of (f) 
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dendritic cells, (g) cytotoxic T lymphocytes and (h) macrophages; (i) impede vesicular 
traffic to the cell front; (j) impeded timely endocytosis; (k) interfere with transcription 
factor transport by motors to the nucleus with (l) up- or down-regulation of tumor 
suppressor or oncogenes, respectively. It is now known that the neurotoxic effect of MTAs 
(major dose-limiting side effect) is because of the activity of MTAs on the interphase of 
the non-dividing neurons. It is yet unknown that which of these effects (displayed in Figure 
11) is the most important for cell death. They could all be responsible for the anticancer 
effect by instigating “thousand cuts” on the cancer cell, which is more susceptible to 
disruption, compared to a normal cell.58 More sophisticated studies to identify the 
differences in interphases of normal and cancer cells are underway.  
 
 (c) Mediating vascular-disruption:59, 60 
 Combretastatin analogs have been long identified as vascular disrupting agents 
(VDAs). The tumor-VDA effect is seen well below the maximum tolerated dose of the 
combretastatins. A tumor-VDA effect can be of advantage in solid tumors, which have a 
different vasculature of endothelial cells and pericytes than normal cells. Tumor cells 
devoid of vascular smooth muscle cells, and are more permeable than normal cells. There 
is no lymphatic drainage in tumors, and hence the cells have higher interstitial pressure. 
The endothelial cells depend on tubulin cytoskeleton to maintain cell shape. Since the 
blood supply to solid tumors is chaotic, tumor-VDAs can cause rapid disruption of blood 
supply to tumors by disruption of vascular endothelial-cadherin at the junction. This causes 
cell shape change, decreased blood flow to the tumor cells and vasoconstriction, causing 
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tumor ischemia and cell death.   
 
Figure 12. Differences between tumor-VDAs and antiangiogenic agents.59 From [Rajak, 
H.; Dewangan, P. K.; Patel, V.; Jain, D. K.; Singh, A.; Veerasamy, R.; Sharma, P. C.; Dixit, 
A., Design of combretastatin A-4 analogs as tubulin targeted vascular disrupting agent with 
special emphasis on their cis-restricted isomers. Curr. Pharm. Des. 2013, 19, 1923-55.] 
Reprinted by permission of Bentham Science Publishers Ltd. 
 
This vascular disrupting effect is cytotoxic and is distinct from the cytostatic effect 
of anti-angiogenic agents (Figure 12). Tumor-VDAs cause tumor necrosis at the core of 
the tumor.60 Anti-angiogenic agents target neovascularization, prevents tumor growth and 
limits the tumors’ metastatic potential and thus their greatest effect is on the periphery of 
the tumor. The tumor-VDA effect and antiangiogenic effect have distinct profiles, offering 
a potential for their use in combination.60 Preclinical studies have produced delayed tumor 
growth with combination of tumor-VDA and antiangiogenic agent, compared to single 
agents.61   
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A.2.2. Angiogenesis 
Angiogenesis occurs during tumor development depending on changing tissue 
requirements. Blood vessels and stromal components respond to pro- and anti-angiogenic 
factors.62 However, in cancer, as the tumor grows, it should obtain its own blood supply. In 
order to achieve this, the tumor tilts balance towards pro-angiogenic factors to drive 
vascular growth by attracting and activating cells from within the microenvironment of the 
tumor (Figure 13).  
 
Figure 13. The development of new vessels in tumor angiogenesis.62 From [Siemann DW: 
Vascular targeting agents: horizons in cancer therapeutics: from bench to 
bedside. 2002, 3:4–15. Excellent review of preclinical trial data of vascular targeting 
agents] Reprinted by permission of Meniscus Educational Institute and Harborside Medical 
Education. 
The process of angiogenic switching (from release of anti-angiogenic factors to pro-
angiogenic factors) in a tumor starts when the tumor grows larger than 2 mm in diameter.63, 
64 Tumor cells exploit their microenvironment by releasing cytokines and growth factors. 
These include vascular endothelial growth factor (VEGF), platelet derived endothelial 
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growth factor (PDGF) and epidermal growth factor (EGF), which promote endothelial cell 
proliferation/migration.65-67 The new blood vessels grow and infiltrate the tumor, thereby 
providing oxygen and nutrients to the tumor. This causes tumor progression and 
metastases.68 The remodeled tumor vasculature is weak and leaky, with irregular blood 
flow. Therefore, tumor vasculature differs from normal tissue vasculature.69 
Treatment of cancer by blocking angiogenesis was proposed by Judah Falkman before 
nearly 45 years.70 It is now an accepted mechanism, with multiple anti-angiogenic agents 
approved by FDA as single agents or in combination with other cytotoxic drugs. Most 
notable angiogenic inhibitors target receptor tyrosine kinases which are involved in the 
process of angiogenesis.71  
 
A.2.2.1 Receptor Tyrosine Kinase (RTKs): 
 
Figure 14. ATP binding site in RTK.72 Reproduced from Le Corre, L.; Girard, A. L.; 
Aubertin, J.; Radvanyi, F.; Benoist-Lasselin, C.; Jonquoy, A.; Mugniery, E.; Legeai-Mallet, 
L.; Busca, P.; Le Merrer, Y., Synthesis and biological evaluation of a triazole-based library 
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of pyrido[2,3-d]pyrimidines as FGFR3 tyrosine kinase inhibitors, Org. Biomol. Chem. 
2010, 8, 2164-73. With permission of The Royal Society of Chemistry.  
Out of 510 protein kinase, 90 belong to the group of tyrosine kinase (TK).73 TK can 
be classified as non-receptor TKs and receptor TK (RTKs). Non-receptor TKs carry out 
intracellular communication and RTKs are involved in signal transduction. RTK has an 
extracellular N-terminal domain, a transmembrane domain, and an intracellular C-terminal 
domain, which has the kinase activity.72 The kinase domain has a bilobar structure and has 
the ATP-binding site between the N- and C-terminal lobes. The ATP-binding domain can 
be further divided into: adenine region, sugar region and phosphate binding region (Figure 
14). The C-terminal lobe forms an activation loop and has aspartic acid, phenylalanine and 
glycine, which is abbreviated as “DFG” motif.   
 
Figure 15. RTK signaling. Reprinted with permission from ref. 74 Copyright 2010 by 
Taylor and Francis Group LLC Books.  
 
Growth factor on binding to the extracellular domain of RTKs results in receptor 
dimerization (homodimerization or heterodimerization) and subsequent auto-
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phosphorylation of the tyrosine residues (Figure 15).74 The phosphorylation then triggers 
a cascade of downstream cell signaling pathways, which are tightly monitored and 
regulated under normal physiological conditions. In cancers, these pathways are 
dysregulated and create the hallmarks of cancer.75 Inhibition of RTKs can thus offer a key 
therapeutic strategy for cancer therapy.76 
 
Figure 16. Representative small molecule RTK inhibitors  
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(a) Vascular endothelial growth factor receptor (VEGFR):77 The VEGFR family 
consists of three related RTKs- VEGFR-1, VEGFR-2 and VEGFR-3. The VEGF family 
has five members- VEGF-A, VEGF-B, VEGF-C, VEGF-D and placental derived growth 
factor (P1GF). VEGF-A is the major facilitator of the tumor angiogenesis and signals 
through VEGFR-2, which is the major VEGF signaling receptor. Some examples of 
approved VEGFR inhibitors are bevacizumab (Avastin®) for colorectal cancer78, sunitinib 
(Sutent®) (Figure 16) for metastatic pancreatic neuroendocrine tumors79 and sorafenib 
(Nexavar®) (Figure 16)  for advanced renal cell carcinoma80. 
(b) Platelet-derived growth actor receptors (PDGFR):81 The second most important 
factor involved in angiogenesis is PDGFR. The PDGF has four members- PDGF-A, 
PDGF-B, PDGF-C and PDGF-D, which can bind to receptors PDGFRα and PDGFRβ. 
PDGFs recruit pericytes and smooth muscle cells and promote maturation and stability of 
the vasculature. Example of an approved PDGFR inhibitor is imatinib (Gleevec®)  (Figure 
16) for chronic myeloid leukemia82. 
(c) Epidermal growth factor receptor (EGFR):83 The EGF family is comprised of eleven 
members and four EGFR family receptors.84 Overexpression of EGFR leads to an increased 
tumor cell proliferation, survival and invasiveness.85 EGFR has been extensively studied 
and targeted by small molecule inhibitors.84 Inhibition of EGFR signaling has been shown 
to promote selective apoptosis in tumor endothelial cells.86 Some examples of approved 
EGFR inhibitors are erlotinib (Tacreva®) (Figure 16) for locally advanced or metastatic 
non-small cell lung cancer87, gefitinib (Iressa®) (Figure 16) for metastatic non-small cell 
lung cancer,88 and afatinib (Gilotrif®) (Figure 16) for squamous non-small cell lung 
cancer89.  
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 There are two major problems with the use of RTK inhibitors as anti-angiogenic 
agents. Firstly, resistance to the therapy in preclinical and clinical settings is commonly 
observed.90-92 This resistance is either acquired or inherent in nature. Secondly, severe 
toxicities (bleeding, hypertension, fatigue) to the treatment have been reported. In patients, 
resistant to anti-VEGF therapy, a non-VEGF could be responsible for signals of 
angiogenesis in tumors. Thus, a combination approach targeting different angiogenesis 
signaling could be highly effective. Additionally, a cross communication between multiple 
angiogenic signaling pathways can generate synergistic effects e.g. Synergism was 
observed in signaling by fibroblast growth factor-2 (FGF-2) and PDGF-BB in tumor 
growth and metastasis.93 Many molecules function as single agents with multi-RTK 
inhibition potential e.g., axitinib (Inlyta®) approved for renal cell carcinoma inhibits 
VEGFR, PDGFR, c-KIT;94 vandetanib (Caprelsa®) approved for advanced medullary 
thyroid cancer inhibits VEGFR2, EGFR, REarranged during Transfection (RET);95 and 
Nindetanib (Ofev®) approved for non-small cell lung cancer inhibits VEGFR, FGFR and 
PDGFR.96 Success of these therapies in clinic validate development of single agents as 
multi-RTK inhibitors. 
 
A.2.3 Combination of anti-angiogenic agents and MTAs 
 Combination therapy is standard of care in cancer, as a means to increase response 
and tolerability, and reduce development of resistance.97 The advantages attributed to a 
combination therapy include: increased patient compliance, emergence of an additive or 
synergistic interaction of the combined drugs, delay or overcome resistance, reduction of 
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drug dosage with a consequence of diminished toxicity. Apart from the listed benefits, the 
effect of combination therapy on tumor heterogeneity plays a significant role.98 Inhibition 
of a single target or pathway is known to be of limited benefit to a cancer patient. Optimal 
drug combination can provide an effective therapy to combat resistance and target tumor 
heterogeneity.99  
 
A.2.3.1 Vascular normalization  
Cytotoxic agents, such as MTAs can kill cancer cells directly, and antiangiogenic 
agents would kill cancer cells indirectly by depriving them of nutrients and oxygen. 
Clinical data has shown success on using a combination of cytotoxic drug with anti-
angiogenic agents.100 The anti-angiogenic therapy instead of blocking delivery of the 
cytotoxic drug augments its effect. Based on this observation, Jain and coworkers101 
formulated the “vascular normalization” hypothesis.  
 
Figure 17. Vessel normalization in tumors in response to anti-angiogenic therapy. 
Reprinted with permission from AAAS from ref.101 From [Jain, R. K., Normalization of 
tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005, 307, 58-
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62]. Copyright 2005 AAAS. 
As illustrated in Figure 17, the cancer cells have haphazard blood vessels, which 
are leaky and tortuous. This creates spatial heterogeneity in blood flow, increased 
interstitial fluid pressure, low pH and hypoxia.102 The heterogeneity in blood flow 
decreases delivery of cytotoxic drug. Acidic pH decreases activity of immune cells and 
hypoxia renders cells resistant to radiotherapy.103 An anti-angiogenic therapy can cause a 
transient increase in vascular patency, decrease in interstitial fluid pressure and hypoxia. 
The blockade of the angiogenic signals of the tumors results in pruning of the immature 
blood vessels and remodeling of the vasculature. It thus normalizes the tumor blood vessels 
and improves the blood, oxygen, and drug delivery.  
 
Figure 18. Proposed effect of drug dose and schedule on vascular normalization of tumor.  
Reprinted with permission from AAAS from ref.101 From [Jain, R. K., Normalization of 
tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005, 307, 58-
62]. Copyright 2005 AAAS. 
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The normalization of vasculature in tumors, limited to a fixed time after the anti-
angiogenic therapy is administered, is defined as the “vascular normalization window” 
(Figure 18).101 This window is short-lived and delivery of cytotoxic drugs in this time 
duration can provide synergistic effect for the targeting the tumor. Lateral dosing, 
scheduling, sequencing and studying the tumor vasculature is required to formulate a 
chemotherapy treatment for a patient. The careful consideration is mandatory to optimize 
the efficacy of a combination of cytotoxic drug and anti-angiogenic agent, and to reduce 
negative side-effects.   
 
A.2.3.2 Combination of anti-angiogenic agents and vascular disrupting agents104 
 A “hallmark” of tumor-VDAs is induction of central necrosis of tumor tissues, 
leading to rim of viable, proliferating cells at the periphery.105 These proliferating cells at 
the periphery can cause metastasis and thus limits the use of tumor-VDAs as monotherapy. 
Anti-angiogenic agents target the periphery. This provides a strong rationale for combining 
tumor-VDAs, such as, MTAs with anti-angiogenic agents.  
 
A.2.3.3 Multitargeted agents with MTA and RTK inhibitory potential 
 Multitargeted drugs are defined as rationally designed single chemical entities 
capable of selectively targeting two or more biological targets or processes.106 They fall 
into a different category than promiscuous drugs, which have a wide-spectrum of non-
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selective target activity and side-effects. Multitargeted drugs offer various advantages over 
combination chemotherapy, namely (i) predictable pharmacodynamic and pharmacokinetic 
effects; (ii) improved patient compliance; and (iii) presence of multiple entities (in one 
agent) with multiple effects simultaneously.106 A combination therapy requires a very 
careful selection of scheduling (Figure 18), which is avoided while designing a 
multitargeted drug. 
Docetaxel (MTA) plus nintedanib (VEGFR, PDGFR and FGFR inhibitor) versus 
docetaxel plus placebo in patients in non-small-cell lung cancer (LUME-Lung 1) phase 3 
trial displayed an increase in overall survival of 10.9 months for the drug combination, 
compared to 7.9 months for docetaxel monotherapy.107 The clinical evidence prompted 
more investigation into the combination therapy of MTAs with multi-RTK inhibitors. 
 
Figure 19. Reported 7-benzyl-N-(substituted)-pyrrolo[3,2-d]pyrimidin-4-amine as single 
agents acting as MTAs, along with inhibitors of VEGFR-2, PDGFRβ and EGFR108 
 
Pavana et al.108 reported 7-benzyl-N-(substituted)-pyrrolo[3,2-d]pyrimidin-4-
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amines (Figure 19) as single agents acting as MTAs, along with inhibitors of VEGFR-2, 
PDGFRβ and EGFR. Among the three compounds, 5 displayed excellent inhibition 
potential across all the four targets. It has a potency of 480 ± 8 nM in inhibiting tubulin 
assembly. Its IC50 against VEGFR-2, PDGFRβ and EGFR was 33 ± 5.0 nM, 2.3 ± 0.3 nM 
and 10.3 ± 1.7 nM  respectively.108 Compound 5 also reduced tumor growth in 4T1 cells 
(mouse mammary carcinoma) significantly, compared to paclitaxel. Gangjee and 
coworkers109, 110 have further reported 4-substituted-2,6-dimethylfuro[2,3-d]pyrimidines as 
multitargeted agents with potential to inhibit VEGFR-2, PDGFRβ and EGFR, along with 
tubulin assembly. These studies attest to the rationale of designing compounds with anti-
angiogenic and MTA potential to produce combination chemotherapy as single agents.  
 
A.3. Single agents with dual action that target tumors via cellular uptake by Folate 
Receptors and/or Proton-Coupled Folate Transporter and inhibit de novo purine 
nucleotide biosynthesis 
 
A.3.1 Folates 
Folate is a generalized term used for water-soluble members of B9-class of 
vitamins. These are essential for growth and survival of all tissues. Folic acid can be 
described as the parent structure of folates (Figure 20). The group encompasses of various 
oxidized forms of folic acid with substitutions at N5 and/or N10, and the presence of γ-linked 
glutamyl residues (2-8). In humans, these are not physiologically synthesized and are 
obtained only from the food ingested. Chemically these are hydrophilic and anionic 
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structures which cannot cross biological membranes by passive diffusion. Hence, the 
human body has devised several sophisticated transporter systems to absorb folic acid.  
 
 
Figure 20. Physiologically important folates 
 
A.3.2 Physiological role of Folates 
Folates are extensively involved in cellular one carbon transfer reactions.111 They 
act as cofactors for the transfer through several of its metabolites (Figure 21).111, 112 In the 
cytosol, the reduced cofactor 10-formyl-THF is used in the purine biosynthesis.111, 113 The 
enzyme glycinamide ribonucleotide formyl transferase (GARFTase) uses 10-formyl-THF 
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for the formation of the imidazole ring of purines.113 
 
Figure 21. Physiological role of folates in the cytosol.112 (Reprinted from Cantarella, C. 
D.; Ragusa, D.; Giammanco, M.; Tosi, S., Folate deficiency as predisposing factor for 
childhood leukaemia: a review of the literature. Genes & Nutrition 2017, i, 14.) 
 
5-Aminoimidazole-4-carboxamide ribonucleotide formyl transferase (AICARFTase) 
enzyme, which is downstream to the GARFTase enzyme in the purine biosynthesis 
pathway, uses 10-formyl-THF to synthesize inosin-5ˊ-monophosphate (IMP).113 5,10-
methylene THF acts as co-factors in reactions catalyzed by thymidylate synthase (TS).111, 
114  TS catalyzes the conversion of 2ˊ-deoxyuridine monophosphate (dUMP) to 2ˊ-
deoxythymidine monophosphate (dTMP). After the conversion, the reaction generates 
DHF.114 The DHF is recycled into THF by the enzyme dihydrofolate reductase (DHFR), 
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which is abundantly expressed in the cytosol.115 Another form of folic acid, 5-CH3-THF 
synthesized by Methylene Tetrahydrofolate Reductase (MTHFR) from 5,10-methylene-
THF in cytosol serves as a cofactor for the reaction catalyzed by Methionine Synthase 
(MS).116 MS causes conversion of cysteine to methionine, which later conjugates with 
Adenosine Triphosphate (ATP) to form S-Adenosyl-Methionine (SAM). SAM serves as a 
methyl group donor for several methylation reactions on DNA, RNA, histones and 
neurotransmitters, and thus can causes an increase or decrease in transcription and 
translation of proteins, such as, tumor suppressor genes or promoter genes.117  
 
THF cofactor can be transported into mitochondria from the cytosol via 
mitochondrial folate transporter (MFT/SLC25A32).118, 119 In the mitochondria, it is majorly 
used in biosynthesis of formate and glycine (Figure 22). The intermediate folic acid 
derivatives can be transferred to the cytosol for various cellular synthetic reactions.120 
Mitochondria accumulates 40% of the folate in the cell.120, 121 Abnormalities in the 
nucleotide biosynthesis, methylation reactions, glycine biosynthesis can affect DNA 
synthesis, DNA repair, DNA methylation, which can cause genomic instability of the 
cellular system, potentially leading to cell death.  
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Figure 22. The physiological role of the mitochondrial folates.122 This research was 
originally published in Journal of Biological Chemistry. Scott A. Lawrence, Steven A. 
Titus, Jennifer Ferguson, Amy L. Heineman, Shirley M. Taylor and Richard G. Moran. 
Mammalian Mitochondrial and Cytosolic Folylpolyglutamate Synthetase Maintain the 
Subcellular Compartmentalization of Folates. J. Biol. Chem. 2014; 289: 29386-29396. © 
the American Society for Biochemistry and Molecular Biology. 
 
Reactions 1, 3, 4, and 5 occur in both the mitochondria and the cytoplasm. Reaction 
2 is limited only to the mitochondria (Figure 22). The enzymes involved are Serine 
hydroxymethytransferase (1); glycine oxidase complex (2); 5,10-methylene 
tetrahydrofolate dehydrogenase (3); methenyltetrahydrofolate cyclohydrolase (4); and 
formyltetrahydrofolate synthetase (5)  
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A.3.3 Cellular folate transport 
A.3.3.1 Transporters that mediate influx of folates 
 
Figure 23. Transport of (anti)folates intracellularly and extracellularly.123 (Reprinted from 
Drug Resistance Updates, 15, Gonen, N; Assaraf, Y., Antifolates in cancer therapy: 
Structure, activity and mechanisms of drug resistance, 183-210, Copyright (2012), with 
permission from Elsevier. 
 
(a) Reduced Folate Carrier (RFC, SLC19A1):123 
RFC belongs to major facilitator superfamily (MFS) of transporter, specifically 
solute carrier (SLC) family of facilitative carriers.124 It is a 591- amino acid transmembrane 
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protein with molecular mass of approximately 85 kDa.125 It has 12 hydrophobic 
transmembrane domains (TMD) with a short hydrophilic N-terminus and long hydrophilic 
C-terminus, both of which are in the cytosol.125 RFC is devoid of ATP-binding site domain 
and thus its transport is not ATP-driven.125 It is a bidirectional antiporter that exchanges 
adenosine nucleotides, thiamine monophosphate and thiamine pyrophosphate (which are 
stored intracellularly) (Figure 23).126 Due to low concentration of folates inside the cell, 
the transport of folates is uphill into the cell by the antiporter.126 It has higher affinity for 
reduced folates (Km = 1-3 µM) and lower affinity for oxidized folates like folic acid (Km 
=200-400 µM).127 In humans, RFC is ubiquitously expressed in normal and malignant 
cells, including bone marrow, breast, lung, heart, small intestine and lymophocytes.128-130  
(b) Proton-Coupled Folate Transporter (PCFT, SLC46A1):123 
PCFT functions as a unidirectional symporter that transports folates with protons 
into the cells (Figure 23).131 For instance, in the upper small intestine, concentration of 
protons is high due to the activity of Na+/H+ exchanger.132 Thus, the high extracellular H+ 
concentration acts as the driving force for the PCFT symport into the cell. It functions 
optimally at pH 5.5.131 The transporter activity decreases as the pH increases.131 Unlike 
RFC, PCFT has equal affinity for both folic acid and reduced folates.132 Similar to RFC, 
PCFT is a MFS with 459 amino acids transmembrane protein with a molecular mass of 55 
kDa.133 It has 12 TMDs and both of its N- and C-termini are in the cytosol.131 PCFT 
displays a 14% amino acid identity with RFC.134 No X-ray crystal structures for PCFT and 
RFC have been resolved so far which impedes a structure-based drug deign approach.  
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(c) Folate receptors (FRα, FRβ, FRγ):123 
The third route of folate influx intracellularly is through FRα and FRβ. These are 
glycoproteins with high affinity for folates, and are encoded by three different loci of FRα, 
FRβ, and FRγ. There is 70-80% amino acid homology among the FRs and have 245-257 
amino acid residues.135  FRα and FRβ are glycosylphosphatidinylinositol (GPI)- anchored 
cell surface glycoproteins and FRγ is a secretory protein.135 The uptake of folates by FRα 
and FRβ is receptor-mediated endocytosis.136 FRα is mostly expressed in epithelial cells of 
uterus, placenta, choroid plexus, retina and kidney. It is also expressed in cancers of 
epithelial origin- adenocarcinoma of ovary, cervix, uterus, kidney, lung, breast, bladder and 
pancreas.135, 137, 138 FRβ is expressed in placenta, thymus, spleen, and malignancies of 
myelomonocytic origin.135  
 
Figure 24. X-ray co-crystal structure of FRα with AGF183 (cyan) (PDB: 5IZQ, 3.6Å)139 
visualized using MOE 2016.0840 
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X-ray crystal structures of FRα and FRβ have been resolved and published.130, 139 
To illustrate the binding of a folate, an image of the co-crystal structure of a known 
antifolate AGF183 is displayed in Figure 24. The 2-amino-4-oxo pyrimidine motif is 
commonly observed across folates and antifolates. The 2-NH2 forms an ion-dipole 
interaction with Asp81 side chain. The 3-NH interacts with Ser174 side chain via hydrogen 
bonding interactions. The 4-oxo forms a hydrogen bonding interaction with side chain of 
Arg103. The pyrrolo[2,3-d]pyrimidine scaffold is stabilized by π-π stacking interactions 
with Tyr85 and Trp171. The L-glutamate side chain extends into a pocket composed of 
hydrophilic side chains. The α-COOH forms ion-dipole interactions with Trp140 side chain 
and backbone NHs of Trp138 and Gly137. The γ-COOH forms ionic interactions with 
Lys136 and ion-dipole interactions with side chains of Trp102 and Gln100.  
 
Figure 25. X-ray co-crystal structure of FRβ with methotrexate (MTX) (PDB: 4KN0, 2.1 
Å)140 visualized using MOE 2016.0840 
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The co-crystal structure of FRβ with MTX has been resolved, which can be 
visualized in Figure 25. The 2,4-diamino scaffold is stabilized by π-π stacking interactions 
with Tyr101 and Trp187. The 2-NH2 forms hydrogen bonding interactions with Ser190 side 
chain and the 4-NH2 forms ion-dipole interaction with Asp97 side chain. The phenyl linker 
is also stabilized by π-π stacking interactions with Phe78 and Trp118. The L-glutamyl NH 
forms a hydrogen bonding interaction with His151 backbone. The anionic side is oriented 
in a solvent exposed pocket. The α-COOH forms ion-dipole interactions with Trp154 and 
Trp156 side chain and backbone NH of Gly153. The γ-COOH forms ionic interactions with 
Arg152 and ion-dipole interactions with side chains of Trp118 and Gln116.  
 
A.3.3.2 Transporters that mediate efflux of folates 
Several ABC transporters exist in humans. Among the multidrug resistance proteins 
(MRP), MRP1-5 are capable of exporting folate derivatives.141 Another exporter of folates 
is breast cancer resistance protein (BRCP/ABCG2).142 (Anti)Folates can get removed from 
the cell by overexpression of these transporters in cancer cells.  
 
A.3.3.3 Cellular retention of folates 
Following uptake, folates may undergo folypolyglutamylation, catalyzed by 
folypoly-γ-glutamate synthetase (FPGS).143 It catalyzes sequential addition of multiple 
equivalent of glutamic acid to γ-carboxyl chain of the folate cofactors. This causes an 
increased retention of these polyanions intracellularly. FPGS has two forms- cytosolic and 
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mitochondrial.122 It is also noted that polyglutamylated folates are much better substrates 
for various folate-dependent enzymes.144 The process of folypolyglutamylation can be 
reversed by enzyme γ-glutamyl hydrolase (GGH), which catalyzed hydrolysis of γ-
glutamyl tail of polyglutamylated folates.145 
 
C.3.4 Antifolates 
Figure 26. Clinically used antifolates 
 The antifolates were the first class of antimetabolites to enter the clinic for treatment 
of cancer before 70 years. The first antifolate was aminopterin, which proved the concept 
of antifolates for cancer therapy.146 Due to its low therapeutic index, aminopterin was 
replaced with methotrexate (MTX) in 1950s.147 MTX is a DHFR inhibitor, which is taken 
up by cells via PCFT and RFC transport (Figure 26).123 Another antifolate Raltitrexate 
(RTX) (Tomudex®) (Figure 26) is a potent inhibitor of TS (Ki = 62 nM) and is transported 
into cells by RFC and FRα.148, 149 Polyglutamylation of RTX increases the activity for TS 
by 100-fold, when compared to the monoglutamylated form.  In 2004, pemetrexed (PMX) 
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(Alimta®) was introduced in the market for treatment of mesothelioma and non-small cell 
lung cancer.78, 150 PMX (Figure 26) is a potent TS inhibitor and is an excellent substrate for 
FPGS. The pentaglutamylated form of PMX displays 84-fold increase in potency for TS, 
compared to the monoglutamylated form.151, 152 The pentaglutamylated form of PMX also 
shows moderate potency against GARFTase and AICARFTase enzymes, the 
monoglutamylated form is inactive against those two targets.151 Thus, the primary target 
for PMX is TS. Pralatrexate (PDX) (Folotyn®) (Figure 26) is a DHFR inhibitor with an 
intracellular uptake through RFC.78, 150  It has been approved in patients with peripheral T-
cell lymphoma.78, 150  
All the clinically used folates utilize RFC transport for entry into the cell. Because 
of the ubiquitous expression of RFC, these compounds do not have inherent selectivity into 
cancer cells and cause dose-limiting toxicities (severe myelosuppression).153, 154 The 
process of polyglutamylation decreases when the concentration of intracellular folates 
(e.g., 5-formyl-THF) increases. Thus, activity of PMX like antifolate will decrease when 
concentration of intracellular folates increases. Also, PMX-resistant cancers have been 
identified which were developed due the mutagenesis in the FPGS active site.155-157 Since 
polyglutamylation is responsible for increased potency, loss of FPGS activity can lead to 
drug resistant cancer cell lines.156 Several studies have displayed a reduced activity of such 
FPGS-dependent antifolates in cancer cells lines, which have low FPGS activity or have 
mutated FPGS incapable of binding to the antifolate.155, 156 An increase in GGH activity 
also can cause decreased activity of antifolates and lead to development of resistance.158 
Overexpression of DHFR or TS, and mutations in the active site of DHFR or TS can also 
lead to resistance.155-157  
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As an approach to combat resistance and dose-limiting toxicities, there is a critical 
need to develop agents with (a) increased selectivity for transport via PCFT or FRs over 
RFC to eradicate dose-limiting toxicities; (b) ability to target two or more intracellular 
enzymes to decrease development of resistance; and (c) no dependence on FPGS for its 
activity against intracellular targets. Dies et al.159 and Wang et al.160 report 6-substituted 
pyrrolo[2,3-d]pyrimidines with selectivity for transport through PCFT and FRs over RFC. 
These compounds are potent inhibitors of GARFTase (inhibit purine synthesis). They also 
display a strong inhibition of GARFTase in their monoglutamylated form and do not 
depend on FPGS to potentiate their activity.  
 
A.3.5 Intracellular targets: inhibition of purine synthesis 
Purines serve as building blocks of DNA and RNA, and as a component of ATP, 
cyclic adenosine monophosphate (cAMP), nicotinamide adenine dinucleotide (NAD) and 
coenzyme A (coA). The synthesis can occur through de novo synthetic pathway or salvage 
pathway.134 The de novo synthetic pathway is a 10-step folate dependent pathway (from 
phosphoribosyl pyrophosphate (PRPP) to IMP) (Figure 27).134 
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Figure 27. De novo purine nucleotide biosynthesis pathway.134  
 
The enzymes catalyzing the reactions enumerated in the figure are: 1, glutamine 
phosphoribosylpyrophosphate amidotransferase (GPAT); 2, GAR synthase (GARS); 3, 
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GAR formyl transferase (GARFTase); 4, formyl glycinamide ribonucleotide synthase 
(FGAM synthetase); 5, 5-amino-4-imidazole ribonucleotide synthase (AIRS); 6, 
carboxyaminoimidazole ribonucleotide synthase (CAIRS); 7, 5-aminoimidazole-4-(N-
succinylocarboxamide) ribonucleotide synthase (SAICARS); 8, adenylosuccinate lyase 
(ASL); 9, 5-amino-4-imidazolecarboxamide ribonucleotide (AICAR) formyl transferase 
(AICARFTase); and 10¸ IMP cyclohydrolase (ATIC). There are two steps that use 10-
formyl THF and are folate-dependent in nature. They are glycinamide ribonucleotide 
formyl transferase (GARFTase, reaction 3) and aminoimidazole carboxamide 
ribonucleotide formyl-transferase (AICARFTase, reaction 9). The reactions 2, 3 and 5 are 
catalyzed by the trifunctional glycinamide ribonucleotide (GAR) formyl transferase 
(GARFTase) which contains GARS (reaction 2), GARFTase (reaction 3) and AIRS 
(reaction 5) activities. Reactions 6 and 7 are catalyzed by the bifunctional phosphoribosyl 
aminoimidazole carboxylase/ phosphoribosyl aminoimidazole succinocarboxamide 
synthetase (PAICS) enzyme, which contains CAIRS (reaction 6) and SAICARS; (reaction 
7) activities. Reactions 9 and 10 are catalyzed by a bifunctional enzyme, 5-amino-4-
imidazolecarboxamide ribonucleotide (AICAR) formyl transferase (AICARFTase)/IMP 
cyclohydrolase (ATIC). The two folate-dependent reactions (reactions 3 and 9) in which 
10-formyl-THF serves as the one-carbon donor are catalyzed by GARFTase and 
AICARFTase.  
Free purine bases which are derived from the turnover of nucleotides or from the 
diet, can be attached to PRPP to form purine nucleoside monophosphates. There are two 
types of phosphoribosyl transferases: adenine phosphoribosyl transferase (APRT) for AMP 
formation and hypoxanthine-guanine phosphoribosyl transferase (HGPRT) for IMP and 
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GMP formation.161 Many enzymes required for salvages pathways get co-deleted in cancer 
cells and cancer cells remain dependent on the de novo synthesis for obtaining purines.162 
Further, methylthioadenosine phosphorylase (MTAP), another salvage enzyme that 
releases adenine from methylthioadenosine is abundantly expressed in normal tissues and 
is co-deleted with CDKN2A in many tumors.163-165   
 
(a) GARFTase  
 Gangjee and coworkers have reported 6-substituted pyrrolo[2,3-
d]pyrimidines which displayed GARFTase inhibition (Table 4).159, 160, 166 Unlike PMX, 
which needs to be polyglutamylated for its activity, the reported compounds show potent 
inhibition of GARFTase in its monoglutamylated form.159  
 
Table 4. GARFTase inhibition constants (Ki)159 
 
 X n Ar Ki 
AGF23 NH 4 1,4-phenyl 17 ± 3 
AGF50 S 4 1,4-phenyl 1067 ± 271 
AGF71 NH 4 2,5-thiophenyl 22 ± 3 
AGF94 NH 3 2,5-thiophenyl 68 ± 11 
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The binding mode of antifolates in GARFTase can be visualized by studying the X-
ray co-crystal structure of GARFTase and antifolate AGF150 (PDB: 4ZZ1, 1.35 Å) (Figure 
28).160 The N1 of the pyrrolo[2,3-d]pyrimidine scaffold forms hydrogen bonding 
interaction with NH of the backbone of Leu899. The 2-NH2 displays hydrogen bonding 
interaction with backbone NHs of Ala947 and Glu948. The 3-NH also forms hydrogen 
bonding interaction with backbone NH of Ala947. The 4-oxo forms hydrogen bonding 
interaction with backbone NH of Asp951. The glutamate side chain is oriented in a solvent 
exposed pocket. The α-COOH forms ionic bonding with Arg871 and ion-dipole interaction 
with backbone NH of Ile898.  
 
Figure 28. X-ray co-crystal structure of GARFTase and antifolate AGF150 (PDB: 4ZZ1, 
1.35 Å).160 AGF150 is displayed in teal color and the substrate GAR is displayed in green 
color. The co-crystal structure was visualized using MOE 2016.0840 
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(b) AICARFTase  
5-Aminoimidazole-4-carboxamide (AICA) and AICAR can be metabolized to 
AICAR monophosphate (ZMP) by adenine phosphoribosyl transferase (APRT) and 
adenosine kinase (AK).134 Thus, this can circumvent the reaction catalyzed by GARFTase. 
Moran and coworkers167 reported an interesting find on the effect of PMX on AICARFTase. 
Inhibition of AICARFTase causes accumulation of its substrate- AICAR (ZMP). The 
accumulated ZMP causes activation of AMP-dependent protein kinase, the activation of 
AMPK causes inhibition of mechanistic target of rapamycin (mTOR) as well as direct 
phosphorylation of the raptor component of mammalian target of rapamycin complex 
(mTORC1 complex). This, it inhibits cell growth through two distinct pathways.  
 
Figure 29. X-ray co-crystal structure of AICARFTase with bicyclic classical antifolate 
compound (PDB: 1P4R, 2.55 Å).168 The ligand and AICAR are displayed in magenta and 
green color, respectively. The co-crystal structure was visualized using MOE 2016.0840 
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To understand the binding mode of compounds in AICARFTase, the X-ray co-
crystal structure of AICARFTase with a bicyclic classical antifolate compound can be 
studied (Figure 29).168 The bicyclic scaffold is stabilized by π-π stacking interaction with 
Phe544. The 2-NH2 displays hydrogen bonding interaction with backbone carbonyl of 
Asn489 and ion-dipole interaction with side chain of Asp546. The 3-NH also displays ion-
dipole interaction with side chain of Asp546. The 4-oxo group forms a hydrogen bonding 
interaction with side chain of Asn547. The sulfone in the linker shows hydrogen bonding 
interaction with backbone NH of Arg541, side chain of Asn431 and ion-dipole interaction 
with Lys266. The glutamate side chain is oriented in a hydrophilic and solvent exposed 
pocket.  
 
Figure 30. 5-substituted pyrrolo[2,3-d]pyrimidine compounds 7-10 with inhibitory activity 
against GARFTase and AICARFTase.169, 170  
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Gangjee and coworkers169, 170 have reported 5-substituted pyrrolo[2,3-
d]pyrimidines 7-10 which displayed inhibition of both GARFTase and AICARFTase 
(Figure 30). This dual inhibition is advantageous as it attacks the purine biosynthetic 
pathway at two distinct sites and could overcome a tumor resistance due to lack of 
sensitivity at a single target. Such a therapy will be effective for drug-resistant tumors.   
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II. CHEMICAL REVIEW 
 
The chemistry related to the work carried out is reviewed in this section and includes 
synthetic approaches to the following heterocyclic ring systems: 
B.1. Pyrrolo[2,3-d]pyrimidines 
B.2. Pyrrolo[3,2-d]pyrimidines 
B.3. Thieno[3,2-d]pyrimidines 
B.4. Pyrido[3,2-d]pyrimidines 
 
B.1. Synthesis of pyrrolo[2,3-d]pyrimidines 
Scheme 1. Synthesis of pyrrolo[2,3-d]pyrimidines  from 6-aminopyrimidin-4(3H)-one 
 
a) Br2; b) Z-1-ethoxy-2-(nbutylstanyl)ethane, Pd(PPh3)4; c) HCl(aq) 
 
6-amino-5-bromopyrimidin-2(1H)-one, 12 (Scheme 1) was synthesized by 
electrophilic substitution of 6-aminopyrimidin-2(1H)-one 11 with bromine. Palladium 
catalyzed Stille coupling of 12 with Z-1-ethoxy-2-(nbutylstanyl)ethane followed by 
deprotection of resulting enol ether 13 with concomitant cyclization gave 4-methyl-1,3,4,7-
tetrahydro-2H-pyrrolo[2,3-d]pyrimidin-2-one, 14.171 
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Scheme 2. Synthesis of pyrrolo[2,3-d]pyrimidines  from ethyl 2-cyano-4,4-
diethoxybutanoate
 
a) thiourea, sodium ethoxide; b) HCl(aq); c) Raney Ni/H2 
 
Cyclocondensation of ethyl 2-cyano-4,4-diethoxybutanoate 15 (Scheme 2) with 
thiourea affords 6-amino-5-(2,2-diethoxyethyl)-2-thioxo-2,3-dihydropyrimidin-4(1H)-
one, 16. Acidic hydrolysis of acetal 16 and cyclization and final desulfurization with Raney 
nickel forms 1,2,3,7-tetrahydro-4H-pyrrolo[2,3-d]pyrimidin-4-one, 18.171 
The synthetic route (Scheme 3), based on Besong’s method172 starts with the 
reaction of 5-bromo-2,4-dichloropyrimidine, 19 and cyclopentylamine in N,N-
diisopropylethylamine to yield compound 20, followed by Pd catalyzed Sonogashira 
coupling with propargyl alcohol afforded 3-(2-chloro-4-(cyclopentylamino)pyrimidin-5-
yl)prop-2-yn-1-ol, 21. Cyclization of 21 was carried out in THF using TBAF to afford (2-
chloro-7-cyclopentyl-7H-pyrrolo[2,3-d]pyrimidin-6-yl)methanol, 22.173 
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Scheme 3. Synthesis of pyrrolo[2,3-d]pyrimidines  from 5-bromo-2,4-dichloropyrimidine 
 
a) cyclopentylamine, DIPEA, EtOAc, r.t.; (b) propargyl alcohol, TBAF, PdCl2(PPh3)2, 
THF, 67°C; (c) TBAF, THF, 60°C 
 
Scheme 4. Synthesis of pyrrolo[2,3-d]pyrimidines from 6-amino-2-
(dimethylamino)pyrimidin-4-(3H)-one 
 
a) n-butanol, reflux 
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Gangjee et al.174 reported the synthesis of 27 (Scheme 4) by the condensation of an 
aqueous solution of α-chloroacetone 23 in presence of NaOAc in 70% yield. Linz et al.175 
also reported the synthesis of a series of pyrrolo[2,3-d]pyrimidines from 6-amino-2-
(dimethylamino)pyrimidin-4(3H)-ones 24 (Scheme 4). Compound 24 on treatment with α-
chloroacetone 25 or α-chloroacetaldehyde 26 provided the corresponding pyrrolo[2,3-
d]pyrimidines 27 or 28 in 68% and 75% yields respectively.  
 
Scheme 5. Synthesis of pyrrolo[2,3-d]pyrimidines using Fisher-Indole reaction  
 
a) methyl 4-(4-oxopentyl)benzoate, 2-methoxyethanol; b) Ph2O 
 
Taylor et al.176 synthesized methyl 4-(2-(2-amino-6-methyl-4-oxo-4,7-dihydro-3H-
pyrrolo[2,3-d]pyrimidin-5-yl)ethyl)benzoate 31 (Scheme 5) by a Fisher-Indole approach. 
Reaction of 2-amino-6-hydrazinylpyrimidin-4(3H)-one, 29 with one equivalent of methyl 
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4-(4-oxopentyl)benzoate in 2-methoxyethanol under reflux afforded the requisite 
intermediate 30, methyl (Z)-4-(4-(2-(2-amino-6-oxo-1,6-dihydropyrimidin-4-
yl)hydrazineylidene)pentyl)benzoate. The cyclization was accomplished by thermolysis of 
31 in refluxing diphenyl ether to regioselectively afford the pyrrolo[2,3-d]pyrimidine 31. 
 
Scheme 6. Synthesis of pyrrolo[2,3-d]pyrimidines from 1-benzyl-2-amino-3-
cyanopyrroles
 
a) (i) Benzylamine, toluene, HCl, reflux; (ii)Malononitrile, toluene, reflux; b) Formic acid  
 
Traxler et al.177 reported the synthesis of a series of pyrrolo[2,3-d]pyrimidines 
(Scheme 6) starting from substituted α-hydroxy ketone 32. Ketone 32 was converted to 2-
amino-1-benzyl-4,5-dimethyl-1H-pyrrole-3-carbonitrile 33 by treatment with benzylamine 
at reflux in toluene and further condensation with malononitrile in toluene at reflux. 2-
Amino-1-benzyl-4,5-dimethyl-1H-pyrrole-3-carbonitrile, 33 underwent condensation with 
85% formic acid at reflux to provide the target 7-benzyl-6-methyl-7H-pyrrolo[2,3-
d]pyrimidin-4-ol, 34. 
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Scheme 7. Synthesis of 2-amino-pyrrolo[2,3-d]pyrimidines from 4-substituted 2,6-
diamino pyrimidines  
 
a) Ethyl acetate/water, reflux 18 h; (b) aqueous solution of NaOH/sulfuric acid 
 
Khalaf et al.178 synthesized pyrrolopyrimidines 38a-e (Scheme 7) with 5-
hydrophobic substituents via Michael addition-based synthesis to include a wide range of 
aryl and some alkyl substituents in both 4-oxo- and 4-aminopyrimidine series. Using 4-
substituted 2,6-diamino pyrimidines 35 with (E)-(2-nitrovinyl)aryl 36 to afford 5-(1-aryl-
2-nitroethyl)pyrimidine-4-substituted-2,6-triamine 37 was obtained in varying yields. 
They note slower reaction rates and poorer yields for the preparation of the 2,4-diamino 
compounds than in the preparation of the 2- amino-4-oxo compounds could be that the 
mildly basic conditions used for the Michael addition step increased the reactivity of the 2-
amino-4-oxo pyrimidine through formation of the anion. Condensation of 37 to 4-
substituted-5-aryl-7H-pyrrolo[2,3-d]pyrimidine-2-amines 38 were accomplished using 
base.  
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Scheme 8. Synthesis of pyrrolo[2,3-d]pyrimidines from 2-bromo-1,1-diethoxyethane 
 
a) malononitrile, K2CO3, DMF, 50°C, 17–18 h; (b) thiourea, potassium tert-butoxide, 
EtOH, reflux, 16–17 h; r.t., 1–2 h; (c) (i) 5 N HCl, H2O, 10 N NaOH, 50°C, 50 min; (ii) 
Raney-Ni, H2O, reflux, 4 h 
 
El-Gamal and Oh179 synthesized the intermediate 2-(2,2-
diethoxyethyl)malononitrile 40 (Scheme 8) from 2-bromo-1,1-diethoxyethane 39 with 
malononitrile by heating in N,N-dimethylformamide (DMF) in the presence of base K2CO3. 
Synthesis of 4,6-diamino-5-(2,2-diethoxyethyl)pyrimidine-2-thiolate 41 was carried out by 
refluxing the geminal dicyano 40 with thiourea in the presence of a stronger base potassium 
tert-butoxide. Cyclization to 41 could be achieved by neutralization of the thiol potassium 
salt 40 using 5 N aqueous HCl followed by heating with 10 N aqueous NaOH. Reduction 
of the thiol compound 41 using Raney nickel afforded 7H-pyrrolo[2,3-d] pyrimidin-4-
amine 42. 
 
 
  57 
Scheme 9. Synthesis of 2-amino-pyrrolo[2,3-d]pyrimidines from 3-acetyldihydrofuran-
2(3H)-one 
 
(a) guanidine carbonate, EtOH, triethylamine, reflux; (b) POCl3, reflux; (c) benzylamine, 
triethylamine, n-BuOH, 90 °C; (d) MnO2, 1,4-dioxane, reflux; (e) Na/liq. NH3, -78 °C 
 
Gangjee et al.180 attempted synthesis of 2-amino-pyrrolo[2,3-d]pyrimidines by 
reacting 3-acetyldihydrofuran-2(3H)-one 43 (Scheme 9) and guanidine carbonate in 
refluxing conditions with absolute ethanol in the presence of triethylamine to afford 44. It 
was converted to 4-chloro-5-(2-chloroethyl)-6-methylpyrimidin-2-amine 45 by refluxing 
with phosphorus oxychloride. Condensation of benzylamine with 45 in the presence of 
triethylamine under reflux in n-BuOH afforded the bicyclic 7-benzyl-4-methyl-6,7-
dihydro-5H-pyrrolo[2,3-d]pyrimidin-2-amine 46. Oxidation to 47 was carried out using the 
manganese dioxide. Removal of benzyl protecting group was carried out using liquid 
ammonia to afford the target compound 4-methyl-7H-pyrrolo[2,3-d]pyrimidin-2-amine 48.  
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B.2. Synthesis of pyrrolo[3,2-d]pyrimidines 
 
Scheme 10. Synthesis of pyrrolo[3,2-d]pyrimidines from (2-substituted-pyrimidin-5-
yl)boronic acids  
  
a) di-tert-butyl-azodicarboxylate , Cu(OAc)2, Methanol, 1 h, 65 ⁰ C  
 
Beveridge and Gerstenberger181 reported one-pot four-step cascade sequence to 
synthesize pyrrolo[3,2-d]pyrimidines via reaction of (2-substituted-pyrimidin-5-yl)boronic 
acids 49  with di-tert-butyl-azodicarboxylate (DBAD) and 1,3-dicarbonyls 51 (Scheme 10). 
The reaction proceeds via a with key steps involving a copper-catalyzed boronic acid 
coupling to DBAD and a Fischer indolization to provide 2-,6- and 7- substituted 
pyrrolo[3,2-d]pyrimidines 52. 
 
Furneaux et al. reported the synthesis of 2-amino-3H,5H-pyrrolo[3,2-d]pyrimidin-
4-one 56 (Scheme 11).182 Nitration of 2-amino-6-methylpyrimidin-4(3H)-one 53 afforded 
compound 2-amino-6-methyl-5-nitropyrimidin-4(3H)-one, 54. On treatment of nitro 
derivative 54 with 6 equivalent of DMF dimethyl acetal in DMF at 100 °C, compound (E)-
Nˊ-(4-((E)-2-(dimethylamino)vinyl)-5-nitro-6-oxo-1,6-dihydropyrimidin-2-yl)-N,N-
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dimethylformimidamide, 55 is obtained which upon subsequent dithionite reduction and 
cyclization affords pyrrolo[3,2-d]pyrimidine 56. 
 
Scheme 11. Synthesis of 2-amino 4-oxo pyrrolo[3,2-d]pyrimidines from 2-amino-6-
methylpyrimidin-4(3H)-one 
 
a) H2SO4, HNO3; b) DMF dimethylacetal, DMF; c) Na2S2O4, H2O  
Taylor et al.183 obtained (E)-N'-(4-((E)-2-(dimethylamino)vinyl)-1-methyl-5-nitro-
6-oxo-1,6-dihydropyrimidin-2-yl)-N,N-dimethylformimidamide, 58 (Scheme 12) upon 
reaction of  2-amino-6-methyl-5-nitropyrimidin-4(3H)-one, 57 with DMF dimethyl acetal. 
Subsequent addition of sodium dithionite provided (E)-N,N-dimethyl-Nˊ-(3-methyl-4-oxo-
4,5-dihydro-3H-pyrrolo[3,2-d]pyrimidin-2-yl)formimidamide 59, which hydrolysis 
provides 2-amino-3-methyl-3,5-dihydro-4H-pyrrolo[3,2-d]pyrimidin-4-one 60. 
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Scheme 12. Synthesis of 2-amino 4-oxo pyrrolo[3,2-d]pyrimidines from 2-amino-6-
methyl-5-nitropyrimidin-4(3H)-one 
 
a) DMF dimethylacetal, DMF; b) Na2S2O4, THF/H2O; c) 1 N NaOH 
 
Tian et al.184 condensed  (Z)-4-(benzyloxy)-3-hydroxybut-2-enenitrile, 61 (Scheme 
13) with diethyl aminomalonate in the present of acetic acid to afford intermediate 62, 
which was further cyclized under basic condition to produce ethyl 3-amino-5-
((benzyloxy)methyl)-1H-pyrrole-2-carboxylate, 63 using methodology published by 
Gangjee et al.185 The pyrrole 63 was condensed with 1,3-bis(methoxycarbonyl)-2-
methylthiopseudourea with acetic acid as catalyst in MeOH to afford 64. The self-
condensation reaction of 64 could be processed in the present of sodium methoxide in 
MeOH to obtain (6-((benzyloxy)methyl)-4-oxo-4,5-dihydro-3H-pyrrolo[3,2-d]pyrimidin-
2-yl)carbamate, 65. Hydrolysis of the carbamate group with aqueous sodium hydroxide at 
60 ºC afforded pyrrolo[3,2-d]pyrimidine 66.  
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Scheme 13. Synthesis of 2-amino 4-oxo pyrrolo[3,2-d]pyrimidines from (Z)-4-
(benzyloxy)-3-hydroxybut-2-enenitrile 
 
a) diethyl aminomalonate, AcOH, r.t.; b) NaOEt, EtOH, r.t.; c) 1,3-bis(methoxycarbonyl) 
-2-methylthiopseudourea, AcOH, N2, r.t.; d) NaOMe, MeOH, r.t.; e)1 N NaOH, 50 ºC  
 
Scheme 14. Synthesis of 2-alkyl-4-oxo-pyrrolo[3,2-d]pyrimidines from ethyl 3-amino-5-
substituted-1H-pyrrole-2-carboxylate 
 
a) (i) Alkylnitrile, HCl(g); (ii) NaOH, EtOH 
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Pyrrolo[3,2-d]pyrimidines with 2-alkyl substituents are obtained by treatment of 5-
substituted pyrrole 67 (Scheme 14) with an alkyl nitriles in anhydrous hydrochloric acid 
followed by heating with sodium hydroxide.186 For R = methyl, the yield was 53%.   
 
Scheme 15. Synthesis of 3H-pyrrolo[3,2-d]pyrimidin-4(5H)-one from ethyl 3-amino-1H-
pyrrole-2-carboxylate 
 
a) formamidine acetate, EtOH 
Pyrrolo[3,2-d]pyrimidines with 2-H are obtained by cyclocondensation of 
substituted ethyl 3-amino-1H-pyrrole-2-carboxylate 69 (Scheme 15) with formamidine in 
refluxing ethanol.182, 187 
 
Scheme 16. Synthesis of 2-sulfanyl-4-oxo-pyrrolo[3,2-d]pyrimidines from ethyl 3-amino-
1H-pyrrole-2-carboxylate 
 
a) S=C=NCOOC2H5, HCl; b) aq. NaOH 
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Pyrrolo[3,2-d]pyrimidine 72 with 2-sulfanyl substituent can be obtained by 
treatment of  2-amino-6-phenyl-3,5-dihydro-4H-pyrrolo[3,2-d]pyrimidin-4-one 71 
(Scheme 16) with an ethyl isothiocyanatoformate and hydrochloric acid in benzene at 
reflux followed by heating with aqueous sodium hydroxide.188 
 
Scheme 17. Synthesis of 2-amino-4-oxo-pyrrolo[3,2-d]pyrimidines from ethyl 3-amino-5-
phenyl-1H-pyrrole-2-carboxylate 
 
a) Cyanamide, HCl dioxane; b) aq. NaOH 
 
Pyrrolo[3,2-d]pyrimidine 73 with 2-amino substituents are obtained by treatment 
of from ethyl 3-amino-5-phenyl-1H-pyrrole-2-carboxylate 71 (Scheme 17) with 
cyanamide and acid in dioxane at reflux followed by heating with aqueous sodium 
hydroxide.186 
Pyrrolo[3,2-d]pyrimidine 74 with 2,4-dioxo substituent is obtained by 
cyclocondensation of ethyl 3-amino-5-phenyl-1H-pyrrole-2-carboxylate 71 (Scheme 18) 
with potassium cyanate under acidic conditions at room temperature followed by heating 
with aqueous sodium hydroxide.189 
  64 
Scheme 18. Synthesis of pyrrolo[3,2-d]pyrimidine 2,4-dione from ethyl 3-amino-5-
phenyl-1H-pyrrole-2-carboxylate 
 
a) KNCO, CH3COOH; b) aq. NaOH 
 
Scheme 19. Synthesis of 5-substituted ethyl 3-amino-1H-pyrrole-2-carboxylate from 
substituted cyanoacetylene 
 
Reagents: (a) NaOEt, EtOH 
 
Treatment of substituted cyanoacetylenes 76 (Scheme 19) with 
diethylaminomalonate 75 followed by a base catalyzed intramolecular cyclization affords 
substituted ethyl 3-amino-1H-pyrrole-2-carboxylate 77a-c.190 The pyrroles can be cyclized 
to afford 2-substituted 4-oxo pyrrolo[3,2-d]pyrimidines, as exemplified in Scheme 13 and 
17 (2-amino), Scheme 14 (2-alkyls), Scheme 15 (2-H), Scheme 16 (2-sulfanyl) and Scheme 
18 (2-oxo). 
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Scheme 20. Synthesis of 5-substituted ethyl 3-amino-1H-pyrrole-2-carboxylate from 3-
oxo-3-substituted propanenitrile 
 
a) Ts2O, triethylamine, DCM; b) NaOEt, EtOH, diethylaminomalonate 
 
Treatment of 3-oxo-3-phenylpropanenitrile 78 (Scheme 20) with p-toluenesulfonic 
anhydride provides the corresponding 2-cyano-1-phenylvinyl 4-methylbenzenesulfonate 
79.191 The crude enol ester 79 is immediately condensed with diethyl aminomalonate using 
sodium ethoxide to provide ethyl 3-amino-5-phenyl-1H-pyrrole-2-carboxylate 71.  Similar 
to Scheme 16, the pyrrole can be further cyclized to 2-substituted pyrrolo[3,2-
d]pyrimidines.  
 
B.3. Synthesis of thieno[3,2-d]pyrimidines 
The thieno[3,2-d]pyrimidin-4(3H)-one 82 was synthesized starting from methyl 3-
aminothiophene-2-carboxylate 80 (Scheme 21).192 This commercially available material 
underwent formylation to 81, followed by cyclization with formamide and ammonium 
formate to afford 82. 
  66 
Scheme 21. Synthesis of thieno[3,2-d]pyrimidin-4(3H)-one from methyl 3-
aminothiophene-2-carboxylate 
 
a) HCOOH, Ac2O, 0 ⁰ C tor.t., 12 h; (b) HCONH2, NH4HCO2, 150 ⁰ C, 17 h 
 
Scheme 22. Synthesis of 2-alkylthieno[3,2-d]pyrimidin-4(3H)-one from ethyl 3-
aminothiophene-2-carboxylate 
 
a) Acetonitrile, HCl, dioxane, r.t.; b) Ac2O, AcOH cat., 120 ⁰ C, MW, 10 min; c) NH4OH 
25%, 105 ⁰ C, 3 h, sealed vial 
 
Piet et al.193 synthesized 2-methylthieno[3,2-d]pyrimidin-4(3H)-one 84 by adding 
a solution of ethyl 2-aminothiophene-3-carboxylate 83 and acetonitrile in dioxane was 
added 4M HCl in dioxane (Scheme 22). To attain other 2-alkylthieno[3,2-d]pyrimidin-
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4(3H)-one, appropriate nitriles can be used instead of acetonitrile. Starting from the 
commercially available 3-aminothiophene-2-carboxylate, Desroches et al.194 carried out 
acetylation of the amino group in presence of Ac2O affords 85. Further cyclization was 
carried out by heating 85 in presence of 25% ammonia in a sealed vial. 
 
Scheme 23. Synthesis of 2-aminothieno[3,2-d]pyrimidin-4(3H)-one from 5-substituted 
ethyl 3-aminothiophene-2-carboxylate 
 
a) chlorformamidine hydrochloride, dimethyl sulfone, 140-150 ⁰ C 
 
Abdillahi et al.195 furnished 2-aminothieno[3,2-d]pyrimidin-4(3H)-ones 87 and 88 
by reacting ethyl 3-aminothiophene-2-carboxylates 83 and 86 with chlorformamidine 
hydrochloride in dimethyl sulfone at 140-150 ⁰ C (Scheme 23). 
Tian et al.196 explored different routes for synthesis of  thieno[3,2-d]pyrimidine-
2,4(1H,3H)-dione 89 (Scheme 24).   The synthesis of thienopyrimidine 89 by condensation 
of commercially available methyl 3-aminothiophene 2-carboxylate 80 with urea at 190 °C 
(Scheme 24, Route a). Another method uses milder conditions for the condensation 
reaction by replacing urea with potassium cyanate in aqueous AcOH and the reaction 
proceeded smoothly to afford 89 (Scheme 24, Route b). 
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Scheme 24. Synthesis of thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione from methyl 3-
aminothiophene-2-carboxylate 
  
a) urea, 190 ⁰ C (75%) or b) (i) Isocyanic acid potassium salt, H2O, AcOH, 2 h; (ii) NaOH, 
H2O, 12 h; (iii) HCl, H2O, 10 ⁰ C, pH 5-6 (77%) 
 
Scheme 25. Synthesis of methyl 3-amino-thiophene-2-carboxylate from 1,4-disubstituted 
butan-2-one 
 
a) POCl3, DMF, 60 ⁰ C, 5 h; b) hydroxylamine chloride, EtOH; c) Ac2O; d) (i) Na2S. 9H2O, 
DMF, X-CH2COOEt/Me (X=Cl, Br), EtONa/MeONa or (ii) HSCH2COOEt/Me, K2CO3, 
DMF 
 
Abdillahi et al.195 devised an efficient synthetic route to synthesize methyl 3-amino-
thiophene-2-carboxylate derivatives from 1,4-disubstituted butan-2-ones (Scheme 25). 
Chlorination of 1,4-disubstituted butan-2-one derivatives, 90 afforded a chloride derivative 
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of 91. Further nucleophilic attack by hydroxylamine and oxidation to nitrile 90 was carried 
out using acetic anhydride. The amino thiophenes esters (92a–g) were synthesized from β-
chloropropenonitrile derivative 91. These thiophene derivatives can be cyclized using 
methodology described in Scheme 21 (2-H), Scheme 22 (2-alkyl), Scheme 23 (2-amino) 
and Scheme 24 (2-oxo).  
 
Scheme 26. Synthesis of methyl 3-amino-thiophene-2-carboxylate from methyl 2-
((acetoxymethyl)thio)acetate
 
a) DCM, Et3N, TiCl3(OiPr); b) hydroxylamine hydrochloride, acetonitrile 
 
Frutos et al.197 regioselectively synthesized  methyl 3-oxotetrahydrothiophene-2 
carboxylate 94 from methyl 2-((acetoxymethyl)thio)acetate using TiCl3(OiPr) and 
triethylamine (Scheme 26).  Oxidation of 94 by boiling hydroxylamine hydrochloride and 
acetonitrile afforded methyl 3-aminothiophene-2-carboxylate, 80, which can be cyclized 
to thieno[3,2-d]pyrimidines using methodology described in Scheme 21 (2-H), Scheme 22 
(2-alkyl), Scheme 23 (2-amino) and Scheme 24 (2-oxo). 
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Scheme 27. Synthesis of key thiophene intermediate using (E)-2-formyl-3-
phenylacrylonitrile 
 
a) H2/Pd, MeOH; b) TsCl, 1.5-diazabicyclo[4.3.0]non-5ene, DCM; c) methyl 2-
mercaptoacetate, NaOMe, MeOH 
 
Another approach to synthesize thiophene intermediate 98 was reported by Ried 
and coworkers (Scheme 27).198 The starting material (E)-2-formyl-3-phenylacrylonitrile 95 
was reduced to 96, which was treated with tosyl chloride to afford (Z)-2-cyano-3-
phenylprop-1-en-1-yl 4-methylbenzenesulfonate 97. The tosyl group was displaced by 
methyl thioglycolate in methanol to give 98 (Scheme 27).  
 
Scheme 28. Synthesis of key thiophene intermediate using one-pot synthesis using O-
ethylthioformate 
 
a) LDA, THF, -40 ⁰C 
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Zhang et al.199 devised a one-pot methodology to synthesize thiophene intermediate 
102a-d (Scheme 28). Treatment of 2-alkyl or aryl substituted acetonitrile 99 sequentially 
with 2.1 equiv of LDA, 1.1 equiv of O-ethyl thioformate 100, and 1.2 equiv of 2-
chloroacetonitrile afforded the thiophenes 102a-d in moderate to good yields.  
 
Figure 31. Proposed mechanism of 102a-d 
The proposed mechanism for this process (Figure 31) involves the deprotonation 
of nitrile 99, followed by a Claisen-like nucleophilic addition of the resulting anion to O-
ethyl thioformate 100 to generate thiolate anion 103 when 1 equiv of LDA was employed. 
The second equivalent of LDA then promotes an elimination reaction of thiolate to afford 
an ethoxide and thiolate anion 104. Upon treatment with 2-chloroacetonitrile, thiolate 104 
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is readily converted to a mixture of isomeric vinyl thiolates 105 and 106. An ethoxide anion 
promotes the isomerization of E-thiolate 106 to Z-thiolate anion 107 and facile cyclization 
of Z-thiolate 107 to the cyclized intermediate 108, which quickly undergoes 
tautomerization to form the desired thiophene 102. 
 
Scheme 29. Synthesis of key thiophene intermediate using methyl thioglycollate 
  
a) NaOMe, MeOH, 2-chloroacrylonitrile, 0 ⁰C 
 
Huddleston and Barker200 synthesized the thiophene intermediate 80 (Figure 29) by 
adding methyl thioglycollate 109 to a solution of sodium methoxide in methanol. A solution 
of 2-chloroacrylonitrile was added dropwise, with stirring, the temperature being 
controlled at 25-30 ⁰C by external cooling. Further workup and chromatographic 
separation afforded thiophene intermediate 80.  
 
Ren and coworkers201 introduced an improved synthesis of 112 (Scheme 30).  The 
in situ generated sodium mercaptoacetonitrile reacted with 110 to give thiophene 111, 
which in turn reacted with guanidine carbonate to afford 112.  
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Scheme 30. Synthesis of 6-substituted-thieno[3,2-d]pyrimidine from acetonitriles 
  
a) S-(cyanomethyl) O-ethyl carbonothioate, NaOMe, MeOH; b) guanidine carbonate, 
NaOMe, MeOH 
 
B.4. Pyrido[3,2-d]pyrimidines 
Scheme 31. Synthesis of 6-chloropyrido[3,2-d]pyrimidine-2,4-diamine from 2,6-
dichloropyridine 
 
a) 90% nitric acid, conc. sulfuric acid, reflux; b) NMP, CuCN, 180 ⁰ C; c) Fe powder, 
conc. HCl, reflux; d) chlorformamidine hydrochloride, dimethyl sulfone, 140 ⁰ C 
 
The 2,4-diamino-6-chloropyrido[3,2-d]pyrimidine 117 (Scheme 31), was obtained 
from 2,6-dichloropyridine 113 via a four-step synthetic procedure.202 The 2,6-
dichloropyridine was nitrated with34 90% nitric acid and sulfuric acid to afford 114. This 
was followed by substitution of the 2-Cl moiety with cuprous cyanide at 180 °C to afford 
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2-cyano-3-nitro-6-chloropyridine 115. Following the reduction of 115 with iron powder in 
acidic methanol to afford the 3-amino-6-chloropicolinonitrile 116. The 2-cyano-3-amino 
function was set up to condense with chloroformamidine hydrochloride in dimethyl sulfone 
to afford the crucial intermediate 117 (85% over four steps). 
 
Scheme 32. Synthesis of 6-substituted pyrido[3,2-d]pyrimidine-2,4-diamine from 6-
chloro-3-nitropicolinonitrile 115 
 
a) Ethoxyethanol, pyridine, 120 ⁰ C, anilines; b) Fe powder, conc. HCl, reflux; c) 
chlorformamidine hydrochloride, dimethyl sulfone, 140 ⁰ C 
 
Gangjee et al.202 synthesized N6-phenylpyrido[3,2-d]pyrimidine-2,4,6-triamines 
120a-c from 6-chloro-3-nitropicolinonitrile 115 by a three step method (Scheme 32). A 
nucleophilic aromatic substitution of appropriate anilines with 115 in ethoxyethanol and 
pyridine at 120 ⁰C for 4 h yielded the compounds 118a-c. Bechaump reduction of 118a-c 
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to 119a-c and later cyclization with chloroformamidine hydrochloride in dimethyl sulfone 
to afford the target compounds 120a-c.  
 
Scheme 33. Synthesis of (E)-6-styrylpyrido[3,2-d]pyrimidine-2,4-diamine from 5-
aminopyrimidine-2,4-diol 
 
a) 20% HCl, reflux, 4 h; b) p-toluenesulfonamide, N,N-dimethylacetamide, substituted 
benzaldehydes, 160 ⁰C, 36 h; c) POCl3, Et3N, reflux, 8 h; d) saturated NH3 in dry 
methanol, 150 ⁰C, 8 h 
 
Wang et al.184 have reported synthesis of (E)-6-styrylpyrido[3,2-d]pyrimidine-2,4-
diamine derivatives 126a-c from  5-aminopyrimidine-2,4-diol 121 (Scheme 33). 
Commercially available 5-aminouracil 121 and crotonaldehyde were cyclized in 20% HCl 
using the Skraup reaction to give 2,4-dihydroxy-6-methylpyrido[3,2-d]pyrimidine 123. 
The 6-methylpyrido[3,2-d]pyrimidine 123 was then reacted with substituted 
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benzaldehydes in the presence of p-toluenesulfonamide using N,N-dimethylacetamide as 
solvent to form (E)-2,4-dihydroxy-6-phenylethylenylpyrido[3,2-d]pyrimidines 124a-c. 
Chlorination of intermediates 124a-c with an excess of POCl3 in the presence of catalytic 
pyridine provided the 2,4-dichloro derivatives 125a-c. Conversion of 125a-c to the 
corresponding 2,4-diamino derivatives  126a-c was achieved using a saturated solution of 
ammonia in dry methanol in a sealed vessel at 150 ⁰C for 8 h.  
 
Scheme 34. Synthesis of pyrido[3,2-d]pyrimidine-2,4-diones from furo[3,4-b]pyridine-
5,7-dione  
 
a) MeOH/reflux; b) (i) ClCO2Et, Et3N, THF, −10°C, (ii) NaN3, H2O, −10°C; c) toluene, 
reflux; d) amino acid, 1 N NaOH, H2O.  
Mamouni et al.203 reported a four step procedure for synthesis of pyrido[3,2-
  77 
d]pyrimidine-2,4-diones from furo[3,4-b]pyridine-5,7-dione (Scheme 34). The 
esterification of pyridine-2,3-dicarboxylic anhydride 127 by methanol afforded a mixture 
of 128 (stable isomer) as a major product and 129 (unstable isomer) as a minor product 
(Scheme 34). Treatment of 2-(methoxycarbonyl)nicotinic acid 128 by ethyl chloroformate 
with triethylamine and sodium azide in the presence of a small amount of water gave the 
methyl 3-(azidocarbonyl)picolinate 130 which was transformed by Curtius rearrangement 
into methyl 3-isocyanatopicolinate 131. The subsequent reaction of isocyanate 131 with 
amino acids under mild conditions by gentle heating led to pyrido[3,2-d]pyrimidinediones 
132a-c. 
 
Scheme 35. Synthesis of 6-aryl-1,3-dimethyl-8-phenylpyrido[3,2-d]pyrimidine-
2,4(1H,3H)-dione from 5-amino-1,3-dimethylpyrimidine-2,4(1H,3H)-dione  
           
 
a) BF3OEt2, toluene, 4 h, reflux 
 
Majmudar et al.204 devised a mild and efficient method for the synthesis of 
pyrido[3,2-d]pyrimidine derivatives 136a-d (Scheme 35) via three-component domino 
reaction of amines, aldehydes, and terminal inactivated alkynes. This method used 
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BF3·OEt2 as Lewis acid catalyst in one pot.  
 
 
Figure 32. Proposed mechanism for the synthesis of pyridopyrimidine derivatives 
 
Mechanistic rationalization for the formation of pyrido[3,2-d]pyrimidine 
derivatives is outlined in Figure 32. Initially, a BF3-catalyzed imine 137 is formed, which 
possesses the aza-heterodiene moiety. This undergoes intermolecular aza-Diels–Alder 
reaction with the ethynylbenzene, which is activated by BF3·OEt2 to give the products 136 
via 139 ↔ 140. 
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III. STATEMENT OF THE PROBLEM 
 
The present section deals with design and molecular modeling studies of compounds in the 
following three areas: 
C.1. Selective pjDHFR inhibitors 
1. 6- and 7-substituted 5-methyl-pyrrolo[2,3-d]pyrimidine-2,4-diamines 
2. N6-substituted pyrido[3,2-d]pyrimidine-2,4,6-triamines 
3. 6-(arylthio)pyrido[3,2-d]pyrimidine-2,4-diamines 
4. 7-(arylthio)pyrido[3,2-d]pyrimidine-2,4-diamines 
C.2. Single agents with combination chemotherapy and multiple RTK inhibitory 
potential  
1. 2-, 4- and 5-substituted pyrrolo[3,2-d]pyrimidines 
2. 2-, 4-, 6- and 7-substituted thieno[3,2-d]pyrimidines 
C.3. Single agents with dual action that target tumors via cellular uptake by Folate 
Receptors and/or Proton-Coupled Folate Transporter and inhibit de novo purine 
nucleotide biosynthesis 
1. 3D QSAR pharmacophore modeling studies for identification of PCFT and 
RFC substrates 
2. 5-substituted 2-amino-3,5-dihydro-4H-pyrrolo[3,2-d]pyrimidin-4-ones 
3. 5-substituted 2-amino-6-methyl-3,5-dihydro-4H-pyrrolo[3,2-d]pyrimidin-4-
ones 
4. 5-substituted 2-amino-3,5-dihydro-4H-pyrrolo[3,2-d]pyrimidin-4-ones with 
heteroatom bridge substitutions 
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C.1. Selective pjDHFR inhibitors 
One of the most efficient strategies to treat PCP infection is to target Pneumocystis 
jirovecii DHFR (pjDHFR).32 DHFR catalyzes the reduction of 7,8-dihydrofolate to the 
5,6,7,8-tetrahydrofolate. Inhibition of DHFR interferes with thymidylate biosynthesis and 
consequently DNA synthesis, and the inhibition of folate-dependent formyl transferases 
causing inhibition of purine synthesis as well.11 This inhibition causes disruption in DNA, 
RNA and protein synthesis of the organism and eventually leads to the death of the 
organism.  
 
 
Figure 33. Superimposition of active sites of pcDHFR and pjDHFR. The blue ribbon and 
amino acid residues co-crystallized with the ligand N6-methyl-N6-(naphthalen-2-
yl)pyrido[2,3-d]pyrimidine-2,4,6-triamine (magenta) represent the active site of pcDHFR 
(PDB: 4QJZ, 1.61 Å)36. The orange ribbon and amino acid residues represent the homology 
model of pjDHFR active site.  
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Pneumocystis infection is host-species specific. Most of the drugs synthesized and 
evaluated thus far for PCP infections were tested against Pneumocystis carinii DHFR 
(pcDHFR), which was presumed to be the causative species of PCP infection in humans.11, 
33 P. carinii however is a distinct species that infects rats, different from P. jirovecii, 
responsible for human infections. The amino acid sequence of the DHFR of P. carinii 
(pcDHFR) differs by 38% when compared to the DHFR of P. jirovecii (pjDHFR).34 
Isolation of pjDHFR along with the development of the homology model for pjDHFR 
provided the amino-acid sequence differences between pjDHFR and pcDHFR, as well as 
hDHFR. The superimposition of the active site of pcDHFR and pjDHFR (Figure 33) 
displays the amino acid differences present in the active sites of the two enzymes and 
underscores the futility of designing and evaluating activity against the surrogate pcDHFR 
as inhibitors of pjDHFR. Hence, drugs evaluated against the surrogate pcDHFR in vitro 
may not translate into activity in the treatment of PCP infection in humans.  
The recently isolated pjDHFR34 has been used to evaluate clinically used agents 
such as TMP (trimethoprim), PTX (piritrexim) and novel DHFR inhibitors.35 These studies 
demonstrated that the inhibition of human(h)DHFR compared with pjDHFR allows a 
selectivity ratio (IC50 hDHFR/ IC50 pjDHFR) that provides a measure of the selectivity of 
the agent for pjDHFR over hDHFR. Compounds, such as PTX and TMQ (trimetrexate) 
due to low selectivity for pjDHFR over hDHFR and are much too toxic, and this explains 
the reason for their discontinuation for the treatment of opportunistic infections. The 
selectivity of TMP for pjDHFR over hDHFR is 266-fold and is an aspect that contributes 
to its clinical success in PCP treatment. However, besides the selectivity for pjDHFR 
another aspect that is highly desirable is its potency for pjDHFR. TMP is a poor inhibitor 
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of pjDHFR and lacks in vivo efficacy against parasitic infections, and must be used with 
SMX. Our long-term goal is to provide analogs with excellent potency along with high 
selectivity for pjDHFR. Such agents could be used alone as well as with sulfonamides and 
other drugs for PCP infections in humans.  
Rational design of pjDHFR inhibitors is hampered due to a lack of X-ray crystal 
structure of pjDHFR. However, homology models can be used with refinement to model 
pjDHFR in the absence of crystal structures.35 Thus along with known hDHFR X-ray 
crystal structures,36 pjDHFR homology models can be used to design potent and selective 
pjDHFR inhibitors. Another significant impediment in the drug discovery of inhibitors of 
pjDHFR is the inability to grow the organism outside the human lung and hence it is 
difficult to develop a tissue culture for in vitro studies or an animal model for in vivo 
evaluation of the synthesized compounds. Due to this drawback, isolation and use of 
pjDHFR enzyme is currently the only direct indicator that a compound could be effective 
(or ineffective) in the treatment of PCP infection in humans. 
In order to study the differences in the active site of pjDHFR and hDHFR, the 
pjDHFR homology model sequence was superimposed on the hDHFR X-ray crystal 
published with pyrido[2,3-d]pyrimidines (Figure 34).35, 36 The amino acid differences are 
displayed. The active site of hDHFR is composed of Phe31, Ile60, Asn64 and Val115. The 
corresponding residues in the active site of pjDHFR are composed of Met33, Leu65, Ser69 
and Ile123. These amino acids possess varied shapes, sizes and electrostatic properties, 
which display different bindings to a potential ligand and can be exploited for selectivity 
and potency over hDHFR 
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Figure 34. Superimposition of active sites of hDHFR and pjDHFR. The amino acid 
residues shown are the residues that are different. The grey ribbon and amino acid residues 
co-crystallized with the ligand N6-methyl-N6-(3,4,5-trifluorophenyl)pyrido[2,3-
d]pyrimidine-2,4,6-triamine (magenta) represent the active site of hDHFR (PDB: 4QJC, 
1.62 Å)36. The orange ribbon and amino acid residues represent the homology model of the 
pjDHFR active site. 
 
C.1.1. Design of 6- and 7-substituted 5-methyl-pyrrolo[2,3-d]pyrimidine-2,4-diamines 
Cody et al.36 published the X-ray crystal structure of hDHFR and pcDHFR with 
several pyrido[2,3-d]pyrimidines. In addition, using the published crystal structures for 
pcDHFR36, the existing homology model of pjDHFR35 was refined to include the cofactor, 
nicotinamide adenine dinucleotide phosphate (NADPH). This refined pjDHFR homology 
model was utilized to evaluate the docking of the proposed compounds in this study. 
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Table 5. Inhibition Concentrations (IC50) against pjDHFR and hDHFR and Selectivity 
Ratios205 
 
# pjDHFR (nM) hDHFR (nM) Selectivity Ratios [hDHFR/pjDHFR] 
141 213 970 5 
TMP 92 24500 266 
PTX 41 2 0.05 
 
Gangjee et al.206 published 6-substituted pyrrolo[2,3-d]pyrimidines as inhibitors of 
pcDHFR (Table 5). Re-evaluation of compound 141 from this previous study,206 indicated 
a moderate inhibitory potency for pjDHFR and marginal selectivity for pjDHFR over 
hDHFR. Since our goal is to obtain potent and selective pjDHFR inhibitors, the discovery 
of 141 provided a lead analog for optimization. We recognized that 141 was overall not as 
good as TMP however it was certainly an improvement in its selectivity over PTX.   
Docking of 141 was carried out in the pjDHFR homology model and hDHFR 
crystal structure (PDB: 4QJC, 1.62 Å),36 in LeadIt 2.1.6.8 using the parameters specified in 
the experimental section (Figure 35). Multiple low energy conformations were obtained on 
docking 141 in the active site of hDHFR and pjDHFR. As a representative example, Figure 
35a shows the best docked conformation of 141 in the pjDHFR homology model. It 
displays a bidentate ionic bond between protonated N1 and the 2-NH2 of 141 with Asp32. 
This interaction is most commonly observed in DHFR crystal structures.207 The 4-NH2 
moiety forms hydrogen bonds with the backbones of Ile10 and Ile123. The pyrrolo[2,3-
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d]pyrimidine scaffold is stabilized by pi-stacking interaction with Phe36. The 3ˊ-
methoxyphenyl moiety is oriented in the pocket formed by Leu25, Met33, Ser64 and 
Leu65. This docked pose generated a docking score of -33.80 kJ/mol. Figure 35b displays 
the best docked conformation of 141 in hDHFR crystal structure (PDB: 4QJC, 1.61 Å).36 
It also exhibits a bidentate ionic interaction of the protonated N1 and 2-NH2 with Glu30. 
The 4-NH2 forms a hydrogen bonding interaction with the backbone of Val8. The 3ˊ-
methoxyphenyl moiety is oriented in the pocket formed by Leu22, Phe31 and Ser69. The 
scaffold is similarly stabilized by pi-stacking interactions with Phe34. This docked pose 
generated a docking score of -29.41 kJ/mol in the hDHFR crystal structure. The N7-H of 
141 orients towards a hydrophobic pocket formed by Phe31 and Leu22 in hDHFR and 
Met33 and Leu25 in pjDHFR (Figure 35).  
 
Figure 35. Docked pose of 141 (cyan) in (a) homology model of pjDHFR and (b) crystal 
structure of hDHFR (PDB: 4QJC, 1.62 Å)36 
Leu22 
(a) (b) 
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Figure 36.  Series I 
 
The amino acid variation of Phe31 (in hDHFR) and Met33 (in pjDHFR) can be 
further exploited to obtain selectivity for pjDHFR. Series I (compounds 142-147, Figure 
36) were designed to accomplish this objective. Met33 (pjDHFR) is comparatively more 
flexible than Phe31 (hDHFR) and hence can lead to different binding interactions with an 
inhibitor. This amino acid variation also affects the size of the hydrophobic pocket and 
therefore appropriate substitution on the N7 of the scaffold can favorably exploit this amino 
acid difference. The predicted distances of N7 in 141 is approximately 5.61 Å from Met33 
in the pjDHFR docked pose and approximately 3.57 Å from Phe31 in the hDHFR docked 
pose (Figure 35). Thus, a methyl substitution on N7 could create favorable hydrophobic 
interactions with Met33 in the pjDHFR active site and an unfavorable clash with Phe31 in 
hDHFR active site. The introduction of the N7-CH3 moiety affords two significant changes 
in the molecule. First, it increases the possible hydrophobic interactions in both pjDHFR 
and hDHFR active sites. The second change is the decrease in the number of low energy 
conformations possible for 142 within 1 kcal/mol, compared to 141, due to the restricted 
rotation of the aryl moiety in the presence of the methyl group. The number of 
conformations possible for 141 and 142 were calculated using Sybyl208 and were found to 
be 122 and 72, respectively. Thus, conformational restriction induced by the N7-CH3 group 
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could provide increased potency. Molecular modeling studies of 142-147 in homology 
model of pjDHFR and X-ray crystal structure of hDHFR displayed favorable binding for 
pjDHFR over hDHFR, compared to the lead compound 141. Thus, it was of interest to 
synthesize N7-alkyl homologs and analogs of 141. 
 
Figure 37. (a) Docked pose of 144 (cyan) in the homology model of pjDHFR; (b) docked 
pose of 144 (cyan) in the crystal structure of hDHFR (PDB: 4QJC, 1.62 Å)36 and (c) 
alternate docked pose of 144 (cyan) in the crystal structure of hDHFR (PDB: 4QJC, 1.62 
Å)36. 
(a) 
(b) (c) 
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 To illustrate the hypothesis, docking of 144 is displayed in the homology model of 
pjDHFR where the N7-propyl moiety displayed binding as predicted. The terminus of the 
propyl chain was at 3.87 Å from Met 33, in pjDHFR (Figure 37a). This pose shows an 
excellent docking score of -35.84 kJ/mol. The modelling of 144 in hDHFR showed two 
distinct poses. The docked scores of the poses as shown in Figure 37b and 37c were -23.89 
kJ/mol and -18.88 kJ/mol, respectively. The low docking scores suggest a less than 
appropriate fit of 144 in the active site of hDHFR in Figure 37c. The flipped pose observed 
in Figure 37c, also, reinforces the possibility of a clash of the propyl moiety with Phe31, 
which could lead to a decreased potency of 144 in the hDHFR enzymatic assay and a 
consequent increase in selectivity for pjDHFR. Molecular modeling studies of 143, 145-
147 were also performed in the homology model of pjDHFR and hDHFR crystal structure. 
All the proposed compounds (Series I, Figure 36) displayed a more favorable docking score 
for pjDHFR than hDHFR, compared to the lead compound 141 (Experimental Section). 
The proposed compounds 142-147 will aid in investigating the optimum length of an 
appropriate substitution at N7 position of pyrrolo[2,3-d]pyrimidine.  
    
 
Figure 38. Series II 
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The pocket where the side chain aryl group binds, is partially composed of Asp24, 
Leu25, Met33, Ser64 and Leu65 in pjDHFR and Asp21, Leu22, Phe31, Ser59 and Ser69 
in hDHFR. Thus, the two active sites have different properties of electrostatics, shape and 
size. To achieve potency and selectivity by targeting these differing residues, the side-chain 
aryl substituents with electron withdrawing, electron donating and sterically bulky groups, 
in place of the 3ˊ-methoxyphenyl group in 142 were chosen for Series II (compounds 148-
154, Figure 38). All the proposed compounds displayed a favorable docking score for 
pjDHFR than hDHFR, similar or better than the lead compound 141 (Experimental 
Section).  
 
Table 6. Inhibition Concentrations (IC50) against pjDHFR and hDHFR and Selectivity 
Ratios202 
# pjDHFR (nM) hDHFR (nM) Selectivity Ratios hDHFR/pjDHFR] 
141 213 970 5 
142 160 1200 8 
TMP 92 24500 266 
PTX 41 2 0.05 
          
   
 
 
 
 
Figure 39. Series III 
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Biological evaluation of 142 against pjDHFR and hDHFR revealed an 1.5-fold 
improvement in activity against pjDHFR and selectivity for pjDHFR versus hDHFR, 
compared to 141.205 Since N7-methylation of 141 afforded an increase in potency and 
selectivity, it was of interest to investigate the effects of N7-methylation of 148-153 (Series 
II) on biological activity to afford Series III (compounds 155-160, Figure 39). All the 
proposed compounds displayed a favorable docking score for pjDHFR than hDHFR, 
similar to 142 and better than 141 (Experimental Section).  
 
C.1.2. Design of N6-substituted pyrido[3,2-d]pyrimidine-2,4,6-triamines 
 
Table 7. Inhibition Concentrations (IC50) against pcDHFR and rlDHFR 
209, 210 
 
# X Y pcDHFR (nM) rlDHFR (nM) 
161 N C 1400 430 
162 C N 6100 500 
 
Gangjee et al.210 published pyrido[2,3-d]pyrimidines and its analogs as inhibitors 
of pcDHFR. Rosowsky et al.209 synthesized and evaluated pyrido[3,2-d]pyrimidines as the 
scaffold replacement of pyrido[2,3-d]pyrimidines. The biological evaluation of pyrido[3,2-
d]pyrimidine 161 in pcDHFR and rat liver DHFR (rlDHFR) displayed a 5-fold increase in 
potency for pcDHFR, compared to its regio analog pyrido[2,3-d]pyrimidine 162  (Table 
7). These results indicated that the scaffold replacement from pyrido[2,3-d]pyrimidine to 
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pyrido[3,2-d]pyrimidine improved the potency for pcDHFR and a similar approach would 
be useful to improve the potency for pjDHFR.   
 
 
Table 8. Inhibition Concentrations (IC50) against pjDHFR and hDHFR and Selectivity 
Ratios36 
 
# 
R pjDHFR 
(nM) 
hDHFR 
(nM) 
Selectivity Ratios 
[hDHFR/pjDHFR] 
163 H 300 190 1 
164 4-CH3 620 2100 3 
165 4-OCH3 400 3650 9 
166 2ˊ,3ˊ-(CH)4 250 2100 8 
167 3ˊ,4ˊ-(CH)4 400 2200 5 
168 3,4,5-triF 870 3100 4 
TMP  92 24500 266 
PTX  41 2 0.05 
 
    
 Gangjee et al.35 reported 6-substituted pyrido[2,3-d]pyrimidines compounds 163-
168 (Table 8). Compounds 163-168 displayed a moderate potency for pjDHFR, but none 
of them were selective for pjDHFR over hDHFR greater than 8-fold. 
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Figure 40. Series IV 
 
Series IV (compounds 169-177, Figure 40) were designed as regio analogs of 163-
168. Compounds 169-172 were designed as analogs of 163-165 (Table 8) to determine the 
influence of the pyrido[3,2-d]pyrimidine system and the electron donating group 
substitution at the side chain aryl group on activity against the pjDHFR and hDHFR. These 
compounds are anticipated to provide a structure activity relationship through electron 
donating groups (inductive and resonance). Compounds 173 and 174 were designed as 
regio analogs of 166 and 167 (Table 8). Due to the bulkier size of the naphthyl group, the 
side chains of these proposed compounds were expected to sterically clash with the side 
chain Phe31 in hDHFR. This clash is avoided in pjDHFR, since the pjDHFR enzyme has 
a flexible Met33 residue instead Phe31 (in hDHFR) at this position. Compounds 175-177 
were designed as analogs of 168 (Table 8). These compounds will evaluate the influence 
of electron withdrawing groups on the side chain aryl moiety. All the proposed compounds 
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displayed a favorable docking score for pjDHFR than hDHFR, better than 163 
(Experimental Section).           
 
Table 9. Inhibition Concentrations (IC50) against pjDHFR and hDHFR and Selectivity 
Ratios35, 202, 205, 211 
 
# 
X Y 
pjDHFR (nM) hDHFR (nM) 
Selectivity Ratios 
[hDHFR/pjDHFR] 
163 N C 300 190 1.60 
169 C N 122 1526 13 
 
Biological evaluation of 169 against pjDHFR and hDHFR displayed an 
improvement of greater than 2-fold in pjDHFR potency, compared to its regio isomer 163 
(Table 9).35, 202 However, its selectivity for pjDHFR over hDHFR significantly improved 
(13-fold), compared to 163.  
 
Table 10. Inhibition Concentrations (IC50) against pjDHFR and hDHFR and Selectivity 
Ratios211 
 
# R1 R2 pjDHFR (nM) hDHFR (nM) 
Selectivity Ratios 
[hDHFR/pjDHFR] 
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163 H H 300 190 1 
178 CH3 H 2.2 57 26 
165 H CH3 620 2100 3 
179 CH3 CH3 2.4 32 13 
 
Figure 41. Series V 
 
The N6-phenylsubstituted pyrido[3,2-d]pyrimidine 169 displayed better activity 
compared to the its pyrido[2,3-d]pyrimidine analog 163 (Table 9). The N6-CH3 analog of 
163, 178 had an improved potency for pjDHFR by interacting with Ile123 via hydrophobic 
interactions (Table 10). Hence, the N6-CH3 analog of 169 would be expected to afford an 
improvement in pjDHFR potency and selectivity over hDHFR. To further evaluate the 
optimum length of the alkyl moiety required to interact with Ile123 (in pjDHFR) and not 
the shorter Val115 (in hDHFR), longer and branched chain alkyl groups were designed for 
evaluation for substitution at the N6-position. Thus, it was of interest to synthesize N6-alkyl 
pyrido[3,2-d]pyrimidines  a shown in Series V (compounds 180-185, Figure 41). 
Compound 185 was included to evaluate the effect of conformationally restricting the 
rotation of phenyl group around the N6-phenyl bond. All the proposed compounds 180-185 
displayed a favorable docking score for pjDHFR over hDHFR, compared to the lead 
compound 169 (Experimental Section). 
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Figure 42. (a) Docked pose of 180 (magenta) and 169 (green) in the homology model of 
pjDHFR; (b) docked pose of 180 (cyan) and 169 (magenta) in the crystal structure of 
hDHFR (PDB: 4QJC, 1.62 Å)36 
Molecular modeling of 169 and 180 in pjDHFR (Figure 42) show the compounds 
display the bidentate ionic bond between the protonated N1 and the 2-NH2 with Asp32. 
The 4-NH2 moiety forms hydrogen bonds with the backbones of Ile10. The pyrrolo[3,2-
d]pyrimidine scaffold is stabilized by pi-stacking interaction with Phe36. The phenyl 
moiety is oriented in the pocket formed by Leu25, Met33, Ser64 and Leu65. The docked 
pose for 169 and 180 generated a docking score of –43.99 kJ/mol and -42.44 kJ/mol, 
respectively. The distance between Ile123 side chain and nitrogen substituted at the 6-
position of pyrido[3,2-d]pyrimidine 169 was 4.94 Å, whereas the distance between Ile123 
side chain and methyl group on the nitrogen substituted at the 6-position of pyrido[3,2-
d]pyrimidine 180 was 3.51 Å. Since all other interactions are similar for 169 and 180, the 
additional N6-CH3 on 180 can potentially have stronger hydrophobic interactions with 
pjDHFR, than 169. Figure 42b displays the best docked conformation of 169 and 180 in 
hDHFR crystal structure (PDB: 4QJC, 1.61 Å).36 The analogs also exhibit a bidentate ionic 
(a) (b) 
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interaction of the protonated N1 and 2-NH2 with Glu30. The 4-NH2 hydrogen bonds with 
the backbone of Ile7. The phenyl moiety is oriented in the pocket formed by Leu22, Phe31 
and Ser59. The scaffold is stabilized by pi-stacking interactions with Phe34. The docked 
pose for 169 and 180 generated a docking score of -35.35 kJ/mol and -37.36 kJ/mol, 
respectively. The distance between Val115 side chain and nitrogen substituted at the 6-
position of the pyrido[3,2-d]pyrimidine 169 was 5.51 Å, whereas the distance between 
Val115 side chain and N6-CH3 of the pyrido[3,2-d]pyrimidine 180 as 4.64 Å. Thus, an 
appropriate alkyl substitution on the nitrogen can lead to compounds that can interact with 
Ile123 (in pjDHFR) and not with Val115 (in hDHFR). This will be evaluated through the 
proposed compounds 180-185.  
 
C.1.3. Design of 6-(arylthio)pyrido[3,2-d]pyrimidine-2,4-diamines 
 
Comparison of active sites of pjDHFR and hDHFR reveal several amino acid 
differences which could be exploited to gain potent and selective pjDHFR inhibitors. For 
instance, Met33/Phe31 in pjDHFR/hDHFR can affect binding due to their distinct steric 
and electronic properties. Biological evaluation of 169 with a nitrogen linker at the 6-
positon of the pyrido[3,2-d]pyrimidine scaffold displayed moderate potency and selectivity 
for pjDHFR (Table 9). It was of interest to perform an isosteric replacement of nitrogen 
with sulfur at the 6-position of 169 to further potentiate the activity for pjDHFR. Compared 
to the lead analog, sulfur and oxygen linked analogs could change bond angle, distance and 
electronics of the side chain aryl group and cause a steric clash with Phe31 in hDHFR, 
whereas they appropriately fit with Met33 in pjDHFR.  
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Table 11. Bond angles and bond distance for C-X-C angle and C-X bond. 
 
Entry X C-X Bond distance (Å) C-X-C Bond angle (⁰ ) 
169 NH 1.38 126 
186 S 1.75 105.3 
187 O 1.37 123.6 
 
Bond angles and bond distances of the energy minimized form for representative 
analogs of 6-substituted pyrido[3,2-d]pyrimidines were calculated using MOE 2016.08.40 
For instance, the increased C-S bond length and reduced C-S-C bond angle (Table 11) 
poses an increase in probability of a steric clash between the side chain aryl ring and the 
Phe31 in hDHFR, and thus decrease binding of such compounds with hDHFR would be 
anticipated. Such a clash is avoided in the binding of 6-substituted sulfur linked pyrido[3,2-
d]pyrimidines to the pjDHFR active site due to the flexible nature of the Met33 side chain 
in place of Phe 31 (hDHFR).  
     
   
   
   
 
Figure 43. Series VI 
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Series VI (compounds 186, 188-197, Figure 43) were designed as extended sulfur 
linked analogs of 169 (Table 9). Compounds 188 and 189 will provide information on the 
influence of electron donating group substitution at the side chain aryl group on activity 
against pjDHFR and hDHFR. Due to the bulkier size of the naphthyl group in 190 and 191, 
the side chains of these proposed compounds could sterically clash with side chain of 
Phe31 (in hDHFR). This clash is avoided in pjDHFR, since the pjDHFR enzyme active 
site has flexible Met33 side chain at the same position where hDHFR active site has Phe31. 
Compounds 192-197 should evaluate the influence of electron withdrawing groups on the 
side chain aryl group and its effect on potency and selectivity towards pjDHFR inhibition. 
 
 
Figure 44. (a) Docked pose of 176 (magenta) and 194 (cyan) in the homology model of 
pjDHFR; (b) docked pose of 176 (magenta) and 194 (cyan) in the crystal structure of 
hDHFR (PDB: 4QJC, 1.62 Å).36 The Phe31 side chain is shown using space filling model 
feature.  
 
Molecular modeling studies of 186, 188-197 (Series VI) in the pjDHFR homology 
model and hDHFR X-ray crystal structure were determined. To illustrate the importance 
(a) 
(b) 
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of the sulfur linker and the substituents on the side chain aryl, molecular modeling studies 
of 194 and its nitrogen linker analog 176 are shown in Figure 44. In pjDHFR, the scaffolds 
interact with the active site as described for its nitrogen linked analog. The docked pose for 
176 and 194 in pjDHFR generated a docking score of -41.09 kJ/mol and -39.06 kJ/mol 
respectively. This suggests that the sulfur linked analog 194 could provide an improved 
binding at the pjDHFR active site. In hDHFR, the docked poses of 176 and 194 displayed 
docking scores of -27.22 kJ/mol and -30.32 kJ/mol, respectively. Phe31 in the active site 
of hDHFR (represented in a space filled model) (Figure 44b) indicated the possibility of a 
steric clash with the trifluorophenyl side chain of 194. The smaller C-S-C angle in 194 
potentiates the risk of such a steric clash, compared to greater C-NH-C angle in 176 (Table 
11) that moves the side chain phenyl away from Phe31. Thus, such sulfur linked analogs 
will show a significantly weaker binding to hDHFR. All the proposed compounds with 
similar structural features as 194 (186-193 and 195-197) displayed a favorable docking 
score for pjDHFR than hDHFR, similar to 194 (Experimental Section). 
 
   
  
 
Figure 45. Series VII 
Sulfur linked compounds are prone to oxidation to their sulfoxide or sulfone 
derivatives on metabolism e.g., thioridazine.212 Similar metabolism can occur on the 6-
substituted sulfur linked pyrido[3,2-d]pyrimidine compounds. Series VII (Compounds 
198-199, Figure 45) were designed as possible metabolite analogs of 191 and their 
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biological evaluation will aid in investigating the activity of such metabolites, in 
comparison to 191. Both the proposed compounds displayed a more favorable docking 
score for pjDHFR than hDHFR, similar to their lead compound 191 (Experimental 
Section). 
 
 
 
 
Figure 46. Series VIII 
 
Series VIII (Compound 187, Figure 46) was designed as an analog of 169 and 186. 
It will aid extend structure activity relationship study at the 6-position heteroatom 
substitution on the pyrido[3,2-d]pyrimidine scaffold. It will also help to evaluate the effect 
of replacement of a hydrogen bond donor -NH- (169) with a hydrogen bond acceptor -O- 
(187). Molecular modeling suggests that the docking score of 187 in the homology model 
of pjDHFR is higher than that of 169 and 186, suggesting that 187 might not display better 
pjDHFR potency than 169 or 186 (Experimental Section). Despite the inappropriate 
docking score of 187 in pjDHFR, biological evaluation of 187 will aid in obtaining an 
optimum heteroaryl substitution at the 6-position on the pyrido[3,2-d]pyrimidine scaffold 
and is considered relevant. 
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C.1.4. Design of 7-(arylthio)pyrido[3,2-d]pyrimidine-2,4-diamines 
 
Table 12. Inhibition Concentrations (IC50) against pjDHFR and hDHFR and Selectivity 
Ratios213 
  
# pjDHFR (nM) hDHFR (nM) Selectivity Ratios [hDHFR/pjDHFR] 
169 122 1526 13 
200 599 32900 55 
TMP 92 24500 266 
PTX 41 2 0.05 
 
Gangjee and coworkers213 have developed several 6-substituted thieno[2,3-
d]pyrimidines as potent and selective pjDHFR inhibitors. Among them, 200 exhibited an 
excellent selectivity of 55-fold for pjDHFR over hDHFR (Table 12). The bulky 
naphthalenethiol side chain can cause steric clash with Phe31 in hDHFR, which could 
explain its inactivity in hDHFR enzyme assay. Despite excellent selectivity, 200 displayed 
a weak inhibition of pjDHFR. Hence to improve its potency, a scaffold replacement of the 
thieno[2,3-d]pyrimidine can be attempted. Pyrido[3,2-d]pyrimidine 169, compared to 200  
displayed a 5-fold improvement in pjDHFR potency. Combining the features from the two 
scaffolds: pyrido[3,2-d]pyrimidine with an arylthio substitution could provide a compound 
with excellent potency and selectivity for pjDHFR.  
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Figure 47. Series IX 
 
Series IX (compounds 201-208, Figure 47) were designed as analogs for 200 and 
169 (Table 12). The 7-subsituted pyrido[3,2-d]pyrimidine compounds were designed by 
employing a scaffold hopping approach from the 5,6-bicyclic system of thieno[2,3-
d]pyrimidines to a 6,6-bicyclic system of pyrido[3,2-d]pyrimidines. The naphthalene 
groups of 201 and 202 due to their bulk could potentiate the steric clash with Phe31 in 
hDHFR and reduce binding to the active site of hDHFR. The 6,6-bicyclic ring could offer 
a deeper penetration of the side chain aryl moiety into the pocket of pjDHFR and could 
thus potentiate the clash with Phe31 in hDHFR, compared to 169 and 200. Compounds 
203-204 will evaluate the influence of electron donating groups on the side chain aryl 
group. Compounds 205-208 will evaluate the influence of electron withdrawing groups on 
the side chain aryl group. All the proposed compounds displayed a favorable docking score 
for pjDHFR than hDHFR, compared to the lead compound 169 and 200 (Experimental 
Section). 
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Figure 48. (a) Docked pose of 202 (cyan) in the homology model of pjDHFR; (b) best 
docked pose of 202 (cyan) in the crystal structure of hDHFR (PDB: 4QJC, 1.62 Å)36 and 
(c) second-best docked pose of 202 (cyan) in the crystal structure of hDHFR (PDB: 4QJC, 
1.62 Å).36 
 
Molecular modeling studies of 202 were performed in pjDHFR displays a perfect 
fit in the active site. In pjDHFR, the scaffolds interact with the active site as described 
previously for the analogs (Figure 48a). The docked pose for 202 in pjDHFR generated a 
docking score of -33.12 kJ/mol. In hDHFR, the best docked poses of 202 showed an 
(a) 
(b) 
(c) 
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inverted pose, with the scaffold binding to the side chain aryl group binding pocket and the 
side chain aryl binding to the pocket where the scaffold generally binds (Figure 48b). This 
unusual inverted pose had a docked score of -26.50 kJ/mol. The reduction in the score 
could be due to the loss of the bidentate interaction of the scaffold with Glu30 of hDHFR. 
The second-best pose displayed a docked pose, which is commonly seen with 
diaminopyrimidine analogs (Figure 48c). In this pose, the bidentate interaction is 
maintained, the docking score was worse at -25.02 kJ/mol, suggesting that 7-substituted 
thioaryl analogs can bind to the pjDHFR active site, but they might not be able to fit and 
bind appropriately to the hDHFR active site. Thus, a subtle size variation on the side chain 
of 7-(arylthio)-pyrido[3,2-d]pyrimidines can create an appropriate fit/clash with amino 
acids (Phe31/Met33: hDHFR/pjDHFR) and can confer selectivity and potency to these 
analogs.  
      
C.2. Single agents with combination chemotherapy and multiple RTK inhibitory 
potential  
 
C.2.1. Design of 2-, 4- and 5-substituted pyrrolo[3,2-d]pyrimidines 
 
Gangjee and coworkers108, 110 reported the design and discovery of novel 
pyrrolo[3,2-d]pyrimidines, some of which possess both RTK (receptor tyrosine kinase) and 
MTA (microtubule targeting agents) activities and displayed potent in vivo antitumor 
activities.  
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Table 13. Inhibition of microtubule polymerization, cellular VEGFR-2, EGFR and 
PDGFR-β RTKs109, 214 110 
 
 
microtubule  
de-
polymerization 
EC50 (nM) 
Cellular RTK Inhibition 
Antiproliferative 
effects 
VEGFR2 
IC50 (nM) ± SD 
PDGFR-β 
IC50 (nM) ± 
SD 
EGFR 
IC50 (nM) ± 
SD 
MDA-MB-435 
IC50 (nM) ± SD 
209 5800 N.D. N.D. N.D. 183 ± 3 
210 1000 N.D. N.D. N.D. 63.2 ± 4.7 
211 807 N.D. N.D. N.D. 61.5 ± 5.6 
212∙HCl 1200 182.3 ± 20.6  250.2 ± 43.0 29.5 ± 3.1 96.6 ± 5.3 
213.HCl 7.4      30.5 ± 5.3 67.0 ± 10.2 25.2 ± 0.41 4.3 ± 0.3 
214.HCl 233.1 80.6 ± 8.2 140.9 ± 19.2 49.2 ± 5.1 42.7 ± 3.2 
215.HCl 39.2 35.7 ± 6.2 29.3 ± 4.8 10.8 ± 1.7 21 ± 3.6 
216.HCl 5700 132.6 ± 22.1 223.2 ± 4.8 132.6 ± 22.1 19.2 ± 1.9 
CA-4 9.8 ND ND ND 4.4 ± 0.5 
sunitinib ND 18.9 ± 2.7 83.1 ± 10.1 ND ND 
erlotinib ND ND ND 1.2 ± 0.2 ND 
 
 
Compounds 209-211 with a pyrrolo[2,3-d]pyrimidine scaffold displayed a 
relatively weak anti-proliferative activity as MTAs (Table 13). Their regio analogs 212-
214 with a pyrrolo[3,2-d]pyrimidines showed a significant improvement in anti-
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proliferative activity and microtubule depolymerization activity by 2 to 16-fold and 5- to 
35-fold, respectively. These analogs also inhibited of EGFR, VEGFR-2 and PDGFR-β 
kinases. Thus, they could inhibit four distinct targets and were single agents with 
combination chemotherapy and multiple RTK inhibitory potential. 
Compound 213, designed as an analog of 212 incorporates an additional 5-CH3 
group. The 5-CH3 group could have two effects: it could allow additional hydrophobic 
interactions with the targets and restrict the rotation around the N-phenyl bond, thus 
providing conformational rigidity which could increase potency. This 5-CH3 moiety led to 
an increase in anti-proliferative activity by 22-fold in 213. Compound 214 and 215 were 
designed as conformationally restricted analogs of 212 and 213, respectively. Compared to 
the N-methylaniline in 212 and 213, the bicyclic quinoline (214 and 215) incorporated on 
the 4-position restricts the conformation of the phenyl ring thereby limiting the rotation 
around the N-phenyl bond, thus affording a much more rigid structure than 212 or 213. 
However, they maintained the phenyl and alkyl substitutions on the N4-position. The 
inhibition of RTKs and microtubule polymerization by 214 and 215 was improved or 
maintained for all the four targets, compared to 212 and 213. Finally, compound 216 was 
designed as an analog of 212 by replacing the 2-CH3 with a 2-H. This replacement led to a 
decreased potency for inhibiting microtubule polymerization and EGFR, but maintained 
and improved the inhibition of PDGFR-β and VEGFR-2, respectively. Thus, subtle 
variation on the scaffolds can  be manipulated to achieve an optimum inhibition of all the 
four targets. Analogs 212-216 were discovered to be potent MTAs with excellent RTK 
inhibitory activities. These attributes make them ideal for the selection of leads for the 
design of multitargeted agents- VEFGR-2, PDGFRβ, EGFR and microtubule assembly. 
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Figure 49. Series X 
 
Series X (Compounds 217-219, Figure 49) were designed as analogs of 216. As 
observed from compounds 212 and 213, a 5-CH3 group (in 213) led to an increase in anti-
proliferative effect and RTK inhibition compared to its 5-H analog (212). The 5-CH3 
substitution on 216 (217) is expected increase potency in antiproliferative assays and RTK 
inhibition. Low energy conformations of the 216 and 217 were generated using Sybyl-X 
2.137 and the number of conformations within 1 kcal/mol obtained were 88 and 53, 
respectively. Thus, 217 displays decreased number of conformations due to conformational 
restriction across bonds ‘a’ and ‘b’. This conformational restriction can lead to an increased 
potency toward the targets. Replacement of 4ˊ-methoxyaniline (212) with 6-
methoxytetrahydroquinoline (214) also restricts the rotation of the unsaturated ring of 
quinoline across N4-phenyl bond. Further compound with methylation at the 5-position of 
the pyrrolo[3,2-d]pyrimidine of 214 (215) displayed a further improvement in the 
inhibition towards all four targets., compared to 214. This suggests that the restricted 
conformation across the N4-phenyl bond is favorable across all the four desired targets. 
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Compounds 218 and 219 were similarly designed replacing the 2- CH3 of 214 and 215 with 
hydrogen.  
 
To better understand the binding of proposed compounds in the colchicine binding 
site and significance of a 5-CH3 group on pyrrolo[3,2-d]pyrimidine compounds, lead 
compound 213 was docked in the X-ray crystal structure of tubulin (PDB: 4O2B, 2.3 Å) 
(Figure 50) using MOE 2016.08.37,215 Multiple low energy conformations were obtained 
on docking. As representative examples, Figure 50 shows the docked conformation of 213 
(cyan) superimposed on the co-crystallized ligand, colchicine (pink). The pyrrolo[3,2-
d]pyrimidine scaffold of 213 forms hydrophobic interactions with Serα178, Alaα180, 
Valα181, Alaβ354 and Metβ259 and occupies the region where the C-ring of colchicine 
binds. The N4-CH3 interacts with Leuβ248, Ileβ318, Thrβ353 and Alaβ354 through 
hydrophobic interactions. The oxygen atom of the 4ˊ-methoxyphenyl group lies within 
hydrogen-bonding distance of a water molecule (3.34 Å), in the crystal structure in the 
vicinity of Cysβ241. Additionally, the N5-CH3 is oriented towards a hydrophobic pocket 
created by Leuβ255, Metβ259, Ileβ278 and Alaβ316, suggesting that alkyl substituents at 
this position can facilitate better biding to the active site of tubulin. The best docked pose 
of 213 had a docked score of -7.21 kcal/mol.  Proposed compounds 217-219 displayed a 
docking score better than -7.21 kcal/mol in tubulin, suggesting an improvement in their 
binding compared to 213.  
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Figure 50. Superimposition of docked pose of 213 (cyan) and colchicine (pink) in tubulin 
(PDB ID: 4O2B). 215 The pink and grey chains represent α and β tubulin, respectively. 
 
 
Figure 51. Cyclopenta[d]pyrimidines 220-221 with MTA activity 
 
Xiang et al.216 designed and evaluated the cyclopenta[d]pyrimidines 220-221 
possessing significant MTA activities (Figure 51). It was noted that replacement of a 4-
methoxyphenyl with 4-methylthiophenyl lead to an improvement in the tubulin assembly 
inhibition by 3-fold.  
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Figure 52. Series XI 
 
Series XI (Compounds 222-225, Figure 52) were designed as the 4-
thiomethylphenyl analogs of 212, 213, 216 and 217. The methoxy group of the lead 
compounds interacts with Cysβ241via a water-mediated hydrogen bonding (Figure 50). 
Series XVII was designed in an attempt to study the effect of replacement of the oxygen 
with sulfur at the 4ˊ-position. It has been widely known that acceptor (or donor) strengths 
correlate with affinity, leading to important insights into the SAR for given scaffolds.217 
Different hydrogen bond acceptors (HBA) can help design molecules with better overall 
properties, as developing a high-affinity inhibitor involves finding a fine balance between 
intermolecular interactions and the unfavorable desolvation penalty suffered when a ligand 
binds to the enzyme or receptor. The strength of HBA based on pKBHX database is as 
follows: dimethylsulfide (0.12) and ether (1.11).218 Based on this data, compounds 222-
225 are designed to engage Cysβ241in the tubulin colchicine binding site with a water-
mediated hydrogen bonding interaction. Sulfides are mild HBA and these compounds will 
also provide insights into the optimum HBA strength. Despite sulfide being a weak HBA, 
its entropic penalty is considerably less than that of an ether, which can lead to an improved 
affinity for the sulfide over ether. Proposed compounds 222-225 displayed a docking score 
lower than -7.21 kcal/mol in tubulin, suggesting an improvement in their binding over that 
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of 213, and in keeping with improvement observed for 220 and 221. 
  
 
        220            226 
Figure 53. Cyclopenta[d]pyrimidines 220 and 226 with MTA activity 
 
Xiang et al.216 also designed and evaluated the 5-methoxynapthalene variation of 
the 4-methoxyphenyl in cyclopenta[d]pyrimidines, which showed excellent MTA 
activities (Figure 53). Compound 226 displayed a 5-fold improvement in antiproliferative 
effect, compared to 220 and was 2-fold better than the standard CA-4. This could be 
attributed to the increased binding of the bulkier compound 226 to the colchicine binding 
site in tubulin.   
 
   
 
  
Figure 54. Series XII 
 
Series XII (Compounds 227-228, Figure 54) were designed as analogs of 213 and 
217. The 5-methoxy naphthalene of 227-228 mimics the 4-methoxyphenyl group of the 
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lead 213 and 217. The oxygen can interact with the Cysβ241 through a water mediated 
hydrogen boding interaction. The 5-CH3 group additionally will potentiate hydrophobic 
interactions with the target and restrict the rotation of the naphthalene group, thus providing 
conformational rigidity which could further increase potency. Proposed compounds 227-
228 displayed a docking score lower than -7.21 kcal/mol in tubulin, suggesting an 
improvement in their binding than 213. 
 
Table 14. Inhibition of Cell Proliferation Activity219, 220  
 
 R T47D GI50 (nM) HCT116 GI50 (nM) ± SD 
229 CH3 6 ± 1 6 ± 1 
230 Cl 1 ± 0.5 2 ± 0.1 
 
Sirisoma et al.219, 220 reported N4-substituted quinazolines derivatives as potent 
apoptosis inducers and anticancer agents (Table 14). Both the compounds exhibited good 
anti-proliferative activity in T47D (ductal carcinoma) and HCT116 (colon carcinoma) cell-
lines. Microtubule assembly was identified as the primary target of these compounds. 
There was no evaluation of these compounds as RTK inhibitors. The 2-Cl substituted 230 
was more potent at inhibiting cell growth than its 2-CH3 derivative 229 by 3 to 6-times. 
Thus, it was of interest to assess the effect of 2-Cl substitution on the pyrrolo[3,2-
d]pyrimidine scaffold of this study. 
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Figure 55. Series XIII 
 
Series XIII (Compounds 231-237, Figure 55) were designed as 2-Cl analogs of 
212-215, 222, 223 and 227. These compounds are expected to have increased inhibition of 
tubulin assembly, while maintaining the required inhibition of targeted RTKs. They 
displayed docking score lowers than -7.21 kcal/mol in tubulin, suggesting an improvement 
in their binding compared to the lead 213. It was of interest to determine if 2-Cl substituent 
retained RTK inhibitory activity. 
Comparison of the pKa of protonated N1 and cLogP for 2-Cl, 2- CH3 and 2-H 
suggests that 2-Cl substitution increases the cLogP and decreases the pKa (Table 15). The 
increased cLogP (increased lipophilicity) will increase passive diffusion of the compound 
and the decreased pKa decreases ionization of the compound at physiological pH.
221 Both 
these effects can increase the intracellular concentration of the proposed compound with 
2-Cl from the Series XIII and improve the antitumor effects, compared to its lead 
compounds with a 2-CH3.  
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Table 15. Calculated LogP and pKa properties of pyrrolo[3,2-d]pyrimidines 
 
 R cLogP pKa 
217 H 3.16 8.40 
213 CH3 3.66 9.30 
233 Cl 3.89 5.70  
cLogP was calculated using ChemDraw 16.0.1.4 
pKa were calculated using ACD labs pKa predictor
83 
To better understand the binding modes of the pyrrolo[3,2-d]pyrimidine 
compounds, molecular modeling studies were carried out using MOE 2016.08,40 in which 
proposed compound 231-237 were docked in the X-ray crystal structure of colchicine 
binding site of tubulin,215 and ATP-binding sites of VEGFR-2222 and EGFR223 and the 
homology model of PDGFR-β.224  
As a representative example, figure 56a shows the docked conformation of 231 
(cyan) superimposed on the co-crystallized ligand, colchicine (yellow). The pyrrolo[3,2-
d]pyrimidine scaffold of 231 forms hydrophobic interactions with Leu348, Ile318, Ala354, 
and Ala316 and occupies the region where the A-ring of colchicine binds. The N4-CH3 
interacts with Ala316, Ile318 and Ala354 through hydrophobic interactions. The oxygen 
atom of the 4ˊ-methoxyphenyl group lies within H-bonding distance of a water molecule 
(3.55 Å). Additionally, N5-H is oriented towards Leu248 and an appropriate substitution 
can make hydrophobic interactions with the amino acid residue. The best docked pose of 
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231 had a score of -6.90 kcal/mol. The binding of 233, the N5-CH3 analog of 231 is similar 
to 231, but showed a better docking score of -7.30 kcal/mol (Figure 56b). All the proposed 
compounds in the series XIII also displayed a docking score within 1 kcal/mol difference 
of -6.90 kcal/mol in tubulin (Experimental Section).   
  
Figure 56. (a) Superimposition of the docked pose of 231 (cyan) and colchicine (yellow) 
in tubulin (PDB ID: 4O2B)215; (b) Superimposition of the docked pose of  231 (cyan) and 
233 (magenta) in tubulin (PDB ID: 4O2B).215 The pink and grey chains represent α and β 
tubulin, respectively 
 
               Figure 57a shows the docked conformation of  231 (cyan) superimposed on the co-
crystallized ligand, axitinib (yellow) in the crystal structure of VEGFR-2.222 The 
pyrrolo[3,2-d]pyrimidine scaffold of 231 is stabilized by H-bonding interactions of N3 
with backbone of Asp1046, cation-π interactions between Lys868 and pyrimidine ring and 
hydrophobic interactions of the scaffold with Val869, Val914 and Val916. The N4-CH3 
(a) (b) 
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group is oriented in the hydrophobic pocket formed by Val 916, Leu1035, Ala1050. The 
N5-H is also oriented in a hydrophobic pocket formed by Val848, Ala866 and Val916. The 
best docked pose of 231 had a score of -7.64 kcal/mol. The binding of compound 233 the 
N5-CH3 analog of 231 is similar to 231, but showed a better docking score of -7.90 
kcal/mol (Figure 57b). The N5-CH3 oriented in the hydrophobic pocket formed by Val848, 
Ala866 and Val916 could be responsible for the docking score and suggests an 
improvement in activity towards VEGFR-2. All the proposed compounds in the series XIII 
also displayed a docking score within 1 kcal/mol difference of -7.64 kcal/mol in VEGFR-
2 indicating these compounds should have VEGFR-2 activity (Experimental Section).   
 
Figure 57. (a) Superimposition of the docked pose of 231 (cyan) and axitinib (yellow) in 
VEGFR-2 (PDB ID: 4AG8);222 (b) Superimposition of the docked pose of 231 (cyan) and 
233 (magenta) in VEGFR-2 (PDB ID: 4AG8)222 
(a) (b) 
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Figure 58. (a) Superimposition of the docked pose of 231 (cyan) and gefitinib (yellow) in 
EGFR (PDB ID: 4WKQ);223 (b) Superimposition of the docked pose of 231 (cyan) and 233 
(magenta) in EGFR (PDB ID: 4WKQ)223 
 
Figure 58a shows the best docked pose of  231 in the X-ray crystal structure of 
EGFR co-crystallized with gefitinib.223 The pyrrolo[3,2-d]pyrimidine scaffold of 231 
forms hydrophobic interactions with Leu718, Val726 and Leu844. The 4ˊ-methoxyphenyl 
group forms hydrophobic interaction with Thr854. The N5-H is at 3.56 Å from a co-
crystallized water molecule. This suggests that an appropriate alkyl substitution can cause 
removal of the water molecule and create significantly higher biding to EGFR via 
hydrophobic interaction.225 The mode of binding of 233 is similar to 231. (Figure 58b). 
The best docked pose of 231 and 233 had docking scores of -6.31 and -6.33 kcal/mol, 
respectively. All the proposed compounds in the series XIII also displayed a docking score 
within 1 kcal/mol difference of -6.31 kcal/mol in EGFR, indicating that EGFR activity 
should be preserved (Experimental Section).     
a b 
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Figure 59. Superimposition of the docked pose of 231 (cyan) and 233 (magenta) in the 
homology model of PDGFR-β.224 
 
The docked conformations of 231 (cyan) and 233 (magenta) in our validated224 
homology model of PDGFR-β indicate that the pyrrolo[3,2-d]pyrimidine scaffold of 231 
and 233 forms hydrophobic interactions with Leu606 and Tyr683 (Figure 59). The 4′-
methoxyphenyl group is oriented in the pocket formed by Ala632, Leu833 and Phe845. 
The N5-H is oriented in the hydrophobic pocket formed lined by Ala632 and Ala848. This 
again suggests that a N5-alkyl substitution would lead to considerable increase in the 
PDGFR-β activity. The docked pose of 233 showed similar binding to the ATP active site, 
similar to 231. The N5-CH3 group forms hydrophobic interaction with Ala832 and Ala848 
at distance of 3.24 Å and 3.97 Å. The best docked poses of 231 and 233 had docking scores 
of -6.61 and -6.73 kcal/mol, respectively. All the proposed compounds in the series XIII 
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also displayed a docking score within 1 kcal/mol difference of -6.61 kcal/mol in PDGFR-
β, suggesting that these analogs would have good PDGFR-β inhibitory activity 
(Experimental Section).     
 
 
Figure 60. Series XIV 
 
Series XIV (Compounds 238, 239, Figure 60) were designed as 2-amino analogs 
of 212 and 213. These compounds are to evaluate the effect of replacing the 2-CH3 with an 
electron donating 2-NH2 group. It will also assess the importance of a hydrogen bond 
donor-acceptor at the 2-position and aids in extending the structure-activity relationship of 
the pyrrolo[3,2-d]pyrimidine scaffold.  
 
    C*- C*-O-CH3 torsion angle = 6 ± 6⁰  
Figure 61. Geometry associated with the low energy conformation of anisole226  
 
  120 
The conformational bias of alkyl aryl ethers can be influenced by a fluorine 
substitution.226 The low energy conformation of anisole, favored by ~3 kcal/mol is where 
the methoxy moiety is coplanar with the phenyl ring (Figure 61). The planar conformation 
is stabilized by interaction between aryl ring π system and oxygen lone pair of electrons, 
which rehybridize to facilitate orbital overlap with the aryl ring. The trifluoromethoxy 
moiety aligns itself orthogonal to the aryl ring and that conformation is favored by ~0.5 
kcal/mol due to the weakened oxygen lone pair donation into the aryl ring.226 Such a 
conformational preference and decreased oxygen lone pair density can influence hydrogen 
bonding with amino acid residues and binding to the active sites.  
 
 
Figure 62. Series XV 
 
Series XV (Compound 240, Figure 62) was designed to evaluate the importance of 
the hydrogen bond acceptor of the 4ˊ-methoxyaniline substitution in 233 and to determine 
the significance of the conformation of the methoxy group with respect to the phenyl ring. 
Molecular modeling studies of 240 in three out of the four targets predicts a similar binding 
to the active site, compared to its methoxy analog 233 (Experimental Section). Its 
biological evaluation will provide the siginificance of contribution of the methoxy group 
to the structure and activity of its analogs.  
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C.2.2. Design of 2-, 4-, 6- and 7- substituted thieno[3,2-d] pyrimidines 
Design and discovery of pyrrolo[2,3-d]pyrimidines, pyrrolo[3,2-d]pyrimidines, 
furo[2,3-d]pyrimidines and cyclopenta[d]pyrimidines as agents with RTK and MTA 
inhibitory activities have been carried out by Gangjee and coworkers.108, 110, 227   
 
Table 16. Inhibition of microtubule polymerization and anti-proliferative activity216  
 
 microtubule depolymerization EC50 (nM) MDA-MB-435 IC50 (nM) ± SD 
216.HCl 5700 193 ± 39 
241 691 50.4 ± 2.4 
242 200 36.9 
CA-4 9.8 4.4 ± 0.5 
 
Compound 242 was designed as a bioisosteric replacement of compounds 216 and 
241 (Table 16).216 To further potentiate the MTA and RTK inhibitory activities, this 
scaffold hopping approach displayed a 5- and 1.5-fold improvement in anti-proliferative 
activity and 28.5- and 3.5-fold improvement in inhibition of microtubule assembly 
compared to 216 and 241 respectively.  
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Table 17. Calculated LogP properties of fused pyrimidines 
 cLogP 
216 3.22 
241 3.31 
242 3.71 
cLogP was calculated using ChemDraw 16.0.1.484 
 
The trend of activity could be explained by the trend in the cLogP values: 
compounds with increased cLogP value displayed increased anti-proliferative effects 
(Table 17). This could be because of increased passive diffusion of these compounds 
intracellularly in cancer cells.  
 
Table 18. Inhibition of cellular VEGFR-2, EGFR and PDGFR-β RTKs by 216.HCl110  
  
Cellular RTK Inhibition 
VEGFR2 
IC50 (nM) ± SD 
PDGFR-β 
IC50 (nM) ± SD 
EGFR 
IC50 (nM) ± SD 
216.HCl 132.6 ± 22.1 223.2 ± 4.8 19.2 ± 1.9 
CA-4 ND ND ND 
sunitinib 18.9 ± 2.7 83.1 ± 10.1 ND 
erlotinib ND ND 1.2 ± 0.2 
 
Multitargeted anticancer agents as combination chemotherapy with separate drugs 
or as single agents with multitargets are designed to circumvent tumor resistance that is 
one of the major contributors to the failure of cancer chemotherapy.106 With the same aim, 
biological evaluation of the pyrrolo[3,2-d]pyrimidine 216 revealed its moderate potency 
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towards VEGFR-2, PDGFRβ and EGFR (Table 18). The thieno[3,2-d]pyrimidine scaffold 
has not been thoroughly explored as RTK inhibitors and MTAs. It is expected that 
compounds designed based on 242 could also have potent MTA and RTK inhibition, as 
observed for 216. To develop a comprehensive evaluation at 2-,4-,6- and 7-position of the 
scaffold, compound 242 was selected as the lead. Since activity is desired across four 
distinct targets, a comprehensive SAR study was initiated to obtain optimized activity for 
multitargeted anticancer agents (inhibitor of microtubule assembly, EGFR, VEGFR-2 and 
PDGFR-β). 
 
 
 
Figure 63. Series XVI 
 
Series XVI (Compounds 243-245, Figure 63) were designed as analogs of 242. 
These compounds will evaluate the effect of electron donating group (243) and electron 
withdrawing group (244, 245) at the 2-position of the scaffold. The effect of the 2-
substituent on its activity also depends on the scaffold i.e., in inhibition of microtubule 
assembly, EGFR, VEGFR-2 and PDGFR-β, 2-NH2 showed the best overall activity for 
pyrimido[4,5-b]indole and 2-CH3 for 7-benzyl pyrrolo[3,2-d]pyrimidines.
108, 228   
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Table 19. Inhibition of microtubule polymerization and anti-proliferative activity216  
 
 microtubule depolymerization EC50 (nM) MDA-MB-435 IC50 (nM) ± SD 
220 25.9 7.0 ± 0.7 
246 10.5 5 ± 0.1 
221 12.6 4.6 ± 0.5 
226 4.5 2.8 ± 0.2 
CA-4 9.8 4.4 ± 0.5 
 
 
Figure 64. Series XVII 
 
Gangjee and coworkers216 evaluated the effect of various N4-subtitutions on 
cyclopenta[d]pyrimidine scaffold (Table 19). In comparison to the 4’-methoxyphenyl, 246 
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was designed as an analog of 220, aimed to potentiate the MTA by restricting the 
conformation of phenyl ring. This afforded an improvement in anti-proliferative and 
inhibition of tubulin assembly. A similar improvement was observed for sulfur analog 221, 
which was designed with the sulfur as a bio-isosteric replacement of the oxygen on the 
phenyl ring. Sulfides can mimic the HBA ability of the ether oxygen with decreased 
desolvation penalty. Compound 226 with a 5-methoxynaphthalene substitution at the N4-
position displayed a 2.5-fold improvement in anti-proliferative effect and a 6-fold 
improvement in disruption in microtubule assembly.  These three variations favorably 
improved the tubulin-associated activities and could be used to improve the activity of the 
thieno[3,2-d]pyrimidines 242 (2-H), 243 (2-NH2) and 244 (2-Cl).  
 
Series XVII (Compounds 247-255, Figure 64) were designed as analogs of 242-
244, based on the cyclopenta[d]pyrimidines series (Table 19) and will evaluate the effect 
of the variation of N4-substitution along with variations of electron donating and electron 
withdrawing groups at the 2-position. The comprehensive evaluation will provide detailed 
understanding of the SAR for the thieno[3,2-d]pyrimidine scaffold. Each of the compounds 
in this series plays an important part as it will define the role of the 4’-substitution on 
potency toward the four distinct targets (microtubule assembly, EGFR, VEGFR-2 and 
PDGFR-β). 
 
  126 
 
Figure 65. Series XVIII 
 
Series XVIII (Compounds 256-259, Figure 65) were designed as analogs of 242, 
247, 250 and 253. The lead compounds are 7-desmethyl compounds. The proposed 
compounds 256-259 have a 7-CH3 substitution, and will determine the SAR of the 
thieno[3,2-d]pyrimidine series at the 7-position. The 7-substitution was proposed based on 
molecular modeling studies, presented below.  
 
The docking studies of the proposed compounds 243-259 and the lead 242 were 
carried out using MOE 2016.08.40 As a representative example, Figure 66a shows the 
docked conformation of the lead 242 (magenta) superimposed on the co-crystallized 
ligand, colchicine (yellow). The thieno[3,2-d]pyrimidine scaffold of 242 forms 
hydrophobic interactions with Leu248, Leu255, Ala354 and Ile378 and occupies the region 
where the C-ring of colchicine binds. The 4-methoxyphenyl forms hydrophobic interaction 
with Met259. Analyzing the lipophilic surface of the pocket indicates a lipophilic surface 
in proximity to the thiophene ring (Figure 66a). The best docked pose of 242 had a score 
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of -7.11 kcal/mol. kcal/mol. The binding of 242 is similar to 256, but showed a better 
docking score of -7.47 kcal/mol (Figure 66b). The 7-CH3 of 256 can form hydrophobic 
interactions with Cys241, Ala354 and Ile378. Compounds 257-259 also displayed a docked 
score in the range of ±1 kcal/mol of -7.11 kcal/mol in the active site of tubulin 
(Experimental Section).   
   
 
Figure 66. (a) Superimposition of the docked pose of 242 (magenta) and colchicine 
(yellow) in tubulin (PDB ID: 4O2B).215 (b) Superimposition of docked pose of 242 
(magenta) and 256 (cyan) in tubulin (PDB ID: 4O2B).215 The pink and grey chains 
represent α and β tubulin, respectively. 
 
(a) (b) 
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Figure 67. (a) Superimposition of the docked pose of 242 (magenta) and axitinib (yellow) 
in VEGFR-2 (PDB ID: 4AG8)222 (b) Superimposition of docked pose 242 (magenta) and 
256 (cyan) in VEGFR-2  (PDB ID: 4AG8) 222 
 
Figure 67a shows the docked conformation of  242 (magenta) superimposed on the 
co-crystallized ligand, axitinib (yellow) in the crystal structure of VEGFR-2.222 The 
thieno[3,2-d]pyrimidine scaffold of 242 is stabilized by H-bonding interactions of N3 with 
the backbone of Asp1046, cation-π interactions between Lys868 and the pyrimidine ring 
and hydrophobic interactions of the scaffold with Val899. The N4-CH3 group is oriented in 
the hydrophobic pocket formed by Leu1035 and Ala1050. The 4-methoxyphenyl forms 
hydrophobic interactions with Val848 and Leu1035 and π-π interaction with Phe1047.The 
best docked pose of 242 had a score of -7.77 kcal/mol. The binding of 256 is similar to 
242, but showed a better docking score of -7.81 kcal/mol (Figure 67b). The 7-CH3 group 
(a) (b) 
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occupies a lipophilic region of the active site (as observed from the lipophilic surface of 
the active site). Compounds 257-259 also displayed a docked score in the range of ±1 
kcal/mol of -7.77 kcal/mol in the active site of VEGFR-2 (Experimental Section).  
 
Figure 68. (a) Superimposition of the docked pose of 242 (magenta) and gefitinib (yellow) 
in EGFR (PDB ID: 4WKQ)223 ( b) Superimposition of docked pose of 242 (magenta) and 
256 (cyan) in EGFR (PDB ID: 4WKQ)223 
 
Figure 68a shows the best docked pose of  242 in the X-ray crystal structure of 
EGFR co-crystallized with gefitinib.223 The thieno[3,2-d]pyrimidine scaffold of 106 forms 
hydrophobic interaction with Thr790. The 4-methoxyphenyl group forms hydrophobic 
interaction with Val726 and Phe793. The mode of binding of 256 is similar to 242. (Figure 
68b). The best docked pose of 242 and 256 had docking scores of -6.24 and -6.61 kcal/mol, 
respectively. Compounds 257-259 also displayed a docked score in the range of ±1 
(b) (a) 
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kcal/mol of -6.24 kcal/mol in the active site of EGFR (Experimental Section) and should 
afford EGFR inhibition.  
 
Figure 69. Docked pose of 242 (magenta) and 256 (cyan) in the homology model of 
PDGFR-β.224 
 
The docked conformations of 242 (magenta) and 256 (cyan) in our validated224 
homology model of PDGFR-β display that the thieno[3,2-d]pyrimidine scaffold of 242 and 
256 forms hydrophobic interactions with Leu606, Ala632, Ala848 and Tyr683 (Figure 69). 
The 4′-methoxyphenyl group is oriented in the pocket formed by Ala632, Leu833 and 
Phe845. Docked pose of 256 showed similar binding to the PDGFR-β active site as 242. 
The best docked poses of 242 and 256 had docking scores of -6.55 and -6.40 kcal/mol, 
respectively. Compounds 257-259 also displayed a docked score in the range of ±1 
kcal/mol of -6.40 kcal/mol in the active site of PDGFR-β (Experimental Section) and 
should be worthwhile to synthesize and evaluate as part of the SAR study for thieno[3,2-
d]pyrimidine as multitargeted agents.  
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Figure 70. Series XIX 
 
Series XIX (Compounds 260 and 261, Figure 70) are 7-CH3 analogs of 243 and 
252. Molecular modeling studies for the 7-methyl-N4-substituted-thieno[3,2-d]pyrimidine 
129 in Figures 66-69 show the presence of hydrophobic surface in proximity of the 
thiophene ring. These proposed compounds could thus have stronger binding to the 
intracellular targets than the lead compounds 243 and 252. Molecular modeling studies of 
260 and 261 in all the four targets (tubulin, EGFR, VEGFR-2 and PDGFR-β) display 
similar docking scores (±1 kcal/mol) as compared to the leads 243 and 252 (Experimental 
Section).  
 
Figure 71. Series XX 
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Series XX (Compound 262, Figure 71) was designed as a 6-CH3 analog of 242. 
Figures 66-69 display a presence of a hydrophobic surface in proximity of the thiophene 
ring. Along with 7-CH3 substituted compounds 256-261, it was of interest to evaluate the 
effect of 6-methyl on the N4- substituted-thieno[3,2-d]pyrimidine. Molecular modeling 
studies of 262 in all the four targets (tubulin, EGFR, VEGFR-2 and PDGFR-β) display 
similar docking scores (±1 kcal/mol) as compared to the lead 242. 
 
 
Figure 72. Series XXI 
 
Series XXI (Compound 263, Figure 72) was designed as an analog of 242. It 
replaces 4’-OCH3 with 4’-OCF3 and can evaluate the importance of the 4’-OCH3 group. 
The trifluoromethoxy group creates a conformational bias on the orientation of the group 
from the phenyl ring.226 The trifluoromethoxy group can create a conformational bias 
effect, as described for 240 (Figures 61 and 62). Thus 240 would be a valuable addition to 
the SAR. 
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C.3. Single agents with dual action that target tumors via cellular uptake by Folate 
Receptors and/or Proton-Coupled Folate Transporter and inhibit de novo purine 
nucleotide biosynthesis 
C.3.1. 3D QSAR pharmacophore modeling studies for identification of PCFT and 
RFC substrates 
RFC is a member of the major facilitative superfamily (MFS) of solute carrier.229 
It is a secondary active anionic exchanger which transports reduced folates by counter 
transport with organic anions. The transport by RFC is optimum at neutral pH (7-7.5) and 
decreases considerably below pH 7.229 PCFT is a proton-folate symporter that functions 
optimally at acidic pH (<7) by coupling the flow of protons down an electrochemical 
concentration gradient against the uptake of folates into the cells. Like RFC, PCFT is also 
a MFS protein, with a 14% amino acid similarity with RFC.135, 230, 231 Clinically used 
antifolate agents, such as, PMX (pemetrexed), PDX (Pralatrexate) and MTX 
(methotrexate), display dose-limiting cytotoxic side-effects, which occur due to their 
transport into normal cells through RFC.229 Given the response-related challenges 
associated with PMX treatment, a promising strategy is to develop agents with selective 
tumor transport for Proton-Coupled Folate Transporter (PCFT) over Reduced Folate 
Carrier (RFC). This can increase specificity for membrane transport by PCFT in cancer 
cells and decrease toxicity in normal cells in which RFC transport is minimal or 
nonexistent. Ideally, these agents will inhibit de novo purine/pyrimidine synthesis and 
circumvent RFC transport related side-effects.  
Cancer cells have increased biosynthetic demand and due to altered metabolism 
undergo aerobic glycolysis (Warburg effect), where cells become highly glycolytic.232, 233 
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Figure 73. General structure of antifolates used in the pharmacophore study 
 
To avoid intracellular acidification, the acid produced in excess is extruded out of the cells 
in their extracellular environment by increased expression of various transport systems:  
H+-ATPases or vacuolar ATPases,234 the Na+/H+ exchanger (NHE1) of the SLA9A 
family,235 monocarboxylate-H+ efflux symporters (MCT1 and MCT4) of the SLC9A 
family,236, 237 carbonic anhydrases (CAIX and CAXII),238 the Cl-/HCO3- Exchanger 
(CBE),239 and the Na+/HCO3- co-transporter (NBC).240 As a result, the tumor cells have 
significant acidification in their extracellular environment (pHe), which is in the range of 
~6.7 to 7.1, while the intracellular pH (pHi) is ≥7.4.134 PCFT-targeted agents can be 
transported to cells in acidic pH and offer a tumor-selective mode of delivery. To achieve 
such a result, Gangjee and coworkers designed, synthesized and evaluated several 
compounds that show high selectivity for tumor transport via PCFT over RFC and display 
highly potent tumor cell inhibition.159, 160, 166, 169, 227, 241-248 These molecules contain a 
bicyclic 6,5-pyrimidine scaffold with a multi-atom linker connecting the bicyclic scaffold 
to a terminal aryl glutamate portion (Figure 73). The intracellular target of some of these 
molecules was found to be GARFTase and/or AICARFTase, which are important enzymes 
in the folate metabolism pathway.134, 160, 166, 241, 242, 246, 249 
Of the three folate transporters (RFC, PCFT, FRs), only the X-ray crystal structures 
of FRs complexed with folic acid and/or antifolates have been reported.140, 160, 249 No crystal 
structure for RFC or PCFT have been resolved, which makes rational design of agents for 
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PCFT-selective transport difficult. PCFT-selective inhibitors are required to develop non-
toxic, targeted therapies and to optimize potential clinical utility for specifically targeting 
solid tumors. Therefore, it was of interest to develop pharmacophores for RFC and PCFT 
to aid in (a) the design of PCFT active-compounds (b) the design of PCFT-selective 
compounds over RFC; and (c) to allow scaffold hopping from known bicyclic fused 
pyrimidines that are PCFT to provide PCFT selective cytotoxic agents.  
 
C.3.2. Design of 5-substituted 2-amino-3,5-dihydro-4H-pyrrolo[3,2-d]pyrimidin-4-
ones 
RFC and PCFT are facilitative folate transporters, whereas FRs (Folate receptors) 
mediate uptake of folates into cells by receptor-mediated endocytosis.229 FRα and FRβ, as 
well as PCFT are narrowly expressed in tissues134, 135 where they perform specialized 
functions such as in the proximal tubules of the kidney where FRα contributes to 
reabsorption of folate from the urine.135 Importantly, FRs in normal tissues are either 
inaccessible to circulating folates (e.g., FRα in renal tubules) or are nonfunctional (e.g., 
FRβ in thymus).135 PCFT is expressed in the upper gastrointestinal tract where it functions 
as the major transporter for dietary folates at acidic pH.131, 230, 231 While PCFT is expressed 
in a number of other normal tissues (e.g., liver, kidney),134 it shows maximum activity at 
acidic pH (pH < 7, optimum at pH 5−5.5),250 thus limiting PCFT mediated folate transport 
in most normal tissues. Several solid tumors (e.g., ovarian, non-small cell lung cancer) 
express PCFT, often together with FRα.160, 248, 251 In tumors FRα is accessible to the 
circulation. Thus selective tumor targeting via PCFT and/or FRs is an attractive approach 
for development of antifolates.138, 252 PCFT is active at the acidic pH typically associated 
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with the tumor microenvironment, which provides additional tumor selectivity.134 FRβ is 
expressed in hematologic malignancies such as acute myeloid leukemia135 and in white 
blood cells of the myeloid lineage135 including tumor-associated macrophages (TAMs).253 
Based on the pattern of expression and functions of FRs, RFC and PCFT in tumors and 
normal tissues, it is possible to design agents with selective targeting. Folic acid-vindesine 
conjugate (vintafolide) was internalized by FRs and its cleavage intracellularly releases the 
cytotoxic vinca alkaloid.254, 255 Another folic acid-tubulysin conjugate is in phase I clinical 
trials.256 In addition small molecule N-[4-[2-propyn-1-yl[(6S)-4,6,7,8-tetrahydro-2-
(hydroxymethyl)-4-oxo-3H-cyclopenta[g]quinazolin-6-yl]amino]benzoyl]-L-γ-glutamyl-
D-glutamic acid (ONX0801) has substrate selectivity for RFs over RFC and has TS as its 
intracellular target.257 In comparison to the conjugates developed, our aim is to design an 
agent with transporter specificity and cytotoxic abilities, which will not require a cleavage 
mechanism intracellularly to release the cytotoxic component. Premature cleavage (before 
reaching the tumor) of the cytotoxic vinca alkaloids or tubulysin results in unacceptable 
toxicities.   
 
Gangjee and coworkers170 synthesized 5-substituted pyrrolo[2,3-d]pyrimidine 
agents as dual-acting inhibitors of glycinamide ribonucleotide formyl transferase 
(GARFTase) and 5-aminoimidazole-4-carboxamide ribonucleotide formyl transferase 
(AICARFTase) in de novo purine nucleotide biosynthesis (Table 20 and 21). These 
compounds were substrates for FRs, PCFT and RFC. Thus, they did not provide tumor-
specificity. PMX (Table 20) has significant uptake through RFC, which is its major 
limitation.  
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Table 20. IC50 Values (nM) for 5-Substituted Pyrrolo[2,3-d]pyrimidine Classical 
Antifolates in RFC-, PCFT-, and FR-Expressing Cell Lines.139, 170  
 
 hRFC hFRα hPCFT 
 PC43-10 R2 RT16 RT16(+FA) R2/hPCFT4 R2(VC) 
PMX 12 ± 1.1  216 ± 8.7 114 ± 31  461 ± 62 120.5 ± 16.8  >1000 
264 68.8 ± 21.2 >1000 72.0 ± 27.1 >1000 329 ± 61 >1000 
265 56.6 ± 5.8 >1000 8.6 ± 2.1 >1000 840 ± 90 >1000 
266 196.4 ± 55.0 >1000 33.5 ± 2.5 >1000 >1000 >1000 
267 >1000 >1000 >1000 >1000 >1000 >1000 
268 >1000 >1000 >1000 >1000 >1000 >1000 
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Table 21. Growth inhibition assays: IC50 Values (nM) for 5-Substituted Pyrrolo[2,3-
d]pyrimidines in KB human tumor sublines (expressing RFC, FRα, and PCFT) and 
protection study results by added metabolites.139, 170 
 
 KB KB (+Thd/Ade/AICA) 
PMX 6.00 ± 0.6 Thd/Ade 
264 49.5 ± 13.2 Ade 
265 12.7 ± 5.4 Ade 
266 17.3 ± 8.9 Ade/AICA 
267 >1000 - 
268 >1000 - 
  
Through 5-substituted pyrrolo[2,3-d]pyrimidines 264 and 265, we have been able 
to circumvent the TS inhibition resistance, as these analogs were inhibitors of GARFTase 
and AICARFTase (Table 21). Dual inhibition in the purine synthesis pathway is beneficial 
as the tumor cell cannot survive in a condition where resistance is developed to one of the 
targets.  Our efforts have been focused on developing agents to achieve: (i) transporter-
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specificity; (ii) dual inhibition of GARFTase and AICARFTase; and (iii) increased KB 
tumor cell inhibition.  
 
 
  
 
 
 
Figure 74. Series XXII 
 
Series XXII (Compounds 269-271, Figure 74) were designed as analogs of 264-
266. These are regio pyrrolo[3,2-d]pyrimidine analogs of the 5-substituted pyrrolo[2,3-
d]pyrimidines. Despite the moderate transporter activity via FRs and PCFT, 264-266 are 
not tumor cell-specific. To investigate the contribution of 7-NH in 264-266 on the uptake 
and intracellular target inhibition, it was interest to design compounds based on a novel 
scaffold. The proposed compounds will evaluate the importance of a hydrogen bond donor 
at the 7-position. Three to five carbon linkers have been proposed in an attempt to achieve 
dual inhibition, as reported for 264 and 265.   
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To understand the binding of these compounds in transporters and intracellular 
targets, molecular modeling studies of 264-266 and 269-270 were carried out in crystal 
structures for FRs,139, 140 GARFTase160 and AICARFTase168 using LeadIt 2.1.6258 and were 
visualized using MOE 2016.08.40 The docking scores of the proposed compounds in all the 
four targets (FRα, FRβ, GARFTase and AICARFTase) were similar to that obtained for 
their respective lead compounds (±4 kJ/mol) (Experimental section).  
 
Figure 75. Molecular modeling studies with human FRα (PDB ID: 5IZQ):139 
Superimposition of docked poses of 265 (magenta) and 270 (cyan).  
 
Figure 75 depicts the binding mode of 265 and 270 in the active site of FRα. For 
both compounds, the 2-NH2 forms a hydrogen bonding interaction with Asp81 and the 4-
oxo interacts with the side chain of Arg103 via hydrogen bond interaction. The scaffold is 
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stabilized by a π-stacking interaction with Tyr85 and Trp134. The acidic groups are in the 
proximity of hydrophilic amino acid residues. The α-COOH forms an ionic bond with 
Lys126 and the γ-COOH forms an ion-dipole interaction with Trp140 and the backbone of 
Gly134. The docking scores for 265 and 270 in FRα were -51.77 kJ/mol and -48.29 kJ/mol, 
respectively. This suggests that 270 would display a transport similar to 265 through FRα.  
 
Figure 76. Molecular modeling studies with human FRβ (PDB ID: 4KNO):140 
Superimposition of docked poses of 265 (magenta) and 270 (cyan).  
 
Figure 76 shows the molecular modeling studies of 265 and 270 in FRβ. The 
scaffold is stabilized by π-stacking interaction with Trp187 and Tyr101. The N1 for both 
compounds interacts via a hydrogen bond with the Arg119 side chain. The α-COOH forms 
ion-dipole interaction with backbone of Arg119 and γ-COOH with Trp156. The docking 
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scores for 265 and 270 in FRβ were -53.99 kJ/mol and -64.54 kJ/mol, respectively. This 
would suggest that 270 would display a higher transport through FRβ than 265 due to its 
higher binding to FRβ than 265.  
 
Figure 77. Molecular modeling studies with human GARFTase (PDB ID: 4ZZ1):247 
Superimposition of docked poses of 265 (magenta) and 270 (cyan).  
 
Figure 77 shows the molecular modeling studies of 265 and 270 in GARFTase. 
Scaffolds for both compounds display similar hydrogen bond interactions in the active site. 
The 4-oxo of 265 interacts with backbone of the Asp951 via a hydrogen bond interaction 
and with the Asp949 backbone via a water-mediated hydrogen bonding. The 4-oxo of 265 
interacts with the Asp949 backbone via a water-mediated hydrogen bonding. The 7-NH 
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for 265 additionally displays an ion-dipole interaction with the side chain of Arg897.  The 
acidic functional groups are extended in a solvent exposed pocket, where the α-COOH 
interacts via an ionic bonding with the Arg871 and γ-COOH with the Arg897. The docking 
scores for 265 and 270 in GARFTase were -67.1 kJ/mol and -60.25 kJ/mol, respectively.  
 
Figure 78. Molecular modeling studies with human AICARFTase (PDB ID: 1P4R):168 
Superimposition of docked poses of 265 (magenta) and 270 (cyan).   
 
Figure 78 shows the molecular modeling studies of 265 and 270 in AICARFTase. 
Scaffolds of 265 and 270 display similar hydrogen bond interactions with the active site- 
the N1 interacts with water, the 2- NH2 forms hydrogen bond with the Asn489 and an ion-
dipole interaction with the Asp546; 3-NH interacts with the Asn 546 via an ion-dipole 
interaction and 4-oxo forms hydrogen bond interaction with Asn547. The scaffold is 
stabilized by a π-stacking interaction with Phe564. The acidic functional groups for 265 
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and 270 show different orientations. For 265, the α-COOH interacts via an ion-dipole 
interaction with the backbone of Ala566.  The γ-COOH of 270 forms hydrogen bonding 
with Ala566. The docking scores for 265 and 270 in AICARFTase were -40.17 kJ/mol and 
-34.14 kJ/mol, respectively.  
 
Figure 79. Superposition of docked pose of 270 in crystal structures for FRα139 (tan), 
FRβ140 (red), GARFTase160 (cyan) and AICARFTase168 (black).  
 
The docking studies of 270 in the targets (Figures 75-78) displayed different 
conformational preferences of the side chain linker in reference to the pyrrolo[3,2-
d]pyrimidine scaffold. Superimposition of the docked poses of 270 was carried out in the 
crystal structures for FRs, GARFTase and AICARFTase enabled visualization of these 
conformations (Figure 79). In reference to the scaffold, the side chains extend at different 
angles to bind to a particular active site. It emphasizes the importance of the necessity of a 
flexible linker, with a specific length to obtain optimal activity at all four targets.  
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Table 22. IC50 Values (nM) for 5-Substituted Pyrrolo[2,3-d]pyrimidine Classical 
Antifolates in RFC-, PCFT-, and FR-Expressing Cell Lines, growth inhibition assays in 
KB human tumor sublines (expressing RFC, FRα, and PCFT) and protection study results 
by added metabolites.169  
 
 hRFC 
(PC43-10) 
hFRα 
(RT16) 
hPCFT 
(R2/hPCFT4) 
KB KB 
(+Thd/Ade/AICA) 
272 59.8 ± 11.1 550 ± 50 80.2 ± 5.5 875 ± 125 - 
273 116.0 ± 22.5 109 ± 44 312 ± 90 211 ± 58 Thd/Ade 
274 38.3 ± 6.6 49.3 ± 11.5 141 ± 40 66.0 ± 14.4 Ade 
275 243.2 ± 49.9 45.5 ± 22.8 57.4 ± 21.4 41.7 ± 10.1 Ade 
276 >1000 >1000 >1000 >1000 - 
277 >1000 >1000 >1000 >1000 - 
 
Gangjee and coworkers169 in an attempt to discover transporter-specific anti-tumor 
agents synthesized and evaluated 5-substituted pyrrolo[2,3-d]pyrimidines with thiophene: 
272-277 with varying chain lengths. These compounds were transported via FRs, PCFT 
and RFC. For the thiophene ring linker, compounds 274 and 275 containing the side chain 
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with three and four carbon linkers displayed dual inhibition of GARFTase and 
AICARFTase (Table 23).  
 
Table 23. IC50 Values (nM) for 5-Substituted Pyrrolo[2,3-d]pyrimidine Classical 
Antifolates in RFC-, PCFT-, and FR-Expressing Cell Lines and in growth inhibition assays 
in KB human tumor sublines (expressing RFC, FRα, and PCFT).160, 169  
 
 hRFC hFRα hPCFT KB 
 PC43-10 RT16 R2/hPCFT4 
278 >1000 6.3 213 1.6 
279 >1000 2 43.4 0.25 
 
Gangjee et al.169, 170 reported GARFTase inhibitors 278 and 279 which showed 
transporter-specificity. The replacement of the phenyl ring in 278 with thiophenyl ring in 
279 improved the transport by FRα by 3-fold; PCFT by 5-fold and KB cell growth 
inhibition by 6-fold. Thus, the replacement of thiophene ring also improved the activity 
towards FRα, PCFT and KB cells, while maintaining the transporter-specificity.  
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Figure 80. Series XXIII 
 
Series XXIII (Compounds 280-282, Figure 80) were designed as analogs of 273-
275 to improve transporter activity and specificity. The lead compounds 274-275 are dual 
inhibitors of GARFTase and AICARFTase, so the proposed compounds are expected to be 
able to inhibit both the intracellular purine synthesis targets. They will also aid in carrying 
out a comprehensive SAR of 5-substituted pyrrolo[3,2-d]pyrimidines. The docking scores 
of the proposed compounds in all four targets (FRs, GARFTase and AICARFTase) were 
similar to that obtained for their respective lead compounds (±4 kJ/mol) (Experimental 
section). 
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C.3.3. Design of 5- substituted 2-amino-6-methyl-3,5-dihydro-4H-pyrrolo[3,2-
d]pyrimidin-4-ones 
  
Figure 81. 7-benzyl pyrrolo[3,2-d]pyrimidine as inhibitors of  EGFR, VEGFR and 
PDGFR-β108  
The flexibility of the linker on the 5-position of the pyrrolo[3,2-d]pyrimidine 
scaffold is required for the compounds’ activities on multiple targets.  The conformation 
which is responsible for binding to PCFT ad RFC is not identified. To obtain an 
understanding of the conformations required to bind to PCFT, FRs and RFC, the flexibility 
of the 5-substituted linker can be manipulated to obtain conformations which can bind to 
PCFT and/or FRS, and not RFC. Several such conformational analyses have been 
performed to achieve increased potency for agents that were designed to inhibit EGFR, 
VEGFR and PDGFR-β. In case of 7-benzyl pyrrolo[3,2-d]pyrimidines, a 5N-CH3 
substitution on 6, led to 283 (Figure 81). The 5N-CH3 of 283 poses a conformational 
restriction to the rotation of the quinolinyl ring and thus limits it in the conformation which 
is conducive to binding to EGFR and increases its potency for inhibiting EGFR by 7-fold, 
compared to 6.108 The conformational restriction induced by the 5N-CH3 of 283 on the 
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contrary did not produce an increase in inhibition for VEGFR-2 and PDGFR-β. Thus, 
conformational restriction can be utilized to obtain pyrrolo[3,2-d]pyrimidines with 
selective uptake by PCFT and/or FRs, over RFC.  
 
 
 
 
 
Figure 82. Series XXIV 
 
Series XXIV (Compounds 284-286, Figure 82) were designed as 6-CH3 analogs of 
269-271 in an attempt to introduce transporter-specificity and improve inhibition for FR α 
and PCFT. The 6-CH3 will pose conformational restriction on the flexible rotation of the 
linker at the 5-position of the pyrrolo[3,2-d]pyrimidine scaffold. The biological evaluation 
of these compounds will provide knowledge of the significance of the conformation of the 
linkers on each of the targets (FRs, PCFT, RFC, GARFTase and AICARFTase).  The 
docking scores of the proposed compounds in all the four targets (FRs, GARFTase and 
AICARFTase) were similar to the ones obtained for their respective leads (±4 kJ/mol) 
(Experimental section). 
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C.3.4. Design of 5- substituted 2-amino-3,5-dihydro-4H-pyrrolo[3,2-d]pyrimidin-4-
ones with heteroatom bridge substitutions 
Table 24. IC50 Values (nM) in RFC-, PCFT-, and FR-Expressing Cell Line and in KB 
human tumor sublines (expressing RFC, FRα, and PCFT).139  
 
 hRFC hFRα hPCFT KB 
PC43-10 RT16 R2/hPCFT4 
287 649 4.1 23 1.7 
288 510 3.64 87.4 0.32 
289 641 1.89 57.5 0.34 
290 >1000 0.34 267 1.66 
 
Golani et al.139 reported 6-substituted pyrrolo[2,3-d]pyrimidines with a three-atom 
chain linker as transporter-specific inhibitors of GARFTase (Table 24). These compounds 
were designed with a heteroatom vicinal to the phenyl ring. The design is based on the 
natural substrate for GARFTase (10-CHOTHF) which has a -CH2N- two atom bridge on a 
6,6 pteridine system. The hetero atom linkers showed improvement in KB activity. There 
was a significant reduction for RFC transport for the sulfur linked compound 290. The 
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variation in activity is due to chain length variation (due to varying C-X bond distances) 
and C-X-C bond angles. 
     
 
 
 
 
Figure 83. Series XXV 
 
Series XXV (Compounds 291-293, Figure 83) were designed as analogs of 270. 
Based on the results obtained on biological evaluation of 287-290 (Table 24), it was of 
interest to synthesize, evaluate and compare the effects of replacing the benzylic CH2 of 
270 with O (291), S (292) and NH (293). The docking scores of the proposed compounds 
in all the four targets (FRα, FRβ, GARFTase and AICARFTase) were similar to the ones 
obtained for 270 (±4 kJ/mol) (Experimental section). 
The bond lengths of C-X follow the trend: C-O < C-NH < C-CH2 < C-S. The C-X-
C bond angle follows the trend: C-S-C < C-CH2-C < C-NH-C < C-O-C (Table 25). Thus, 
replacing the benzylic CH2 can increase or decrease the bond angle and/or bond length. 
Collectively, these structural alterations could impact transport specificity and GARFTase 
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and AICARFTase inhibition and it was of interest to determine how these variations would 
affect biological activity in the new pyrrolo[3,2-d]pyrimidine scaffold.  
 
Table 25. Distances and bond angle variations predicted by the nature of the bridge at the 
benzylic position (X).  
 
 X C-X Bond distance (Å) C-X-C Bond angle (⁰ ) 
270 CH2 2.63 109.5 
291 O 2.42 126.1 
292 S 2.88 99 
293 NH 2.52 111 
     
Bond angles for X = CH2, O and S obtained from literature.
259 Distances and angles for X 
=NH were measured using energy-minimized conformations of compounds with MOE 
2016.08.40  
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IV. CHEMICAL DISCUSSION 
The present section deals with development of synthesis or models for compounds in the 
following three areas: 
D.1. Synthesis of selective pjDHFR inhibitors 
1. 6- and 7-substituted 5-methyl-pyrrolo[2,3-d]pyrimidine-2,4-diamines 
2. N6-substituted pyrido[3,2-d]pyrimidine-2,4,6-triamines 
3. 6-(arylthio)pyrido[3,2-d]pyrimidine-2,4-diamines 
4. 7-(arylthio)pyrido[3,2-d]pyrimidine-2,4-diamines 
D.2. Synthesis of single agents with combination chemotherapy and multiple RTK 
inhibitory potential  
1. 2-, 4- and 5-substituted pyrrolo[3,2-d]pyrimidines 
2. 2-, 4-, 6- and 7-substituted thieno[3,2-d]pyrimidines 
D.3. Single agents with dual action that target tumors via cellular uptake by Folate 
Receptors and/or Proton-Coupled Folate Transporter and inhibit de novo purine 
nucleotide biosynthesis 
1. 3D QSAR pharmacophore modeling studies for identification of PCFT and 
RFC substrates 
2. 5-substituted 2-amino-3,5-dihydro-4H-pyrrolo[3,2-d]pyrimidin-4-ones 
3. 5-substituted 2-amino-6-methyl-3,5-dihydro-4H-pyrrolo[3,2-d]pyrimidin-4-
ones 
4. 5-substituted 2-amino-3,5-dihydro-4H-pyrrolo[3,2-d]pyrimidin-4-ones with 
heteroatom bridge substitutions 
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D.1. Selective pjDHFR inhibitors 
D.1.1. Synthesis of 6- and 7- substituted 5-methyl-pyrrolo[2,3-d]pyrimidine-2,4-
diamines 
Scheme 36. Synthesis of target compounds 141, 148-154 
  
a) malononitrile, TEA, EtOH, r.t., 12 h; b) NaOMe, guanidine HCl, EtOH, reflux, 24 h; c) 
thiophenol, I2, 2:1 EtOH: H2O, reflux, 24 h 
 
The synthetic method for the synthesis of 141, 148-154 utilized a modification of 
the literature method.260 To a solution of hydroxyacetone 294 (Scheme 36) and 
malononitrile in ethanol, triethylamine was added and stirred overnight under argon to 
afford 295. The cyclization of 295 without purification was carried out with guanidine and 
sodium methoxide at reflux to obtain 296. The intermediate 296 was unstable and was used 
for the next step in less than 24 hours. To a solution of iodine and the appropriate thiophenol 
(2:1 ethanol: water), 296 was added and maintained at reflux to give 141 and 148-154. The 
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low yields of 150-154 could be attributed to the electron withdrawing substituents, but it 
could also be due to the unstable intermediate 296. 
 
Scheme 37. Synthesis of target compounds 142, 155-160 
 
a) CH3I, NaH, DMF, r.t., 0.5- 2 h 
 
The pyrrole nitrogen on 141 and 148-153 was methylated using sodium hydride 
and methyl iodide in DMF to afford 142 and 155-160 (Scheme 37).  
 
Scheme 38. Synthesis of target compounds 143-147 
 
a)  R-X, NaH, DMF, r.t., 0.5- 2 h 
 
For the N7-alkylated series, 141 was alkylated using appropriate alkyl halides to 
afford 143-147 (Scheme 38).  
     
 
  156 
D.1.2. Synthesis of N6- substituted pyrido[3,2-d]pyrimidine-2,4,6-triamines 
 
Scheme 39. Synthesis of 169-177 and 180-185 via intermediate 115  
      
a) 90% HNO3, H2SO4, reflux, 3 h; b) CuCN, 180 ⁰ C, 15 min   
 
Intermediate 115 (Scheme 39) was synthesized following the reported 
procedure.258, 261 The 2,6-dichloropyridine 113 was nitrated with 90% nitric acid and 
sulfuric acid, followed by substitution of the 2-Cl moiety with cuprous cyanide at 180 °C 
to afford 2-cyano-3-nitro-6-chloropyridine 115. The structure of 115 was confirmed by 
investigating the coupling constants (J) of the protons [1H-NMR (400 Hz) δ 7.80 (d, J = 
7.2 Hz, 1 H), 8.58 (d, J = 7.2 Hz, 1 H)]. The coupling constants match the characteristic J 
constants for ortho coupling between aromatic protons.262 
 
Scheme 40. Attempted synthesis of 176 via intermediate 297 using pyridine  
 
a) monoethyl glycol, pyridine, 140 °C, 12 h  
 
Following the reported procedure,263 synthesis of 297 (Scheme 40) was attempted. 
Compound 115 was substituted with the 3,4,5-trifluoroaniline in monoethylglycol in the 
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presence of pyridine at 140 °C. The reaction did not yield any product after 12 h. The 
reason for the failure of the reaction could be the low nucleophilicity of the 3,4,5-
trifluoroaniline for carrying out attack on the chloro of 115. 
 
Scheme 41. Synthesis of intermediate 297 using LDA for synthesis of 176 
 
a) LDA, THF, -78 °C, 12 h  
 
In order to carry out the displacement with a weak nucleophile such as 3,4,5-
trifluoroaniline on 297, the methodology reported by Gangjee et al.263 was followed 
(Scheme 41). The 3,4,5-trifluoroaniline was first treated with LDA at -78 °C to afford a 
more reactive nitrogen anion, followed by displacement of the 6-chloro group of 115 to 
afford 297 in 10% yield.  
  
The syntheses of 169-177 and 180-184 for synthesis of 176 were accomplished 
from 115 as shown in Scheme 42. To a solution of 6-chloro-3-nitro-2-pyridinecarbonitrile 
(115) in isopropanol, appropriate aniline was heated at 130 °C (Scheme 42). After 3-16 h, 
the solution was concentrated under reduced pressure to afford 297, 298-309. This step 
using isopropanol afforded increased yields and provided safer conditions, compared to the 
displacement carried out using LDA. During the reduction of 300 to 312 (R2= 4-OCH3), 
the methoxy group undergoes partial ether cleavage in the work up step and afforded two 
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very close spots on the TLC (possibly for 312 and 313).  The mixture was not separated 
and treated for the next step. The nitro compounds 297, 298-309 were reduced using iron 
powder in concentrated hydrochloric acid to afford 310-322 (Bechaump reaction 
conditions).263 The formation of the amino compounds 310-322 is indicated by a blue 
fluorescence on TLC under the UV lamp. The amino compounds 310-322 were not 
separated and advanced to the cyclization step with the impurities. To obtain the target 
compounds, the reported method263 was followed for the cyclization of 310-322 was 
carried out in dimethyl sulfone at 140 ⁰ C to afford 169-177 and 180-184.  
 
Scheme 42. Synthesis of target compounds 169-177, 180-184 
 
a) substituted aniline, isopropanol, 130 ⁰ C, 3-16 h; b) conc. HCl, Fe powder, reflux, 0.5-
2 h; c) chlorformamidine HCl, dimethyl sulfone, 140 ⁰ C, 3-16 h 
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Using the method in Scheme 43, the reaction was a carried out to afford 185 with 1,2,3,4-
tetrahydroquinoline, instead of the substituted anilines.  
 
Scheme 43. Synthesis of target compound 185               
 
a) 1,2,3,4-tetrahydroquinoline, isopropanol, 130 ⁰ C, 10 h; b) conc. HCl, Fe powder, reflux, 
2 h; c) chlorformamidine HCl, Dimethyl sulfone, 140 ⁰ C, 3 h 
 
D.1.3. Synthesis of 6-(arylthio)pyrido[3,2-d]pyrimidine-2,4-diamines 
Intermediate 116 (Scheme 44) was obtained on reduction of 6-chloro-3-
nitropicolinonitrile using iron powder in concentrated hydrochloric acid. New spot for the 
amino derivative 116 appears below the nitro derivative in a 1:2 ethyl acetate: hexane 
solvent system. The spot is notable due to a distinct blue fluorescence on the TLC. The 
cyclization of 6-chloro-3-nitropicolinonitrile 116 with chlorformamidine hydrochloride in 
dimethyl sulfone at 140C afforded 6-chloropyrido[3,2-d]pyrimidine-2,4-diamine 117. 
Without any purification step, the cyclized 117 was reacted with appropriate thiols in 
dimethyl sulfone at 180C to afforded 186 and 188-197 in 19-41% yields over two steps.  
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Scheme 44. Synthesis of target compounds 186 and 188-197 
 
a) conc. HCl, Fe powder, reflux, 2 h; b) chlorformamidine HCl, Dimethyl sulfone, 140 ⁰ C, 
4 h; c) arylthiol, Dimethyl sulfone, 180 ⁰ C 
 
Scheme 45. Synthesis of target compound 198 
 
a) mCPBA, dichloromethane, 0 ⁰ C, 2 h 
 
The conversion of sulfide 191 (Scheme 45) to sulfoxide 198 was  carried out by 
following the reported method.264 The formation of the product was monitored using TLC. 
The sulfide 191 and the sulfoxide 198 showed the same Rf value of 0.25 in MeOH:CHCl3 
(1:5) system, but the sulfoxide 198 was visible as a blue fluorescent spot on the TLC 
(compared to deep brown spot for sulfide 191), which suggested a formation of the product. 
Thus, oxidation of 191 with meta-chloroperoxybenzoic acid in dichloromethane at ⁰ 0 C 
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provided the sulfone analog 198 in 40 % yield. The structure was further confirmed with 
elemental analysis.  
 
Scheme 46. Synthesis of target compound 199 
  
a) H2O2, Glacial acetic acid, r.t., 72 h  
 
The oxidation of sulfide 191 (Scheme 46) to sulfone 199 was carried out using the 
reported procedure.263 Oxidation of 191 with hydrogen peroxide in glacial acetic acid 
provided the sulfone analog 199 in 55 % yield. Similar to the sulfoxide 198 (Scheme 45), 
the sulfone 199 was visible as a blue fluorescent spot on the TLC and the structure was 
further confirmed with elemental analysis.  
 
Scheme 47. Attempted synthesis of target compound 187 from 326 
 
a) Sodium phenoxide, isopropanol, 130 ⁰ C, 12 h 
 
There are no reported methods for synthesis of 3-nitro-6-phenoxypicolinonitrile 
326 in the literature. Following the method developed for the synthesis of 186 and 188-197 
(Scheme 44), the displacement reaction was attempted using sodium phenoxide in 
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isopropanol at 130 ⁰ C for 12 h (Scheme 47). The use of isopropanol as the solvent, caused 
the conversion of the phenoxide to the phenol, decreasing the nucleophilicity of the phenol. 
The reaction yielded no product, possibly due to the low nucleophilicity of the phenol 
compared to aniline. 
 
Scheme 48. Attempted synthesis of target compound 187 via 117 
 
a) Sodium phenoxide, dimethyl sulfone, 190 ⁰ C, 12 h 
 
Using the intermediate 117 (Scheme 44), synthesized previously, the synthesis for 
187 (Scheme 48) was attempted following the method published for thiol displacements 
on 6-chloropyrido[3,2-d]pyrimidine-2,4-diamine 117.263 This method also did not yield the 
targeted compound 187. The electrophilicity of 117 is less than 115, which could be 
responsible for the failure of the reaction.   
 
It was decided that the use of phenoxide anion as a nucleophile would be successful 
in carrying out SNAr displacement on 115. 6-Chloro-3-nitropicolinonitrile 115 (Scheme 
49) was reacted with excess sodium phenoxide in DMF to afford 3-nitro-6-
phenoxypicolinonitrile 326. The use of DMF avoids the reduction of nucleophilicity of 
phenol and the nucleophilic phenoxide anion is strong enough under these conditions to 
attack the electrophilic 115. The subsequent reduction was carried out using catalytic 
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hydrogenation to afford 3-amino-6-phenoxypicolinonitrile 327. Without purification of the 
amino derivative, cyclization of 327 with chlorformamidine hydrochloride in dimethyl 
sulfone at 190 C afforded the target compound 187.  
 
Scheme 49. Synthesis of target compound 187 
 
a) Sodium phenoxide, DMF, r.t., 12 h; b) 10% Pd/C, H2, 55 psi, methanol, r.t., 1 h; c) 
chlorformamidine HCl, dimethyl sulfone, 140 ⁰C, 3 h 
 
 
C.1.4. Synthesis of 7-(arylthio)pyrido[3,2-d]pyrimidine-2,4-diamines 
 
There are no reported methods for synthesis of 7-(arylthio)pyrido[3,2-d]pyrimidine-2,4-
diamines in the literature. The methodology for the synthesis of the 6-(arylthio)pyrido[3,2-
d]pyrimidine-2,4-diamines was followed, as shown in Scheme 50. 3-Nitro-5-
chloropicolinonitrile 328 (Scheme 50) was reduced using iron powder and hydrochloric 
acid to afford 3-amino-5-chloropicolinonitrile 329.  The cyclization of 329 with 
chlorformamidine hydrochloride in dimethyl sulfone at 140 C afforded the intermediate 
7-chloropyrido[3,2-d]pyrimidine-2,4-diamine 330. In the same pot, the displacement 
reaction using the appropriate thiols was carried out without purifying 330 in dimethyl 
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sulfone at higher temperatures afforded target compounds 201-208 in 24-46% yields over 
2 steps. To characterize the 7-position regioisomeric displacement for 201-208 compared 
to 6-position regioisomeric displacement for 186 and 188-197, the coupling constants for 
6-H and 8-H on 207 were investigated. [1H-NMR (500 MHz) (Me2SO-d6) δ 8.16 (d, J = 
2.1 Hz, 1 H, Ar), 7.60 (d, J = 8.9 Hz, 2 H, Ar), 7.45 (s, br, 2 H, NH2, exch.), 7.44 (d, J = 
8.2 Hz, 2 H, Ar), 7.24 (d, J = 2.1 Hz, 1 H, Ar), 6.34 (s, 2H, NH2, exch.)]. The coupling 
constant of 2.1 Hz for 6-H and 8-H on 207 match the characteristic J constants for meta 
coupling between aromatic protons.262 
 
Scheme 50. Synthesis of target compound 201-208 
 
a) conc. HCl, Fe powder, reflux, 2 h; b) chlorformamidine HCl, dimethyl sulfone, 140 ⁰ C, 
4 h; c) arylthiol, dimethyl sulfone, 180 ⁰ C 
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D.2. Single agents with combination chemotherapy and multiple RTK inhibitory 
potential  
C.2.1. Synthesis of 2-, 4- and 5- substituted pyrrolo[3,2-d]pyrimidines 
Scheme 51. Synthesis of target compounds 217, 224 and 225 
 
a) aniline, isopropanol, 130 ⁰ C, microwave; b) sodium hydride, iodomethane, DMF, r.t. 
 
Commercially available 4-chloro-5H-pyrrolo[3,2-d]pyrimidine 331 method 
(Scheme 51) and appropriate anilines were dissolved in isopropanol (12 mL) and heated in 
a microwave reactor at 130 C for 4 hours to afford 216 and 224 using the reported.108 The 
N5-methylation was carried out using sodium hydride and iodomethane with 216 and 224 
to afford 217 and 225 respectively.   
 
Compound 331 (Scheme 52) and 6-methoxy-1,2,3,4-tetrahydroquinoline were 
dissolved in isopropanol (12 mL) and heated in a microwave reactor at 130C for 4 hours 
to afford 218 using a reported method.108 The N5-methylation was carried out using sodium 
hydride and iodomethane with 218 to afford 219. 
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Scheme 52. Synthesis of target compounds 218 and 219 
 
a) 6-methoxy-1,2,3,4-tetrahydroquinoline, isopropanol, 130 ⁰C, microwave; b) 
sodium hydride, iodomethane, DMF, r.t. 2 h 
 
Scheme 53. Synthesis of target compound 228 
 
a) 6-aminonaphthalen-1-ol, isopropanol, 130 ⁰ C, microwave; b) sodium hydride, 
iodomethane, DMF, r.t., 2 h 
 
Commercially available 4-chloro-5H-pyrrolo[3,2-d]pyrimidine 331 (Scheme 53) 
and 6-aminonaphthalen-1-ol were dissolved in isopropanol (12 mL) and heated in a 
microwave reactor at 130 C to afford 6-((5H-pyrrolo[3,2-d]pyrimidin-4-
yl)amino)naphthalen-1-ol 332 using the reported method.108 Methylation of N5, O1ˋ and 
N4 with sodium hydride and iodomethane with 332 afforded 228. 
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Scheme 54. Synthesis of target compounds 222 and 223 
 
a) Hydrochloric acid gas, acetonitrile, r.t., 2h; b) POCl3, reflux, 4 h; c) N-methyl-4-
(methylthio)aniline, isopropanol, 130 ⁰C, 4 h, microwave; d) sodium hydride, 
iodomethane, DMF, r.t. 2 h 
 
 
The synthesis of the bicyclic pyrrolo[3,2-d]pyrimidine 335 (Scheme 54) was 
accomplished by treatment of pyrrole 333 with acetonitrile under acidic conditions.186 The 
2-methyl-4-oxo-pyrrolo[3,2-d]pyrimidine 334 was then chlorinated265 with phosphorus 
oxychloride to generate 2-methyl-4-chloro-pyrrolo[3,2-d]pyrimidine 335 which was 
subjected to a nucleophilic aromatic substitution reaction35 using N-methyl-4-
(methylthio)aniline to afford 222. The N5-methylation was carried out using sodium 
hydride and iodomethane with 222 to afford 223. 
 
Compound 335 (Scheme 55) and 6-aminonaphthalen-1-ol were dissolved in 
isopropanol (12 mL) and heated in a microwave reactor at 130 C to afford 6-((2-methyl-
5H-pyrrolo[3,2-d]pyrimidin-4-yl)amino)naphthalen-1-ol 336 using the reported 
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method.108 Methylation of N5-H, N4H and 5ˋ-OH was carried out using sodium hydride 
and iodomethane with 336 to afford 227.  
 
Scheme 55. Synthesis of target compound 227 
 
a) 6-aminonaphthalen-1-ol, isopropanol, 130 ⁰ C, microwave; b) sodium hydride, 
iodomethane, DMF, r.t. 2 h 
 
Scheme 56. Synthesis of target compounds 231-234 and 240 
 
a) Aniline, isopropanol, 130 ⁰ C, microwave; b) sodium hydride, iodomethane, DMF, r.t. 
  
Commercially available 2,4-dichloro-5H-pyrrolo[3,2-d]pyrimidine 337 (Scheme 
56) and appropriate anilines were dissolved in isopropanol (12 mL) and heated in a 
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microwave reactor at 130C to afford 231, 232 and 338 using the reported method.108 The 
N5-methylation with sodium hydride and iodomethane with 231, 232, and 338 afforded 
233, 234, and 240, respectively.  
 
Scheme 57. Synthesis of target compounds 235 and 236 
 
a) 6-methoxy-1,2,3,4-tetrahydroquinoline, isopropanol, 130 ⁰ C, microwave; b) sodium 
hydride, iodomethane, DMF, r.t. 2 h 
 
Commercially available 2,4-dichloro-5H-pyrrolo[3,2-d]pyrimidine 337 (Scheme 
57) and 6-methoxy-1,2,3,4-tetrahydroquinoline were dissolved in isopropanol (12 mL) and 
heated in a microwave reactor at 130C to afford 235 using the reported method.108 The 
N5-methylation was carried out using sodium hydride and iodomethane with 235 to afford 
236. 
 
Commercially available 2,4-dichloro-5H-pyrrolo[3,2-d]pyrimidine 337 (Scheme 
58) and 6-aminonaphthalen-1-ol were dissolved in isopropanol (12 mL) and heated in a 
microwave reactor at 130C to afford 6-((2-chloro-5H-pyrrolo[3,2-d]pyrimidin-4-
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yl)amino)naphthalen-1-ol 392 using the reported method.108 Methylation of N5, O1ˋ and 
N4 was carried out using sodium hydride and iodomethane with 335 to afford 237.  
 
Scheme 58. Synthesis of target compound 237 
 
a) 6-aminonaphthalen-1-ol, isopropanol, 130 ⁰ C, microwave; b) sodium hydride, 
iodomethane, DMF, r.t., 2 h 
 
Figure 84. 1H-NMR chemical shifts of selected protons in (400 MHz) (DMSO-d6) for 337, 
340 and 231. 
 
To confirm the SNAr reaction at the 4-position of 337, 
1H-NMR studies were carried 
out. Comparing the chemical shift of the proton at 5-NH for 337266 with the chemical shift 
of proton at 5-NH for 231, it is clear that the protons after the displacement with p-
methoxyaniline are shielded by 3 ppm or more (Figure 84). Such a shielding effect, due to 
the anisotropy of the phenyl ring of aniline is only possible if the SNAr attack occurs at the 
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4-position of 337. Similar effect is seen on comparing the chemical shift of proton at 5-NH 
of  340267 with the chemical shift of proton at 5-NH for 231. 
 
Scheme 59. Synthesis of target compound 238 
 
a) 4-methoxy-N-methylaniline, isopropanol, 130 ⁰ C, microwave 
 
Using the reported method,108 N4-(4-methoxyphenyl)-N4-methyl-5H-pyrrolo[3,2-
d]pyrimidine-2,4-diamine 238 (Scheme 59) was synthesized using commercially available 
4-chloro-5H-pyrrolo[3,2-d]pyrimidin-2-amine 341 and 4-methoxy-N-methylaniline using 
isopropanol at 130 ⁰ C in a microwave reactor .  
 
Scheme 60. Synthesis of target compound 239 
 
a) 6-methoxy-1,2,3,4-tetrahydroquinoline, isopropanol, 130 C, microwave 
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Using the reported method,108 4-(6-methoxy-3,4- dihydroquinolin-1(2H)-yl)-5H-
pyrrolo[3,2-d]pyrimidin-2-amine 239 (Scheme 60) was synthesized using commercially 
available 4-chloro-5H-pyrrolo[3,2-d]pyrimidin-2-amine 341 and 6-methoxy-1,2,3,4-
tetrahydroquinoline using isopropanol at 130 ⁰ C in a microwave reactor. 
 
C.2.2. Synthesis of 2-, 4-, 6- and 7- substituted thieno[3,2-d]pyrimidines 
 
Scheme 61. Attempted synthesis of target compound 244 
  
a) 4-methoxy-N-methylaniline, isopropanol, 130 C, 4 h, microwave 
  
For the synthesis of 2-chloro-N-(4-methoxyphenyl)-N-methylthieno[3,2-
d]pyrimidin-4-amine 244  (Scheme 61), the displacement method as previously reported110 
was followed. 2,4-Dichlorothieno[3,2-d]pyrimidine 342 was reacted with 4-methoxy-N-
methylaniline under microwave conditions at 130 ⁰ C. After 2 hours, monitoring the 
reaction through TLC, the reaction showed disappearance of 4-methoxy-N-methylaniline, 
a faint product spot and significant spot for 342. Hence, one equivalent of 4-methoxy-N-
methylaniline was further added and reaction was continued. Chromatographic separation 
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using Combiflash yielded the product which was characterized using 1H-NMR. The 1H-
NMR showed a total of 10 aromatic protons for the compound (Experimental Section), 
whereas the 1H-NMR from 244 should show 6 such aromatic protons. Due to the high 
electrophilicity at both 2-position and 4-position of 342, the SNAr reaction using 4-
methoxy-N-methylaniline afforded N2,N4-bis(4-methoxyphenyl)-N2,N4-
dimethylthieno[3,2-d]pyrimidine-2,4-diamine 343 
 
Scheme 62. Synthesis of target compound 244 
 
a) 4-methoxy-N-methylaniline, isopropanol, r.t., 72 h 
 
To avoid the displacement at both the 2- and 4-positions of the 2,4-
dichlorothieno[3,2-d]pyrimidine 342, the reaction with 4-methoxy-N-methylaniline in 
isopropanol was carried out at room temperature (Scheme 62). The aniline undergoes a 
slow mono displacement and the reaction takes 60 h for completion to afford 2-chloro-N-
(4-methoxyphenyl)-N-methylthieno[3,2-d]pyrimidin-4-amine 244 in 67% yield.  
The regioselectivity of the SNAr attack at the 4 position of 342 has been very well 
determined and addressed in multiple publications.268, 269 Cabrera et al.268 followed the 
reaction procedure as demonstrated in Scheme 62 and used ethanol instead of isopropanol 
in the reaction Using 342 and isobutyl amine, they obtained 348. The X-ray crystal 
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structure of the compound 348 (Figure 85) demonstrated the selective nucleophilic 
substitution at the 4-position.  
   
Figure 85. Chemical structure and X-ray crystal structure of 348268 Reprinted with 
permission from (Gonzàlez Cabrera, D.; Douelle, F.; Le Manach, C.; Han, Z.; Paquet, T.; 
Taylor, D.; Njoroge, M.; Lawrence, N.; Wiesner, L.; Waterson, D.; Witty, M. J.; Wittlin, 
S.; Street, L. J.; Chibale, K., Structure–Activity Relationship Studies of Orally Active 
Antimalarial 2,4-Diamino-thienopyrimidines. Journal of medicinal chemistry 2015, 58, 
7572-7579). Copyright (2015) American Chemical Society. 
 
Scheme 63. Synthesis of target compound 245 
 
a) 4-methoxy-N-methylaniline, isopropanol, 130 ⁰ C, microwave 
 
To synthesize N-(4-methoxyphenyl)-N-methyl-2-(trifluoromethyl)thieno[3,2-
d]pyrimidin-4-amine 245, the SNAr as reported for 216 (Scheme 51)
110 was followed 
(Scheme 63). Commercially available 4-chloro-2-(trifluoromethyl)thieno[3,2-
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d]pyrimidine 344 was reacted with 4-methoxy-N-methylaniline under microwave 
conditions at 130 ⁰ C to afford N-(4-methoxyphenyl)-N-methyl-2-
(trifluoromethyl)thieno[3,2-d]pyrimidin-4-amine 245 in 63% yield.  
 
Scheme 64. Attempted synthesis of target compound 248 
 
a) 4-(methylthio)aniline, isopropanol, 130 ⁰ C, 4 h, microwave; b) sodium hydride, DMF, 
iodomethane, r.t., 2 h 
 
To attain 2-chloro-N-(4-methoxyphenyl)-N-methylthieno[3,2-d]pyrimidin-4-
amine 248 (Scheme 64), the SNAr as reported
110 was adopted. Commercially available 2,4-
dichlorothieno[3,2-d]pyrimidine 342 was reacted with 4-(methylthio)aniline under 
microwave conditions at 130 ⁰ C. However due to the higher electrophilicity at both the 2-
position and 4-position, the product attained was N2,N4-bis(4-
(methylthio)phenyl)thieno[3,2-d]pyrimidine-2,4-diamine 345 in 78% yield. The 
methylation of the aniline nitrogen was carried out using sodium hydride and iodomethane 
with 345 to afford N2,N4-dimethyl-N2,N4-bis(4-(methylthio)phenyl)thieno[3,2-
d]pyrimidine-2,4-diamine 346.  
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Scheme 65. Synthesis of target compound 248 
 
a) 4-(methylthio)aniline, isopropanol, r.t., 72 h; b) sodium hydride, DMF, iodomethane, 
r.t., 2 h 
 
Similar to 2-chloro-N-(4-methoxyphenyl)-N-methylthieno[3,2-d]pyrimidin-4-
amine 244 (Scheme 62), 2,4-dichlorothieno[3,2-d]pyrimidine 342 (Scheme 65) was 
subjected to a SNAr
35 using N-methyl-4-(methylthio)aniline at room temperature for 72 h 
to afford 347. The N4-methylation was carried out using sodium hydride and iodomethane 
to afford 248 in 77% yield. 
 
Scheme 66. Synthesis of target compound 247 
 
a) 4-(methylthio)aniline, isopropanol, 130 ⁰ C, 4 h, microwave; b) sodium hydride, DMF, 
iodomethane, r.t., 2 h 
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For synthesis of N-(4-methoxyphenyl)-N-methyl-2-(trifluoromethyl)thieno[3,2-
d]pyrimidin-4-amine 247, the displacement method reported110 earlier was followed 
(Scheme 66). 4-Chlorothieno[3,2-d]pyrimidine 349 was reacted with 4-(methylthio)aniline 
under microwave conditions at 130 ⁰ C to afford N-(4-(methylthio)phenyl)thieno[3,2-
d]pyrimidin-4-amine 350 in 55% yield.108 The N4-methylation was carried out using 
sodium hydride and iodomethane with 350 to afford N-methyl-N-(4-
(methylthio)phenyl)thieno[3,2-d]pyrimidin-4-amine 247 in 77% yield.  
 
Scheme 67. Synthesis of target compounds 243 and 249 
 
a) 7 N ammonia in methanol, 140 ⁰ C, 60 h, microwave 
 
The syntheses of 2-amino-fused pyrimidines require cyclization using guanidine or 
chlorformamidine or a pseudothiourea derivative, which affords the product with low 
yields over 1-2 steps.185, 206, 270 In order to synthesize 2-amino derivatives of 244 and 248 
with higher yields in one step, 12 mL 7N ammonia in methanol was added in a microwave 
vial with 244 or 248 and the temperature was set at 140 ⁰ C for 10 h (Scheme 67). The 
conversion of 2-chloro to 2-amino was not incomplete after 10 h. The solvent was 
evaporated under reduced pressure and refilled with 12 mL ammonia in methanol and the 
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temperature was set at 140 ⁰ C for 10 h under microwave conditions. This step of 
evaporating and recharging was carried out 4 more times (for a total of 5 times) to obtain 
target compounds 243 and 249 with 2-amino substitutions, using 244 and 248, respectively 
as starting materials.   
 
Scheme 68. Synthesis of target compound 250 
 
a) 6-methoxy-1,2,3,4-tetrahydroquinoline, isopropanol, 130 ⁰ C, 4 h, microwave 
 
The synthesis of 4-(6-methoxy-3,4-dihydroquinolin-1(2H)-yl)thieno[3,2-
d]pyrimidine 250 (Scheme 68), the SNAr reported
110 was followed. 4-Chlorothieno[3,2-
d]pyrimidine 349 was reacted with 6-methoxy-1,2,3,4-tetrahydroquinoline under 
microwave conditions at 130 ⁰ C to afford the target compound 250 in 77% yield.108  
 
Similar to the synthesis of 2-chloro-N-(4-methoxyphenyl)-N-methylthieno[3,2-
d]pyrimidin-4-amine 244 (Scheme 62) described above, the reaction of 2,3-
dichlorothieno[3,2-d]pyrimidine  with 6-methoxy-1,2,3,4-tetrahydroquinoline in 
isopropanol was carried out at room temperature (Scheme 69). The reaction is a slow 
displacement as before, and takes 60 h for completion to afford 2-chloro-4-(6-methoxy-
3,4-dihydroquinolin-1(2H)-yl)thieno[3,2-d]pyrimidine 251 in 79% yield. To obtain the 2-
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amino derivative of 251, 12 mL 7 N ammonia in methanol was added in a microwave vial 
and the reaction was carried out as described for Scheme 69 to afford 4-(6-methoxy-3,4-
dihydroquinolin-1(2H)-yl)thieno[3,2-d]pyrimidin-2-amine 252 in 58% yield.  
 
Scheme 69. Synthesis of target compounds 251 and 252 
 
a) 6-methoxy-1,2,3,4-tetrahydroquinoline, isopropanol, r.t., 60 h; b) 7 N ammonia in 
methanol, 140 ⁰ C, 72 h, microwave  
 
Scheme 70. Synthesis of target compound 253 
 
a) 6-aminonaphthalen-1-ol, isopropanol, 130 ⁰ C, microwave; b) sodium hydride, 
iodomethane, DMF, r.t., 2 h 
  
To synthesize  N-(5-methoxynaphthalen-2-yl)-N-methylthieno[3,2-d]pyrimidin-4-
amine 253 (Scheme 70), the SNAr displacement method reported
110 was followed. 4-
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Chlorothieno[3,2-d]pyrimidine 349 was reacted with 6-aminonaphthalen-1-ol under  
microwave conditions at 130 ⁰ C to afford 6-(thieno[3,2-d]pyrimidin-4-
ylamino)naphthalen-1-ol 352 in 75% yield.108 The N5, O1ˋ and N4-methylation was carried 
out using sodium hydride and iodomethane with 352 to afford N-(5-methoxynaphthalen-2-
yl)-N-methylthieno[3,2-d]pyrimidin-4-amine 253 in 77% yield.  
 
Scheme 71. Synthesis of target compounds 254 and 255 
 
a) 6-aminonaphthalen-1-ol, isopropanol, r.t., 60 h; b) sodium hydride, iodomethane, DMF, 
r.t. 2 h; c) 7N ammonia in methanol, 140 ⁰ C, 60 h, microwave 
 
Similar to the synthesis of 2-chloro-N-(4-methoxyphenyl)-N-methylthieno[3,2-
d]pyrimidin-4-amine 244 (Scheme 62), the reaction of 2,3-dichlorothieno[3,2-
d]pyrimidine 342 with 6-aminonaphthalen-1-ol in isopropanol was carried out at room 
temperature to obtain 6-((2-chlorothieno[3,2-d]pyrimidin-4-yl)amino)naphthalen-1-ol 353 
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(Scheme 71). The N5, O1ˋ and N4-methylation was carried out using sodium hydride and 
iodomethane with 353 to afford 2-chloro-N-(5-methoxynaphthalen-2-yl)-N-
methylthieno[3,2-d]pyrimidin-4-amine 254 in 71% yield. To obtain the 2-amino derivative 
of 254, 12 mL 7 N ammonia in methanol was added in a microwave vial and the reaction 
as carried as explained in Scheme 78, to afford N4-(5-methoxynaphthalen-2-yl)- N4-
methylthieno[3,2-d]pyrimidine-2,4-diamine 255 in 46% yield.  
 
Scheme 72. Synthesis of target compounds 256 and 258 
 
a) Formamide, reflux, 16 h; b) POCl3 reflux, 4 h; c) anilines, isopropanol, 130 ⁰ C, 
microwave, 4 h 
 
Commercially available ethyl 3-amino-4-methylthiophene-2-carboxylate 354 was 
subjected to a condensation with formamide under reflux to afford bicyclic 7-
methylthieno[3,2-d]pyrimidin-4(3H)-one 355 (Scheme 72), following the reported 
procedure.182 The 7-methylthieno[3,2-d]pyrimidin-4(3H)-one 355 was chlorinated with 
phosphorus oxychloride to generate 4-chloro-7-methylthieno[3,2-d]pyrimidine 356 which 
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was subjected to SNAr reaction using the appropriate anilines in isopropanol under 
microwave conditions to afford 256 and 258 in 78% and 63% yields, respectively.  
 
Scheme 73. Synthesis of target compound 257 
 
a) N-methyl-4-(methylthio)aniline, isopropanol, 130 ⁰ C, 4 h, microwave; b) sodium 
hydride, DMF, iodomethane, r.t., 2 h 
 
Using the intermediate 356 generated in Scheme 72, SNAr reaction was carried out 
using N-methyl-4-(methylthio)aniline in isopropanol at 130 ⁰ C for 4 h in a microwave 
reactor to afford 357 (Scheme 73).108  The N4-methylation of 357 was carried out using 
sodium hydride and iodomethane to afford N,7-dimethyl-N-(4-
(methylthio)phenyl)thieno[3,2-d]pyrimidin-4-amine 257 in 86% yield. 
 
Using the intermediate 356 generated in Scheme 72, nucleophilic aromatic 
substitution reaction was carried out using N-methyl-6-aminonaphthalen-1-ol in 
isopropanol at 130 ⁰ C for 4 h in microwave reactor to afford 6-((7-methylthieno[3,2-
d]pyrimidin-4-yl)amino)naphthalen-1-ol 358 in 81% yield (Scheme 74).108  The N4, N5ˊ 
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and O1ˊ-methylation of 358 was carried out using sodium hydride and iodomethane to 
afford N-(5-methoxynaphthalen-2-yl)-N,7-dimethylthieno[3,2-d]pyrimidin-4-amine 259 
in 77% yield. 
 
Scheme 74. Synthesis of target compound 259 
 
a) 6-aminonaphthalen-1-ol, isopropanol, 130 ⁰ C, microwave; b) sodium hydride, 
iodomethane, DMF, r.t. 2 h 
 
Using the reported procedure185, synthesis of 2-amino-5-benzyl-3,5-dihydro-4H-
pyrrolo[3,2-d]pyrimidin-4-one 260 (Scheme 75) was synthesized with  1,3-
bis(methoxycarbonyl)-2-methyl-2-thiopseudourea and ethyl 3-amino-1-benzyl-1H-
pyrrole-2-carboxylate. Following a similar reported method, cyclization of ethyl 3-amino-
4-methylthiophene-2-carboxylate 354 was carried out using 1,3-bis(methoxycarbonyl)-2-
methyl-2-thiopseudourea to afford 2- amino-7-methylthieno[3,2-d]pyrimidin-4(3H)-one 
359 in 78% yield. The amino group of 2-amino-7-methylthieno[3,2-d]pyrimidin-4(3H)-
one 359 was protected using pivalic anhydride to afford tert-butyl (7-methyl-4-oxo-3,4-
dihydrothieno[3,2-d]pyrimidin-2-yl)carbamate 360 in 77% yield. The (7-methyl-4-oxo-
3,4-dihydrothieno[3,2-d]pyrimidin-2-yl)carbamate 360 was chlorinated with phosphorus 
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oxychloride to generate tert-butyl (4-chloro-7-methylthieno[3,2-d]pyrimidin-2-
yl)carbamate 361, which was subjected to SNAr reaction using N-methyl-4-methoxyaniline 
in isopropanol under microwave conditions to afford 362. The carbamate group of 362 was 
deprotected using sodium hydroxide to afford N4-(4-methoxyphenyl)-N4,7-
dimethylthieno[3,2-d]pyrimidine-2,4-diamine 260 in 45% yields, over two steps. 
 
Scheme 75. Synthesis of target compound 260 
 
a) (i) 1,3-bis(methoxycarbonyl)-2-methyl-2-thiopseudourea, MeOH, r.t.,16 h; (ii) NaOMe, 
MeOH, 16 h, r.t.; (iii) 1 N NaOH, 55 ⁰ C, 3 h; b) pivalic anhydride, 60 ⁰ C; 24 h; c) POCl3, 
reflux, 4h; d) N-methyl-4-methoxyaniline, isopropanol, 4 h, 130 ⁰ C, microwave; e) 1 N 
NaOH, methanol 
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Scheme 76. Synthesis of target compound 261 
 
a) 6-methoxy-1,2,3,4-tetrahydroquinoline, isopropanol, 4h, 130 ⁰  C, microwave; b) 1N 
NaOH, methanol, 2 h, r.t.  
 
The tert-butyl(4-chloro-7-methylthieno[3,2-d]pyrimidin-2-yl)carbamate 361 
(Scheme 75), obtained as an intermediate for the synthesis of 260 was subjected to SNAr 
reaction using 6-methoxy-1,2,3,4-tetrahydroquinoline under microwave conditions to 
afford 363 (Scheme 76). The carbamate group of 363 was deprotected using sodium 
hydroxide to afford 4-(6-methoxy-3,4-dihydroquinolin-1(2H)-yl)-7-methylthieno[3,2-
d]pyrimidin-2-amine 261 in 37% yields, over two steps. 
 
The synthesis of target compound 262 (Scheme 77) was attained followed a similar 
procedure, as that for 256 (Scheme 72). Commercially available ethyl 3-amino-5-
methylthiophene-2-carboxylate 364 was subjected to a condensation with formamide 
under reflux to afford bicyclic 6-methylthieno[3,2-d]pyrimidin-4(3H)-one 365.182 The 6-
methylthieno[3,2-d]pyrimidin-4(3H)-one 365 was chlorinated with phosphorus 
oxychloride to generate 4-chloro-6-methylthieno[3,2-d]pyrimidine 366 which was 
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subjected to a SNAr reaction using N-methyl-4-methoxyaniline under microwave 
conditions to afford 262 in 84% yield. 
 
Scheme 77. Synthesis of target compound 262 
 
a) formamide, reflux, 16 h; b) POCl3, reflux, 4 h; d) N-methyl-4-methoxyaniline, 
isopropanol, 4 h, 130 ⁰ C, microwave 
 
Scheme 78. Synthesis of target compound 263 
 
a) N-methyl-4-(trifluoromethoxy)aniline, isopropanol, 4 h, 130⁰ C, microwave 
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N-Methyl- N -(4-(trifluoromethoxy)phenyl)thieno[3,2-d]pyrimidin-4-amine 263  
(Scheme 78) was synthesized via the displacement method reported for 247 (Scheme 66)110 
was followed. 4-Chlorothieno[3,2-d]pyrimidine 349 was reacted with N-methyl-4-
(trifluoromethoxy)aniline in microwave conditions at 130 ⁰ C afforded the target 
compound 263 in 56% yield.108  
 
D.3. Single agents with tumor targeting via cellular uptake by Folate Receptors 
and/or Proton-Coupled Folate Transporter and inhibition of de novo purine 
nucleotide biosynthesis 
D.3.1. 3D QSAR pharmacophore modeling studies for identification of PCFT and 
RFC substrates 
 
Table 26. Structures and activities of the compounds used in the pharmacophore study.  
 
 hPCFT hRFC 
G152160 >1000 54.00 
G163160 >1000 >1000 
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Table 26. Structures and activities of the compounds used in the pharmacophore study 
(contd.) 
 
 Position  X Y Ar hPCFT hRFC 
G94241 6 NH -(CH2)3- 2,5-thiophenyl 3.40 101.00 
G150244 6 NH -(CH2)3- 2,4-thiophenyl 5.39 50.70 
G117244 6 NH -(CH2)4- 2,4-thiophenyl 41.54 >1000 
G71241 6 NH -(CH2)4- 2,5-thiophenyl 43.40 >1000 
G182139 6 NH -(CH2)2O- 1,4-phenyl 57.50 641.00 
G118244 6 NH -(CH2)4- 3,5-thiophenyl 63.82 >1000 
G183139 6 NH -(CH2)2NH- 1,4-phenyl 87.40 510.00 
G72241 6 NH -(CH2)5- 2,5-thiophenyl 101.40 >1000 
G100241 6 NH -(CH2)2- 2,5-thiophenyl 134.80 >1000 
G136169 5 NH -(CH2)4- 2,5-thiophenyl 141.00 38.32 
G126170 5 NH -(CH2)3- 1,4-phenyl 238.5 68.80 
G140139 6 NH -(CH2)2S- 1,4-phenyl 267.00 >1000 
G155241 6 NH -CH2- 2,5-thiophenyl 291.20 >1000 
G135169 5 NH -(CH2)3- 2,5-thiophenyl 396.00 110.00 
G133169 5 NH -CH2- 2,5-thiophenyl 444.60 >1000 
G127170 5 NH -(CH2)4- 1,4-phenyl 840.00 56.60 
G209139 6 NH -(CH2)2NCOCF3- 1,4-phenyl 109.7 626.1 
G137169 5 NH -(CH2)5- 2,5-thiophenyl 574.4 243.20 
G174139 6 NH -CH2)2NCOCH3- 1,4-phenyl 81.70 >1000 
G145245 6 NH -(CH2)6- - >1000 >1000 
G134169 5 NH -(CH2)2- 2,5-thiophenyl 80.2 59.88 
G154244 6 NH -(CH2)3- 3,5-thiophenyl 6.51 189.00 
G128170 5 NH -(CH2)5- 1,4-phenyl >1000 194.6 
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To generate the pharmacophore models, training set of published antifolates was 
used (Table 26). 
 
Material and Methods:271 
1 Data Preparation. 
1.1 Data Preparation for PCFT. A training set of 16 compounds tested against 
CHO cells engineered with PCFT was created, containing fused bicyclic pyrimidines 
linked with varying chain lengths and aromatic side chains. The 3D QSAR module in 
Discovery Studio 16.1.0 (DS) was used to develop the pharmacophore for PCFT. The 2D 
structures sketched in MOE 2016.0940 were used to create the database in DS. The training 
set of compounds was chosen with IC50 values in the range of 3.4 nM to 840 nM. To stretch 
the IC50 values across four orders of magnitudes, rescale function was implemented during 
the input ligands selection.  
 
1.2 Data Preparation for RFC. A training set of 15 compounds tested against CHO 
cells engineered with RFC was created, containing fused pyrimidines linked with varying 
chain lengths and aromatic side chains. The 3D QSAR module in Discovery Studio 16.1.0 
(DS)271 was used in developing the pharmacophore for PCFT. The 2D structures sketched 
in MOE 2016.0940 were used to create the database in DS. The training set of compounds 
was chosen with IC50 values in the range of 38.3 nM to 641 nM. Similar to the set for 
PCFT, to stretch the IC50 values across four orders of magnitudes, rescale function was 
implemented during the input ligands selection.  
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2 Pharmacophore Model Generation. 
2.1 Pharmacophore Model Generation for PCFT. The catalyst HypoGen algorithm 
was used to derive the pharmacophore from the training set of molecules with known 
activity towards PCFT. Conformations of ligands were generated using the BEST method 
to generate 300 conformations with an energy threshold value of 20 kcal/mol. To create 
the pharmacophore hypotheses, the features selected were Hydrogen Bond Donor (HBD), 
Hydrogen Bond Acceptor (HBA), Ring Aromatic (RA) and Negative Ionizable (NI). The 
HypoGen generates the pharmacophore based on the chemical features of active 
compounds in the training set. DS was instructed to generate 10 pharmacophore hypotheses 
using the features and active compounds in the training sets. The minimum spacing 
between the feature points was kept at default 2.97 Å. 
 
2.2 Pharmacophore Model Generation for RFC. The catalyst HypoGen algorithm 
was used to derive the pharmacophore from the training set of molecules with known 
activity towards RFC. All the other parameters were set similar to that described above for 
the pharmacophore model generation for PCFT.  
 
3 Pharmacophore validation and selection. The pharmacophore model is validated 
by using cost analysis, Fisher’s randomization test and test set prediction.  
3.1 Cost Analysis. The HypoGen algorithm selects the best hypotheses from many 
possibilities by applying the cost analysis. The overall cost is the summation of weight 
cost, error cost and configuration cost. The weight component is a value that increases in a 
gaussian form as the feature weight deviates from an ideal value (2.0). The error component 
  191 
increases as the root mean squared difference between the estimated and measured 
activities for the training set molecules increases. The configuration component is a 
constant cost, which depends on the complexity of the hypothesis space being optimized 
and is equal to the entropy of the hypothesis space. The algorithm also calculates theoretical 
costs –null and fixed cost. The overall cost values of the optimized hypotheses should be 
between these fixed cost and null cost. The fixed cost represents the simplest model. Null 
cost is calculated assuming no features. The closer the overall cost is to the fixed cost and 
the further it is from the null cost, the greater statistically significant the hypothesis is.  
 
3.2 Fisher’s randomization test. Fisher’s randomization test was used to perform 
statistical validation to evaluate the significance of the pharmacophore models. The 95% 
and 90% confidence levels were selected to validate the study for the PCFT model and the 
RFC model, respectively.  
   
3.3 Test set prediction. The set of 5 published compounds tested for PCFT activity was 
used to create the test set for PCFT. These compounds were then scanned using the Ligand 
pharmacophore mapping function` in DS with the BEST conformation generation tool and 
flexible fitting method through the PCFT pharmacophore model. The set of 3 published 
compounds tested for RFC activity was used to create the test set for RFC. These 
compounds were then scanned using the Ligand pharmacophore mapping function in DS 
with the BEST conformation generation tool and flexible fitting method through the RFC 
pharmacophore model. 
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Results and Discussion: 
A. PCFT pharmacophore model. 
 
Table 27. Statistical results of the generated pharmacophore models for PCFT. 
Hypo Confidence 
level (%) 
Total 
cost 
∆Costa RMSb Correlationc Maximum 
FitValued 
Features 
A1 95 73.9
1 
70.42 0.923 0.965 9.53 HBA, NI, RA 
A2 95 79.3
4 
64.97 1.244 0.935 9.42 HBA, HBD, 
NI, RA 
A3 95 79.6
3 
64.70 1.189 0.942 10.45 HBA, NI, RA 
A4 95 79.7
3 
64.61 1.210 0.939 10.24 HBA, HBD, 
NI, RA 
A5 95 79.9
9 
64.34 1.167 0.945 10.86 HBA, NI, RA 
A6 95 80.1
7 
64.16 1.284 0.940 9.40 HBA, HBD, 
NI 
A7 90 80.8
2 
63.51 1.215 0.940 10.82 HBA, HBD, 
NI 
A8 90 81.3
8 
62.95 1.215 0.940 11.09 HBA, HBD, 
NI 
A9 90 82.0
6 
62.27 1.358 0.922 9.72 HBA, NI, RA 
A10 85 83.2
2 
61.11 1.453 0.910 8.27 HBA, HBD, 
NI, RA 
Fixed cost = 66.295; Null cost = 144.33; aCost difference = Null cost- Total cost; bRMS is 
the deviation of log (estimated activity) from log (measured activity) normalized to log 
(uncertainty); cCorrelation is the coefficient based on linear regression derived from the 
geometric fit index; dMaximum FitValue is the highest FitValue obtained for the best 
compound in the pharmacophore 
 
A.1 Pharmacophore Generation for PCFT. The top 10 hypotheses for PCFT 
pharmacophores were generated using the HypoGen algorithm in DS using HBA, HBD, 
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HA and NI features. The cost values, correlation, RMS, maximum FitValue and features 
of the 10 hypotheses are summarized in Table 27.  
 
A.2 Pharmacophore Validation for PCFT.  
(a) Cost analysis: The model is validated by the difference between null cost and total cost. 
If the difference between the costs is greater than 60, then the model has an excellent 
chance to represent a true correlation (>90% probability). If the difference is between 40-
60, then there is high probability (75-90%) that the pharmacophore is correlated. All the 
10 hypotheses generated showed that the cost differences were greater than 60; suggesting 
that they represent high correlation (Table 27).  
 
(b) Fisher’s randomization test: Using the fisher randomization the activity of the training 
set of compounds was randomly scrambled. This is used to create a random pharmacophore 
using the same parameters as described for the HypoGen hypotheses. Confidence level of 
95% was set and it created 19 columns. All the 19 columns had higher cost values than 
Hypo-A1-A10 (Experimental section) and lower correlation than Hypo-A1-A10 
(Experimental section). Since Hypo-A1-A6 displayed a confidence level of greater than 
95%, Hypo-A1-A6 are statistically sound and there is a 95% chance that Hypo-A1-A6 
represents a true correlation in the training set activity data. Hypo-A1 presents the highest 
correlation of 0.965, suggesting a linear dependence of the experimental and estimated 
activities. Hypo-A1 also displays the lowest RMS, suggesting a highly accurate predictive 
model. Hence, we selected Hypo-A1 as the model for predicting PCFT activities.  
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Table 28. Actual IC50 values and estimated IC50 values of 16 training set compounds and 
5 test set molecules compounds through the pharmacophore Hypo-A1 (A-active M-
moderately active) 
 Actual IC50 
(nM) 
Extended 
IC50 (nM) 
Estimated 
IC50 (nM) 
Error FitValue Status 
G94 3.40 3.4 3.4 1.00 9.18 A 
G150 5.39 7.3 13 1.80 8.61 A 
G117 41.54 220 430 1.90 7.08 M 
G71 43.40 240 310 1.30 7.23 M 
G182 57.50 380 600 1.60 6.94 M 
G118 63.82 460 340 -1.30 7.18 M 
G183 87.40 770 690 -1.10 6.87 M 
G72 101.40 990 620 -1.60 6.92 M 
G100 134.80 1600 2500 1.60 6.31 M 
G136 141.00 1700 2600 1.50 6.30 M 
G126 238.5 4100 5900 1.40 5.94 M 
G140 267.00 5000 1000 -5.00 9.71 M 
G155 291.20 5800 9300 1.60 5.75 M 
G135 396.00 9700 5000 -2.00 6.02 M 
G133 444.60 12000 21000 1.80 5.39 M 
G127 840.00 34000 12000 -2.90 5.65 M 
G209* 109.7 - 126.45 1.20 7.61  
G137* 574.4 - 366.30 1.60 7.15  
G174* 81.70 - 78.03 -1.05 7.82  
G163* >1000 - 52227.28 - 6.00  
G145* >1000 - 2279.09 - 6.36  
* are the compounds in the test set. 
 (c) Test set prediction: To further validate Hypo-A1, 5 reported PCFT compounds were 
analyzed to check the predictive capability of Hypo-A1. The Ligand Pharmacophore 
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Mapping protocol was implemented using FAST conformation generation to consider 300 
conformations and considering the maximum omitted features as -1 and flexible fitting 
method. All the compounds in the test set gave prediction with less than 5% error (Table 
28). On the basis of the training set prediction, test set prediction, fisher validation and cost 
analysis, Hypo-A1 shows a clear ability to classify active and inactive PCFT compounds.  
 
 
                 
 
Figure 86. (a) Plot of correlation between the experimental and the Hypo-A1 estimated 
PCFT activity values of the 16 training set compounds; (b) Chemical features of Hypo-A1. 
Green color represents HBA, orange represents an aromatic ring and blue represents a 
negative ionizable feature; (c) Hypo-A1 aligned to the most active PCFT compound 
AGF94; (d) Hypo-A1 aligned to an inactive PCFT compound AGF127. 
(a) (b) 
(d) (c) 
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Figure 86a shows the excellent correlation of Hypo-A1. Compound AGF94, the 
most active PCFT compound, shows a perfect alignment with the Hypo-A1 model (Figure 
86c) and it fulfills the need for all the required features, whereas compound AGF127, 
which was inactive in the PCFT assays, showed a low FitValue in the Hypo-A1 model 
(Figures 86d) and also clearly displayed an incorrect fit in the model. 
 
B. RFC pharmacophore model. 
 
B.1 Pharmacophore Generation for RFC. Top 10 hypotheses for RFC pharmacophores 
were generated using the HypoGen algorithm in DS using HBA, HBD, HA and NI features. 
The cost values, correlation, RMS, maximum FitValue and features of the 10 hypotheses 
are summarized in Table 28.  
 
B.2 Pharmacophore Validation for RFC.  
(a) Cost analysis: The model is validated by the difference between null cost and total cost. 
Hypo-B1-B3 showed a difference greater than 60 and Hypo-B1 showed the maximum cost 
difference of 67.60. Since the cost difference is greater than 60, these models have an 
excellent chance to represent a true correlation (>90% probability) (Table 29). 
 
(b) Fisher’s randomization test: Confidence level of 90% was set for the test, which created 
9 columns for cost and correlation values. Due to a small set of training compounds (14 
active and 2 inactive RFC compounds), the only Hypo-B1-B5 showed a low confidence 
level of 90%, suggesting that there is a 90% chance these hypotheses represent a true 
  197 
correlation in the training set activity data. All the 9 columns had higher cost values than 
Hypo-B1-B10 (Experimental section) and lower correlation than Hypo- B1-B10 
(Experimental section). Hypo-B1 presents the highest correlation of 0.96, suggesting a 
linear relationship between the experimental and estimated activities. Hypo-B1 also 
displays the lowest RMS, suggesting a highly accurate predictive model. Hence, we 
selected Hypo-B1 as the model for predicting the RFC activities. Hypo-B1 also accurately 
detected the inactive RFC compounds in the training set and this further validated the 
model. 
 
(c) Test set prediction: To further validate Hypo-B1, 3 reported RFC compounds were 
analyzed to check the predictive capability of Hypo-B1. The Ligand Pharmacophore 
Mapping protocol was implemented using FAST conformation generation to consider 300 
conformations and considering the maximum omitted features as -1 and flexible fitting 
method. All the compounds in the test set gave prediction with less than 4% error (Table 
30). On the basis of the training set prediction, test set prediction, fisher validation and cost 
analysis; Hypo-B1 shows a clear ability to classify active and inactive RFC transportable 
compounds.  
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Table 29. Statistical results of the generated pharmacophore models for RFC. 
Hypo Confidence 
level (%) 
Total 
cost 
∆Costa RMSb Correlationc Maximum 
FitValued 
Features 
B1 90 88.05 67.60 1.096 0.964 13.31 HBA, HBD, 
NI 
B2 90 89.89 65.76
3 
1.252 0.948 13.01 HBA, HBD, 
NI, RA 
B3 90 92.26 63.40 1.398 0.932 12.79 HBA, NI, RA 
B4 90 98.24 57.42 1.668 0.898 12.59 HBA, HBD, 
NI, RA 
B5 90 102.82 52.84 1.746 0.892 13.31 HBA, NI, RA 
B6 50 105.87 49.79 1.897 0.867 9.69 HBA, NI, RA 
B7 50 105.94 49.72 1.967 0.851 12.26 HBA, HBD, 
NI 
B8 40 109.14 46.52 2.008 0.848 12.87 HBA, HBD, 
NI 
B9 40 109.38 46.28 1.998 0.851 13.03 HBA, NI, RA 
B10 40 109.46 46.20 1.968 0.859 13.33 HBA, HBD, 
NI, RA 
Fixed cost = 68.764; Null cost = 155.655; aCost difference = Null cost- Total cost; bRMS 
is the deviation of log (estimated activity) from log (measured activity) normalized to log 
(uncertainty); cCorrelation is the coefficient based on linear regression derived from the 
geometric fit index; dMaximum FitValue is the highest FitValue obtained for the best 
compound in the pharmacophore. 
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Table 30. Actual IC50 values and estimated IC50 values of 15 training set and 3 test set 
molecules through pharmacophore Hypo-B1 (A-active, M-moderately active, I-inactive) 
AG# Actual 
IC50 (nM) 
Extended 
IC50 (nM) 
Estimated 
IC50 (nM) 
Error FitValue Status 
PMX 30.57 31 99 3.20 12.29 A 
G136 38.32 56 25 -2.20 12.89 A 
G150 50.70 120 230 2.00 11.93 A 
G152 54.00 140 290 2.10 11.82 A 
G127 56.60 160 380 2.50 11.71 A 
G134 59.88 180 270 1.50 11.86 A 
G126 68.80 260 440 1.70 11.64 M 
G94 101.00 720 750 1.00 11.41 M 
G135 110.00 900 820 -1.10 11.38 M 
G154 189.00 3800 4500 1.20 10.63 M 
G128 194.6 4100 2900 -1.40 10.83 M 
G137 243.20 7300 17000 2.30 10.07 M 
G183 510.00 52000 34000 -1.50 9.76 M 
G182 641.00 94000 12000 -7.80 10.21 M 
G71 >1000 310000 61000 -5.00 9.50 I 
LMX* 12 - 39.17 3.26 13.12  
RTX* 6.3 - 12.88 2.04 13.60  
MTX* 12 - 10.66 -1.13 13.68  
* are the compounds in the test set. 
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Figure 87. (a) Plot of correlation between the experimental and the Hypo-B1 estimated 
RFC activity values of the 15 training set compounds; (b) Chemical features of Hypo-B1. 
Magenta color represents HBD, green represents HBA and blue represents a negative 
ionizable feature; (c) Hypo-B1 aligned to an active RFC compound AGF136; (d) Hypo-
B1 aligned to an inactive RFC compound AGF71. 
 
Figure 87a shows the excellent correlation of Hypo-B1. Compound AGF136, the 
most active RFC compound, shows a perfect alignment with the Hypo-B1 model (Figures 
87b, c) and it fulfills the need for all the features required, whereas compound AGF71, 
which was inactive in the RFC assays showed a low FitValue in the Hypo-B1 model 
(Figures 87b, c) and clearly displayed an incorrect fitting in the model. 
(a) (b) 
(d) 
(c) 
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D.3.2. Synthesis of 5-substituted 2-amino-3,5-dihydro-4H-pyrrolo[3,2-d]pyrimidin-4-
ones 
Synthesis of the target compounds 269-271 started with a palladium-catalyzed 
Sonogashira coupling of 4-iodobenzoate methyl ester 367 (Scheme 79) with the 
appropriate alkyne alcohols to afford the ethyl 4-substituted alcohol benzoates 368-370 in 
78-88% yields. Catalytic hydrogenation afforded the saturated alcohols 371-373 90-98% 
yields.160 The alcohols 371-373 were converted to the mesylate derivatives using  mesyl 
chloride and triethylamine base at 0 ⁰ C.272 The mesylate derivatives were not purified and 
after workup were converted to their respective iodide 374-376 using the Finkelstein 
reaction in 72-85% yields. The N-alkylation of iodides, 374-376 using ethyl 3-amino-1H-
pyrrole-2-carboxylate and sodium hydride under anhydrous conditions afforded the N-5 
substituted pyrroles 377-379.185 This reaction was incomplete as observed on TLC. Longer 
reaction times resulted in decomposition of the product (TLC). The intermediates 377-379 
could not be isolated due to presence of multiple spots, even after repeated column 
chromatography. The crude N-substituted pyrroles 377-379 were directly subjected to 
condensation with 1,3-bis(methoxycarbonyl)-2-methylthiopseudourea with 5 equivalents 
of acetic acid as catalyst and MeOH. The hydrolysis of the carbamate group formed was 
carried out in situ with aqueous sodium hydroxide at 55 °C to afforded the 2-amino-4-oxo-
pyrrolo[3,2-d]pyrimidines 380-382 in yields that ranged from 28-30% (over three steps).185 
This hydrolysis required higher temperature (55 °C). Performing the hydrolysis at room 
temperature causes the hydrolysis of the ester, but not the carbamate (as observed on the 
1H-NMR). However, temperatures greater than 70 ⁰ C caused degradation of the starting 
material 
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Scheme 79. Synthesis of target compounds 269-271 
 
a) PdCl2, PPh3, alcohol, TEA, toluene, 1h, 100 ⁰ C, microwave; b) H2/Pd, high parr vessel, 
24h, r.t.; c) (i)  mesyl chloride, DCM, 0 ⁰ C, 2 h; (ii) NaI, acetone, 4 h, reflux; d) ethyl 3-
amino-1H-pyrrole-2-carboxylate, NaH, DMF, 2h, r.t.; e) (i) 1,3-bis(methoxycarbonyl)-2-
methyl-2-thiopseudourea, MeOH, r.t.,16 h; (ii) NaOMe, MeOH, 16 h, r.t.; (iii) 1 N NaOH, 
55 ⁰ C, 3 h; f) L-glutamic acid diethyl ester hydrochloride, 2-chloro-4,6-dimethoxy-
triazine, NMM, DMF, r.t., 12 h; g) 1N NaOH, r.t., 1 h 
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 The optimum temperature for hydrolysis of both ester and carbamate was found to be 55 
⁰ C. Conversion of free acids 380-382 to the corresponding L-glutamic acid diethyl esters 
383-385 involved conventional peptide coupling with L-glutamic acid diethyl ester 
hydrochloride using 2-chloro-4,6-dimethoxy-l,3,5-triazine followed by chromatographic 
purification to afford the coupled products in 43-75% yields.185 Hydrolysis of 383-385 with 
aqueous NaOH at room temperature, followed by acidification with 1 N HCl in the cold, 
afforded target compounds 269-271 in 56-80% yields.  
 
Using the method for synthesis of target compounds 269-271 (Scheme 79), instead 
of the 4-iodobenzoate ethyl ester 367 (Scheme 80), 4-bromo-thiophene-2-carboxylic acid 
ethyl ester 386 was employed for the Sonogashira coupling with the appropriate alkyne 
alcohols to afford the 5-substituted alcohol thiophene derivatives 387-389 in 61-70% 
yields. Catalytic hydrogenation afforded the saturated alcohols 390-392 82-89% yields.160 
The alcohols 390-392 were converted to the mesylate derivatives using  mesyl chloride and 
triethylamine base at 0 ⁰ C. The mesylate derivatives were not separated and on workup 
were converted to their respective iodides 393-395 using the Finkelstein reaction in 61-
64% yields over two steps. The N-alkylation of the iodides, 393-395 using ethyl 3-amino-
1H-pyrrole-2-carboxylate and sodium hydride under anhydrous conditions afforded the N-
5 substituted pyrroles 396-398.185 The crude N-substituted pyrroles 396-398 were directly 
subjected to condensation with 1,3-bis(methoxycarbonyl)-2-methylthiopseudourea with 5 
equivalent of acetic acid as catalyst and MeOH.185  
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Scheme 80. Synthesis of target compounds 280-282 
 
a) PdCl2, PPh3, alcohol, TEA, toluene, 1h, 100 ⁰ C, microwave; b) H2/Pd, high parr vessel, 
24h, r.t.; c) (i)  mesyl chloride, DCM, 0 ⁰ C, 2 h; (ii) NaI, acetone, 4 h, reflux; d) ethyl 3-
amino-1H-pyrrole-2-carboxylate, NaH, DMF, 2h, r.t.; e) (i) 1,3-bis(methoxycarbonyl)-2-
methyl-2-thiopseudourea, MeOH, r.t.,16 h; (ii) NaOMe, MeOH, 16 h, r.t.; (iii) 1 N NaOH, 
55 ⁰ C, 3 h; f) L-glutamic acid diethyl ester hydrochloride, 2-chloro-4,6-dimethoxy-
triazine, NMM, anhydrous DMF, r.t., 12 h; g) 1 N NaOH, r.t., 1 h 
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The hydrolysis of the carbamate group formed was carried out in situ with aqueous sodium 
hydroxide at 55 °C to afforded the 2-amino-4-oxo-pyrrolo[3,2-d]pyrimidines  399-401 in 
yields that ranged from 17-33% (over three steps).185 Conversion of free acids 399-401 to 
the corresponding L-glutamic acid diethyl esters 402-404 involved conventional peptide 
coupling with L-glutamic acid diethyl ester hydrochloride using 2-chloro-4,6-dimethoxy-
l,3,5-triazine followed by chromatographic purification to afford the coupled products in 
37-72% yields.185 Hydrolysis of 402-404 with aqueous NaOH at room temperature, 
followed by acidification with 1 N HCl in the cold, afforded target compounds 280-282 in 
50-81% yields. 
 
D.3.3. Synthesis of 5- substituted 2-amino-6-methyl-3,5-dihydro-4H-pyrrolo[3,2-
d]pyrimidin-4-ones 
 
Scheme 81. Synthesis of intermediate 407 
 
a) MeOH, 5 h, r.t.; b) NaOEt, EtOH, 60 ⁰ C, 6 h 
 
Using the literature method,185 the synthesis for ethyl 3-amino-5-methyl-1H-
pyrrole-2-carboxylate, 407 was attempted (Scheme 81). The crucial intermediate 406 (E/Z-
mixture) was readily obtained from 3-aminobut-2-enenitrile 77 (E/Z-mixture) and diethyl 
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aminomalonate hydrochloride, 75, in methanol at room temperature for 5 h. The TLC 
shows multiple spots and the reaction required extensive chromatographic separation 
efforts. The formation of a light pink spot on TLC is an indication of the required 
intermediate 406, and it was advanced to the cyclization along with impurities. The 
intermediate diethyl 2-((1-cyanoprop-1-en-2-yl)amino)malonate 406  under reflux 
conditions with sodium ethoxide in ethanol afforded intermediate 407 in 44% yield over 
two steps.  
 
Scheme 82. Synthesis of target compounds 284-286 
 
a) 407, NaH, DMF, 2 h, r.t.; b) (i) 1,3-bis(methoxycarbonyl)-2-methyl-2-thiopseudourea, 
MeOH, r.t.,16 h; (ii) NaOMe, MeOH, 16 h, r.t.; (iii) 1N NaOH, 55 ⁰ C, 3 h; c) L-glutamic 
acid diethyl ester hydrochloride, 2-chloro-4,6-dimethoxy-triazine, NMM, anhydrous DMF, 
r.t., 12 h; d) 1N NaOH, r.t., 1 h 
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The N-alkylation of iodides 374-376 using ethyl 5-methyl-3-amino-1H-pyrrole-2-
carboxylate 407 (Scheme 82) and sodium hydride in anhydrous conditions afforded the N-
5-substituted pyrroles 408-410.185 The crude N-substituted pyrroles 408-410 were directly 
subjected to condensation with 1,3-bis(methoxycarbonyl)-2-methylthiopseudourea with 5 
equivalent of acetic acid as catalyst and MeOH.185 Hydrolysis of the carbamate group with 
aqueous sodium hydroxide at 55 °C afforded the 2-amino-4-oxo-6-methyl-pyrrolo[3,2-
d]pyrimidines 411-413 in yields that ranged from 14-22% (over three steps).185 Conversion 
of the free acids 411-413 to the corresponding L-glutamic acid diethyl esters 414-416 
involved conventional peptide coupling with L-glutamic acid diethyl ester hydrochloride 
using 2-chloro-4,6-dimethoxy-l,3,5-triazine followed by chromatographic purification to 
afford the coupled products in 53-64% yields.185 Hydrolysis of 414-416 with aqueous 
NaOH at room temperature, followed by acidification with 1 N HCl, afforded target 
compounds 284-286 in 61-73% yields.  
 
 
D.3.4. Synthesis of 5- substituted 2-amino-3,5-dihydro-4H-pyrrolo[3,2-d]pyrimidin-
4-ones with heteroatom bridge substitutions 
The intermediates substituted phenol 418 (Scheme 83) was via performing a SN2 
like attack using ethyl 4-hydroxybenzoate 417 and K2CO3 following a slight modified 
version of the reported method.273 Instead of DMF, acetonitrile was used as a solvent to 
avoid the necessity of evaporation at higher temperatures or the extensive workup 
procedure, which could cause loss of the product 418 in the water layer. The alcohol was 
converted into the iodide, following a similar method as for 374-376 (Scheme 79).  
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Scheme 83. Synthesis of target compound 291  
 
a) K2CO3, acetonitrile, 3-bromopropanol, reflux, 24 h; b) (i)  mesyl chloride, DCM, 0 ⁰ C, 
2 h; (ii) NaI, acetone, 4 h, reflux; c) ethyl 3-amino-1H-pyrrole-2-carboxylate, NaH, DMF, 
2 h, r.t.; d) (i) 1,3-bis(methoxycarbonyl)-2-methyl-2-thiopseudourea, MeOH, r.t.,16 h; (ii) 
NaOMe, MeOH, 16 h, r.t.; (iii) 1N NaOH, 55 ⁰ C, 3 h; e) L-glutamic acid diethyl ester 
hydrochloride, 2-chloro-4,6-dimethoxy-triazine, NMM, anhydrous DMF, r.t., 12 h; f) 1N 
NaOH, r.t., 1 h 
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The N-alkylation of iodide 419 using ethyl 3-amino-1H-pyrrole-2-carboxylate and sodium 
hydride under anhydrous conditions afforded the N-5 substituted pyrrole 420.185 The crude 
N-substituted pyrroles were directly subjected to condensation with 1,3-
bis(methoxycarbonyl)-2-methylthiopseudourea with 5 equivalent of acetic acid as catalyst 
and MeOH.185 Hydrolysis of the carbamate with aqueous sodium hydroxide at 55 °C 
afforded 2-amino-4-oxo-pyrrolo[3,2-d]pyrimidine 421.185 Conversion of the free acid 421 
to the corresponding L-glutamic acid diethyl ester 422 involved conventional peptide 
coupling with L-glutamic acid diethyl ester hydrochloride using 2-chloro-4,6-dimethoxy-
l,3,5-triazine followed by chromatographic purification to afford the coupled product 422 
in 38% yield.185 Hydrolysis of 422 with aqueous NaOH at room temperature, followed by 
acidification with 1 N HCl in the cold, afforded target compound 291 in 78% yield.  
 
The methyl ester of thiophenol 423 (Scheme 84) was obtained using concentrated 
sulfuric acid and methanol.274 The intermediate substituted thiophenol, 425, similar to 418 
(Scheme 83) was obtained via a SN2 type attack with 4-mercaptobenzoate 424 and Cs2CO3 
(Scheme 84).273 Instead of using of potassium carbonate, cesium carbonate was used as it 
is a better counterion for sulfur.275 The alcohols were converted into iodides, following a 
similar method as for 374-376 (Scheme 79). The N-alkylation of the iodide 426 using ethyl 
3-amino-1H-pyrrole-2-carboxylate and sodium hydride under anhydrous conditions 
afforded the N-5 substituted pyrrole 427.185  
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Scheme 84. Synthesis of target compound 292 
 
a) MeOH, conc. sulfuric acid, reflux, 16 h; b) 3-bromopropanol, Cs2CO3, acetonitrile, 
reflux, 24 h; c) (i)  mesyl chloride, DCM, 0 ⁰ C, 2 h; (ii) NaI, acetone, 4 h, reflux; d) ethyl 
3-amino-1H-pyrrole-2-carboxylate, NaH, DMF, 2 h, r.t.; e) (i) 1,3-bis(methoxycarbonyl)-
2-methyl-2-thiopseudourea, MeOH, r.t.,16 h; (ii) NaOMe, MeOH, 16 h, r.t.; (iii) 1 N 
NaOH, 55 ⁰ C, 3 h; f) L-glutamic acid diethyl ester hydrochloride, 2-chloro-4,6-
dimethoxy-triazine, NMM, anhydrous DMF, r.t., 12 h; g) 1 N NaOH, r.t., 1 h 
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The crude N-substituted pyrrole 427 was directly subjected to condensation with 
1,3-bis(methoxycarbonyl)-2-methylthiopseudourea with 5 equivalent of acetic acid as 
catalyst and MeOH.185 Hydrolysis of the carbamate group with aqueous sodium hydroxide 
at 55 °C afforded the 2-amino-4-oxo-pyrrolo[3,2-d]pyrimidine 428  in 19% yield (over 
three steps).185 Conversion of the free acid 428  to the corresponding L-glutamic acid 
diethyl ester 429  involved conventional peptide coupling with L-glutamic acid diethyl ester 
hydrochloride using 2-chloro-4,6-dimethoxy-l,3,5-triazine followed by chromatographic 
purification to afford the coupled products 429 in 43% yield.185 Hydrolysis of 429  with 
aqueous NaOH at room temperature, followed by acidification with 1 N HCl in the cold, 
afforded target compound 292 in 83% yield. 
 
Scheme 85. Attempted synthesis of intermediate 431 
 
a) aminoalcohol, CuI, L-proline, dimethyl sulfoxide, r.t., 48 h; b)  mesyl chloride, DCM, 0 
⁰ C, 2 h 
 
The intermediate methyl 4-((3-hydroxypropyl)amino)benzoate, 430 (Scheme 85) 
was synthesized using methyl 4-iodobenzoate, 367, CuI as catalyst, L-proline and 2-amino 
ethanol in dimethyl sulfoxide.276 No base was added, as the addition of base leads to 
aggregation. Instead 5 equivalents of the 2-amino ethanol was used to function as both the 
base and nucleophile. The reaction was carried out to its completion, to afford 430 in 90% 
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yield. To attempt the conversion of alcohols to iodides, following a similar method as for 
374-376 (Scheme 79), 4-((3-hydroxypropyl)amino)benzoate 430 was converted to its 
mesylate salt: methyl 4-((3-((methylsulfonyl)oxy)propyl)amino)benzoate 431. This 
reaction gave multiple spots. Hence, another method for the conversion of alcohols to 
iodide needed to be employed. 
The ethyl 4-((3-ydroxypropyl)amino)benzoate 430 was synthesized using the 
method for 430 (Scheme 85). To afford the iodide, a one pot conversion was attempted by 
following a reported procedure.277 To a solution of triphenylphosphine in dry methylene 
chloride was added iodine and imidazole at 0 ºC. The resulting solution was stirred for 10 
min, followed by an addition of a solution of the amino alcohol in dry methylene chloride 
was added. Chromatographic separation afforded the iodide (Scheme 86). This method was 
a significant improvement over the previous method reported272 for conversion of the 
alcohol to mesylate to iodide (Scheme 85). It requires one step, one workup and one column 
chromatographic separation, compared to the previous method (Scheme 85), which needs 
two steps, two workups and a column chromatographic separation. It is also less time 
consuming. The N-alkylation of iodide 432 using ethyl 3-amino-1H-pyrrole-2-carboxylate 
and sodium hydride in anhydrous conditions afforded the N-5 substituted pyrrole 433.185 
The crude N-substituted pyrrole 433 was directly subjected to condensation with 1,3-
bis(methoxycarbonyl)-2-methylthiopseudourea with 5 equivalent of acetic acid as catalyst 
and MeOH.185 Hydrolysis of the carbamate group with aqueous sodium hydroxide at 55 °C 
afforded the 2-amino-4-oxo-pyrrolo[3,2-d]pyrimidine 434.185 
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Scheme 86. Synthesis of target compounds 292 and 293 
 
a) 3-aminopropanol, CuI, L-proline, dimethyl sulfoxide, r.t., 48 h; b) PPh3, iodine, 
imidazole, DCM, 0 ⁰ C; c) ethyl 3-amino-1H-pyrrole-2-carboxylate, NaH, DMF, r.t., 2 h; 
d) (i) 1,3-bis(methoxycarbonyl)-2-methyl-2-thiopseudourea, MeOH, r.t.,16 h; (ii) NaOMe, 
MeOH, 16 h, r.t.; e) 1 N NaOH, 55 ⁰ C, 3 h; f L-glutamic acid diethyl ester hydrochloride, 
2-chloro-4,6-dimethoxy-triazine, NMM, anhydrous DMF, r.t., 12 h; g) 1 N NaOH, r.t., 1 h 
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Conversion of free acid 434 to the corresponding L-glutamic acid ester involved 
conventional peptide coupling with L-glutamic acid diethyl ester hydrochloride using 2-
chloro-4,6-dimethoxy-l,3,5-triazine followed by chromatographic purification to afford the 
coupled product 435 in 50% yield.185 Hydrolysis of 435 with aqueous NaOH at room 
temperature, followed by acidification with 1 N HCl in the cold, afforded target compound 
293 in 75% yield. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  215 
V. EXPERIMENTAL 
 
All evaporations were carried out in reduced pressure with a rotary evaporator. Analytical 
samples were dried in vacuo in a CHEM-DRY drying apparatus over P2O5 at 50 °C. 
Melting points were determined either using a MEL-TEMP, II melting point apparatus with 
FLUKE 51 K/J electronic thermometer or using an MPA100 OptiMelt automated melting 
point system and are uncorrected. Nuclear magnetic resonance spectra for proton (1H 
NMR) were recorded on the Bruker Avance II 400 (400 MHz) or Bruker Avance II 500 
(500 MHz) NMR systems with TopSpin processing software. The chemical shift values 
(δ) are expressed in, (parts per million) relative to tetramethylsilane as an internal standard: 
s, singlet; d, doublet; dd, doublet of doublet; t, triplet; q, quartet; m, multiplet; br, broad 
singlet; td, triplet of doublet; dt, doublet of triplet; quin, quintet; exch., exchangeable using 
D2O. Thin-layer chromatography (TLC) was performed on Whatman® PE SIL G/UV254 
flexible silica gel plates and the spots were visualized under 254 and 365 nm ultraviolet 
illumination. Proportions of solvents used for TLC are by volume. All analytical samples 
were homogeneous on TLC in at least two different solvent systems. Column 
chromatography was performed on the silica gel (70 to 230 meshes, Fisher Scientific) 
column. Flash chromatography was carried out on the CombiFlash® Rf systems, model 
COMBIFLASH RF. Pre-packed RediSep® Rf normal-phase flash columns (230 to 400 
meshes) of diverse sizes were used. The amount (weight) of silica gel for column 
chromatography was in the range of 50-100 times the amount (weight) of the crude 
compounds being separated. Elemental analyses were performed by Atlantic Microlab, 
Inc., Norcross, GA. Element compositions are within ± 0.4% of the calculated values. 
Fractional moles of water or organic solvents frequently found in some analytical samples 
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could not be prevented despite 24 to 48 hours of drying in vacuo and were confirmed where 
possible by their presence in the 1H NMR spectra.  
 
2-Amino-4-methyl-furan-3-carbonitrile (295) 
 To a solution of acetol (10 g, 135 mmol) in methanol (200mL) at room temperature was 
added malononitrile (8.9 g, 135 mmol) and triethylamine (13.7 g, 135 mmol). The resulting 
mixture was stirred at room temperature overnight. The reaction mixture was then stripped 
of solvent in vacuo. The residue was washed with Hexane-ethyl acetate (5:1) (250mL × 5). 
The resulting Hexane-ethyl acetate solution of the product was collected. After the 
evaporation of solvent under reduced pressure, 13 g (79%) of the crude product was 
obtained as an orange powder and was used directly in the next reaction without any 
analysis.  
 
2,4-diamino-5-methyl-pyrrolo[2,3-d]pyrimidine (296) 
To a solution of guanidine free base (from 82 mmol of NaOMe) in anhydrous ethanol (150 
mL) was added aminonitrile 295 (10.0 g, 82 mmol). The mixture was refluxed for 24 h, 
cooled, and filtered. The filtrate was evaporated in vacuo, and the residue was 
chromatographed on silica gel with 10% MeOH:CHCl3 as the eluent. Fractions containing 
the product were combined and evaporated to give 296 (7.3g, 55%) as a brown semi-solid; 
TLC Rf = 0.63 (MeOH:CHCl3:NH4OH, 1:5:0.5). 
1H NMR (400 Hz) (Me2SO-d6) δ 10.43 
(s, 1 H, exch., -NH), 6.42 (s, 1 H, Ar), 6.19 (s, 2 H, exch, 4-NH2,.), 5.25-5.78 (br, 2 H, 
exch., 2-NH2), 2.23 (s, 3 H, 5-CH3). The 
1H NMR matches the 1H NMR of the reported 
compound.206  
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6-((3-methoxyphenyl)thio)-5-methyl-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine (141) 
To a solution of 296 (0.5 g, 3.06 mmol) in a mixture of ethanol/water (2:1, 50 mL) was 
added iodine (1.56 g, 6.12 mmol) followed by 3-methoxythiophenol (0.86 g, 6.12mmol) 
and the reaction mixture was heated to reflux for 4 h. The mixture was cooled at room 
temperature and concentrated under reduced pressure. The residue was washed with 20 mL 
of saturated sodium thiosulfate solution in water and was chromatographed on silica gel 
with 10% MeOH:CHCl3 as the eluent. Fractions containing the product were combined 
and evaporated to give the title compound 141 (0.46 g, 50%) as a white solid. TLC Rf = 
0.50 (MeOH:CHCl3:NH4OH, 1:5:0.5); mp, 264.4-268.3 °C (lit.
206  264.4-268.3 °C); 1H 
NMR (400 Hz) (Me2SO-d6) δ 10.96 (s, 1 H, exch., -NH), 7.18 (t, J = 7.5 Hz , 1 H, Ar), 6.71 
(d, J = 8.1 Hz, 1 H, Ar), 6.54 (t, J = 8.8 Hz, 2 H, Ar), 6.24 (s, 2 H, 4-NH2, exch.), 5.64 (s, 
2 H, exch., 2-NH2), 3.69 (s, 3 H, 3-OCH3), 2.32 (s, 3 H, 5-CH3). 
 
6-((2-methoxyphenyl)thio)-5-methyl-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine (148)  
Compound 148 (0.46 g, 50%) was obtained from 296 as a white solid (0.10 g, 0.61 mmol), 
2-methoxythiophenol (0.18 g, 1.23 mmol), and iodine (0.22 g, 0.86 mmol); TLC Rf = 0.50 
(MeOH:CHCl3:NH4OH, 1:5:0.5); mp, 306.7-313.7 °C (lit.
206   306.7-313.7 °C); 1H NMR 
(400 Hz) (Me2SO-d6) δ 10.88 (s, 1 H, exch., -NH), 7.09 (m, 1 H, Ar), 6.99 (d, J = 7.6 Hz, 
1 H, Ar), 6.81 (t, J = 7.6 Hz, 1 H, Ar), 6.37 (d, J = 7.6 Hz, 1 H, Ar), 6.24 (s, 2 H, exch., 4-
NH2), 5.60 (s, 2 H, exch., 2-NH2), 3.86 (s, 3 H, 2-OCH3), 2.28 (s, 3 H, 5-CH3). 
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6-((4-methoxyphenyl)thio)-5-methyl-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine (149) 
Using the procedure for synthesis of 141, 149 as a white solid (0.2 g, 21%) was obtained 
from 296 (0.5 g, 3.06 mmol), 4-methoxythiophenol (0.86 g, 6.12mmol), and iodine (1.56 
g, 6.12 mmol); TLC Rf = 0.50 (MeOH:CHCl3:NH4OH, 1:5:0.5); mp, 293.7-296.0 °C (lit.
206   
291.7-295.8°C); 1H NMR (400 Hz) (Me2SO-d6) δ 10.93 (s, 1 H, exch., -NH), 7.04 (d, J = 
7.5 Hz, 2 H, Ar), 6.86 (d, J = 7.5 Hz, 2 H, Ar), 6.25 (s, 2 H, exch., 4-NH2), 5.60 (s, 2 H, 
exch., 2-NH2), 3.68 (s, 3 H, 3-OCH3), 2.33 (s, 3 H, 5-CH3). 
 
5-methyl-6-(naphthalen-2-ylthio)-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine (150) 
Using the procedure for synthesis of 141, 150 as a white solid (0.32 g, 21%) was obtained 
from 296 (0.8 g, 4.4 mmol), 2-thionapthalene (1.42 g, 8.8 mmol), and iodine (2.25 g, 8.8 
mmol); TLC Rf = 0.50 (MeOH:CHCl3:NH4OH, 1:5:0.5); mp, 258.8-265.5 °C (lit.
206 276.2-
283.2 ⁰ C); 1H NMR (400 Hz) (Me2SO-d6) δ 11.05 (s, 1 H, exch., -NH), 7.84 (m, 1 H, Ar), 
7.82 (s, 1 H, Ar), 7.76 (d, J=8.3 Hz, 1 H, Ar), 7.45 (m, 3 H, Ar) , 7.17 (dd, J=1.8 Hz, J=8.7 
Hz, 1 H, Ar) , 6.32 (s, 2 H, exch., 4-NH2), 5.66 (s, 2 H, exch., 2-NH2), 2.09 (s, 3H, 5-CH3). 
 
5-methyl-6-(naphthalen-1-ylthio)-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine (151) 
Using the procedure for synthesis of 141, 151 as a white solid (0.4 g, 27%) was obtained 
from 296 (0.8 g, 4.4 mmol), 1-thionapthalene (1.42 g, 8.8 mmol), and iodine (2.25 g, 8.8 
mmol); TLC Rf  0.50 (MeOH:CHCl3:NH4OH, 1:5:0.5); mp, 291.5-294.8 °C (lit.
206   288.7-
293 °C); 1H NMR (500 Hz) (Me2SO-d6) δ 10.98 (s, 1 H, exch., -NH), 8.26 (d, J=8.2 Hz, 1 
H, Ar), 7.96 (d, J=7.9 Hz, 1 H, Ar), 7.73 (d, J=8.1 Hz, 1 H, Ar), 7.62 (td, J=7.0 Hz, J=14.7 
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Hz, 2 H, Ar), 7.37 (t, J= 7.7 Hz, 1 H, Ar,) 6.85 (d, J=7.3 Hz, 1 H, Ar), 6.66 (s, 2 H, exch., 
4-NH2), 5.98 (s, 2 H, exch., 2-NH2), 2.37 (s, 3 H, 5-CH3), 
 
6-((3,4-difluorophenyl)thio)-5-methyl-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine 
(152) 
Using the procedure for synthesis of 141, 152 as a white solid (0.35 g, 24.3%) was obtained 
from 296 (0.8 g, 4.4 mmol), 3,4-difluorothiophenol (1.30 g, 8.8 mmol), and iodine (2.25 g, 
8.8 mmol); TLC Rf = 0.50 (MeOH:CHCl3:NH4OH, 1:5:0.5); mp, 292.0-295.2 °C. 
1H NMR 
(500 Hz) (Me2SO-d6) δ 10.99 (s, 1 H, exch., -NH), 7.37 (dd, J=8.6 Hz, J=19.2 Hz, 1 H, 
Ar), 7.06 (d, J=19.2 Hz, 1 H, Ar), 6.81 (d, J=8.7 Hz, 1 H, Ar), 6.28 (s, 2 H, exch., 4-NH2), 
5.65 (s, 2 H, exch., 2-NH2), 2.33 (s, 3 H, 5-CH3).  Anal. Calcd.  for C13H11F2N4S 0.34 
CH3OH: C, 50.87; H, 4.05; F, 11.76; N, 21.68; S, 9.93. Found: C, 50.97; H, 3.88; F, 11.55; 
N, 21.65; S, 10.06. 
 
5-methyl-6-((4-(trifluoromethoxy)phenyl)thio)-7H-pyrrolo[2,3-d]pyrimidine-2,4-
diamine (153)  
Using the procedure for synthesis of 141, 153 as a white solid (0.38 g, 28%) was obtained 
from 296 (0.8 g, 4.4 mmol), 4-trifluromethoxythiophenol (1.26 g, 8.8 mmol), and iodine 
(2.25 g, 8.8 mmol); TLC Rf = 0.50 (MeOH:CHCl3:NH4OH, 1:5:0.5); mp, 291.7-295.0 °C. 
1H NMR (500 Hz) (Me2SO-d6) δ 10.98 (s, 1 H, exch., -NH), 7.30 (d, J= 8.1 Hz, 2 H, Ar), 
7.08 (d, J=8.9 Hz, 2 H, Ar), 6.28 (s, 2 H, exch., 4-NH2), 5.66 (s, 2 H, exch., 2-NH2), 2.33 
(s, 3 H, 5-CH3). Anal. Calcd.  for C14H12F3N5OS: C, 47.32; H, 3.40; F, 16.04; N, 19.71; O, 
4.50; S, 9.02. Found: C, 47.13; H, 3.50; F, 15.99; N, 19.57; S, 8.91. 
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5-methyl-6-((4-nitrophenyl)thio)-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine (154) 
Using the procedure for synthesis of 141, 154 as a white solid (0.4 g, 27%) was obtained 
from 296 (0.8 g, 4.4 mmol), 4-nitrothiophenol (0.86 g, 8.8 mmol), and iodine (2.25 g, 8.8 
mmol); TLC Rf = 0.50 (MeOH:CHCl3:NH4OH, 1:5:0.5); mp, 193.6-198.5 °C: 
1H NMR 
(400 Hz) (Me2SO-d6) δ 11.08 (s, 1 H, exch., -NH), 8.14 (d, J= 9.0 Hz, 2 H, Ar), 7.17 (d, 
J=8.7 Hz, 2 H, Ar), 6.34 (s, 2 H, exch., 4-NH2), 5.70 (s, 2 H, exch., 2-NH2), 2.31 (s, 3 H, 
5-CH3). Anal. Calcd.  for C13H12N6O2S 0.4 CH3OH 0.05 H2O 0.05 CHCl3: C, 48.03; H, 
4.12; N, 25.01; S, 9.54. Found: C, 48.16; H, 3.71; N, 24.58; S, 9.38. 
 
General Procedure for the Synthesis of Compounds 142-175 and 155-160. 
Mixture of 6-substituted pyrrolo[2,3-d]pyrimidine and sodium hydride was added to a three 
neck RBF. The RBF was made anhydrous using argon gas balloon. To this mixture, 
anhydrous DMF (10 mL) was added and stirred for 30 minutes. Subsequently, appropriate 
alkyl halide was injected in the reaction mixture, and the resulting reaction mixture was 
stirred and monitored by TLC until reaction was completed. The DMF was evaporated 
under reduced pressure and silica plug was prepared. It was chromatographed on silica gel 
with 10% MeOH:CHCl3 as the eluent. Fractions containing the product were combined 
and evaporated to give the targeted compounds. 
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6-((3-methoxyphenyl)thio)-5,7-dimethyl-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine 
(142) 
 Reaction of 141 (0.150 g, 0.32 mmol), sodium hydride (0.012g, 0.5 mmol) and 
iodomethane (31 mmL, 0.5 mmol) using the general procedure described above gave 142 
(0.120 g, 76.44%) as white solid; TLC Rf = 0.58 (MeOH:CHCl3:NH4OH, 1:5:0.5); mp, 
277.4-279.4 °C; 1H NMR (400 Hz) (Me2SO-d6) δ 7.19 (t, J=7.96 Hz, 1 H, Ar), 6.73 (dd, 
J=2.35, J=8.20 Hz, 1 H, Ar), 6.49 (dd, J=1.76, J=10.55 Hz, 2 H, Ar), 6.37 (s, 2 H, exch., 4-
NH2), 5.81 (s, 2 H, exch, 2-NH2.), 3.69 (s, 3 H, 3`-OCH3), 3.37 (s, 3 H, 7-CH3), 2.38 (s, 3 
H, 5-CH3). HRMS (ESI) calculated for C15H17N5OS [M+H]
+, 316.12266. Found: 
316.12198. HPLC analysis: retention time, 22.79 min; peak area, 96.08%; eluent A, H2O: 
eluent B, ACN; gradient elution (100% H2O to 10% H2O) over 60 min with flow rate of 
0.5 mL/min and detection at 245 nm; column temperature, rt. 
 
7-ethyl-6-((3-methoxyphenyl)thio)-5-methyl-7H-pyrrolo[2,3-d]pyrimidine-2,4-
diamine (143) 
Reaction of 141 (0.150 g, 0.50 mmol), sodium hydride (0.012g, 0.5 mmol) and 
bromoethane (53 mmL, 0.5 mmol) using the general procedure described above gave 143 
(0.095 g, 60.5%) as white solid; TLC Rf=  0.58 (MeOH:CHCl3:NH4OH, 1:5:0.5); mp, 
136.9-139.4 °C; 1H NMR (400 Hz) (Me2SO-d6) δ 7.19 (t, Ar, J = 8.2 Hz, 1 H), 6.72 (dd, J 
= 2.1 Hz, J = 7.2 Hz, 1 H, Ar), 6.49 (d, J = 7.2 Hz, 2 H, Ar), 6.35 (s, 2 H, exch., 4-NH2), 
5.80 (s, 2 H, exch., 2-NH2), 3.92 (q, J = 7.0 Hz, 2 H, -CH2-), 3.68 (s, 3 H, 3`-OCH3), 2.37 
(s, 3 H, 5-CH3), 1.04 (t, J = 7.0 Hz, 3 H, -CH3). Anal. Calcd.  for C16H19N5OS: C, 58.34; 
H, 5.81; N, 21.26; O, 4.86; S, 9.73. Found: C, 58.03; H, 5.97; N, 21.05; S, 9.52. 
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6-((3-methoxyphenyl)thio)-5-methyl-7-propyl-7H-pyrrolo[2,3-d]pyrimidine-2,4-
diamine (144) 
Reaction of 141 (0.120 g, 0.50 mmol), sodium hydride (0.012g, 0.5 mmol) and 1-
bromopropane (62 mmL, 0.5 mmol) using the general procedure described above gave 144 
(0.050 g, 37%) as white solid; TLC Rf = 0.60 (MeOH:CHCl3:NH4OH, 1:5:0.5); mp, 266.4-
268.2 °C; 1H NMR (400 Hz) (Me2SO-d6) δ 7.19 (t, J = 8.2 Hz, 1 H, Ar), 6.72 (dd, J = 2.1 
Hz, J = 7.2 Hz, 1 H, Ar), 6.49 (d, J = 7.2 Hz, 2 H, Ar), 6.35 (s, 2 H, exch., 4-NH2) 5.79 (s, 
2 H, exch., 2-NH2), 3.92 (q, J = 7.0 Hz, 2 H, -CH2-),3.83 (t, J=14.5 Hz, 2H, -CH2-), 3.35 
(s, 3 H, 3-OCH3), 2.37 (s, 3 H, 5-CH3), 1.51 (qd, J=7.2 Hz, J=14.5 Hz, 2 H, -CH2-), 0.73 
(t, J=7.4 Hz, 3 H, -CH3).  Anal. Calcd.  for C17H21N5OS: C, 59.45; H, 6.16; N, 20.39; O, 
4.66; S, 9.34. Found: C, 58.72; H, 6.23; N, 19.87; S, 8.98. 
 
7-isopropyl-6-((3-methoxyphenyl)thio)-5-methyl-7H-pyrrolo[2,3-d]pyrimidine-2,4-
diamine (145) 
Reaction of 141 (0.090 g, 0.30 mmol), sodium hydride (0.009g, 0.36 mmol) and 2-
bromopropane (38 mmL, 0.36 mmol) using the general procedure described above gave 
145 (0.060 g, 59%) as white solid; TLC Rf = 0.60 (MeOH:CHCl3:NH4OH, 1:5:0.5); mp, 
157.4-160.1 °C; 1H NMR (400 Hz) (Me2SO-d6) δ 7.19 (t, J = 8.2 Hz, 1 H, Ar), 6.72 (dd, J 
= 2.1 Hz, J = 7.2 Hz, 1 H, A r), 6.49 (d, J = 7.2 Hz, 2 H, Ar), 6.49 (s, 2 H, exch., 4-NH2), 
5.80 (s, 2 H, exch., 2-NH2), 4.13 (m, 1 H, -CH-), 3.68 (s, 3 H, 3`-OCH3), 2.38 (s, 3 H, 5-
CH3), 1.40 (d, J=6.7 Hz, 6 H, -CH3).  Anal. Calcd.  for C17H21N5OS: C, 59.45; H, 6.16; N, 
20.39; O, 4.66; S, 9.34. Found: C, 59.12; H, 6.08; N, 19.65; S, 8.87. 
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7-butyl-6-((3-methoxyphenyl)thio)-5-methyl-7H-pyrrolo[2,3-d]pyrimidine-2,4-
diamine (146)  
Reaction of 141 (0.100 g, 0.33 mmol), sodium hydride (0.010g, 0.4 mmol) and 1-
bromobutane (55 mmL, 0.5 mmol) using the general procedure described above gave 146 
(0.065 g, 55%) as white solid; TLC Rf = 0.62 (MeOH:CHCl3:NH4OH, 1:5:0.5); mp, 282.4-
284.2 °C; 1H NMR (400 Hz) (Me2SO-d6) δ 7.19 (t, J = 8.2 Hz, 1 H, Ar), 6.72 (dd, J = 2.1 
Hz, J = 7.2 Hz, 1 H, Ar), 6.49 (d, J = 7.2 Hz, 2 H, Ar), 6.42 (s, 2 H, exch., 4-NH2), 5.80 (s, 
2 H, exch., 2-NH2), 3.92 (q, J = 7.0 Hz, 2 H, -CH2-),3.68 (s, 3 H, 3`-OCH3), 2.38 (s, 3 H, 
5-CH3), 1.45 (td, J=7.5 Hz, J=14.7 Hz, 2 H, -CH2-),1.14 (qd, J=7.2 Hz, J=14.6 Hz, 2 H, -
CH2-),0.76 (t, J=7.3 Hz, 3 H, -CH3).  Anal. Calcd.  for C18H23N5OS 0.03 CHCl3: C, 59.98; 
H, 6.43; N, 19.40; O, 4.48; S, 8.88. Found: C, 59.94; H, 6.25; N, 19.38; S, 8.78. 
 
7-benzyl-6-((3-methoxyphenyl)thio)-5-methyl-7H-pyrrolo[2,3-d]pyrimidine-2,4-
diamine (147)  
Reaction of 141 (0.100 g, 0.33 mmol), sodium hydride (0.010g, 0.4 mmol) and benzyl 
bromide (85 mg, 0.5 mmol) using the general procedure described above gave 147 (0.060 
g, 46%) as white solid; TLC Rf = 0.80 (MeOH:CHCl3:NH4OH, 1:5:0.5); mp, 165.3-17.6 
°C; 1H NMR (400 MHz) (Me2SO-d6) δ 7.47 – 6.92 (m, 5 H), 6.87 – 6.36 (m, 4 H), 5.96 (s, 
2 H, exch., 4-NH2), 5.14 (s, 2 H, exch., 2-NH2), 4.01 (s, 3 H, 3ˊ-OCH3), 3.61 (s, 3 H, 5-
CH3), 2.02 (s, 2 H, CH2). Anal. Calcd.  for C21H21N5OS: C, 64.43; H, 5.41; N, 17.89; O, 
4.48; S, 8.19. Found: C, 64.13; H, 5.50; N, 17.63; S, 8.14. 
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6-((2-methoxyphenyl)thio)-5,7-dimethyl-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine 
(155) 
Reaction of 148 (0.150 g, 0.5 mmol), sodium hydride (0.012g, 0.5 mmol) and iodomethane 
(31 mmL, 0.5 mmol using the general procedure described above gave 155 (0.1 g, 64%) as 
a white solid; TLC Rf = 0.58 (MeOH:CHCl3:NH4OH, 1:5:0.5); mp, 180.6-209.6 °C; 
1H 
NMR (400 Hz) (Me2SO-d6) δ 7.11 (d, J=7.8 Hz, 1 H, Ar), 7.01 (d, J=6.7 Hz, 1 H, Ar), 
6.83-6.76 (m, 2 H, Ar), 6.35 (s, 2 H, exch., 4-NH2), 5.76 (s, 2 H, exch., 2-NH2), 3.89 (s, 3 
H, 2-OCH3), 2.34 (s, 3 H, 5-CH3). HRMS (ESI) calculated for C15H17N5OS [M+H]
+, 
316.12266. Found: 316.12402. HPLC analysis: retention time, 21.99 min; peak area, 97.37 
%; eluent A, H2O: eluent B, ACN; gradient elution (100% H2O to 10% H2O) over 60 min 
with flow rate of 0.5 mL/min and detection at 245 nm; column temperature, rt. 
 
6-((4-methoxyphenyl)thio)-5,7-dimethyl-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine 
(156) 
Reaction of 149 (0.150 g, 0.32 mmol), sodium hydride (0.012g, 0.5 mmol) and 
iodomethane (31 mmL, 0.5 mmol) using the general procedure described above gave 156 
(0.135 g, 86%) as white solid; TLC Rf = 0.58 (MeOH:CHCl3:NH4OH, 1:5:0.5); mp, 266.0-
267.8 °C; 1H NMR (400 Hz) (Me2SO-d6) δ 7.19 (t, J=7.96 Hz, 7.96 Hz, 1 H, Ar), 6.73 (dd, 
J=2.35, 8.20 Hz, 1 H, Ar), 6.49 (dd, J=1.76, 10.55 Hz, 2 H, Ar), 6.37 (s, 2 H, exch., 4-
NH2), 5.81 (s, 2 H, exch., 2-NH2), 3.69 (s, 3 H, 4-OCH3), 3.37 (s, 3 H, 7-CH3), 2.38 (s, 3 
H, 5-CH3). Anal. Calcd.  for C15H17N5OS: C, 57.12; H, 5.43; N, 22.21; O, 5.07; S, 10.17. 
Found: C, 56.90; H, 5.48; N, 21.94; S, 10.01. 
5,7-dimethyl-6-(naphthalen-2-ylthio)-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine (157) 
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Reaction of 150 (0.18 g, 0.56 mmol), sodium hydride (0.016g, 0.67 mmol) and 
iodomethane (40 mmL, 0.64 mmol) using the general procedure described above gave 157 
(0.11 g, 59%) as white solid; TLC Rf = 0.57 (MeOH:CHCl3:NH4OH, 1:5:0.5); mp, 266.0-
267.8 °C 1H NMR (400 Hz) (Me2SO-d6) δ 7.78 (d, J=7.8 Hz, 1 H, Ar), 7.85 (d, J=8.6 Hz, 
2 H, Ar), 7.45 (dd, J=6.7 Hz, J=12.8 Hz, 3 H, Ar), 7.13 (d, J=8.7 Hz, 1 H, Ar), 6.39 (s, 2 
H, exch., 4-NH2), 5.82 (s, 2 H, exch., 2-NH2), 3.40 (s, 3 H, 7-CH3), 2.43 (s, 3 H, 5-CH3). 
Anal. Calcd.  for C18H17N5S: C, 64.45; H, 5.11; N, 20.88; S, 9.56. Found: C, 64.21; H, 
5.25; N, 20.68; S, 9.29. 
 
5,7-dimethyl-6-(naphthalen-1-ylthio)-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine (158) 
Reaction of 151 (0.20 g, 0.62 mmol), sodium hydride (0.017g, 0.75 mmol) and 
iodomethane (46 mmL, 0.72 mmol) using the general procedure described above gave 158 
(0.12 g, 57%) as white solid; TLC Rf = 0.57 (MeOH:CHCl3:NH4OH 1:5:0.5); mp, 232.6-
235.6 °C  1H NMR (400 Hz) (Me2SO-d6) δ 8.28 (d, J=8.3 Hz, 1 H, Ar), 7.96 (d, J=8.0 Hz, 
1 H, Ar), 7.72 (d, J=8.1 Hz, 1 H, Ar), 7.63 (td, J=6.9 Hz, J=14.9 Hz, 2 H, Ar), 7.34 (t, J= 
7.8 Hz, 1 H, Ar), 6.64 (d, J=7.3 Hz, 1 H, Ar), 6.49 (s, 2 H, exch., 4-NH2), 5.89 (s, 2 H, 
exch., 2-NH2), 3.39 (s, 3H, 7-CH3), 2.51 (s, 3H, 5-CH3). Anal. Calcd.  for C18H17N5S: C, 
64.45; H, 5.11; N, 20.88; S, 9.56. Found: C, 64.68; H, 5.25; N, 20.82; S, 9.59. 
 
6-((3,4-difluorophenyl)thio)-5,7-dimethyl-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine 
(159) 
Reaction of 152 (0.120 g, 0.39 mmol), sodium hydride (0.012g, 0.5 mmol) and 
iodomethane (31 mmL, 0.5 mmol) using the general procedure described above gave 159 
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(0.08 g, 64%) as white solid; TLC Rf = 0.57 (MeOH:CHCl3:NH4OH, 1:5:0.5); mp, 266.0-
267.8 °C  1H NMR (500 Hz) (Me2SO-d6) δ 7.37 (ddd, J=2.3 Hz, J=7.4 Hz, J=10.8 Hz, 1 H, 
Ar), 7.06 (ddd, J=2.3 Hz, J=7.4 Hz, J=10.8 Hz, 1 H, Ar), 6.75 (d, J=8.7 Hz, 1 H, Ar), 6.38 
(s, 2 H, exch., 4-NH2), 5.83 (s, 2 H, exch., 2-NH2), 3.34 (s, 3H, 7-CH3), 2.38 (s, 3H, 5-
CH3). Anal. Calcd.  for C14H13F2N5S 0.04 CHCl3: C, 51.71; H, 4.03; F, 11.65; N, 21.47; S, 
9.64. Found: C, 51.75; H, 4.01; F, 11.47; N, 21.30; S, 9.74. 
 
5,7-dimethyl-6-((4-(trifluoromethoxy)phenyl)thio)-7H-pyrrolo[2,3-d]pyrimidine-2,4-
diamine (160) 
Reaction of 153 (0.150 g, 0.42 mmol), sodium hydride (0.012g, 0.5 mmol) and 
iodomethane (32 mmL, 0.5 mmol) using the general procedure described above gave 160 
(0.1 g, 48%) as white solid; TLC Rf = 0.57 (MeOH:CHCl3:NH4OH, 1:5:0.5); mp, 282.0-
283.8 °C  1H NMR (400 Hz) (Me2SO-d6) δ 7.29 (d, J= 8.3 Hz, 2 H, Ar), 7.06 (d, J=8.2 Hz, 
2 H, Ar), 6.47 (s, 2 H, exch., 4-NH2), 5.88 (s, 2 H, exch., 2-NH2), 3.38 (s, 3H, 7-CH3), 2.39 
(s, 3H, 5-CH3). Anal. Calcd.  for C15H14F3N5OS: C, 48.78; H, 3.82; F, 15.43; N, 18.96; O, 
4.33; S, 8.68. Found: C, 49.03; H, 4.01; F, 18.93; N, 15.17; S, 8.61. 
 
2,6-dichloro-3-nitropyridine (114) 
2,6-dichloro-pyridine 142 (10 g, 67.5 mmol) was nitrated using 10 mL concentrated nitric 
acid and 2 mL concentrated sulfuric acid, by heating the mixture at 110 ⁰ C for 4 hours. 
To this solution, water (20 mL) was added. The water layer was extracted with ethyl acetate 
(3 times, with 50 mL). The solvent was removed under reduced pressure to afford crude 
114 as yellow solid (7.5 g, 58%). The product was a white solid with TLC Rf = 0.32 
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(EtOAc:Hexane, 1:2); mp, 62.8 °C (lit.258 62.5-63.5 °C); 1H NMR (400 Hz) (Me2SO-d6) δ 
8.63 (d, J = 8.4 Hz, 1 H, Ar), 7.87 (d, J = 8.4 Hz, 1 H, Ar). 
 
6-chloro-3-nitropicolinonitrile (115) 
N-methyl pyrrolidinone (20 mL) was heated at 180 ⁰ C, and to it was added 2,6-dichloro-
3-nitropyridine (143) (6 g, 31.10 mmol) and copper cyanide (4.18 g, 46.64 mmol) and 
stirred for 15 minutes. To this solution, water (20 mL) was added. The water layer was 
extracted with ethyl acetate (3 times, with 50 mL). The solvent was removed under reduced 
pressure to afford crude 115 as yellow solid (4.5 g, 79%). The product was a pink solid 
with TLC Rf = 0.44 (EtOAc: Hexane, 1:2); mp, 173.2-178.2 ⁰ C (lit.258 171.5-175 ⁰ C); 
1H-NMR (400 Hz) (CDCl3) δ 8.58 (d, J = 7.2 Hz, 1 H), 7.80 (d, J = 7.2 Hz, 1 H). 
 
General Procedure for the Synthesis of Compounds 169-177, 180-184.  
A solution of 6-chloro-3-nitropicolinonitrile (115) (0.60 g, 2.7 mmol) and an appropriate 
aniline was heated at 130 °C in isopropanol. After 3-16 h, the solution was concentrated 
under reduced pressure. The precipitate obtained was neutralized with solution of ammonia 
in methanol to afford 300-313 as a crude product. The next step was carried out without 
any purification. To a suspension of 297-309 in methanol (20 mL) and concentrated 
hydrochloric acid (36%, 2 - 4.0 mL) was added iron powder. The mixture was refluxed 
until all the starting material had reacted (monitored on TLC). The hot reaction mixture 
was poured into water (20 mL) and stirred for 5 min. The unreacted iron was removed 
using a stirring bar retriever, and the aqueous solution was neutralized with ammonium 
hydroxide to pH 4. The solution was then extracted with chloroform (3 × 20 mL), and the 
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combined organic layer was washed with water (2 × 5.0 mL), sodium bicarbonate solution 
(5.0 mL), and brine (5.0 mL) and dried over anhydrous sodium sulfate. The product is a 
gummy brown semi-solid. The next step was carried out without any purification and 
characterization. Mixture of 310-322, chloroformamidine hydrochloride (1 g), and 
dimethyl sulfone (4.0 g) was heated in an oil bath at 140 °C under nitrogen for 15 min. The 
oil bath was removed, and water (10 mL) was added slowly to the hot reaction mixture. 
The aqueous solution was cooled to room temperature and extracted with chloroform (3 × 
5 mL) to remove dimethyl sulfone. The aqueous phase was made basic to pH 10 with 
ammonium hydroxide, followed by removal of water under reduced pressure. The residue 
was dissolved in a mixture of 50:50 methanol-acetone (v/v), and silica gel was added (3.0 
g). After the removal of solvent with a rotary evaporator, the silica gel plug was loaded 
onto a column and eluted with 1:5 MeOH-CHCl3 (v/v). The fractions containing the 
required compound were evaporated under reduced pressure to afford the targeted 
compounds. 
 
N6-phenylpyrido[3,2-d]pyrimidine-2,4,6-triamine (169)  
Solution of 115 (0.60 g, 3.27 mmol), aniline (0.365 g, 3.92 mmol) was reacted in 
isopropanol for 8 hours to afford 298  as a yellow solid. TLC Rf 0.7 (EtOAc:Hexane, 1:2). 
No separation was performed to purify and characterize the intermediate. Suspension of 
298, concentrated hydrochloric acid, iron powder in methanol was heated for 4 hours to 
afford 310. TLC Rf 0.65 (EtOAc:Hexane, 1:2). No separation was performed to purify and 
characterize the intermediate. Compound 169 (0.12 g, 15% over three steps) was obtained 
on heating  310, chlorformamidine hydrochloride (1 g), and dimethyl sulfone (4.0 g) for 4 
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hours, as a yellow solid; TLC Rf = 0.62 (MeOH:CHCl3:NH4OH, 1:5:0.5); mp, 174.5-178.2 
°C; 1H NMR (500 Hz) (Me2SO-d6) δ  9.19 (s, 1H, -NH, exch.), 7.73 (d, J=7.9 Hz, 2 H, Ar), 
7.50 (d, J=8.9 Hz, 1 H, Ar), 7.29 (t, J=7.2 Hz, 2 H, Ar), 7.16 (d, J=8.9 Hz, 1 H, Ar), 6.90 
(t, J=7.3 Hz, 1 H, Ar), 6.56-7.40 (collapsed br, 2 H, exch., 4-NH2), 5.93 (br s, 2 H, exch., 
2-NH2). Anal. Calcd.  for C13H12N6 0.46 CH3OH: C, 60.71; H, 5.17; N, 31.70. Found: C, 
60.43; H, 5.12; N, 31.53. 
 
 N6-(p-tolyl)pyrido[3,2-d]pyrimidine-2,4,6-triamine (170) 
Solution of 115 (0.60 g, 3.27 mmol), 4-methyl aniline (0.420 g, 3.92 mmol) was reacted in 
isopropanol for 7 hours to afford 299. TLC Rf 0.7 (EtOAc:Hexane, 1:2). No separation was 
performed to purify and characterize the intermediate. Suspension of 299, concentrated 
hydrochloric acid, iron powder in methanol was heated for 6 hours to afford 311. TLC Rf 
= 0.60 (EtOAc:Hexane, 1:2). No separation was performed to purify and characterize the 
intermediate 311. Compound 170 (0.12 g, 14% over three steps) was obtained on heating 
311, chlorformamidine hydrochloride (1 g), and dimethyl sulfone (4.0 g) for 4 hours, as a 
yellow solid; TLC Rf =  0.58 (MeOH:CHCl3:NH4OH, 1:5:0.5); mp, 233.3-236.1°C; 
1H 
NMR (400 Hz) (Me2SO-d6) δ  9.10 (s, 1 H, -NH, exch.), 7.66 (d, J=8.4 Hz, 2 H, Ar), 7.47 
(d, J=9.0 Hz, 1 H, Ar), 7.13 (d, J= 8.4 Hz, 2 H, Ar), 7.11 (d, J=9.0 Hz, 1 H, Ar), 6.23-6.60 
(collapsed br, 2 H, exch., 4-NH2), 5.85 (br s, 2 H, exch., 2-NH2). Anal. Calcd.  for C14H14N6 
0.01 CHCl3:C, 62.91; H, 5.28; N, 31.42. Found: C, 62.65; H, 5.41; N, 31.80. 
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N6-(4-methoxyphenyl)pyrido[3,2-d]pyrimidine-2,4,6-triamine (171) 
Solution of 115 (0.60 g, 3.27 mmol), 4-methoxyaniline (0.420 g, 3.92 mmol) was reacted 
in isopropanol for 12 hours to afford 300. TLC Rf 0.72 (EtOAc:Hexane, 1:2). No separation 
was performed to purify and characterize the intermediate. An impurity was also obtained 
with TLC Rf 0.6 (EtOAc:Hexane, 1:2), which was also taken to the next reaction. 
Suspension of 300, concentrated hydrochloric acid, iron powder in methanol was heated 
for 2 hours to afford 312. TLC Rf 0.66 (EtOAc:Hexane, 1:2). No separation was performed 
to purify and characterize the intermediate. Compound 171 (0.03 g, 3% over three steps) 
was obtained on heating 312, chlorformamidine hydrochloride (1 g), and dimethyl sulfone 
(4.0 g) for 3 hours, as a yellow solid; TLC Rf = 0.42 (MeOH:CHCl3:NH4OH, 1:5:0.5); mp, 
165.7-171.2 °C; 1H NMR (400 Hz) (Me2SO-d6) δ  8.99 (s, 1 H, exch., -NH), 7.52 (d, J=8.9 
Hz, 2 H, Ar), 7.42 (d, J=9.1 Hz, 1 H, Ar), 7.06 (d, J=9.1 Hz, 1 H, Ar), 6.73 (d, J=8.9  Hz, 
2 H,  Ar), 6.36-7.00 (collapsed br, 2 H, exch., 4-NH2), 5.77 (br s, 2 H, exch., 2-NH2), 3.73 
(s, 3 H, 4-OCH3). Anal. Calcd.  for C14H14N6O 0.47 CH3COCH3 C, 59.80; H, 5.50; N, 
26.99; O, 5.67. Found: C, 59.87; H, 5.35; N, 27.13. 
 
4-((2,4-diaminopyrido[3,2-d]pyrimidin-6-yl)amino)phenol (172) 
Suspension of 300, concentrated hydrochloric acid, iron powder in methanol was heated 
for 2 hours to afford 313. TLC Rf   0.56 (EtOAc:Hexane, 1:2). No further separation was 
performed to purify and characterize the intermediate. Compound 172 (0.04 g, 4% over 
three steps) was obtained as a yellow solid; TLC Rf = 0.35 (MeOH:CHCl3:NH4OH, 
1:5:0.5); mp, decomposes at 134 °C; 1H NMR (400 Hz) (Me2SO-d6) δ 8.95 (s, 1 H, exch., 
-NH), 8.85 (s, 1 H, -OH, exch.), 7.52 (d, J=8.9 Hz, 2 H, Ar), 7.42 (d, J=9.1 Hz, 1 H, Ar), 
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7.06 (d, J=9.1 Hz, 1 H, Ar), 6.73 (d, J=8.9 Hz, 2 H, Ar), 6.26-7.10 (collapsed br, 2 H, exch., 
4-NH2), 5.75 (br s, 2 H, exch., 2-NH2). Anal. Calcd. for C13H12N6O 0.3 CH3COCH3 0.09 
HCl C, 57.75; H, 4.84; N, 29.07; O, 5.96. Found: C, 57.70; H, 4.92; N, 29.34. 
 
N6-(naphthalen-1-yl)pyrido[3,2-d]pyrimidine-2,4,6-triamine (173) 
Solution of 115 (0.60 g, 3.27 mmol), naphthalen-1-amine (0.560 g, 3.92 mmol) was reacted 
in isopropanol for 10 hours to afford 301. TLC Rf = 0.7 (EtOAc:Hexane, 1:2). No 
separation was performed to purify and characterize the intermediate. Suspension of 301, 
concentrated hydrochloric acid, iron powder in methanol was heated for 6 hours to afford 
314. TLC Rf 0.63 (EtOAc:Hexane, 1:2). No further separation was performed to purify and 
characterize the intermediate. Compound 173 (0.12 g, 12% over three steps) was obtained 
on heating 314 (0.2 g, 0.76 mmoles), chlorformamidine hydrochloride (1 g), and dimethyl 
sulfone (4.0 g) for 5 hours, as a yellow solid; TLC Rf = 0.50 (MeOH:CHCl3:NH4OH, 
1:5:0.5); mp, 267.9-270.1 °C; 1H NMR (400 Hz) (Me2SO-d6) δ  9.10 (s, 1 H, exch., -NH), 
8.14 (d, J=8.8 Hz, 1 H, Ar), 8.01 (d, J=7.3Hz, 1 H, Ar), 7.91 (d, J=8.9 Hz, 1 H, Ar), 7.63 
(d, J=8.5 Hz, 1 H, Ar), 7.50 (m, 4 H, Ar), 7.30 (d, J=9.1Hz, 1 H, Ar), 6.46-6.93 (collapsed 
br, 2 H, exch., 4-NH2), 5.92 (br s, 2 H, exch., 2-NH2). Anal. Calcd.  for C17H14N6 0.07 
CHCl3: C, 65.99; H, 4.59; N, 27.05. Found: C, 66.06; H, 4.66; N, 27.07. 
 
N6-(naphthalen-2-yl)pyrido[3,2-d]pyrimidine-2,4,6-triamine (174) 
Solution of 115 (0.60 g, 3.27 mmol), naphthalen-2-amine (0.560 g, 3.92 mmol) was reacted 
in isopropanol for 3 hours to afford 302. TLC Rf 0.71 (EtOAc:Hexane, 1:2). No separation 
was performed to purify and characterize the intermediate. Suspension of 302, concentrated 
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hydrochloric acid, iron powder in methanol was heated for 5.5 hours to afford 315. TLC 
Rf 0.65 (EtOAc:Hexane, 1:2). No further separation was performed to purify and 
characterize the intermediate. Compound 174 (0.15 g, 15% over three steps) was obtained 
on heating 315, chlorformamidine hydrochloride (1 g), and dimethyl sulfone (4.0 g) for 5 
hours, as a yellow solid; TLC Rf = 0.50 (MeOH:CHCl3:NH4OH, 1:5:0.5); mp, 216.5-218.2 
°C; 1H NMR (400 Hz) (Me2SO-d6) δ  9.44 (s, 1 H, exch., -NH), 8.47 (d, J = 2.3 Hz, 1 H, 
Ar), 7.88 – 7.74 (m, 3 H, Ar), 7.66 (dd, J = 8.7, 2.1 Hz, 1 H, Ar), 7.53 (d, J = 9.0 Hz, 1 H, 
Ar), 7.42 (t, J = 7.5 Hz, 1 H, Ar), 7.37 – 7.21 (m, 2 H, Ar), 6.46-7.16 (collapsed br, 2 H, 
exch., 4-NH2), 5.91 (br s, 2 H, exch., 2-NH2). Anal. Calcd.  for C17H14N6 0.2 H2O: C, 66.64; 
H, 4.74; N, 27.47. Found: C, 66.31; H, 4.73; N, 27.92. 
 
N6-(3,4-difluorophenyl)pyrido[3,2-d]pyrimidine-2,4,6-triamine (175) 
Solution of 115 (0.60 g, 3.27 mmol), 3,4-difluoroaniline (0.506 g, 3.92 mmol) was reacted 
in isopropanol for 8.5 hours to afford 303. TLC Rf 0.67 (EtOAc:Hexane, 1:2). No 
separation was performed to purify and characterize the intermediate. Suspension of 303, 
concentrated hydrochloric acid, iron powder in methanol was heated for 5 hours to afford 
316. TLC Rf 0.60 (EtOAc:Hexane, 1:2). No further separation was performed to purify and 
characterize the intermediate. Compound 175 (0.10 g, 21% over three steps) was obtained 
on heating 316, chlorformamidine hydrochloride (1 g), and dimethyl sulfone (4.0 g) for 4 
hours, as a yellow solid; TLC Rf =  0.36 (MeOH:CHCl3:NH4OH, 1:5:0.5); mp, 242.4-248.9 
°C; 1H NMR (400 Hz) (Me2SO-d6) δ 9.42 (s, 1 H, exch., -NH), 7.75 (dd, J=6.9 Hz, J=12.1 
Hz, 1 H, Ar), 7.51 (d, J=6.7 Hz, 2 H, Ar), 7.29 (dd, J=9.5 Hz, J=19.7 Hz, 1 H, Ar),  7.13 
(d, J=9.0 Hz, 1 H, Ar), 6.80-7.26 (collapsed br, 2 H, exch. 4-NH2), 6.02 (br s, 2 H, exch., 
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2-NH2). Anal. Calcd.  for C13H10F2N6 0.71 CH3OH 0.5 H2O: C, 51.47; H, 4.35; N, 26.29; 
F, 11.89. Found: C, 51.37; H, 4.21; N, 26.22; F, 11.96. 
 
3-nitro-6-((3,4,5-trifluorophenyl)amino)picolinonitrile (297) 
Solution of 115 (0.60 g, 3.27 mmol), 3,4,5-trifluroaniline 0.577 g, 3.92 mmol) was reacted 
in isopropanol for 6 hours to afford 297 (0.45 g, 47%) as yellow solid after performing a 
flash chromatography using ethyl acetate and Hexane as eluent. TLC Rf = 0.7 
(EtOAc:Hexane, 1:2); mp, 165.7-169.0 °C; 1H NMR (400 Hz) (Me2SO-d6) δ 10.55 (s, br, 
1 H, -NH), 8.42 (d, J=6.4 Hz, 1 H, Ar), 7.56 (d, J=6.4 Hz, 2 H, Ar), 7.14 (d, J=9.4 Hz, 1 H, 
Ar). Anal. Calcd.  for C12H5F3N4O2: C, 48.99; H, 1.71; F, 19.37; N, 19.04; O, 10.88. Found: 
C, 49.13; H, 1.76; F, 19.15; N, 18.94. 
 
N6-(3,4,5-trifluorophenyl)pyrido[3,2-d]pyrimidine-2,4,6-triamine (176) 
Suspension of 297, concentrated hydrochloric acid, iron powder in methanol was heated 
for 4 hours to afford 317. TLC Rf 0.68 (EtOAc:Hexane, 1:2). No further separation was 
performed to purify and characterize the intermediate. Compound 176 (0.16 g, 16% over 
three steps) was obtained on heating 317, chlorformamidine hydrochloride (1 g), and 
dimethyl sulfone (4.0 g) for 4 hours, as a yellow solid; TLC Rf = 0.35 
(MeOH:CHCl3:NH4OH, 1:5:0.5); mp, 293.3-297.8°C; 
1H NMR (500 Hz) (Me2SO-d6) δ  
9.53 (s, 1 H, exch., -NH), 7.63 (dd, J=6.4 Hz, J=10.9 Hz, 2 H, Ar), 7.54 (d, J=9.0 Hz, 1 H, 
Ar), 7.12 (d, J=9.1 Hz, 1 H, Ar), 6.56-7.40 (collapsed br, 2 H, exch., 4-NH2), 5.93 (br s, 2 
H, exch., 2-NH2). Anal. Calcd.  for C13H9F3N6 0.85 CH3OH: C, 49.63; H, 4.24; F, 17.00; 
N, 25.07. Found: C, 50.31; H, 3.65; N, 24.99; F, 16.63. 
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N6-(4-(trifluoromethoxy)phenyl)pyrido[3,2-d]pyrimidine-2,4,6-triamine (177) 
Solution of 115 (0.60 g, 3.27 mmol), 4-trifluromethoxyaniline (0.750 g, 3.92 mmol) was 
reacted in isopropanol for 12 hours to afford 304. TLC Rf 0.75 (EtOAc:Hexane, 1:2). No 
separation was performed to purify and characterize the intermediate. Suspension of 304, 
concentrated hydrochloric acid, iron powder in methanol was heated for 3 hours to afford 
318. TLC Rf = 0.70 (EtOAc:Hexane, 1:2). No further separation was performed to purify 
and characterize the intermediate. Compound 177 (0.095 g, 9% over three steps) was 
obtained on heating 318, chlorformamidine hydrochloride (1 g), and dimethyl sulfone (4.0 
g) for 4 hours, as a yellow solid; TLC Rf  0.40 (MeOH:CHCl3:NH4OH, 1:5:0.5); mp, 190.6-
193.5 °C; 1H NMR (500 Hz) (Me2SO-d6) δ 9.40 (s, 1 H, exch., -NH), 7.87 (d, J=9.1Hz, 2 
H, Ar), 7.51 (d, J=9.1 Hz, 1 H, Ar), 7.27 (d, J=9.0 Hz, 2 H, Ar), 7.16 (d, J=9.1 Hz, 1 H, 
Ar), 6.60-7.20 (collapsed br, 2 H, exch., 4-NH2), 5.87 (br s, 2 H, exch., 2-NH2). Anal. 
Calcd.  for C14H11F3N6O: C, 50.00; H, 3.30; F, 16.95; N, 24.99; O, 4.76. Found: C, 49.72; 
H, 3.48; F, 16.69; N, 24.70. 
 
N6-methyl-N6-phenylpyrido[3,2-d]pyrimidine-2,4,6-triamine (180) 
Solution of 115 (0.60 g, 3.27 mmol), N-methylaniline (0.420 g, 3.92 mmol) was reacted in 
isopropanol for 14 hours to afford 305. TLC Rf = 0.75 (EtOAc:Hexane, 1:2). No separation 
was performed to purify and characterize the intermediate. Suspension of 305, concentrated 
hydrochloric acid, iron powder in methanol was heated for 3 hours to afford 319. TLC Rf 
0.71 (EtOAc:Hexane, 1:2). No further separation was performed to purify and characterize 
the intermediate. Compound 180 (0.09 g, 10% over three steps) was obtained on heating 
319, chlorformamidine hydrochloride (1 g), and dimethyl sulfone (4.0 g) for 4 hours, as a 
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yellow solid; TLC Rf  0.63 (MeOH:CHCl3:NH4OH, 1:5:0.5); mp, 201.4-205.2 °C; 
1H NMR 
(500 Hz) (Me2SO-d6) δ 7.42 (d, J=7.8 Hz, 2 H, Ar), 7.34 (d, J=9.2 Hz, 1 H, Ar), 7.29 (t, 
J=7.6 Hz, 2 H, Ar), 7.20 (d, J=7.3 Hz, 1 H, Ar), 6.89 (t, J=9.2 Hz, 1 H, Ar), 6.90-7.20 
(collapsed br, 2 H, exch., 4-NH2), 5.87 (br s, 2 H, exch., 2-NH2), 3.48 (s,  3 H, -CH3). Anal. 
Calcd.  for C13H12N4: C, 63.14; H, 5.30; N, 31.56 Found: C, 63.18; H, 5.35; N, 31.39. 
 
N6-ethyl-N6-phenylpyrido[3,2-d]pyrimidine-2,4,6-triamine (181) 
Solution of 115 (0.60 g, 3.27 mmol), N-ethylaniline (0.475 g, 3.92 mmol) was reacted in 
isopropanol for 9 hours to afford 306. TLC Rf = 0.75 (EtOAc:Hexane, 1:2). No separation 
was performed to purify and characterize the intermediate. Suspension of 306, concentrated 
hydrochloric acid, iron powder in methanol was heated for 7 hours to afford 320. TLC Rf 
0.73 (EtOAc:Hexane, 1:2). No further separation was performed to purify and characterize 
the intermediate. Compound 181 (0.08 g, 9% over three steps) was obtained on heating 
320, chlorformamidine hydrochloride (1 g), and dimethyl sulfone (4.0 g) for 3 hours, as a 
yellow solid; TLC Rf  0.63 (MeOH:CHCl3:NH4OH, 1:5:0.5); mp, 237.1-240.3°C; 
1H NMR 
(400 Hz) (Me2SO-d6) δ 7.42 (t, J=7.6 Hz, 2 H, Ar), 7.29 (d, J=9.3 Hz, 1 H, Ar), 7.24 (d, 
J=7.3 Hz, 1 H, Ar), 7.20 (d, J=7.3 Hz, 2 H, Ar), 6.71 (d, J=9.3Hz, 1 H, Ar), 6.90-7.20 
(collapsed br, 2 H, exch., 4-NH2), 5.80 (br s, 2 H, exch., 2-NH2), 4.07 (q, J = 6.9 Hz, 2 H, 
-CH2-),1.15 (t, J=7.3 Hz, 3 H, -CH3). Anal. Calcd.  for C15H16N6 0.07 CHCl3: C, 62.70; H, 
5.61; N, 29.11. Found: C, 62.87; H, 5.55; N, 29.11 
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N6-phenyl N6-propyl-pyrido[3,2-d]pyrimidine-2,4,6-triamine (182) 
Solution of 115 (0.60 g, 3.27 mmol), N-propylaniline (0.530 g, 3.92 mmol) was reacted in 
isopropanol for 15 hours to afford 307. TLC Rf = 0.79 (EtOAc:Hexane, 1:2). No separation 
was performed to purify and characterize the intermediate. Suspension of 307, concentrated 
hydrochloric acid, iron powder in methanol was heated for 6 hours to afford 321. TLC Rf 
0.75 (EtOAc:Hexane, 1:2). No further separation was performed to purify and characterize 
the intermediate.  Compound 182 (0.15 g, 16% over three steps) was obtained on heating 
321, chlorformamidine hydrochloride (1 g), and dimethyl sulfone (4.0 g) for 3 hours, as a 
yellow solid; TLC Rf  0.63 (MeOH:CHCl3:NH4OH, 1:5:0.5); mp, 170.6-175.8 °C; 
1H NMR 
(400 Hz) (Me2SO-d6) δ 7.42 (t, J=7.5 Hz, 2 H, Ar), 7.31 (d, J=9.2 Hz, 1 H, Ar), 7.23 (t, 
J=9.3 Hz, 3 H, Ar), 6.90-7.20 (collapsed br, 2 H, exch., 4-NH2), 6.71 (d, J=9.3 Hz, 1 H, 
Ar), 5.87 (br s, 2 H, exch., 2-NH2), 3.95 (t, J=14.5 Hz, 2 H, -CH2-),1.53 (qd, J=7.1Hz, 
J=14.5Hz, 2 H, -CH2-),0.85 (t, J=7.3 Hz, 3 H, -CH3). Anal. Calcd.  for C16H18N6 0.1 CH3OH 
0.05 CHCl3: C, 63.91; H, 6.13; N, 27.69. Found: C, 63.76; H, 5.95; N, 27.57. 
 
N6-isopropyl-N6-phenylpyrido[3,2-d]pyrimidine-2,4,6-triamine (183) 
Solution of 115 (0.60 g, 3.27 mmol), N-isopropylaniline (0.530 g, 3.92 mmol) was reacted 
in isopropanol for 13 hours to afford 308. TLC Rf = 0.82 (EtOAc:Hexane, 1:2). No 
separation was performed to purify and characterize the intermediate. Suspension of 308, 
concentrated hydrochloric acid, iron powder in methanol was heated for 6 hours to afford 
322. TLC Rf 0.78 (EtOAc:Hexane, 1:2). No further separation was performed to purify and 
characterize the intermediate. Compound 183 (0.075 g, 8% over three steps) was obtained 
on heating 322, chlorformamidine hydrochloride (1 g), and dimethyl sulfone (4.0 g) for 2 
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hours, as a yellow solid; TLC Rf  0.63 (MeOH:CHCl3:NH4OH, 1:5:0.5); mp, 201.4-202.2 
°C; 1H NMR (500 Hz) (Me2SO-d6) δ 7.48 (t, J=7.1 Hz, 2 H, Ar), 7.38 (t, J=6.9 Hz, 1 H, 
Ar), 7.23 (d, J=9.1 Hz, 1 H, Ar), 7.13 (d, J=7.3 Hz, 2 H, Ar), 6.24 (d, J=9.3 Hz, 1 H, Ar), 
6.96-7.24 (collapsed br, 2 H, exch., 4-NH2), 5.97 (br, s, 2 H, exch., 2-NH2), 5.24-5.28 (m, 
1 H, -CH), 1.05 (d, J=6.4 Hz, 6 H, -CH3). Anal. Calcd.  for C16H18N6 0.03 CHCl3: C, 65.07; 
H, 6.16; N, 28.40. Found: C, 64.56; H, 5.99; N, 28.29. 
 
N6-butyl-N6-phenylpyrido[3,2-d]pyrimidine-2,4,6-triamine (184) 
Solution of 115 (0.60 g, 3.27 mmol), N-isopropylaniline (0.585 g, 3.92 mmol) was reacted 
in isopropanol for 12 hours to afford 309. TLC Rf = 0.85 (EtOAc:Hexane, 1:2). No 
separation was performed to purify and characterize the intermediate. Suspension of 309, 
concentrated hydrochloric acid, iron powder in methanol was heated for 6 hours to afford 
322. TLC Rf 0.81 (EtOAc:Hexane, 1:2). No further separation was performed to purify and 
characterize the intermediate. Compound 184 (0.18 g, 18% over three steps) was obtained 
on heating 322, chlorformamidine hydrochloride (1 g), and dimethyl sulfone (4.0 g) for 2 
hours, as a yellow solid; TLC Rf  0.63 (MeOH:CHCl3:NH4OH, 1:5:0.5); mp, 136.5 -142.5 
°C; 1H NMR (500 Hz) (Me2SO-d6) δ 7.00-7.40 (collapsed br, 2 H, 4-NH2, exch.), 7.32 (d, 
J=7.8 Hz, 2 H, Ar), 7.24 (d, J=9.2 Hz, 1 H, Ar), 7.09 (t, J=7.6 Hz, 2 H, Ar), 6.95 (d, J=7.3 
Hz, 1 H, Ar), 6.27 (t, J=9.2 Hz, 1 H, Ar), 5.79 (br s, 2 H, 2-NH2, exch.), 3.95 (t, J=8.4Hz, 
2 H, -CH2-) , 1.49 (m, 2H, -CH2-),1.27 (m, 2H, -CH2-), 0.80 (t, J=7.3 Hz, 3 H, -CH3). Anal. 
Calcd.  for C17H20N6 0.04 CHCl3: C, 62.10; H, 6.13; N, 27.49. Found: C, 62.19; H, 6.03; 
N, 25.34. 
 
  238 
6-(3,4-dihydroquinolin-1(2H)-yl)-3-nitropicolinonitrile (324) 
A solution of 6-chloro-3-nitro-2-pyridinecarbonitrile (294) (0.60 g, 2.7 mmol), 1,2,3,4-
tetrahydroquinoline (0.520 g, 3.92 mmol)) was heated at 130 °C in isopropanol. After 12 
h, the solution was concentrated under reduced pressure.  The precipitate obtained was 
neutralized with solution of ammonia in methanol. The residue was dissolved in a mixture 
of 50:50 methanol-acetone (v/v), and silica gel was added (3.0 g). After the removal of 
solvent with a rotary evaporator, the silica gel plug was loaded onto a column and eluted 
with 1:5 MeOH-CHCl3 (v/v). The fractions containing the required compound was 
evaporated under reduced pressure to afford 324 (0.45 g, 49%), as a yellow solid. TLC Rf 
= 0.85 (EtOAc:Hexane, 1:2); mp, 210.0-215.2 °C; 
1H NMR (400 Hz) (Me2SO-d6) δ 8.36 
(d, J = 9.8 Hz, 1 H, Ar), 7.74 – 7.37 (m, 2 H, Ar), 7.34 – 6.96 (m, 3 H, Ar), 3.96 (t, J = 6.4 
Hz , 2 H, -CH2-), 2.74 (t, J = 6.4 Hz, 2 H, -CH2-), 1.96 (t, 2 H, J = 6.4 Hz, -CH2-).  Anal. 
Calcd.  for C15H12N4O2 0.15 CH3OH 0.2 H2O: C, 63.03; H, 4.54; N, 19.41. Found: C, 63.09; 
H, 4.54; N, 19.46 
 
6-(3,4-dihydroquinolin-1(2H)-yl)pyrido[3,2-d]pyrimidine-2,4-diamine (185) 
Suspension of 324 (0.40 g, 1.43 mmol)), 2ml concentrated hydrochloric acid, iron powder 
(0.150 g, 2.85 mmol) in methanol was heated for 3 hours to afford 325 (following the 
method of synthesis for 313) TLC Rf 0.80 (EtOAc:Hexane, 1:2). No separation was 
performed to purify and characterize the intermediate. Compound 325, chlorformamidine 
hydrochloride (1 g), and dimethyl sulfone (4.0 g) were heated for 4 hours at 180 ⁰ C. The 
oil bath was removed, and water (10 mL) was added slowly to the hot reaction mixture. 
The aqueous solution was cooled to room temperature and extracted with chloroform (3 × 
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5 mL) to remove dimethyl sulfone. The aqueous phase was made basic to pH 10 with 
ammonium hydroxide, followed by removal of water under reduced pressure. The residue 
was dissolved in a mixture of 50:50 methanol-acetone (v/v), and silica gel was added (3.0 
g). After the removal of solvent with a rotary evaporator, the silica gel plug was loaded 
onto a column and eluted with 1:5 MeOH-CHCl3 (v/v). The fractions containing the 
required compound was evaporated under reduced pressure to afford 185 (0.24 g, 57% over 
two steps) as a yellow solid; TLC Rf = 0.74 (MeOH:CHCl3:NH4OH, 1:5:0.5); mp, 229.2-
234.0; 1H NMR (400 Hz) (Me2SO-d6) δ 7.47-7.42 (m, 1 H, Ar), 7.10 (dt, J = 24.8, 7.7 Hz, 
4 H, Ar), 7.00 (s, br, exch., -NH2), 6.90 (t, J = 7.2 Hz, 1 H, Ar), 5.90 (s, 2 H, exch., -NH2), 
3.44 (dt, J = 30.0, 5.1 Hz, 2 H, -CH2-), 2.70 (t, J = 6.2 Hz, 2 H, -CH2-), 1.96 – 1.76 (m, 2 
H, -CH2-). Anal. Calcd.  for C13H12N6 0.2 CH3OH 0.7 H2O: C, 62.19; H, 5.92; N, 26.86. 
Found: C, 62.04; H, 5.34; N, 26.45. 
 
3-amino-6-chloropicolinonitrile (116) 
To a suspension of 115 (6 g, 32.69 mmol) in methanol (20 mL) and concentrated 
hydrochloric acid (36%, 6.0 mL) was added iron powder (2.74 g, 49.03 mmol). The 
mixture was refluxed for 5 hours. The hot reaction mixture was poured into water (20 mL) 
and stirred for 5 min. The unreacted iron was removed using a stirring bar retriever, and 
the aqueous solution was neutralized with ammonium hydroxide to pH 14. The solution 
was then extracted with chloroform (3 × 20 mL), and the combined organic layer was 
washed with water (2 × 5.0 mL), sodium bicarbonate solution (5.0 mL), and brine (5.0 mL) 
and dried over anhydrous sodium sulfate. TLC Rf = 0.17 (EtOAc:Hexane, 1:2); mp, 175 
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°C (lit.258  175-176.5 °C); 1H NMR (500 Hz) (CDCl3-d) δ 7.81 (d, J = 2.0, 0.6 Hz, 1 H, Ar), 
7.75 (s, 2 H, exch., NH2), 7.06 – 6.99 (d, J = 2.0, 0.6 Hz, 1 H, Ar). 
 
General Procedure for the Synthesis of Compounds 186-197 
A mixture of 116, chloroformamidine hydrochloride, and dimethyl sulfone was heated in 
an oil bath at 140 °C for 3 hours. The formation of 117 was noted as a new spot appears 
TLC Rf 0.16 (MeOH:CHCl3:NH4OH, 1:10:0.5). The product was not separated or 
characterized. To the mixture, appropriate thiols were added and heated at 180 ⁰ C. The 
reaction was terminated on disappearance of the spot for 117. To the heated solution, was 
added water and for 15 mins. To the water mixture, ethyl acetate (50 mL) was added and 
extracted three times. The solvent was evaporated under reduced pressure and to this was 
added methanol (50 mL). The residue was dissolved in a mixture of 50:50 methanol-
acetone (v/v), and silica gel was added (3.0 g). After the removal of solvent with a rotary 
evaporator, the silica gel plug was loaded onto a column and eluted with 1:5 MeOH-CHCl3 
(v/v). The fractions containing the required compound were evaporated under reduced 
pressure to afford target compounds 186-197.   
 
6-(phenylthio)pyrido[3,2-d]pyrimidine-2,4-diamine (186) 
Following the procedure stated above, treatment of 116 (400 mg, 2.60 mmol) with 
chlorformamidine hydrochloride (600 mg, 5.21 mmol) in dimethyl sulfone at 140C for 4 
hours yielded 117. The cyclized 117 was reacted with benzenethiol (290 mg, 2.6 mmol) in 
dimethyl sulfone at 180C afforded 186 (200 mg, 29% yield after 2 steps) as a yellow solid. 
TLC Rf = 0.21 (MeOH:CHCl3:NH4OH, 1:10:0.5);  mp, 188.6 -190.2 C; 1H NMR (400 
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MHz) (Me2SO-d6) δ 7.77 – 7.30 (m, 6 H, Ar), 7.50 (s, 2 H, NH2, exch.), 7.16 (d, J = 9.0 
Hz, 1 H, Ar), 6.29 (s, 2 H, NH2, exch.). Anal. Calcd.  for C13H11N5S 0.2 H2O: C, 57.21; H, 
4.21; N, 25.66; S, 11.75. Found: C, 57.29; H, 4.06; N, 25.59; S, 11.76. 
 
6-((3-methoxyphenyl)thio)pyrido[3,2-d]pyrimidine-2,4-diamine (188) 
Treatment of 116 (400 mg, 2.60 mmol) with chlorformamidine hydrochloride (600 mg, 
5.21 mmol) in dimethyl sulfone at 140C for 4 hours yielded 117. The cyclized 117 was 
reacted with 3-methoxybenzenethiol (365mg, 2.6 mmol) in dimethyl sulfone at 180C 
afforded 5 (180 mg, 23% yield after 2 steps) as a yellow solid. TLC Rf = 0.22 
(MeOH:CHCl3:NH4OH, 1:10:0.5);  mp, 189.2C; 1H-NMR (400 MHz) (Me2SO-d6) δ 7.49 
(dd, J = 8.9, 1.4 Hz, 1 H, Ar), 7.39 (t, J = 7.6 Hz, 2 H, Ar), 7.18 (dd, J = 8.8, 1.4 Hz, 2 H, 
Ar), 7.14 – 7.05 (m, 2 H, exch., NH2), 7.05 – 6.98 (m, 1 H, Ar), 6.28 (s, 2 H, exch., NH2), 
3.77 (s, 3 H, -OCH3). Anal. Calcd.  for C14H13N5OS 0.10 CHCl3: C, 54.40; H, 4.24; N, 
11.50; O, 5.34; S, 10.30. Found: C, 54.61 H, 4.38; N, 22.30; S, 10.27. 
 
6-((3,4-dimethoxyphenyl)thio)pyrido[3,2-d]pyrimidine-2,4-diamine (189) 
Treatment of 116 (400 mg, 2.60 mmol) with chlorformamidine hydrochloride (600 mg, 
5.21 mmol) in dimethyl sulfone at 140C for 4 hours yielded 117. The cyclized 117 was 
reacted with 3, 4-dimethoxybenzenethiol (439 mg, 2.6 mmol) in dimethyl sulfone at 180C 
afforded 189 (260 mg, 30.31% yield after 2 steps) as a yellow solid. TLC Rf =  0.24 
(MeOH:CHCl3:NH4OH, 1:10:0.5);  mp, 229.8C. 1H-NMR (400 MHz) (Me2SO-d6)  δ 8.20 
(s, 1 H, Ar), 7.45 (d, J=8.5 Hz, 1 H, Ar), 7.35 (s, 1 H, Ar), 7.18 (s, 2 H, NH2, exch.), 7.05 
(dd, J=7.9 Hz, J=22.7 Hz, 2 H, Ar), 6.20 (s, 2 H, NH2, exch.), 3.82 (m, 3H, -OCH3), 3.77 
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(s, 3 H, -OCH3). Anal. Calcd.  for C15H15N5O2S 0.8 H2O: C, 52.41; H, 4.87; N, 20.37; S, 
9.33. Found: C, 52.06; H, 4.41; N, 19.96; S, 9.17. 
 
6-(naphthalen-1-ylthio)pyrido[3,2-d]pyrimidine-2,4-diamine (190) 
Treatment of 116 (400 mg, 2.60 mmol) with chlorformamidine hydrochloride (600 mg, 
5.21 mmol) in dimethyl sulfone at 140C for 4 hours yielded 117. The cyclized 117 was 
reacted with naphthalene-1-thiol (420 mg, 2.6 mmol) in dimethyl sulfone at 180C afforded 
190 (340 mg, 41% yield after 2 steps) as a yellow solid. TLC Rf = 0.24 
(MeOH:CHCl3:NH4OH, 1:10:0.5);  mp, 234.8-240.6 C; 1H-NMR (400 MHz) (Me2SO-d6)  
δ 8.20 (d, J=6.9 Hz, 1 H, Ar), 8.10 (d, J=7.7 Hz, 1 H, Ar), 8.03 (d, J=6.1 Hz, 1 H, Ar), 7.93 
(d, J=6.5 Hz, 1 H, Ar), 7.59 (dd, J=5.9 Hz, J=15.6 Hz, 3 H, Ar),7.35 (d, J=8.9 Hz, 1 H, Ar), 
6.87 (d, J=8.6 Hz, 1 H, Ar), 6.90 (s, 2 H, NH2, exch.), 6.24 (s, 2 H, NH2, exch.). Anal. 
Calcd.  for C17H13N5S 0.4 CH3OH 0.05 CHCl3: C, 61.98; H, 4.37; N, 20.71; S, 9.48. Found: 
C, 61.90; H, 4.15; N, 20.52; S, 9.49. 
 
6-(naphthalen-2-ylthio)pyrido[3,2-d]pyrimidine-2,4-diamine (191) 
Treatment of 116 (400 mg, 2.60 mmol) with chlorformamidine hydrochloride (600 mg, 
5.21 mmol) in dimethyl sulfone at 140C for 4 hours yielded 117. The cyclized 117 was 
reacted with naphthalene-2-thiol (300 mg, 2.6 mmol) in dimethyl sulfone at 180C afforded 
191 (340 mg, 36% yield after 2 steps) as a white solid. TLC Rf = 0.26 
(MeOH:CHCl3:NH4OH, 1:10:0.5);  mp, 238.9-243.7 C; 1H-NMR (400 MHz) (Me2SO-d6)  
1H-NMR (400 MHz) δ 8.21 (d, J=1.6 Hz, 1 H, Ar), 7.98 (m, 3 H, Ar), 7.59 (ddd, J=2.0 Hz, 
J=3.5 Hz, J=7.3 Hz, 3 H, Ar), 7.47 (d, J=8.8 Hz, 1 H, Ar), 7.20 (d, J=8.8 Hz, 1 H, Ar), 6.96 
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(s, 2 H, NH2, exch.), 6.26 (s, 2 H, NH2, exch.). Anal. Calcd.  for C17H13N5S 0.7 CHCl3: C, 
62.76; H, 3.43; N, 21.38; S, 9.96. Found: C, 62.46; H, 4.24; N, 21.53; S, 9.80. 
 
6-((4-fluorophenyl)thio)pyrido[3,2-d]pyrimidine-2,4-diamine (192) 
Treatment of 116 (400 mg, 2.60 mmol) with chlorformamidine hydrochloride (600 mg, 
5.21 mmol) in dimethyl sulfone at 140C for 4 hours yielded 117. The cyclized 117 was 
reacted with 4-fluorobenzenethiol (333 mg, 2.6 mmol) in dimethyl sulfone at 180C 
afforded 192 (180 mg, 24% yield after 2 steps) as a yellow solid. TLC Rf = 0.22 
(MeOH:CHCl3:NH4OH, 1:10:0.5);  mp, 200.7-206.9 C; 1H NMR (400 MHz) (Me2SO-d6) 
δ 7.66 (dd, J = 8.5, 5.4 Hz, 2 H, Ar), 7.48 (d, J = 8.8 Hz, 1 H, Ar), 7.34 (t, J = 8.5 Hz, 2 H, 
Ar), 7.16 (d, J = 8.8 Hz, 1 H, Ar), 6.89 (s, br, NH2, 2 H, exch.), 6.26 (s, 2 H, NH2, exch.). 
Anal. Calcd.  for C13H10FN5S 0.20 CH3OH: C, 53.98; H, 3.71; F, 6.47; N, 23.84; S, 10.92. 
Found: C, 53.83; H, 3.48; F, 6.35; N, 23.85; S, 11.03. 
 
6-((3,4-difluorophenyl)thio)pyrido[3,2-d]pyrimidine-2,4-diamine (193) 
Treatment of 116 (400 mg, 2.60 mmol) with chlorformamidine hydrochloride (600 mg, 
5.21 mmol) in dimethyl sulfone at 140C for 4 hours yielded 117. The cyclized 117 was 
reacted with 3,4-difluorobenzenethiol (380mg, 2.6 mmol) in dimethyl sulfone at 180C 
afforded 193 (290 mg, 36% yield after 2 steps) as a yellow solid. TLC Rf = 0.22 
(MeOH:CHCl3:NH4OH, 1:10:0.5);  mp, 265.3-268.3C 1H-NMR (400 MHz) (Me2SO-d6) 
δ 7.45 (s, 2 H, exch., NH2), 7.29-7.59 (m, 5 H, Ar), 6.32 (s, 2 H, exch., NH2). Anal. Calcd.  
for C13H9F2N5S: C, 51.14; H, 2.97; F, 12.45; N, 22.94; S, 10.50. Found: C, 50.68; H, 3.02; 
F, 13.51; N, 22.30; S, 10.49 
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6-((3,4,5-trifluorophenyl)thio)pyrido[3,2-d]pyrimidine-2,4-diamine (194) 
Treatment of 145 (400 mg, 2.60 mmol) with chlorformamidine hydrochloride (600 mg, 
5.21 mmol) in dimethyl sulfone at 140C for 4 hours yielded 117. The cyclized 117 was 
reacted with 3,4,5-trifluorobenzenethiol (490 mg, 2.6 mmol) in dimethyl sulfone at 180C 
afforded 194 (220 mg, 26% yield after 2 step) as a yellow solid. TLC Rf = 0.23 
(MeOH:CHCl3:NH4OH, 1:10:0.5);  mp, 245.0-251.3C; 1H-NMR (400 MHz) (Me2SO-d6) 
δ 7.61 (d, J=2.9 Hz, 1 H, Ar), 7.58 (d, J=6.6 Hz, 1 H, Ar), 7.52 (d, J=8.8 Hz, 1 H, Ar), 7.38 
(d, J=8.8 Hz, 1 H, Ar), 7.08 (s, 2 H, NH2, exch.), 6.35 (s, 2 H, NH2, exch.). Anal. Calcd.  
for C13H8F3N5S 0.15 CH3OH:  C, 48.14; H, 2.64; F, 17.37; N, 21.34; S, 9.77. Found: C, 
48.30; H, 2.63; F, 17.27; N, 21.15; S, 9.81. 
 
6-((2,4-difluorophenyl)thio)pyrido[3,2-d]pyrimidine-2,4-diamine (195) 
Treatment of 145 (400 mg, 2.60 mmol) with chlorformamidine hydrochloride (600 mg, 
5.21 mmol) in dimethyl sulfone at 140C for 4 hours yielded 117. The cyclized 117 was 
reacted with 2,4-difluoro benzenethiol (380 mg, 2.6 mmol) in dimethyl sulfone at 180C 
afforded 195 (220 mg, 28% yield after 2 steps) as a yellow solid. TLC Rf = 0.22 
(MeOH:CHCl3:NH4OH, 1:10:0.5);   mp, 110.8-113.8 C;1H-NMR (400 MHz) (Me2SO-d6) 
δ 7.66 (td, J = 8.3, 7.8, 3.9 H z, 1 H, Ar), 7.55 – 7.45 (m, 2 H, Ar), 7.43 (s, 2 H, NH2, exch.), 
7.41 (s, 1 H, Ar), 7.29 (d, J = 8.8 Hz, 1 H, Ar), 6.31 (s, 2 H, NH2, exch.). Anal. Calcd.  for 
C13H9F2N5S.: C, 51.14; H, 2.97; F, 12.45; N, 22.94; S, 10.50. Found: C, 50.90; H, 3.11; F, 
12.71; N, 22.81; S, 10.32. 
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6-((4-(trifluoromethoxy)phenyl)thio)pyrido[3,2-d]pyrimidine-2,4-diamine (196) 
Treatment of 145 (400 mg, 2.60 mmol) with chlorformamidine hydrochloride (600 mg, 
5.21 mmol) in dimethyl sulfone at 140C for 4 hours yielded 117. The cyclized 117 was 
reacted with 4-(trifluoromethoxy)benzenethiol (505mg, 2.6 mmol) in dimethyl sulfone at 
180C afforded 196 (320 mg, 35% yield after 2 steps) as a yellow solid. TLC Rf = 0.21 
(MeOH:CHCl3:NH4OH, 1:10:0.5); mp, 195.6C; 1H-NMR (400 MHz) (Me2SO-d6) δ 7.67 
(d, J=8.5 Hz, 2 H, Ar), 7.52 (d, J=8.8 Hz, 1 H, Ar), 7.44 (d, J=8.5 Hz, 2 H, Ar), 7.28 (d, 
J=8.8 Hz, 1 H, Ar), 6.97 (s, 2 H, exch., NH2), 6.35 (s, 2 H, exch., NH2). Anal. Calcd.  for 
C14H10F3N5OS: C, 47.59; H, 2.85; F, 16.13; N, 19.82; O, 4.53; S, 9.07. Found: C, 47.62; 
H, 2.85; F, 16.08; N, 20.02; S, 9.24. 
 
6-((4-nitrophenyl)thio)pyrido[3,2-d]pyrimidine-2,4-diamine (197) 
Treatment of 145 (400 mg, 2.60 mmol) with chlorformamidine hydrochloride (600 mg, 
5.21 mmol) in dimethyl sulfone at 140C for 4 hours yielded 117. The cyclized 117 was 
reacted with 4-nitrobenzenethiol (400 mg, 2.6 mmol) in dimethyl sulfone at 180C afforded 
197 (160 mg, 19% yield after 2 steps, yellow solid). TLC Rf = 0.20 (MeOH:CHCl3:NH4OH, 
1:10:0.5);   mp, C 250.6C; 1H-NMR (400 MHz) (Me2SO-d6) δ 8.23 – 8.17 (m, 2 H, Ar), 
7.63 – 7.56 (m, 4 H, Ar), 7.17 (s, 2 H, NH2, exch.), 6.43 (s, 2 H, NH2, exch.). Anal. Calcd.  
for C13H10N6O2S: C, 49.68; H, 3.21; N, 26.74; O, 10.18; S, 10.20. Found: C, 49.64; H, 
3.26; N, 26.60; S, 10.42. 
 
6-(naphthalen-2-ylsulfinyl)pyrido[3,2-d]pyrimidine-2,4-diamine (198) 
To 191 (150 mg, 0.5 mmol) was added 10 mL dichloromethane and the reaction was stirred 
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at 0 ⁰C for 10 minutes. To the mixture was added 70% 3-chloroperoxybenzoic acid in 
water (175 mg, 0.7 mmol) and the reaction was stirred for 2 hours. Saturated solution of 
sodium bicarbonate was added to the reaction mixture and the target compound was 
extracted 3 times with 50 mL dichloromethane. The solvent was evaporated and silica gel 
was added to it. A flash chromatography was performed on it using chloroform and 
10%methanol in chloroform. The fraction containing the desired compound was 
evaporated to afford 199 as yellow solid (60 mg, 40%). TLC Rf = 0.26 
(MeOH:CHCl3:NH4OH, 1:5:0.5); mp, 123.6-130.0 ⁰C; 1H-NMR (400 MHz) (Me2SO-d6) 
δ 8.54 (d, J = 1.8 Hz, 1 H, Ar), 8.49 (d, J = 2.0 Hz, 1 H, Ar), 8.12 (dd, J = 6.2, 3.4 Hz, 1 H, 
Ar), 8.08 (d, J = 8.7 Hz, 1 H, Ar), 8.00 (dd, J = 6.2, 3.4 Hz, 1 H, Ar), 7.94 – 7.88 (m, 1 H, 
Ar), 7.87 (d, J = 2.0 Hz, 1 H, Ar), 7.77 (dd, J = 8.6, 1.8 Hz, 1 H, Ar), 7.69 – 7.63 (m, 1 H, 
Ar), 7.59 – 7.49 (s, 2 H, exch., NH2), 6.48 (s, 2 H, exch., NH2). MS (ESI+) calculated for 
C15H17N5OS [M+H]+, 336.08. Found: 336.30. HPLC analysis: retention time, 23.56 min; 
peak area, 98.06 %; eluent A, H2O: eluent B, ACN; gradient elution (100% H2O to 10% 
H2O) over 40 min with flow rate of 0.5 mL/min and detection at 245 nm; column 
temperature, rt. 
 
6-(naphthalen-2-ylsulfonyl)pyrido[3,2-d]pyrimidine-2,4-diamine (199) 
To 191 (300 mg, 0.93 mmol) was added 3 mL of glacial acetic acid and 10 mL of 30% 
hydrogen peroxide solution and the reaction was stirred for 3 days. The acetic acid was 
then evaporated with a rotary evaporator, and to the residue was added water (10 mL) with 
stirring. The resulting solution was carefully brought to pH 9-10 with ammonium 
hydroxide, and the precipitate formed was filtered, washed with water and ether, and 
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dissolved in 50:50 methanol-acetone (v/v). Silica gel (3.0 g) was added to the solution 
followed by removal of the solvent under reduced pressure. The silica gel plug and eluted 
with 10% methanol in chloroform. The fraction containing the desired compound was 
evaporated to afford 199 as yellow solid (180 mg, 55%). TLC Rf = 0.26 
(MeOH:CHCl3:NH4OH, 1:5:0.5); mp, decomposition> 230.0 ⁰C; 1H-NMR (400 MHz) 
(Me2SO-d6) δ 8.78 (s, 1 H, Ar), 8.20 (dd, J = 11.9, 8.5 Hz, 2 H, Ar), 8.10 (q, J = 8.8 Hz, 2 
H, Ar), 8.02 (d, J = 7.9 Hz, 1 H, Ar), 7.69 (dt, J = 18.8, 7.8 Hz, 3 H, Ar), 7.43 (s, 2 H, NH2, 
exch.), 6.75 (s, 2 H, NH2, exch). Anal. Calcd.  for C17H13N5O2S 0.09 CHCl3: C, 56.68; H, 
3.97; N, 19.34; S, 8.86. Found: C, 56.60; H, 3.97; N, 19.39; S, 8.96. 
 
3-nitro-6-phenoxypicolinonitrile (326) 
A solution of 6-chloro-3-nitro-2-pyridinecarbonitrile (115) (0.50 g, 2.72 mmol), sodium 
phenoxide (380 mg, 3.27 mmol) in anhydrous dimethyl formamide was stirred for 12 h. 
The solution was concentrated under reduced pressure.  The residue was dissolved in a 
mixture of 50:50 methanol-acetone (v/v), and silica gel was added (3.0 g). After the 
removal of solvent with a rotary evaporator, the silica gel plug was loaded onto a column 
and eluted with 1:5 MeOH-CHCl3 (v/v). The fractions containing the required compound 
were evaporated under reduced pressure to afford 326 as white solid (0.42 g, 62% yield). 
TLC Rf = 0.32 (EtOAc:Hexane, 1:2); mp, 145.5-147.5 C; 1H-NMR (400 MHz) (Me2SO-
d6) δ 8.79 (d, J = 9.2 Hz, 2 H, Ar), 7.37 (m, 1 H, Ar), 7.32 – 7.25 (m, 2 H, Ar), 7.29 (d, J= 
8 Hz, 2 H, Ar). Anal. Calcd.  for C12H7N3O3: C, 59.75; H, 2.93; N, 17.42; O, 19.90. Found: 
C, 59.82; H, 3.02; N, 17.55. 
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6-phenoxypyrido[3,2-d]pyrimidine-2,4-diamine (187) 
To a Parr flask was added 326 (0.4 g, 1.24 mmol), 10% palladium on activated carbon 
(50% w/w), and MeOH (100 mL). Hydrogenation was carried out at 55 psi of H2 for 1 h. 
The reaction mixture was filtered through Celite, washed with MeOH (100 mL), and 
concentrated under reduced pressure to afford 327 as a yellow liquid. Mixture of 327 (0.3 
g, 1.24 mmol), chloroformamidine hydrochloride (1 g), and dimethyl sulfone (4.0 g) was 
heated in an oil bath at 190 °C under nitrogen for 3 h. The oil bath was removed, and water 
(10 mL) was added slowly to the hot reaction mixture. The aqueous solution was cooled to 
room temperature and extracted with chloroform (3 × 5 mL) to remove dimethyl sulfone. 
The aqueous phase was made basic to pH 10 with ammonium hydroxide, followed by 
removal of water under reduced pressure. The residue was dissolved in a mixture of 50:50 
methanol-acetone (v/v), and silica gel was added (3.0 g). After the removal of solvent with 
a rotary evaporator, the silica gel plug was loaded onto a column and eluted with 1:5 
MeOH-CHCl3 (v/v). The fractions containing the required compound were evaporated 
under reduced pressure to afford 187 as a white solid (0.18 g, 52% over two steps). TLC 
Rf = 0.27 (MeOH:CHCl3:NH4OH, 1:5:0.5); mp, 195.6 C; 1H-NMR (400 MHz) (Me2SO-
d6) δ 7.69 (d, J = 8.9 Hz, 1 H, Ar), 7.48 – 7.39 (m, 2 H, Ar), 7.26 – 7.13 (m, 4 H), 7.20 (s, 
br, 2 H, exch., -NH2), 6.15 (s, 2 H, exch., -NH2). Anal. Calcd.  for C13H11N5O 0.25 CH3OH 
0.05 H2O 0.05 CHCl3: C, 59.57; H, 4.57; N, 26.12. Found: C, 59.74; H, 4.36; N, 25.97. 
 
General Procedure for the Synthesis of Compounds 201-208 
Reduction of 328 (6g, 32.69 mmol) using 10% Pd/C (3.48 g, 32.69 mmol) produced 329 
(4.8g, 80% yield) as a yellow semi-solid on filtration and further evaporation. It was carried 
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out to next step without any column separation. A mixture of 329, chloroformamidine 
hydrochloride (1 g), and dimethyl sulfone (4.0 g) was heated in an oil bath at 140 °C for 4 
hours. The formation of 330 was noted as a new spot appears TLC Rf = 0.17 
(MeOH:CHCl3:NH4OH, 1:10:0.5). The product was not separated or characterized. To the 
mixture, appropriate thiols were added and heated at 180 ⁰C. The reaction was terminated 
on disappearance of the spot for 330. To the heated solution, was added water and for 15 
mins. To the water mixture, ethyl acetate (50 mL) was added and extracted three times. The 
solvent was evaporated under reduced pressure and to this was added methanol (50 mL). 
Silica gel was added to make a plug and flash chromatography was carried out using 
methanol-chloroform as eluent to afford 201-208.  
 
7-(naphthalen-1-ylthio)pyrido[3,2-d]pyrimidine-2,4-diamine (201) 
Using the procedure mentioned above, treatment of 329 (400 mg, 2.60 mmol) with 
chlorformamidine hydrochloride (600 mg, 5.21 mmol) in dimethyl sulfone at 140C for 4 
hours yielded 330, which was reacted with naphthalene-1-thiol (420 mg, 2.6 mmol) at 
180C afforded 201 (340 mg, 41% yield after 2 steps) as a yellow solid). TLC Rf = 0.21 
(MeOH:CHCl3:NH4OH, 1:10:0.5);  mp, 201.7 C; 1H-NMR (400 MHz) (Me2SO-d6) δ 8.23 
(m, 1 H, Ar), 8.11 (m, 3 H, Ar), 7.94 (d, J=7.1 Hz, 1 H, Ar), 7.63 (dd, J=5.4 Hz, J=10.2 Hz, 
3 H, Ar), 7.37 (s, 2 H, NH2, exch.), 7.37 (s, 2 H, NH2, exch.), 6.78 (d, J=1.2 Hz, 1 H, Ar), 
6.20 (s, 2 H, NH2, exch.). Anal. Calcd. for C17H13N5S 0.06 CHCl3:  C, 62.86; H, 3.73; N, 
21.48; S, 9.83. Found: C, 62.95; H, 3.92; N, 21.31; S, 9.65. 
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7-(naphthalen-2-ylthio)pyrido[3,2-d]pyrimidine-2,4-diamine (202) 
Using the procedure mentioned above, treatment of 329 (400 mg, 2.60 mmol) with 
chlorformamidine hydrochloride (600 mg, 5.21 mmol) in dimethyl sulfone at 140C for 4 
hours yielded 330. The cyclized 330 was reacted with naphthalene-2-thiol (300 mg, 2.6 
mmol) in dimethyl sulfone at 180C afforded 202 (265 mg, 28% yield after 2 steps) as a 
yellow solid. TLC Rf = 0.21 (MeOH:CHCl3:NH4OH, 1:10:0.5);  mp, 186.4C 1H-NMR 
(400 MHz) (Me2SO-d6) δ 8.33 (d, J=1.8 Hz, 1 H, Ar), 7.98 (m, 3 H, Ar), 7.56 (m, 4 H, Ar), 
7.45 (s, 2 H, NH2, exch.), 7.19 (d, J=1.7 Hz, 1 H, Ar), 6.30 (s, 2 H, NH2, exch.). Anal. 
Calcd.  for C17H13N5S 0.14 CHCl3:  C, 61.25; H, 3.94; N, 20.84; S, 9.54. Found: C, 61.27; 
H, 4.04; N, 20.82; S, 9.32. 
 
7-((3-methoxyphenyl)thio)pyrido[3,2-d]pyrimidine-2,4-diamine (203) 
Using the procedure mentioned above, treatment of 329 (400 mg, 2.60 mmol) with 
chlorformamidine hydrochloride (600 mg, 5.21 mmol) in dimethyl sulfone at 140C for 4 
hours yielded 330. The cyclized 330 was reacted with 3-methoxybenzenethiol (365mg, 2.6 
mmol) in dimethyl sulfone at 180C afforded 203 (230 mg, 30% yield after 2 steps) as a 
yellow solid. TLC Rf = 0.22 (MeOH:CHCl3:NH4OH, 1:10:0.5);  mp, decomposition > 217.5 
⁰C; 1H-NMR (400 MHz) (Me2SO-d6) δ 8.13 (d, J=1.9 Hz, 1 H, Ar), 7.43 (s, 2 H, NH2, 
exch.), 7.38 (t, J = 8.1 Hz, 1 H, Ar), 7.20 (d, J=1.8 Hz, 1 H, Ar), 7.08 (t, J=8.2 Hz, 2 H, Ar), 
7.02 (t, J=9.7 Hz, 1 H, Ar), 6.30 (s, 2H,  NH2, exch.), 3.75 (s, 3H, -OCH3). Anal. Calcd.  
for: C14H13N5OS: C, 56.17; H, 4.38; N, 23.40; O, 5.34; S, 10.71. Found: C, 55.96; H, 4.45; 
N, 21.69; S, 10.64 
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7-((3,4-dimethoxyphenyl)thio)pyrido[3,2-d]pyrimidine-2,4-diamine (204) 
Using the procedure mentioned above, treatment of 329 (400 mg, 2.60 mmol) with 
chlorformamidine hydrochloride (600 mg, 5.21 mmol) in dimethyl sulfone at 140C for 4 
hours yielded 330. The cyclized 330 was reacted with 3, 4-dimethoxybenzenethiol (439 
mg, 2.6 mmol) in dimethyl sulfone at 180C afforded 204 (300 mg, 35% yield after 2 steps) 
as a yellow solid. TLC Rf = 0.20 (MeOH:CHCl3:NH4OH, 1:10:0.5);  mp, 193.7C. 1H- 
NMR (400 MHz) (Me2SO-d6) δ 7.56 (m, 3 H, Ar), 7.38 (d, J=8.8 Hz, 1 H, Ar), 7.22 (d, 
J=7.7 Hz, 1 H, Ar), 7.05 (s, 2 H, NH2, exch.), 6.30 (s, 2 H, NH2, exch.), 3.38 (s, 6 H, -
OCH3). Anal. Calcd.  for C15H15N5O2S 0.15 CHCl3: C, 52.40; H, 4.40; N, 20.17; S, 9.23. 
Found: C, 52.57; H, 4.40; N, 20.32; S, 9.36. 
 
7-((3,4-difluorophenyl)thio)pyrido[3,2-d]pyrimidine-2,4-diamine (205) 
Using the procedure mentioned above, treatment of 329 (400 mg, 2.60 mmol) with 
chlorformamidine hydrochloride (600 mg, 5.21 mmol) in dimethyl sulfone at 140C for 4 
hours yielded 330. The cyclized 330 was reacted with 3,4-difluorobenzenethiol (380mg, 
2.6 mmol) in dimethyl sulfone at 180C afforded 205 (330 mg, 41% yield after 2 steps) as 
a yellow solid. TLC Rf = 0.21 (MeOH:CHCl3:NH4OH, 1:10:0.5);  mp, 204.5C; 1H-NMR  
(400 MHz) (Me2SO-d6) δ 8.16 (d, J=2.1 Hz, 1 H, Ar), 7.26 (d, J=2.1 Hz, 1 H, Ar), 7.37 (m, 
1 H, Ar), 7.44 (s, 2 H, NH2, exch.), 7.54 (td, J=8.6 Hz, J=10.6 Hz, 1 H, Ar), 7.69 (ddd, 
J=2.3 Hz, J=7.5 Hz, J=10.5 Hz, 1H, Ar), 6.33 (s, 2 H, NH2, exch.). Anal. Calcd.  for 
C13H9F2N5S:  C, 51.14; H, 2.97; F, 12.45; N, 22.94; S, 10.50. Found: C, 51.16; H, 3.08; F, 
12.17; N, 22.65; S, 10.49 
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7-((3,4,5-trifluorophenyl)thio)pyrido[3,2-d]pyrimidine-2,4-diamine (206)  
Using the procedure mentioned above, treatment of 329 (400 mg, 2.60 mmol) with 
chlorformamidine hydrochloride (600 mg, 5.21 mmol) in dimethyl sulfone at 140C for 4 
hours yielded 330. The cyclized 330 was reacted with 3,4,5-trifluorobenzenethiol (490 mg, 
2.6 mmol) in dimethyl sulfone at 180C afforded 206 (310 mg, 37% yield after 2 steps) as 
a yellow solid. TLC Rf = 0.21 (MeOH:CHCl3:NH4OH, 1:10:0.5);  mp, 200.7-208.1 C; 1H-
NMR (400 MHz) (Me2SO-d6) δ 8.19 (d, J=2.2 Hz, 1 H, Ar), 7.45-7.38 (m, J=2.1 Hz, 3 H, 
Ar), 7.48 (s, 2 H, NH2, exch.), 6.37 (s, 2 H, NH2, exch.). Anal. Calcd.  for C13H8F3N5S 0.4 
CH3OH: C, 48.59; H, 2.80; F, 16.81; N, 20.66; S, 9.46. Found: C, 48.23; H, 2.51; F, 16.57; 
N, 20.56; S, 9.64. 
 
7-((4-(trifluoromethoxy)phenyl)thio)pyrido[3,2-d]pyrimidine-2,4-diamine (207) 
Using the procedure mentioned above, treatment of 329 (400 mg, 2.60 mmol) with 
chlorformamidine hydrochloride (600 mg, 5.21 mmol) in dimethyl sulfone at 140C for 4 
hours yielded 330. The cyclized 330 was reacted with 4-(trifluoromethoxy)benzenethiol 
(505mg, 2.6 mmol) in dimethyl sulfone at 180C afforded 207 (400 mg, 44% yield after 2 
steps) as a yellow solid TLC Rf =  0.21 (MeOH:CHCl3:NH4OH, 1:10:0.5);  mp, 198.4-201.3 
C; 1H-NMR (500 MHz) (Me2SO-d6) δ 8.16 (d, J = 2.1 Hz, 1 H, Ar), 7.60 (d, J = 8.9 Hz, 2 
H, Ar), 7.45 (s, br, 2 H, NH2, exch.), 7.44 (d, J = 8.2 Hz, 2 H, Ar), 7.24 (d, J = 2.1 Hz, 1 H, 
Ar), 6.34 (s, 2H, NH2, exch.). Anal. Calcd.  for C14H10F3N5OS: C, 47.59; H, 2.85; F, 16.13; 
N, 19.82; O, 4.53; S, 9.07. Found: C, 47.72; H, 2.95; F, 15.86; N, 19.59; S, 8.88. 
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7-((4-nitrophenyl)thio)pyrido[3,2-d]pyrimidine-2,4-diamine (208) 
Using the procedure mentioned above, treatment of 329 (400 mg, 2.60 mmol) with 
chlorformamidine hydrochloride (600 mg, 5.21 mmol) in dimethyl sulfone at 140C for 4 
hours yielded 330. The cyclized 330 was reacted with 4-nitrobenzenethiol (400 mg, 2.6 
mmol) in dimethyl sulfone at 180C afforded 208 (200 mg, 24% yield after 2 steps, yellow 
solid). TLC Rf = 0.22 (MeOH:CHCl3:NH4OH, 1:10:0.5);  mp, 201.6-205.6 C; 1H-NMR 
(400 MHz) (Me2SO-d6) δ 6.50 (s, 2 H, NH2, exch.), 7.46 (d, J=8.3 Hz, 2 H, Ar), 7.61 (s, 2 
H, NH2, exch.), 7.71 (s, 1 H, Ar), 8.16 (d, J=8.3 Hz, 2 H, Ar), 8.29 (s, 1 H, Ar) Anal. Calcd.  
for C13H10N6O2S 0.06 CHCl3: C, 49.29; H, 3.42; N, 26.13; O, 10.18; S, 9.97. Found: C, 
48.92; H, 3.14; N, 25.65; S, 10.33. 
 
General method for synthesis of 216, 218, 224 and 332 
Commercially available 331 (0.30 g, 1.95 mmol) and equivalent aniline were dissolved in 
12 ml isopropanol (12 mL) and heated in a microwave reactor at 130C for 4 hours. The 
solvent was evaporated in vacuo, silica gel was added to make a plug and flash 
chromatography was carried out using methanol-chloroform as eluent. The fractions 
containing the required compound were evaporated under reduced pressure to afford the 
target compounds. 
 
N-methyl-N-(4-methoxyphenyl)-5H-pyrrolo[3,2-d]pyrimidin-4-amine (216):  
Following the procedure for synthesis of 216, 218, 224 and 332, compound 216 was 
obtained as a white solid (360 mg, 72% yield). 1H-NMR (400 MHz) (Me2SO-d6) δ 9.96 (s, 
1 H, exch., -NH), 8.71 (s, 1 H, Ar), 7.56 (s, 1 H, Ar), 7.4 (d, J = 8.7Hz, 2 H, Ar), 7.1 (d, J 
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= 8.8 Hz, 2 H, Ar), 6.55 (s, 1 H, Ar), 3.84 (s, 3 H, -OCH3), 3.65 (s, 3 H, -NCH3). The 
1H-
NMR matches the 1H-NMR of the reported compounds in the literature.214  
 
6-methoxy-1-(5H-pyrrolo[3,2-d]pyrimidin-4-yl)-1,2,3,4-tetrahydroquinoline (218) 
Following the procedure for synthesis of 216, 218, 224 and 332, compound 218 was 
obtained as a white solid (360 mg, 66% yield); TLC = Rf  0.15 (MeOH:CHCl3:NH4OH, 
1:10:0.5); mp, 100 C; 1H NMR (400 MHz) (Me2SO-d6) δ 10.30 (s, 1 H, 5-NH, exch.), 
8.40 (s, 1 H, 2-H), 7.45 (t, J=3.0 Hz, 1 H, Ar), 6.81 (d, J=2.8 Hz, 1 H, Ar), 6.76 (d, J=8.8 
Hz, 1 H, Ar), 6.68 (dd, J=2.9 Hz, J=8.8 Hz, 1 H, Ar), 6.46 (dd, J=1.7 Hz, J=2.9 Hz, 1 H, 
Ar), 3.94 (t, J=6.3 Hz, 2 H, -CH2-), 3.74 (s, 3 H, -OCH3), 2.78 (t, J=6.5 Hz, 2 H, -CH2-) , 
1.93 (p, J=6.5 Hz, 2 H, -CH2-) Anal. Calcd.  for C16H16N4O 0.1 CHCl3: C, 68.94; H, 5.53; 
N, 19.09; O, 5.71 Found: C, 68.97; H, 5.55; N, 19.05. 
 
N-methyl-N-(4-(methylthio)phenyl)-5H-pyrrolo[3,2-d]pyrimidin-4-amine (224) 
Following the procedure for synthesis of 216, 218, 224 and 332, compound 224 was 
obtained as a white solid (310 mg, 59% yield); TLC Rf = 0.15 (MeOH:CHCl3:NH4OH, 
1:5:0.5); mp, 120.3 C; 1H NMR (400 MHz) (Me2SO-d6) δ 9.41 (s, 1 H, 5-NH, exch.), 8.38 
(s, 1 H, Ar), 7.31 (m, 3 H, Ar), 7.21 (d, J=8.5 Hz, 2 H, Ar), 6.40 (d, J=2.5 Hz, 1 H, Ar), 
3.52 (s, 3 H, -N4CH3), 2.51 (s, 3 H, -SCH3) Anal. Calcd.  for C14H14N4S: C, 62.20; H, 5.22; 
N, 20.72; S, 11.86. Found: C, 62.07; H, 5.31; N, 20.47; S, 11.80. 
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General method for synthesis of 217, 219, 225 and 228 
In the solution of 216, 218, 224 and 332 (0.25 g) in DMF, 1 equivalent NaH was added 
and the solution was stirred for 15 minutes. 1.2 equivalent iodomethane was added to 217, 
219 and 225 3.5 equivalent iodomethane to 332, respectively. The solvent was evaporated 
in vacuo, silica gel was added to make a plug and flash chromatography was carried out 
using methanol-chloroform as eluent to afford. The fractions containing the required 
compound were evaporated under reduced pressure to afford the target compounds. 
 
N-(4-methoxyphenyl)-N,5-dimethyl-5H-pyrrolo[3,2-d]pyrimidin-4-amine (217) 
Following the procedure for synthesis of 217, 219, 225 and 228, compound 217 was 
obtained as a white solid (0.18 g, 64% yield); mp, 108.4 C; TLC Rf = 0.24 
(MeOH:CHCl3:NH4OH, 1:10:0.5); 
1H NMR (400 MHz) (Me2SO-d6) δ 8.50 (s, 1 H, Ar), 
7.42 (d, J = 3.1 Hz, 1 H, Ar), 7.07 – 6.76 (m, 4 H, Ar), 6.46 (d, J = 2.9 Hz, 1 H, Ar), 3.71  
(s, 3 H, -OCH3), 3.43 (s, 3 H, -N
4CH3), 3.10 (s, 3 H, -N5CH3). Anal. Calcd.  for C13H12N4O: 
C, 67.15; H, 6.01; N, 20.88; O, 5.96. Found: C, 67.14; H, 5.98; N, 20.83. 
 
6-methoxy-1-(5-methyl-5H-pyrrolo[3,2-d]pyrimidin-4-yl)-1,2,3,4-
tetrahydroquinoline (219) 
Following the procedure for synthesis of 217, 219, 225 and 228, compound 219 was 
obtained as a white solid (165 mg, 63% yield); TLC Rf = 0.20 (MeOH:CHCl3:NH4OH, 
10:0.5); mp,122.2 C; 1H NMR (400 MHz) (Me2SO-d6) δ 8.51 (s, 1 H, Ar), 7.59 (d, J=3.1 
Hz, 1 H, Ar), 6.79 (d, J=2.7 Hz, 1 H, Ar), 6.54 (dd, J=3.0 Hz, J=7.2 Hz, 2 H, Ar), 6.20 (d, 
J=7.2 Hz, 1 H, Ar), 3.77 (t, J=6.6 Hz, 2 H, -CH2-), 3.68 (s, 3 H, -OCH3), 3.36 (s, 3 H, 
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N5CH3), 2.82 (t, J=6.6 Hz, 2 H, -CH2-), 2.01 (m, 2 H, -CH2-). Anal. Calcd.  for C17H18N4O: 
C, 69.37; H, 6.16; N, 19.03; O, 5. Found: C, 69 .35; H, 6.16; N, 18.76. 
 
N,5-dimethyl-N-(4-(methylthio)phenyl)-5H-pyrrolo[3,2-d]pyrimidin-4-amine (225) 
Following the procedure for synthesis of 217, 219, 225 and 228, compound 225 was 
obtained as a white solid (0.2 g, 72% yield). TLC Rf = 0.05 (MeOH:CHCl3:NH4OH, 
1:10:0.5); mp, 108C; 1H NMR (400 MHz) (Me2SO-d6) δ 7.63 (s, 1 H, Ar, 2-H), 7.13 (dd, 
J=5.8 Hz, J=8.9 Hz, 1 H, Ar), 7.10-7.08 (m, 2 H, Ar), 6.97 (d, J=8.5 Hz, 2 H, Ar), 6.20 (d, 
J=3.0 Hz, 1 H, Ar), 4.05 (s, 3 H, -N4CH3), 3.51 (s, 3 H, -N5CH3), 2.38 (s, 3 H, -SCH3). 
Anal. Calcd.  for C15H16N4S 0.33 CH3OH: C, 62.43; H, 5.91; N, 18.99; S, 10.88. Found: 
C, 62.52; H, 5.83; N, 19.01; S, 10.59. 
 
N-(5-methoxynaphthalen-2-yl)-N,5-dimethyl-5H-pyrrolo[3,2-d]pyrimidin-4-amine 
(228) 
Following the procedure for synthesis of 216, 218, 224 and 332, compound 332 was 
obtained as a white solid (330 mg, 61% crude yield); TLC Rf = 0.74 
(MeOH:CHCl3:NH4OH, 1:5:0.5); mp, 120.3C; 1H NMR (400 MHz) (Me2SO-d6) δ 12.91 
(s, 1 H, exch.), 11.34 (s, 1 H, exch.), 10.19 (s, 1 H, exch.), 8.75 (s, 1 H, Ar), 8.49 (d, J = 
2.1 Hz, 1 H, Ar), 8.16 (d, J = 9.0 Hz, 1 H, Ar), 7.98 – 7.90 (m, 2 H, Ar), 7.36 – 7.27 (m, 2 
H, Ar), 6.83 (dd, J = 5.6, 3.0 Hz, 1 H, Ar), 6.66 – 6.59 (m, 1 H, Ar). Following the procedure 
for synthesis of 217, 219, 225 and 228, compound 228 was obtained using 332 as a white 
solid (200 mg, 69% yield); TLC Rf = 0.24 (MeOH:CHCl3:NH4OH, 1:10:0.5); mp, 156.8 
C; 1H NMR (500 MHz) (Me2SO-d6) δ 7.96 (d, J = 8.8 Hz,  1 H, Ar), 7.77 (s, 1 H, Ar), 
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7.42 (d, J = 2.2 Hz, 1 H, Ar), 7.34 – 7.17 (m, 4 H, Ar), 6.75 (dd, J = 6.6, 2.0 Hz, 1 H, Ar), 
6.25 (d, J = 3.0 Hz, 1 H, Ar), 4.16 (s, 3 H, -CH3), 3.94 (s, 3 H, -CH3), 3.58 (s, 3 H, -
CH3).Anal. Calcd.  for C19H18N4O: C, 70.10; H, 6.02; N, 16.79; O, 5.03. Found: C, 70.11; 
H, 5.70; N, 16.60. 
 
2-Methyl-3H-pyrrolo[3,2-d]pyrimidin-4(5H)-one (334) 
To a solution of 333 (3g, 19.46 mmol) in (100 mL), hydrogen chloride gas was bubbled 
through for 2 hours. The reaction mixture was neutralized with ammonium hydroxide and 
the solvent was evaporated and flash chromatographed (CHCl3: CH3OH; 100:1 to 50:3; 
v/v) to yield 334 as a light brown solid (2.25g, 74%). TLC Rf = 0.42 (CH3OH: CHCl3; 
1:10); mp, 259 °C (lit.278 260-262 ⁰ C); 1H NMR (400 MHz) (Me2SO-d6) δ 11.89 (br, 1 H, 
exch., NH), 11.74 (br, 1 H, exch., NH), 7.27 - 7.31 (m, 1 H, Ar), 6.21 - 6.24 (m, 1 H, Ar), 
2.27 (s, 3 H, CH3). 
 
4-Chloro-2-methyl-5H-pyrrolo[3,2-d]pyrimidine (335) 
2-Methyl-3H-pyrrolo[3,2-d]pyrimidin-4(5H)-one (2 g, 13.23 mmol) was added to 
phosphorus oxychloride (20 mL) and heated at reflux for 4 h. The solvent was evaporated 
in vacuo, and the pH of the residue was adjusted to 8 with ammonia solution. The resulting 
precipitate was filtered and purified by column chromatography (CHCl3: CH3OH; 100:1 to 
50:3; v/v) to give a light yellow solid (1.6 g, 71%). TLC Rf = 0.32 (CH3OH: CHCl3; 1:10) 
mp, 192.4-196.5 °C (lit.279 195-197 ⁰ C); 1H NMR (400 MHz) (Me2SO-d6) 12.26 (s, 1 H, 
exch., NH), 7.90 (m, 1 H, 6-CH), 6.60 (m, 1 H, 7-CH), 2.60 (s, 3 H, CH3). 
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N,2-dimethyl-N-(4-(methylthio)phenyl)-4a,7a-dihydro-5H-pyrrolo[3,2-d]pyrimidin-
4-amine (222) 
Compound 335 (0.45 g, 2.65 mmol) and N-methyl-4-(methylthio)aniline (0.40 g, 2.65 
mmol) were dissolved in isopropanol (12 mL) and heated in a microwave reactor at 130C. 
The solvent was evaporated in vacuo, and the residue was purified by column 
chromatography (CHCl3: CH3OH; 50:1; v/v) to give a brown solid (0.41 mg, 54%). TLC 
Rf = 0.42 (CH3OH: CHCl3; 1:10). mp, 154.7-156.2 °C; 
1H NMR (400 MHz) (Me2SO-d6) 
9.20 (s, 1 H, exch., -NH), 7.34 – 7.27 (m, 2 H, Ar), 7.24 (t, J = 2.7 Hz, 1 H, Ar), 7.22 – 
7.17 (m, 2 H, Ar),6.28 (d, J = 3.0 Hz, 1 H, Ar), 3.50 (s, 3 H, -CH3), 2.51 (s, 3 H, -CH3), 
2.49 (s, 3 H, -CH3).  Anal. Calcd.  for C15H18N4S: C, 62.91; H, 6.34; N, 19.56; S, 11.19 
Found: C, 63.07; H, 5.63; N, 19.53; S, 11.04. 
 
N,2,5-trimethyl-N-(4-(methylthio)phenyl)-4a,7a-dihydro-5H-pyrrolo[3,2-
d]pyrimidin-4-amine hydrochloride salt (223) 
To the solution of 222 (0.3 g, 1.05 mmol) in DMF, NaH (28 mg, 1.15 mmol) was added 
and suspension was stirred for 15 minutes. Iodomethane (0.07 ml, 1.15 mmol) was added 
to the suspension and the solution was further stirred for 2 hours. The solvent was 
evaporated in vacuo, and the residue was purified by column chromatography (CHCl3: 
CH3OH; 50:1; v/v) to give a brown liquid. HCl gas was passed through solution of 223 in 
ether to obtain the HCl salt of 223 as a white solid (0.21 g, 67%). TLC Rf = 0.20 
(MeOH:CHCl3:NH4OH, 1:10:0.5); mp, decomposition> 183.5 ⁰ C; 1H NMR (500 MHz) 
(Me2SO-d6) δ 10.35 (s, 1 H, exch., -HCl), 7.69 (d, J=3.0 Hz, 1 H, Ar), 7.31 (q, J=8.8 Hz, 4 
H, Ar), 6.55 (d, J=3.0 Hz, 1 H, Ar), 3.66 (s, 3 H, -CH3), 2.89 (s, 3 H, -CH3), 2.71 (s, 3 H, -
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CH3), 2.48 ((s, 3 H, -CH3). Anal. Calcd.  for C16H21ClN4S: C, 57.05; H, 6.28; Cl, 10.52; N, 
16.63; S, 9.52. Found: C, 57.10; H, 5.65; Cl, 10.39; N, 16.74; S, 9.50. 
 
6-((2-methyl-4a,7a-dihydro-5H-pyrrolo[3,2-d]pyrimidin-4-yl)amino)naphthalen-1-ol 
(336) 
Compound 335 (0.45 g, 2.65 mmol) and 6-aminonaphthalen-1-ol (0.465 g, 2.92 mmol) 
were dissolved in isopropanol (12 mL) and heated in a microwave reactor at 130C. The 
solvent was evaporated in vacuo, and the residue was purified by column chromatography 
(CHCl3: CH3OH; 50:1; v/v) to give a brown solid 336 (0.38 mg, 49%). TLC Rf = 0.42 
(CH3OH: CHCl3; 1:10). mp, decomposes >217 °C; 
1H NMR (500 MHz) (Me2SO-d6) δ 
11.08 (s, 1 H, 5-NH, exch.), 10.09 (s, 1 H, -N4H, exch.), 9.34 (s, 1 H, exch., -OH), 8.58 (s, 
1 H, Ar), 8.14 (d, J=9.0 Hz, 1 H, Ar), 7.78 (d, J=9.3 Hz, 1 H, Ar), 7.62 (s, 1 H, Ar), 7.27 
(d, J=2.6 Hz, 2 H, Ar), 6.76 (m, 1 H, Ar), 6.40 (s, 1 H, Ar), 2.58 (s, 3 H, 2-CH3) Anal. 
Calcd.  for C17H16N4O 0.70 H2O: C, 67.18; H, 5.44; N, 18.44 Found: C, 67.55; H, 5.29; N, 
18.21. 
 
N-(5-methoxynaphthalen-2-yl)-N,2,5-trimethyl-4a,7a-dihydro-5H-pyrrolo[3,2-
d]pyrimidin-4-amine (227) 
In the solution of 336 (0.3 g, 1.05 mmol) in DMF, NaH (86 mg, 3.59 mmol) and let to stir 
for 15 minutes. Iodomethane (0.23 ml, 3.59 mmol) was added and stirred for 2 hours. The 
solvent was evaporated in vacuo, and the residue was purified by column chromatography 
(CHCl3: CH3OH; 50:1; v/v) to give a white solid 7 (220 mg, 64%). HCl gas was passed 
through solution of 227 in ether to obtain salt. TLC Rf = 0.35 (MeOH:CHCl3:NH4OH, 
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1:10:0.5); mp, 80.3 C; 1H NMR (400 MHz) (Me2SO-d6) δ 7.95 (d, J = 8.8 Hz, 1 H, Ar), 
7.48 (d, J = 2.1 Hz, 1 H, Ar), 7.34 (dd, J = 8.9, 2.1 Hz, 1 H, Ar), 7.26 (d, J = 4.4 Hz, 2 H, 
Ar), 7.17 (d, J = 3.0 Hz, 1 H, Ar), 6.72 (t, J = 4.3 Hz, 1 H, Ar), 6.23 (d, J = 2.9 Hz, 1 H, 
Ar), 4.14 (s, 3 H, -OCH3), 3.94 (s, 3 H, -N
4CH3), 3.54 (s, 3 H, -N5CH3), 2.27 (s, 3 H, 2-
CH3). Anal. Calcd.  for C20H23ClN4O 1.15 H2O 0.5 HCl: C, 58.75; H, 5.87; Cl, 13.28; N, 
13.70 Found: C, 58.77; H, 5.91; Cl, 13.28; N, 13.58 
 
General method for synthesis of 231, 232, 235, 338 and 339 
Commercially available 2,4-dichloropyrrolo[3,2-d]pyrimidine 337 (0.30 g, 1.6 mmol) and 
equivalent aniline were dissolved in isopropanol (12 mL) and heated in a microwave 
reactor at 130C for 4 hours. The solvent was evaporated in vacuo, silica gel was added to 
make a plug and flash chromatography was carried out using methanol-chloroform as 
eluent to afford the target compounds. 
 
2-chloro-N-(4-methoxyphenyl)-N-methyl-5H-pyrrolo[3,2-d]pyrimidin-4-amine (231) 
Following the procedure for synthesis of 231, 232, 235, 338 and 339, compound 231 was 
obtained as a white solid (380 mg, 83%). TLC Rf = 0.50 (MeOH:CHCl3:NH4OH, 1:10:0.5); 
mp, 173.2-176.4 ⁰ C; 1H NMR (400 MHz) (Me2SO-d6) δ 8.90 (s, 1 H, 5-NH, exch.), 7.32 
(d, J=8.8 Hz, 2 H, Ar), 7.27 (d, J=3.0 Hz, 1 H, Ar), 7.04 (d, J=8.8 Hz, 2 H, Ar), 6.31 (d, 
J=3.0 Hz, 1 H, Ar), 3.81 (s, 3 H, -OCH3), 3.71 (s, 3 H, N
4CH3). Anal. Calcd.  for 
C14H13ClN4O: C, 58.24; H, 4.54; Cl, 12.28; N, 19.40; O, 5.54 Found: C, 58.36; H, 4.62; 
Cl, 12.15; N, 19.35. 
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2-chloro-N-methyl-N-(4-(methylthio)phenyl)-5H-pyrrolo[3,2-d]pyrimidin-4-amine 
(232) 
Following the procedure for synthesis of 231, 232, 235, 338 and 339, compound 232 was 
obtained as a white solid (300 mg, 62% yield) TLC Rf = 0.10 (MeOH:CHCl3:NH4OH, 
1:10:0.5); mp, 156.1-159.9 ⁰ C; 1H NMR (400 MHz) (Me2SO-d6) δ 9.40 (s, 1 H, exch., 5-
NH), 7.32 (m, 5 H, Ar), 6.35 (m, 1 H, Ar), 3.48 (s, 3 H, -N4CH3), 2.52 (s, 3 H, -SCH3). 
Anal. Calcd.  for C14H13ClN4S: C, 55.17; H, 4.30; Cl, 11.63; N, 18.38; S, 10.52 Found: C, 
55.30; H, 4.35; Cl, 11.79; N, 18.26; S, 10.39. 
 
1-(2-chloro-5H-pyrrolo[3,2-d]pyrimidin-4-yl)-6-methoxy-1,2,3,4-
tetrahydroquinoline (235) 
Following the procedure for synthesis of 231, 232, 235, 338 and 339, compound 235 was 
obtained as a white solid (350 mg, 70% yield) TLC Rf = 0.63 (MeOH:CHCl3:NH4OH, 
1:10:0.5); mp, 204.9-206.9 ⁰ C; 1H NMR (400 MHz) (Me2SO-d6) δ 10.33 (s, 1 H, 5-NH, 
exch.), 7.46 (t, J=3.1 Hz, 1 H, Ar), 6.87 (dd, J=5.8 Hz, J=9.2 Hz, 2 H, Ar), 6.73 (dd, J=2.8 
Hz, J=8.8 Hz, 1 H, Ar), 6.41 (dd, J=1.7 Hz, J=2.9 Hz, 1 H, Ar), 3.92 (m, 2 H, -CH2-), 3.76 
(s, 3 H, -OCH3), 2.77 (t, J=6.4Hz, 2 H, -CH2-), 1.95 (td, J=6.2Hz, J=12.5Hz, 2 H, -CH2-). 
Anal. Calcd.  for C16H15ClN4O: C, 61.05; H, 4.80; Cl, 11.26; N, 17.80; O, 5.08 Found: C, 
60.60; H, 5.00; Cl, 10.89; N, 17.28. 
 
2-chloro-N-(4-(trifluoromethoxy)phenyl)-5H-pyrrolo[3,2-d]pyrimidin-4-amine (338) 
Following the procedure for synthesis of 231, 232, 235, 338 and 339, compound 338 was 
obtained as a white solid (420 mg, 84%); TLC Rf = 0.32 (MeOH:CHCl3:NH4OH, 1:5:0.5); 
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mp, 142.5-146.7 ⁰ C; 1H NMR (400 MHz) (Me2SO-d6) δ 11.25 (s, 1 H, -N4H, exch.), 9.74 
(s, 1H, 5-NH, exch.), 7.88 (d, J=8.8 Hz, 2 H, Ar), 7.75 (s, 1 H, Ar), 7.43 (d, J=8.7 Hz, 2 H, 
Ar), 6.47 (s, 1 H, Ar). Anal. Calcd.  for C13H8ClF3N4O: C, 47.51; H, 2.45; Cl, 10.79; F, 
17.34; N, 17.05; O, 4.87 Found: C, 47.54; H, 2.50; Cl, 10.90; F, 17.09; N, 16.93. 
 
6-((2-chloro-5H-pyrrolo[3,2-d]pyrimidin-4-yl)amino)naphthalen-1-ol (339) 
Following the procedure for synthesis of 231, 232, 235, 338 and 339, compound 339 was 
obtained as a white solid (320 mg, 70% yield); TLC Rf = 0.40 (MeOH:CHCl3:NH4OH, 
1:10:0.5); mp, 234.2-238.9 ⁰ C;1H NMR (400 MHz, Me2SO-d6) 1H NMR (400 MHz) 
(Me2SO-d6) δ 11.36 (s, 1 H, exch., 5-NH), 10.29 (s, 1 H, exch., -N4H), 9.87 (s, 1 H, exch., 
-OH), 8.72 – 8.32 (m, 1 H, Ar), 8.13 (d, J = 9.0 Hz, 1 H, Ar), 7.93 – 7.61 (m, 2 H, Ar), 7.49 
– 6.94 (m, 2 H, Ar), 6.78 (dd, J = 7.0, 1.6 Hz, 1 H, Ar), 6.46 (d, J = 3.0 Hz, 1 H, Ar). Anal. 
Calcd.  for C16H11ClN4O 0.55 H2O: C, 59.93; H, 3.80; Cl, 11.06; N, 17.47. Found: C, 58.18; 
H, 3.74; Cl, 12.80; N, 16.41. 
 
General method for synthesis of 233, 234, 236, 237 and 240  
To the solution of 231, 232, 235 and 338 (0.25 g) in DMF, 1 equivalent NaH was added 
and to solution of 339, 3.5 equivalent NaH was added and the mixture was stirred for 15 
minutes. 1.2 equivalent iodomethane was added and stirred for 2 hours for 231, 232, 235 
and 338 and 3.5 equivalent to the solution containing 339. . The solvent was evaporated in 
vacuo, silica gel was added to make a plug and flash chromatography was carried out using 
methanol-chloroform as eluent to afford the target compounds. 
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2-chloro-N-(4-methoxyphenyl)-N,5-dimethyl-5H-pyrrolo[3,2-d]pyrimidin-4-amine 
(233) 
Following the procedure for synthesis of 233, 234, 236, 237 and 240, compound 233 was 
obtained as a white solid (180 mg, 69%); TLC Rf = 0.71 (MeOH:CHCl3:NH4OH, 1:10:0.5); 
mp, 140.6 C; 1H NMR (500 MHz) (Me2SO-d6) δ 7.45 (d, J=8.9 Hz, 1 H, Ar), 7.01 (d, J = 
8.4 Hz, 2 H, Ar), 6.91 (d, J = 8.9 Hz, 2 H, Ar), 6.46 – 6.36 (m, 1 H, Ar), 3.48 (s, 3 H, -
OCH3), 3.41 (s, 3 H, -N
4CH3), 2.98 (s, 3 H, 5-NCH3). Anal. Calcd.  for C15H15ClN4O: C, 
59.51; H, 4.99; Cl, 11.71; N, 18.51; O, 5.28. Found: C, 59.60; H, 5.10; Cl, 11.73; N, 18.58. 
 
2-chloro-N,5-dimethyl-N-(4-(methylthio)phenyl)-5H-pyrrolo[3,2-d]pyrimidin-4-
amine hydrochloride salt (234) 
Following the procedure for synthesis of 233, 234, 236, 237 and 240, a brown liquid was 
obtained on reacting 232; TLC Rf = 0.22 (MeOH:CHCl3:NH4OH, 1:5:0.5). To the product 
was dissolved in 5 mL ether and HCl gas was passed over the solution for 1 min to afford 
234 (150 mg, 57%); TLC Rf = 0.22 (MeOH:CHCl3:NH4OH, 1:10:0.5); mp, 253.0-256.5 
⁰ C; 1H NMR (400 MHz) (Me2SO-d6) δ 10.40 (s, br, exch., 1 H, -HCl), 7.55 (d, J = 3.1 Hz, 
1 H, Ar), 7.23 (d, J = 8.2 Hz, 2 H, Ar), 6.99 (d, J = 8.3 Hz, 2 H, Ar), 6.45 (d, J = 3.2 Hz, 1 
H, Ar), 3.44 (d, J = 14.1 Hz, 3 H, -N4CH3), 3.07 (s, 3 H, -N5CH3), 2.46 (s, 3 H, -SCH3). 
Anal. Calcd.  for C15H16Cl2N4S: C, 50.71; H, 4.54; Cl, 19.96; N, 15.77; S, 9.02. Found: C, 
50.84; H, 4.38; Cl, 19.66; N, 15.39; S, 8.81. 
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1-(2-chloro-5-methyl-5H-pyrrolo[3,2-d]pyrimidin-4-yl)-6-methoxy-1,2,3,4-
tetrahydroquinoline (236) 
Following the procedure for synthesis of 233, 234, 236, 237 and 240, compound 236 was 
obtained as a white solid (200 mg, 77%); TLC Rf = 0.72 (MeOH:CHCl3:NH4OH, 1:10:0.5); 
mp, 174.4 C; 1H NMR (400 MHz) (Me2SO-d6) δ 7.62 (d, J=2.9 Hz, 1 H, Ar), 6.83 (d, 
J=2.5 Hz, 1 H, Ar), 6.60 (dd, J=2.6 Hz, J=9.0 Hz, 1 H, Ar), 6.48 (d, J=3.0 Hz, 1 H, Ar), 
6.39 (d, J=8.9 Hz, 1 H, Ar), 3.78 (m, 2 H, -CH2-), 3.71 (s, 3 H, -OCH3), 2.82 (t, J=6.6Hz, 
2 H,  -CH2-), 3.22 (s, 3 H, N5-CH3), 2.02 (m, 2 H, -CH2-). Anal. Calcd.  for C17H17ClN4O 
0.05 CH3OH 0.25 H2O: C, 60.77; H, 5.34; Cl, 10.55; N, 16.67 Found: C, 60.87; H, 5.14; 
Cl, 10.84; N, 16.47. 
 
2-chloro-I-(5-methoxynaphthalen-2-yl)-I,5-dimethyl-5H-pyrrolo[3,2-d]pyrimidin-4-
amine hydrochloride salt (237) 
Following the procedure for synthesis of 233, 234, 236, 237 and 240, compound 237 was 
obtained. The product was a brown liquid. HCl gas was passed through a solution of the 
product in ether to obtain the salt of 237 as a white solid (150 mg, 52%) TLC Rf =  0.40 
(MeOH:CHCl3:NH4OH, 1:10:0.5); mp, 146.8 C; 1H NMR (400 MHz) (Me2SO-d6) δ 10.70 
(s, br, exch., -HCl), 8.07 (d, J=9.1 Hz, 1 H, Ar), 7.47 (d, J=2.8 Hz, 1 H, Ar), 7.35 (m, 2 H, 
Ar), 7.23 (m, 2 H, Ar), 6.87 (d, J=7.5 Hz, 1 H, Ar), 6.47 (d, J=2.9 Hz, 1 H, Ar), 3.55 (s, 3 
H, -OCH3), 3.92 (s, 3 H, -N
4CH3), 2.97 (s, 3 H, -N5CH3). Anal. Calcd.  for C19H18Cl2N4O 
1.0 HCl 0.6 CH3OH: C, 58.62; H, 4.66; Cl, 18.21; N, 14.39; O, 4.11 Found: C, 59.74; H, 
4.77; Cl, 15.22; N, 14.41 
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2-chloro-N,5-dimethyl-N-(4-(trifluoromethoxy)phenyl)-5H-pyrrolo[3,2-d]pyrimidin-
4-amine (240) 
Following the procedure for synthesis of 233, 234, 236, 237 and 240, compound 240 was 
obtained as a white solid (140 mg, 67%). TLC Rf = 0.51 (MeOH:CHCl3:NH4OH, 1:5:0.5); 
mp, 120.9-127.7 ⁰ C; 1H NMR (400 MHz) (Me2SO-d6) δ 7.65 (d, J=3.1 Hz, 1 H, Ar), 7.33 
(d, J=8.8 Hz, 2 H, Ar), 7.11 (d, J=9.0 Hz, 2 H, Ar), 6.51 (d, J=3.1 Hz, 1 H, Ar), 3.50 (s, 3 
H, -N4CH3), 3.16 (s, 3 H, -N5CH3). Anal. Calcd.  for C15H12ClF3N4O: C, 50.50; H, 3.39; 
Cl, 9.94; F, 15.98; N, 15.71; O, 4.48. Found: C, 50.62; H, 3.53; Cl, 9.54; F, 15.60; N, 15.31. 
 
N4-(4-methoxyphenyl)-N4-methyl-5H-pyrrolo[3,2-d]pyrimidine-2,4-diamine (238) 
Commercially available 2-amino-4-dichloropyrrolo[3,2-d]pyrimidine 341 (0.30 g, 1.62 
mmol) and 4-methoxy-N-methylaniline (220 mg, 1.62 mmol) were dissolved in 
isopropanol (12 mL) and heated in a microwave reactor at 130C. The solvent was 
evaporated in vacuo, and the residue was purified by column chromatography (CHCl3: 
CH3OH; 50:1; v/v) to obtain 238 (280 mg, 64%, white solid). TLC Rf = 0.18 
(MeOH:CHCl3:NH4OH, 1:10:0.5); mp, 228.1 C; 1H NMR (400 MHz) (Me2SO-d6) δ 8.10 
(s, 1 H, 5-NH, exch.), 7.23 (m, 2 H, Ar), 7.01 (d, J=8.8 Hz, 2 H, Ar), 6.97 (t, J=3.0 Hz, 1 
H, Ar), 5.92 (m, 1 H, Ar), 5.40 (s, 2 H, 2-NH2, exch.), 3.81 (s, 3 H, -OCH3), 3.39 (s, 3 H, -
N4CH3). Anal. Calcd.  for C14H15N5O 0.25 H2O: C, 61.42; H, 5.71; N, 25.58. Found: C, 
61.33; H, 5.63; N, 25.78. 
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4-(6-methoxy-3,4-dihydroquinolin-1(2H)-yl)-5H-pyrrolo[3,2-d]pyrimidin-2-amine 
(239) 
Commercially available 2-amino-4-dichloropyrrolo[3,2-d]pyrimidine 341  (0.30 g, 1.62 
mmol) and 6-methoxy-1,2,3,4-tetrahydroquinoline (263 mg, 1.62 mmol) were dissolved in 
isopropanol (12 mL) and heated in a microwave reactor at 130C. The solvent was 
evaporated in vacuo, and the residue was purified by column chromatography (CHCl3: 
CH3OH; 50:1; v/v) to obtain 239 (320 mg, 67%, white solid). TLC Rf =  0.21 
(MeOH:CHCl3:NH4OH, 1:10:0.5); mp, 18 1C; 1H NMR (400 MHz) (Me2SO-d6) δ 9.62 
(s, 1 H, 5-NH, exch.), 7.16 (s, 1 H, Ar), 6.78 (dd, J=5.6 Hz, J=10.8 Hz, 2 H, Ar), 6.68 (dd, 
J=2.6 Hz, J=8.8 Hz, 1 H, Ar), 6.02 (d, J=1.7 Hz, 1 H, Ar), 5.47 (s, 2 H, 2-NH2, exch.), 3.85 
(t, J=6.1 Hz, 2 H, -CH2-), 3.74 (s, 3 H, -OCH3), 2.78 (t, J=6.5 Hz, 2 H,-CH2-), 1.91 (m, 2 
H, -CH2-). Anal. Calcd.  for C16H17N5 0.45 H2O: C, 63.35; H, 5.65; N, 22.97. Found: C, 
63.33; H, 5.81; N, 23.10. 
 
N2,N4-bis(4-methoxyphenyl)-N2,N4-dimethylthieno[3,2-d]pyrimidine-2,4-diamine 
(343) 
Commercially available 2,4-dichloro-thieno[3,2-d]pyrimidine (300 mg, 1.46 mmol) was 
reacted with 4-methoxy-N-methylaniline (200 mg, 1.46 mmol)  in 12 ml isopropanol for 4 
hours at 130 °C in a microwave reactor. Silica gel was added to the solvent mixture and 
plug was prepared. A flash column chromatography was performed using ethyl acetate-
Hexane as eluent. The fractions containing the required compound was evaporated under 
reduced pressure to afford 343 as a white solid (200 mg, 47% yield); TLC Rf =  0.56 
(MeOH:CHCl3:NH4OH, 1:10:0.5); mp, 144.2 C; 1H-NMR (400 MHz) (Me2SO-d6) δ 7.69 
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(dd, J = 5.5, 1.1 Hz, 1 H, Ar), 7.36 – 7.27 (m, 4 H, Ar), 7.07 – 6.99 (m, 2 H, Ar), 6.99 – 
6.90 (m, 3 H, Ar), 3.79 (d, J = 18.0 Hz, 6 H, -OCH3), 3.35 (s, 3 H, -N
4CH3), 3.28 (s, 3 H, -
N4CH3). Anal. Calcd.  for C22H22N4O2S: C, 65.00; H, 5.46; N, 13.78; S, 7.89 Found: C, 
65.59; H, 5.85; N, 13.30; S, 7.49. 
  
2-chloro-N-(4-methoxyphenyl)-N-methylthieno[3,2-d]pyrimidin-4-amine (244) 
Commercially available 2,4-dichloro-thieno[3,2-d]pyrimidine (300 mg, 1.46 mmol) was 
reacted with 4-methoxy-N-methylaniline (200 mg, 1.46 mmol)  for 72 hours at room 
temperature in isopropanol.  Silica gel was added to the solvent mixture and plug was 
prepared. A flash column chromatographic separation using ethyl acetate-hexane as eluent 
afforded 244 as a white solid (300 mg, 67% yield). TLC Rf =  0.50 (MeOH:CHCl3:NH4OH, 
1:10:0.5); mp, 140.6 C; 1H-NMR (400 MHz) (Me2SO-d6) δ 7.99 (d, J=5.5 Hz, 1 H, Ar), 
7.45 (d, J=5.5 Hz, 2 H, Ar), 7.24 (d, J=5.5 Hz, 1 H, Ar), 7.08 (d, J=5.5 Hz, 2 H, Ar), 3.84 
(s, 3 H, -OCH3), 3.47 (s, 3 H, -N
4CH3). Anal. Calcd.  for C14H12ClN3OS: C, 54.99; H, 3.96; 
Cl, 11.59; N, 13.74; S, 10.48 Found: C, 55.20; H, 3.96; Cl, 11.61; N, 13.61; S, 10.41. 
 
N-(4-methoxyphenyl)-N-methyl-2-(trifluoromethyl)thieno[3,2-d]pyrimidin-4-amine 
(245) 
Commercially available 2-trifluromethyl-4-chloro-thieno[3,2-d]pyrimidine 392 (200 mg, 
0.838 mmol) and 4-methoxy-N-methylaniline (115 mg, 0.838 mmol) were reacted for 4 
hours at 130 °C in isopropanol using a microwave reactor. Silica gel was added to the 
solvent mixture and plug was prepared. A flash column chromatography using ethyl 
acetate-Hexane as eluent afforded 245 as a white solid (180 mg, 63% yield). TLC Rf = 0.58 
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(MeOH:CHCl3:NH4OH, 1:10:0.5); mp, 112.8-116.2 ⁰ C; 1H NMR (400 MHz) (Me2SO-d6) 
δ 8.10 (d, J=5.5 Hz, 1 H, Ar), 7.49 (m, 2 H, Ar), 7.44 (d, J=5.5 Hz, 1 H, Ar), 7.09 (m, 2 H, 
Ar), 3.81 (s, 3 H, OCH3), 3.54 (s, 3 H, -N
4CH3). Anal. Calcd.  for C15H12F3N3OS: C, 53.02; 
H, 3.61; F, 16.72; N, 12.32; S, 9.41. Found: C, 53.17; H, 3.68; F, 16.66; N, 12.26; S, 9.25. 
 
N2,N4-bis(4-(methylthio)phenyl)thieno[3,2-d]pyrimidine-2,4-diamine (345) 
Commercially available 2,4-dichloro-thieno[3,2-d]pyrimidine (300 mg, 1.46 mmol) was 
reacted with 4-(methylthio)aniline (203 mg, 1.46 mmol)  for 4 hours at 130°C in 
isopropanol using a microwave reactor. Silica gel was added to the solvent mixture and 
plug was prepared. A flash column chromatography using ethyl acetate-Hexane as eluent 
afforded 345 as a white solid (450 mg, 78% yield). TLC Rf = 0.52 (MeOH:CHCl3:NH4OH, 
1:10:0.5); mp, 142.6-148.0 ⁰ C; 1H-NMR NMR (400 MHz) (Me2SO-d6) δ 9.59 (s, 1 H, 
exch., -NH), 9.24 (s, 1H, exch., -NH), 8.10 (d, J=5.3 Hz, 4 H, Ar), 7.76 (dd, J=8.8 Hz, 
J=10.7 Hz, 1 H, Ar), 7.29 (d, J=8.7 Hz, 2 H, Ar), 7.23 (d, J=5.3 Hz, 1 H, Ar), 7.19 (d, J=8.7 
Hz, 2 H, Ar), 2.50 (s, 3 H, -SCH3), 2.45 (s, 3 H, -SCH3). This compound was used for the 
next reaction without further characterization.  
 
N2,N4-dimethyl-N2,N4-bis(4-(methylthio)phenyl)thieno[3,2-d]pyrimidine-2,4-diamine 
(346) 
Treatment of 345 (400 mg, 974 µmol) with 60% NaH suspension (80 mg, 1.95 mmol) in 
DMF created the anion of 345. Iodomethane (0.2 ml, 1.95 mmol) was added to the 
suspension and the reaction was stirred for 2 hours. Silica gel was added to the solvent 
mixture and plug was prepared. A flash column chromatography using ethyl acetate-
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Hexane as eluent afforded 346 as a white solid (380 mg, 88% yield) TLC Rf =  .60 
(MeOH:CHCl3:NH4OH, 1:10:0.5); mp, 144.7 C; 1H-NMR (400 MHz) (Me2SO-d6) δ 7.74 
(d, J=5.5 Hz, 1 H, Ar), 7.39 (d, J=8.6 Hz, 2 H, Ar), 7.34 (m, 4 H, Ar), 7.27 (d, J=8.6 Hz, 2 
H, Ar), 7.01 (d, J=5.5 Hz, 1 H, Ar), 3.51 (s, 3 H, -CH3), 3.32 (s, 3 H, -CH3), 2.53 (s, 3 H, -
CH3), 2.49 (s, 3 H, -CH3). Anal. Calcd.  for C22H22N4S3: C, 60.24; H, 5.06; N, 12.77; S, 
21.93 Found: C, 60.08; H, 5.08; N, 12.79; S, 22.02. 
 
2-chloro-N-(4-(methylthio)phenyl)thieno[3,2-d]pyrimidin-4-amine (347) 
Commercially available 2,4-dichloro-thieno[3,2-d]pyrimidine (300 mg, 1.46 mmol) was 
reacted with 4-(methylthio)aniline (203 mg, 1.46 mmol)  for 72 hours at room temperature 
in isopropanol. Silica gel was added to the solvent mixture and plug was prepared. A flash 
column chromatography using ethyl acetate-Hexane as eluent afforded 347 as a white-
yellowish solid (260 mg, 58% yield). TLC Rf =  0.86 (MeOH:CHCl3:NH4OH, 1:10:0.5); 
mp, 201.3-206.1 ⁰ C; 1H-NMR (400 MHz) (Me2SO-d6) δ 10.15 (s, 1 H, exch., -NH), 8.27 
(d, J=5.4 Hz, 1 H, Ar), 7.65 (d, J=7.5 Hz, 2 H, Ar), 7.40 (d, J=5.3 Hz, 1 H, Ar), 7.32 (d, 
J=7.2 Hz, 2 H, Ar), 2.49 (s, 3 H, -SCH3). Anal. Calcd.  for C13H10ClN3S2: C, 50.73; H, 
3.27; Cl, 11.52; N, 13.65; S, 20.83. Found: C, 50.73; H, 3.33; Cl, 11.50; N, 13.60; S, 20.90. 
 
2-chloro-N-methyl-N-(4-(methylthio)phenyl)thieno[3,2-d]pyrimidin-4-amine (248) 
To a solution 347 (200 mg, 650 µmol) in DMF, 60% NaH suspension (26 mg,  650 µmol) 
was added. Iodomethane (0.5 ml, 650 µmol) was added to the suspension and the reaction 
mixture was stirred for 2 hours. Silica gel was added to the solvent mixture and plug was 
prepared. A flash column chromatography using ethyl acetate-Hexane as eluent was 
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performed to afford 248 as a white solid (160 mg, 77% yield) TLC Rf =  0.26 
(MeOH:CHCl3:NH4OH, 1:10:0.5); mp, 183.2 C; 1H-NMR (400 MHz) (Me2SO-d6) δ 8.01 
(d, J=5.4 Hz, 1 H, Ar), 7.46 (d, J=8.4 Hz, 2 H, Ar), 7.40 (d, J=8.4 Hz, 2 H, Ar), 7.25 (d, 
J=5.4 Hz, 1 H, Ar), 3.49 (s, 3 H, -CH3), 2.55 (s, 3 H, -CH3). Anal. Calcd.  for C14H12ClN3S2 
0.1 CH3OH: C, 52.10; H, 3.85; Cl, 10.91; N, 12.93; S, 19.73. Found: C, 52.74; H, 4.01; Cl, 
10.03; N, 13.81; S, 19.94. 
 
N-(4-(methylthio)phenyl)thieno[3,2-d]pyrimidin-4-amine (350) 
Commercially available 4-chloro-thieno[3,2-d]pyrimidine 349 (300 mg, 1.76 mmol) was 
reacted with 4-(methylthio)aniline (270 mg, 1.76 mmol) in microwave reactor with 
isopropanol at 130°C.  Silica gel was added to the solvent mixture and plug was prepared. 
A flash column chromatography using ethyl acetate-Hexane as eluent afforded 350 (300 
mg, 55% yield, white solid); TLC Rf =  0.24 (MeOH:CHCl3:NH4OH, 1:10:0.5); mp, 181.7 
C; 1H-NMR (400 MHz) (Me2SO-d6) δ 9.72 (s, 1 H, exch., -NH), 8.58 (s, 1 H, 2-H), 8.22 
(d, J=5.5 Hz, 1 H, Ar), 7.76 (d, J=8.7 Hz, 2 H, Ar), 7.47 (d, J=5.4 Hz, 1 H, Ar), 7.29 (d, 
J=8.7 Hz, 2 H, Ar), 2.48 (s, 3 H, -SCH3). Anal. Calcd. for C13H11N3S2 0.42 H2O: C, 55.56; 
H, 4.25; N, 14.96; S, 22.83. Found: C, 55.46; H, 3.91; N, 15.00; S, 23.14. 
 
N-methyl-N-(4-(methylthio)phenyl)thieno[3,2-d]pyrimidin-4-amine (247) 
Reaction of N-(4-(methylthio)phenyl)thieno[3,2-d]pyrimidin-4-amine 350 (250 mg, 0.812 
mmol) with 60% NaH suspension (32 mg,  0.812 mmol) in DMF created the anion. 
Iodomethane (0.5 ml, 0.812 mmol) was added to the suspension and the reaction was stirred 
for 2 hours.  Silica gel was added to the solvent mixture and plug was prepared. A flash 
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column chromatography was performed using ethyl acetate-Hexane to afford 247 as yellow 
solid (200 mg, 77% yield); TLC Rf = 0.27 (MeOH:CHCl3:NH4OH, 1:10:0.5); mp, 137.9-
140.9 ⁰ C; 1H-NMR (400 MHz) (Me2SO-d6) δ 8.60 (s, 1 H, Ar), 7.95 (d, J=5.3 Hz, 1 H, 
Ar), 7.40 (q, J=8.6 Hz, 4 H, Ar), 7.30 (d, J=5.4 Hz, 1 H, Ar), 3.52 (s, 3 H, -N4CH3), 2.55 
(s, 3 H, -SCH3). Anal. Calcd.  for C14H13N3S2: C, 58.51; H, 4.56; N, 14.62; S, 22.31. Found: 
C, 58.53; H, 4.69; N, 14.35; S, 22.24. 
 
N4-(4-methoxyphenyl)-N4-methylthieno[3,2-d]pyrimidine-2,4-diamine (243) 
Compound 244 (250 mg, 0.818 mmol) was reacted with excess 7 N ammonia in methanol 
in a microwave reactor at 140°C for 60 hours. Silica gel was added to the solvent mixture 
and plug was prepared. A flash column chromatography using ethyl acetate-hexane 
afforded 243 as a white solid (100 mg, 43% yield). TLC Rf = 0.15 (MeOH:CHCl3:NH4OH, 
1:10:0.5); mp, 197.7C; 1H NMR (400 MHz) (Me2SO-d6) δ 7.60 (d, J=5.4 Hz, 1 H, Ar), 
7.27 (d, J=8.7 Hz, 2 H, Ar), 7.00 (d, J=8.8 Hz, 2 H, Ar), 6.86 (dd, J=1.6 Hz, J=5.5 Hz, 1 H, 
Ar), 5.86 (s, 2 H, exch. -2NH2), 3.77 (s, 3 H, -OCH3), 3.37 (s, 3 H, -N
4CH3). Anal. Calcd.  
for C14H14N4OS: C, 58.72; H, 4.93; N, 19.57; O, 5.59; S, 11.20. Found: C, 58.33; H, 5.07; 
N, 18.48; S, 10.67. 
 
N4-methyl-N4-(4-(methylthio)phenyl)thieno[3,2-d]pyrimidine-2,4-diamine (249) 
Compound 248 (160 mg, 0.498 mmol) was reacted with excess 7 N ammonia in methanol 
in a microwave reactor at 140°C for 60 hours. Silica gel was added to the solvent mixture 
and plug was prepared. A flash column chromatography using ethyl acetate-hexane 
afforded 249 as a white solid (85 mg, 57% yield); TLC Rf = 0.20 (MeOH:CHCl3:NH4OH, 
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1:10:0.5); mp, 159.9 C; 1H-NMR (500 MHz) (Me2SO-d6) δ 7.64 (d, J=5.3 Hz, 1 H, Ar), 
7.31 (m, 4 H, Ar), 6.95 (d, J=5.3 Hz, 1 H, Ar), 4.46 (s, 2 H, exch., 2-NH2) 3.12 (s, 3 H, -
SCH3), 3.42 (s, 3 H, -N
4CH3). Anal. Calcd.  for C14H14N4S2 0.33 CH3(CH2)4CH3: C, 58.00; 
H, 5.67; N, 16.94; S, 19.40. Found: C, 58.06; H, 5.43; N, 16.93; S, 19.37. 
 
4-(6-methoxy-3,4-dihydroquinolin-1(2H)-yl)thieno[3,2-d]pyrimidine (250) 
Commercially available 4-chloro-thieno[3,2-d]pyrimidine 349 (300 mg, 1.76 mmol) was 
reacted with 6-methoxy-1,2,3,4-tetrahydroquinoline (290 mg, 1.76 mmol) in microwave 
reactor with isopropanol at 130°C for 4 hours. Silica gel was added to the solvent mixture 
and plug was prepared. A flash column chromatography was performed using ethyl acetate-
Hexane  afforded 250 as a white solid (450 mg, 77% yield); TLC Rf =  0.50 
(MeOH:CHCl3:NH4OH, 1:10:0.5); mp, 124.3-133.2 ⁰ C; 1H-NMR (400 MHz) (Me2SO-
d6) δ 8.65 (s, 1 H, 2-H), 8.00 (d, J=5.5 Hz, 1 H, Ar), 7.36 (d, J=5.5 Hz, 1 H, Ar), 7.04 (d, 
J=8.6 Hz, 1 H, Ar), 6.90 (d, J=2.8 Hz, 1 H, Ar), 6.77 (dd, J=2.9 Hz, J=8.7 Hz, 1 H, Ar), 
4.02 (t, J=6.7 Hz, 2 H, -CH2-), 3.79 (s, 3 H, -OCH3), 2.70 (t, J=6.5 Hz, 2 H, -CH2-), 1.93 ( 
p, J=6.6 Hz, 2 H, -CH2-). Anal. Calcd.  for C16H15N3OS: C, 64.62; H, 5.08; N, 14.13; O, 
5.38; S, 10.78. Found: C, 64.25; H, 5.03; N, 14.02; S, 11.02. 
 
2-chloro-4-(6-methoxy-3,4-dihydroquinolin-1(2H)-yl)thieno[3,2-d]pyrimidine (251) 
Commercially available 2,4-dichloro-thieno[3,2-d]pyrimidine 342 (300 mg, 1.46 mmol) 
was reacted with 6-methoxy-1,2,3,4-tetrahydroquinoline (240 mg, 1.46 mmol)  in 
isopropanol for 72 hours at room temperature. Silica gel was added to the solvent mixture 
and plug was prepared. A flash column chromatography was performed using ethyl acetate-
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Hexane afforded 251 as a white solid (380 mg, 79% yield); TLC Rf =  0.62 
(MeOH:CHCl3:NH4OH, 1:10:0.5); mp, 116.3 C; 1H-NMR (400 MHz) (Me2SO-d6) δ 8.06 
(d, J=5.5 Hz, 1 H, Ar), 7.31 (d, J=5.5 Hz, 1 H, Ar), 7.17 (d, J=8.6 Hz, 1 H, Ar), 6.94 (d,  
J=2.8 Hz, 1 H, Ar), 6.80 (dd, J=2.9 Hz, J=8.6 Hz, 1 H, Ar), 3.99 (t, J=6.7 Hz, 2 H, -CH2-), 
3.80 (s, 3 H, -OCH3), 2.70 (t, J=6.5 Hz, 2 H, -CH2-), 1.95 (m, 2 H, -CH2-). Anal. Calcd.  
for C16H14ClN3OS: C, 57.92; H, 4.25; Cl, 10.68; N, 12.66; O, 4.82; S, 9.66. Found: C, 
58.02; H, 4.37; Cl, 10.55; N, 12.62; S, 9.50. 
 
4-(6-methoxy-3,4-dihydroquinolin-1(2H)-yl)thieno[3,2-d]pyrimidin-2-amine (252) 
2-chloro-4-(6-methoxy-3,4-dihydroquinolin-1(2H)-yl)thieno[3,2-d]pyrimidine 291 (200 
mg, 0.603 mmol) was reacted with excess 7 N ammonia in methanol in a microwave reactor 
at 140°C for 60 hours.  Silica gel was added to the solvent mixture and plug was prepared. 
A flash column chromatographic separation was performed using ethyl acetate-hexane to 
afford 252 as a white solid (110 mg, 58% yield); TLC Rf =  0.23 (MeOH:CHCl3:NH4OH, 
1:10:0.5); mp, 212.9 C; 1H-NMR (400 MHz) (Me2SO-d6) δ 7.74 (d, J=5.3 Hz, 1 H, Ar), 
6.96 (dd, J=7.0 Hz, J=16.3 Hz, 2 H, Ar), 6.86 (m, 1 H, Ar), 6.15 (s, 2 H, exch., 2-NH2), 
6.75 (dd, J=8.4 Hz, J=2.8 Hz, 1 H, Ar), 3.93 (t, J=6.4 Hz, 2 H, -CH2-), 3.77 (s, 3 H, -OCH3), 
2.70 (t, J=6.3 Hz, 2 H,-CH2-), 1.90 (p, J=6.1 Hz, 2 H, -CH2-). Anal. Calcd.  for 
C16H16N4OS: C, 60.40; H, 5.49; N, 17.14; S, 9.81. Found: C, 60.68; H, 5.22; N, 16.90; S, 
9.77. 
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N-(5-methoxynaphthalen-2-yl)-N-methylthieno[3,2-d]pyrimidin-4-amine (253) 
Commercially available 4-chloro-thieno[3,2-d]pyrimidine (300 mg, 1.76 mmol) was 
reacted with 6-methoxy-6-aminonaphthalen-1-ol (280 mg, 1.76 mmol) in microwave 
reactor with isopropanol at 130°C for 4 hours. The solvent was evaporated afford 352 (430 
mg, 75% crude yield, white solid); TLC Rf = 0.43 (MeOH:CHCl3:NH4OH, 1:10:0.5);
1H 
NMR (400 MHz) (Me2SO-d6) δ 10.10 (s, 1 H, exch., -NH), 9.90 (s, 1 H, exch., -OH), 8.65 
(d, J = 1.5 Hz, 1 H, 2-H), 8.30 (d, J = 2.0 Hz, 1 H, Ar), 8.24 (dd, J = 5.4, 1.3 Hz, 1 H, Ar), 
8.12 (dd, J = 9.1, 1.7 Hz, 1 H, Ar), 7.82 (dt, J = 9.1, 2.0 Hz, 1 H, Ar), 7.49 (dd, J = 5.3, 1.3 
Hz, 1 H, Ar), 7.38 – 7.25 (m, 2 H, Ar), 6.82 – 6.76 (m, 1 H, Ar). Compound 352 (250 mg, 
0.763 mmol) and 60% NaH suspension (30 mg, 0.763 mmol) in DMF created the anion in 
15 minutes. Iodomethane (0.5 ml, 0.763 mmol) was added to the suspension and the 
reaction was stirred for 2 hours. Silica gel was added to the solvent mixture and plug was 
prepared A flash column chromatographic separation was performed using ethyl acetate-
hexane to afford 253 as a white solid (240 mg, 88% yield); TLC Rf = 0.40 
(MeOH:CHCl3:NH4OH, 1:10:0.5); mp, 167.5-170.0 ⁰ C;1H NMR (400 MHz) (Me2SO-d6) 
δ 8.66 (s, 1 H, 2-H), 8.27 (d, J = 8.9 Hz, 1 H, Ar), 7.99 (d, J = 2.3 Hz, 1 H, Ar), 7.81 (d, J 
= 5.5 Hz, 1 H, Ar), 7.56 (dd, J = 8.8, 2.2 Hz, 1 H, Ar), 7.52 – 7.49 (m, 2 H, Ar), 7.28 (d, J 
= 5.5 Hz, 1 H, Ar), 7.11 – 7.02 (m, 1 H, Ar), 4.02 (s, 3 H, -OCH3), 3.63 (s, 3 H, -N4CH3). 
Anal. Calcd.  for C18H15N3OS: C, 67.27; H, 4.70; N, 13.07; O, 4.98; S, 9.98. Found: C, 
67.26; H, 4.84; N, 13.16; S, 9.94. 
 
6-((2-chlorothieno[3,2-d]pyrimidin-4-yl)amino)naphthalen-1-ol  (353): Commercially 
available 2,4-dichloro-thieno[3,2-d]pyrimidine (300 mg, 1.46 mmol) was reacted with 6-
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aminonaphthalen-1-ol (233 mg, 1.46 mmol)  for 72 hours at room temperature in 
isopropanol. Silica gel was added to the solvent mixture and plug was prepared. A flash 
column chromatography using ethyl acetate-hexane afforded 353 as a white solid (400 mg, 
83% yield). TLC Rf = 0.42 (MeOH:CHCl3:NH4OH, 1:10:0.5); mp, 225.7 C; 1H-NMR 
(400 MHz) (Me2SO-d6) δ 10.20 (s, 1 H, exch.), 10.08 (s, 1 H, exch.), 8.29 (d, J = 8.8 Hz, 1 
H, Ar), 8.07 (d, J = 2.2 Hz, 1 H, Ar), 7.88 (d, J = 5.4 Hz, 1 H, Ar), 7.60 (dd, J = 8.8, 2.2 
Hz, 1 H, Ar), 7.56 – 7.49 (m, 2 H, Ar), 7.23 (d, J = 5.5 Hz, 1 H, Ar), 7.09 (dd, J = 6.3, 2.4 
Hz, 1 H, Ar). Anal Calcd. for C16H10ClN3OS: C, 58.63; H, 3.08; Cl, 10.81; N, 12.82; O, 
4.88; S, 9.78. Found: C, 58.36; H, 3.23; Cl, 10.57; N, 12.54; S, 9.53. 
 
2-chloro-N-(5-methoxynaphthalen-2-yl)-N-methylthieno[3,2-d]pyrimidin-4-amine 
(254) 
Compound 353 (350 mg, 1.07 mmol) was stirred with 60% NaH suspension (42 mg, 1.07 
mmol) in DMF for 15 minutes. Iodomethane (0.7 ml, 1.07 mmol) was added to the 
suspension and was stirred for 2 hours. Silica gel was added to the solvent mixture and 
plug was prepared. A flash column chromatography was performed using ethyl acetate-
Hexane afforded 254 as a white solid (270 mg, 71% yield); TLC Rf =  0.50 
(MeOH:CHCl3:NH4OH, 1:10:0.5); mp, 222.6 C; 1H-NMR (400 MHz) (Me2SO-d6) δ 8.28 
(d, J = 8.9 Hz, 1 H, Ar), 8.03 (dd, J = 4.4, 2.4 Hz, 1 H, Ar), 7.88 – 7.81 (m, 1 H, Ar), 7.62 
– 7.54 (m, 1 H, Ar), 7.52 (d, J = 6.5 Hz, 2 H, Ar), 7.21 (dd, J = 5.5, 2.3 Hz, 1 H, Ar), 7.08 
(dd, J = 6.5, 2.3 Hz, 1 H, Ar), 4.00 (s, 3 H, -OCH3), 3.75 (s, 3 H, -N
4CH3). Anal. Calcd.  
for C18H14ClN3OS: C, 60.55; H, 4.05; Cl, 9.87; N, 11.70; S, 8.93. Found: C, 60.58; H, 4.08; 
Cl, 9.75; N, 11.63; S, 8.96. 
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N4-(5-methoxynaphthalen-2-yl)-N4-methylthieno[3,2-d]pyrimidine-2,4-diamine (255) 
Compound 254 (230 mg, 0.636 mmol) was reacted with excess 7 N ammonia in methanol 
in a microwave reactor at 140°C for 60 hours. Silica gel was added to the solvent mixture 
and plug was prepared. A flash column chromatography using methanol-chloroform 
produced 255 as a white solid (100 mg, 46% yield); TLC Rf =  0.26 
(MeOH:CHCl3:NH4OH, 1:10:0.5); mp, 112.9C; 1H NMR (400 MHz) (Me2SO-d6) δ 8.32 
(d, J = 8.8 Hz, 1 H, Ar), 8.01 (d, J = 4.4 Hz, 1 H, Ar), 7.76 (t, J = 5.7 Hz, 1 H, Ar), 7.52 
(dt, J = 11.0, 8.1 Hz, 3 H, Ar), 7.08 (d, J = 7.4 Hz, 1 H, Ar), 7.03 (dd, J = 5.9, 3.0 Hz, 1 H, 
Ar), 6.11 (s, 2 H, exch., 2-NH2), 3.97 (d, J = 4.2 Hz, 3 H, -OCH3), 3.61 (d, J = 1.9 Hz, 3 H, 
-N4CH3). Anal. Calcd.  for C18H16N4OS 0.45 CH3OH: C, 63.17; H, 5.11; N, 15.94; S, 9.14. 
Found: C, 63.33; H, 5.10; N, 15.80; S, 8.87. 
 
7-methylthieno[3,2-d]pyrimidin-4(3H)-one (355) 
Commercially available 350 (2.5 g, 13.50 mmol) was reacted with formamide (12 mL) in 
reflux conditions for 12 hours. Water (50 mL) was added to the mixture and the precipitate 
was collected on filtration. The precipitate was dried over P2O5 overnight to afford 350 (2 
g, 90% crude yield). TLC Rf = 0.20 (MeOH:CHCl3:NH4OH, 1:5:0.5); mp assessment 
suggested presence of impurities; 1H-NMR (400 MHz) (Me2SO-d6) δ 8.19 (s, 1 H, Ar), 
7.79 (s, 1 H, Ar), 3.17 (s, 3 H, -CH3). The 
1H-NMR matched the NMR values for the 
reported compound.280  
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4-chloro-7-methylthieno[3,2-d]pyrimidine (356) 
Chlorination of 201 (1.8 g,10.83 mmol) was carried out using 12 mL of POCl3 and reflux 
conditions for 4 hours. The solvent was evaporated using reduced pressure. To this mixture, 
7 N ammonia in methanol was added for neutralization. The evaporation of the solvent 
afforded 402 (1.5 g, 75% crude yield). TLC Rf = 0.42 (MeOH:CHCl3:NH4OH, 1:5:0.5); 
mp assessment suggested presence of impurities; 1H-NMR (500 MHz) (Me2SO-d6) δ 9.04 
(s, 1 H, Ar), 8.23 (s, 1 H, Ar), 3.17 (s, 3 H, -CH3). The 
1H-NMR matched the NMR values 
for the reported compound.281  
 
N-(4-methoxyphenyl)-N,7-dimethylthieno[3,2-d]pyrimidin-4-amine (256) 
Compound 356 (300 mg, 1.62 mmol) was reacted with 4-methoxy-N-methylaniline (223 
mg, 1.62 mmol) for 4 hours at 130°C in isopropanol for 4 hours. Silica gel was added to 
the solvent mixture and plug was prepared. A flash column chromatographic separation 
was performed using ethyl acetate-hexane as eluent to afford 256 as a white solid (360 mg, 
78% yield); TLC Rf = 0.52 (MeOH:CHCl3:NH4OH, 1:10:0.5); mp, 151.2 C; 1H NMR 
(400 MHz) (Me2SO-d6) δ 8.64 (s, 1 H, Ar), 7.65 – 7.50 (m, 1 H, Ar), 7.46 – 7.28 (m, 4 H, 
Ar), 3.50 (s, 3 H, -OCH3), 2.54 (s, 3 H, 7-CH3), 2.37 – 2.19 (m, 3 H, -N4CH3). Anal. Calcd.  
for C15H15N3OS: C, 63.13; H, 5.30; N, 14.73; O, 5.61; S, 11.23. Found: C, 63.26; H, 5.42; 
N, 14.69; S, 11.33. 
 
4-(6-methoxy-3,4-dihydroquinolin-1(2H)-yl)-7-methylthieno[3,2-d]pyrimidine (258) 
4-chloro-7-methylthieno[3,2-d]pyrimidine 356 (300 mg, 1.62 mmol) was reacted with 6-
methoxy-1,2,3,4-tetrahydroquinoline (265 mg, 1.62 mmol) in microwave reactor with 
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isopropanol at 130°C for 4 hours. Silica gel was added to the solvent mixture and plug was 
prepared. A flash column chromatographic separation was performed using ethyl acetate-
hexane as eluent to afford 258 as a white solid (320 mg, 63% yield); TLC Rf = 0.41 
(MeOH:CHCl3:NH4OH, 1:10:0.5); mp, 154.9 C; 1H-NMR (400 MHz) (Me2SO-d6) δ 8.70 
(s, 1 H, Ar), 7.64 (s, 1 H, Ar), 7.00 (d, J=8.6 Hz, 1 H, Ar), 6.90 (dd, J=2.6 Hz, 1 H, Ar), 
6.76 (dd, J=2.6 Hz, J=8.6 Hz, 1 H, Ar), 4.01 (t, J=6.6 Hz, 2 H, -CH2-), 3.78 (s, 3 H, -OCH3), 
2.70 (t, J=6.5 Hz, 2 H, -CH2-), 2.32 (s, 3 H, 7-CH3), 1.93 (p, J=6.5 Hz, 2 H, -CH2-). Anal. 
Calcd.  for C17H17N3OS: C, 65.57; H, 5.50; N, 13.49; O, 5.14; S, 10.30. Found: C, 65.30; 
H, 5.39; N, 13.30; S, 10.09. 
 
N,7-dimethyl-N-(4-(methylthio)phenyl)thieno[3,2-d]pyrimidin-4-amine (257) 
Compound 356 (150 mg, 0.81 mmol) was reacted with 4-(methylthio)aniline (227 mg, 1.62 
mmol) in microwave reactor with isopropanol at 130°C for 4 hours. The solvent was 
evaporated under reduced pressure. To the semi-solid mixture containing 357, 60% NaH 
suspension (28 mg, 0.696 mmol) was added in DMF and the reaction was stirred for 15 
minutes. Iodomethane (0.5 ml, 0.700 mmol) was added to the suspension and the reaction 
was stirred for 2 hours. Silica gel was added to the solvent mixture and plug was prepared. 
A flash column chromatographic separation was performed using ethyl acetate-hexane as 
eluent to afford 257 as a white solid (280 mg, 86% yield); TLC Rf = 0.44 
(MeOH:CHCl3:NH4OH, 1:10:0.5); mp, 151.3 C; 1H NMR (400 MHz) (Me2SO-d6) δ 8.64 
(s, 1 H, Ar), 7.65 – 7.50 (m, 1 H, Ar), 7.46 – 7.28 (m, 4 H, Ar), 3.50 (s, 3 H, -OCH3), 2.54 
(s, 3 H, -CH3), 2.37 – 2.19 (m, 3 H, -N4CH3). Anal. Calcd.  for C15H15N3S2 C, 59.77; H, 
5.02; N, 13.94; S, 21.27. Found: C, 59.69; H, 5.00; N, 14.15; S, 21.33. 
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6-(methyl(7-methylthieno[3,2-d]pyrimidin-4-yl)amino)naphthalen-1-ol (259) 
Compound 356 (300 mg, 1.62 mmol) was reacted with 6-aminonaphthalen-1-ol  (260 mg, 
1.62 mmol) in microwave reactor with isopropanol at 130°C for 4 hours. The solvent was 
evaporated to afford 358 as a white solid (400 mg, 81% crude yield). TLC Rf =  0.40 
(MeOH:CHCl3:NH4OH, 1:10:0.5); mp assessment suggested impurities; 
1H-NMR (400 
MHz) (Me2SO-d6) δ 10.08 (s, 1 H, exch., -NH), 9.82 (s, 1 H, exch., -OH), 8.68 (d, J = 1.4 
Hz, 1 H, Ar), 8.31 (d, J = 2.1 Hz, 1 H, Ar), 8.10 (d, J = 9.0 Hz, 1 H, Ar), 7.93 – 7.85 (m, 1 
H, Ar), 7.81 (dd, J = 9.1, 2.2 Hz, 1 H, Ar), 7.28 (d, J = 4.4 Hz, 2 H, Ar), 6.78 (t, J = 4.3 Hz, 
1 H, Ar), 2.39 (s, 3 H, 7-CH3). Compound 358 (200 mg, 0.651 mmol) with 60% NaH 
suspension (26 mg,  0.651 mmol) in DMF created the anion in 15 minutes. Iodomethane 
(0.5 ml, 0.700 mmol) was added to the suspension and the reaction was stirred for 2 hours. 
Silica gel was added to the solvent mixture and plug was prepared. A flash column 
chromatographic separation was performed using ethyl acetate-hexane as eluent to afford 
259 as white solid (160 mg, 77% yield); TLC Rf = 0.46 (MeOH:CHCl3:NH4OH, 1:10:0.5); 
mp, 261.2 ⁰ C; 1H-NMR (400 MHz) (Me2SO-d6) δ 8.69 (s, 1 H, Ar), 8.25 (d, J=8.9 Hz, 1 
H, Ar), 7.95 (d, J=1.9 Hz, 1 H, Ar), 7.53 (dd, J=2.0 Hz, J=8.8 Hz, 1 H, Ar), 7.48 (dd, J=7.1 
Hz, J=9.6 Hz, 3 H, Ar), 7.05 (dd, J=2.8 Hz, J=5.8 Hz, 1 H, Ar), 4.01 (s, 3 H, -CH3), 3.62 
(s, 3 H, -CH3), 2.26 (s, 3 H, 7-CH3). Anal. Calcd.  for C19H17N3OS: C, 68.04; H, 5.11; N, 
12.53; O, 4.77; S, 9.56. Found: C, 67.67; H, 5.22; N, 12.35; S, 9.33. 
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N4-(4-methoxyphenyl)-N4,7-dimethylthieno[3,2-d]pyrimidine-2,4-diamine (260) 
Cyclization of commercially available ethyl 3-amino-4-methylthiophene-2-carboxylate  
(2.5 g, 13.50 mmol) with chlorformamidine hydrochloride (5 g, 31.41 mmol) in 
dimethylsulfone at 140°C for 4 hours afforded 359 (1.9 g, 78% crude yield). The product 
was not subjected to separation efforts and taken to the next step without any 
characterization. Protection of 2-amino 359 was carried out with pivalic anhydride at 60 
⁰ C overnight. 50 mL hexane was added to the solution and 360 were collected as light 
yellow semi-solid (2.1 g, 77% yield). Chlorination of 360 (2g, 10.80 mmol) with POCl3 
under reflux conditions over 4 hours. The reaction was neutralized with 7 N ammonia 
solution in methanol and the mixture was filtered. The filtrate was evaporated to afford 361 
as white solid (2.2g, 68% crude yield). The product was not subjected to separation efforts 
and taken to the next step without any characterization. Compound 361 (1 g, 3.34 mmol) 
was reacted with 4-methoxy-N-methylaniline (460 mg, 3.34 mmol) for 4 hours at 130°C 
in isopropanol in microwave reactor. The solvent was evaporated at reduced pressure.  To 
the semi-solid residue of 362, 2 mL 1 N NaOH in 5 mL methanol was added and the 
reaction was stirred for 2 hours. Methanol was evaporated and the water layer was 
subjected with 50 mL ethyl acetate (3 times) and the ethyl acetate with the extracted 
compound was collected. Silica gel was added to the solvent mixture and plug was 
prepared. A flash column chromatographic separation was performed using ethyl acetate-
hexane as eluent to afford 260 as white solid (450 mg, 45% yield over 2 steps); TLC Rf = 
0.23 (MeOH:CHCl3:NH4OH, 1:5:0.5); mp, 206.1 C; 1H-NMR (400 MHz) (Me2SO-d6) δ 
7.30 (d, J=8.8 Hz, 3 H, Ar), 7.01 (d, J=8.8 Hz, 2 H, Ar), 6.07 (s, 2 H, exch., 2-NH2), 3.82 
(s, 3 H, -OCH3), 3.41 (s, 3 H, N
4-CH3), 2.12 (s, 3 H, 7-CH3). Anal. Calcd.  for C15H16N4OS: 
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C, 59.86; H, 5.41; N, 18.55; S, 10.62. Elemental Analysis calculated: C, 59.87; H, 5.53; N, 
18.08; S, 11.10. 
 
4-(6-methoxy-3,4-dihydroquinolin-1(2H)-yl)-7-methylthieno[3,2-d]pyrimidin-2-
amine (261) 
Compound 361 (1 g, 3.34 mmol) was reacted with 6-methoxy-1,2,3,4-tetrahydroquinoline 
(550 mg, 3.34 mmol)  for 4 hours at 130°C in isopropanol in microwave reactor. The 
solvent was evaporated under reduced pressure to afford 363. It was used in the next 
reaction, without further separation or characterization efforts. Hydrolysis of 363 was 
accrued out using 2 ml 1 N NaOH in 5 mL methanol for 2 hours. Methanol was evaporated 
and the water layer was subjected with 50 mL ethyl acetate (3 times) and the ethyl acetate 
with the extracted compound was collected. Silica gel was added to the solvent mixture 
and plug was prepared. A flash column chromatographic separation was performed using 
ethyl acetate-hexane as eluent to afford 261 as a white solid (400 mg, 37% yield over 2 
steps). TLC Rf = 0.25 (MeOH:CHCl3:NH4OH, 1:5:0.5); mp, 216.4 C; 1H-NMR (400 
MHz) (Me2SO-d6) δ 7.35 (d, J=1.2 Hz, 1 H, Ar), 6.92 (d, J=8.7 Hz, 1 H, Ar), 6.83 (d, J=2.8 
Hz, 1 H, Ar), 6.71 (dd, J=2.9 Hz, J=8.6 Hz, 1 H, Ar), 6.18 (s, 2H, exch., -2NH2), 3.94 (s, 3 
H, -OCH3), 3.88 (t, J=6.9 Hz, 2 H, -CH2-), 2.65 (t, J=6.6 Hz, 2 H, -CH2-), 2.13 (s, 3 H, 7-
CH3), 1.86 (p, J=6.5 Hz, 2 H, -CH2-). Anal. Calcd.  for C17H18N4OS: C, 62.55; H, 5.56; N, 
17.16; O, 4.90; S, 9.82. Found: C, 62.72; H, 5.49; N, 17.24; S, 9.84. 
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4-chloro-6-methylthieno[3,2-d]pyrimidine (366) 
Treatment of commercially available ethyl 3-amino-5-methylthiophene-2-carboxylate 364 
(3 g, 16.20 mmol) with 12 mL formamide was carried out under reflux conditions for 12 
hours. To the mixture, 50 mL water was added and the precipitate was collected and dried 
under high vacuum to afford 365 as brown liquid. Chlorination of 365 (1.7 g, 10.23 mmol) 
was performed using POCl3 and reflux conditions for 4 hours. The solvent was evaporated 
using reduced pressure. To the residue, was added methanol and 5 g silica gel. The solvent 
was reduced under pressure and silica plug was prepared. A flash column chromatographic 
separation was performed using ethyl acetate-hexane as eluent to afford 366 as a white 
solid (1.5 g, 50% yield over 2 steps). mp, 140.9 C; TLC Rf = 0.30 (MeOH:CHCl3:NH4OH, 
1:5:0.5); 1H-NMR (400 MHz) (Me2SO-d6) δ 8.97 (s, 1 H, Ar), 7.51 (q, J=1.2 Hz, 1 H, Ar), 
2.74 (d, 3 H, J=1.2 Hz, -CH3); Anal. Calcd.  for C7H5ClN2S: C, 45.54; H, 2.73; Cl, 19.20; 
N, 15.17; S, 17.36. Found: C, 45.72; H, 2.76; Cl, 19.08; N, 15.13; S, 17.49. 
 
N-(4-methoxyphenyl)-N,6-dimethylthieno[3,2-d]pyrimidin-4-amine  (262) 
Compound 366 (300 mg, 1.62 mmol) was reacted with 4-methoxy-N-methylaniline (223 
mg, 1.62 mmol)  for 4 hours at 130°C in isopropanol. Silica gel was added to the solvent 
mixture and plug was prepared by evaporating the solvent under reduced pressure. A flash 
column chromatographic separation was performed using ethyl acetate-hexane as eluent to 
afford 262 as white solid (390 mg, 84% yield). TLC Rf = 0.36 (MeOH:CHCl3:NH4OH, 
1:5:0.5); mp, 128.4 C; 1H-NMR (400 MHz) (Me2SO-d6) δ 8.52 (s, 1 H, Ar), 7.43 – 7.32 
(m, 2 H, Ar), 7.10 – 7.02 (m, 2 H, Ar), 7.00 (s, 1 H, Ar), 3.84 (s, 3 H, -OCH3), 3.46 (s, 3 
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H, -N4CH3), 2.38 (s, 3 H, 6-CH3). Anal. Calcd. for C15H15N3OS: C, 63.13; H, 5.30; N, 
14.73; O, 5.61; S, 11.23. Found: C, 63.26; H, 5.15; N, 14.71; S, 11.06. 
 
N-methyl-N-(4-(trifluoromethoxy)phenyl)thieno[3,2-d]pyrimidin-4-amine (263) 
Commercially available thieno[3,2-d]pyrimidine (300 mg, 1.76 mmol) was reacted with 
N-methyl-4-(trifluoromethoxy)aniline (340 mg, 1.76 mmol)  for 4 hours at 130°C in 
isopropanol. Silica gel was added to the solvent mixture and plug was prepared. A flash 
column chromatographic separation was performed using ethyl acetate-hexane as eluent to 
afford 263 as a yellow solid (320 mg, 56% yield). TLC Rf = 0.40 (MeOH:CHCl3:NH4OH, 
1:10:0.5); mp, 88.4 C; 1H-NMR (400 MHz) (Me2SO-d6) δ  8.62 (s, 1 H, Ar), 8.27 (d, J=5.5 
Hz, 1 H, Ar), 7.94 (d, J=9.0 Hz, 2 H, Ar), 7.50 (d, J=5.3 Hz, 1 H, Ar), 7.38 (d, J=8.8 Hz, 2 
H, Ar), 3.36 (s, 3 H, -N4CH3). Anal. Calcd.  for C14H10F3N3OS 0.2 H2O: C, 51.12; H, 3.19; 
F, 17.33; N, 12.78; S, 9.75. Found: C, 50.30; H, 2.58; F, 18.11; N, 13.56; S, 10.09. 
 
General procedure for synthesis of 368-370 and 387-389  
In a 20 mL vial for microwave reaction were added a mixture of palladium chloride (71 
mg, 0.40 mmol), triphenylphosphine (131 mg, 0.40 mmol), triethylamine (10.1 g, 100 
mmol), methyl 4-iodobenzoate, 367 (2.21 g, 8.43 mmol) or ethyl 5-bromothiophene-2-
carboxylate 386 (1.9 g, 8 mmol), and anhydrous acetonitrile (10 mL). To the stirred mixture 
were added copper(I) iodide (304 mg, 1.60 mmol) and appropriate alkyne alcohol (1.05 
equiv), and the vial was sealed and put into the microwave reactor at 100 C for 10 min. 
Silica gel (5 g) was added, and the solvent was evaporated under reduced pressure. The 
resulting plug was loaded on to a silica gel column (3.5 12 cm) and eluted with Hexane 
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followed by 20% EtOAc in Hexane. The desired fraction (TLC) was collected, and the 
solvent was evaporated under reduced pressure to afford the target compounds.  
 
Methyl 4-(3-hydroxyprop-1-yn-1-yl)benzoate (368) 
Compound 368 was synthesized using the general method described for the preparation of 
368-370 and 387-443 using prop-2-yn-1-ol (0.5 ml, 8 mmol), to give 1.3 g of 368 as yellow 
solid (1.36 g, 85%); TLC Rf = 0.16 (EtOAc:Hexane, 1:2); 
1H-NMR (400 MHz) (Me2SO-
d6) δ 8.06 – 7.87 (d, J = 8.4 Hz, 2 H, Ar), 7.55 (d, J = 8.4 Hz, 2 H, Ar), 4.30 (s, 1H, exch., 
-OH), 4.15 (s, 2 H, -CH2-), 3.81 (s, 3 H, -OCH3). The 
1H-NMR matched the 1H-NMR 
reported in the literature.282 
 
Methyl 4-(4-hydroxybut-1-yn-1-yl)benzoate (369) 
Compound 369 was synthesized using the general method described for the preparation of 
368-370 and 387-389, using but-3-yn-1-ol (0.6 ml, 8 mmol), to give 1.2 g of 369 as yellow 
solid (1.53 g, 78%); TLC Rf = 0.16 (EtOAc:Hexane, 1:2); mp,
283 92.3-94.6 ⁰ C; 1H-NMR 
(400 MHz) (Me2SO-d6) δ 7.90 (d, J = 8.7 Hz, 2 H, Ar), 7.51 (d, J = 8.7 Hz, 2 H, Ar), 4.96 
(s, 1 H, exch., -OH), 3.84 (s, 3 H, -OCH3), 3.61 (m, 2 H, -CH2-), 2.60 (t, J =6.0 Hz, 2 H, -
CH2-). The 
1H-NMR matched the 1H-NMR reported in the literature.284 
 
Methyl 4-(5-hydroxypent-1-yn-1-yl)benzoate (370) 
Compound 370 was synthesized using the general method described for the preparation of 
368-370 and 387-389, using pent-4-yn-1-ol (0.67 ml, 8 mmol), to give 1.34 g of 370 as 
yellow semi-solid (1.62 g, 88%);  TLC Rf  0.16 (EtOAc:Hexane, 1:2); 
1H-NMR (400 MHz) 
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(Me2SO-d6) δ 6.50 (d, J = 8.4 Hz, 2 H, Ar), 6.37 (d, J = 8.4 Hz, 2 H, Ar), 5.15 (s, 1 H, 
exch., -OH), 3.61 (s, 3 H, -OCH3), 3.11 (t, J = 4.9 Hz, 2 H, -CH2-), 2.64 (t, J = 6.5 Hz, 2 
H, -CH2-), 1.83 – 1.67 (m, 2 H, -CH2-). The 1H-NMR matched the 1H-NMR reported in 
the literature.285 
 
Ethyl 5-(3-hydroxyprop-1-yn-1-yl)thiophene-2-carboxylate (387) 
Compound 387 was synthesized using the general method described for the preparation of 
368-370 and 387-389, using prop-2-yn-1-ol (0.5 ml, 8 mmol), to give 1.2 g of 387 as yellow 
semi-solid (70%); TLC Rf = 0.11 (EtOAc:Hexane, 1:2); 
1H-NMR (400 MHz) (Me2SO-d6) 
δ 7.73 (d, J = 4.0 Hz, 1 H, Ar), 7.36 (d, J = 3.9 Hz, 1 H, Ar), 5.49 (t, J = 6.0 Hz, 1 H, -OH, 
exch.), 4.37 – 4.28 (m, 4 H, -OCH2 and -CH2-), 1.29 (t, J = 7.1 Hz, 3 H, -CH3). This 
compound was used for the next reaction without further characterization. 
  
Ethyl 5-(4-hydroxybut-1-yn-1-yl)thiophene-2-carboxylatee (388) 
Compound 388 was synthesized using the general method described for the preparation of 
368-370 and 387-389, using but-3-yn-1-ol (0.6 ml, 8 mmol), to give 1.1 g of 388 as yellow 
semi-solid (61%); TLC Rf = 0.11 (EtOAc:Hexane, 1:2); 1H-NMR (400 MHz) (Me2SO-d6) 
δ 7.70 (d, J = 4.0 Hz, 1 H, Ar), 7.28 (d, J = 4.0 Hz, 1 H, Ar), 4.96 (t, J = 5.6 Hz, 1 H, OH, 
exch.), 3.91-3.81 (m, 2 H, -OCH2), 3.57 (t, J = 6.4 Hz, 2 H, -CH2), 2.61 (t, J = 6.4 Hz, 2 H, 
-CH2), 1.30 (t, J = 7.1 Hz, 3 H, -CH3). The 
1H-NMR matches the 1H-NMR reported 
previously.246 
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Ethyl 5-(5-hydroxypent-1-yn-1-yl)thiophene-2-carboxylate (389) 
Compound 389 was synthesized using the general method described for the preparation 
368-370 and 387-389, using pent-4-yn-1-ol (0.67 ml, 8 mmol), to give 1.3 g of 389 as 
yellow semi-solid (68%); TLC Rf = 0.11 (EtOAc:Hexane, 1:2); 
1H-NMR (400 MHz) 
(Me2SO-d6)  δ 7.63 (d, J= 3.8 Hz, 1 H, Ar), 6.95 (d, J = 3.8 Hz, 1 H, Ar), 4.44 (t, J = 7.5 
Hz, exch., -OH), 4.26 (q, J = 7.0 Hz, 2 H, -OCH2), 2.83 (t, J = 7.6 Hz, 2 H, -CH2-), 1.66 (p, 
J = 6.5 Hz, 2 H, -CH2-), 1.46 (p, J = 6.5 Hz, 2 H, -CH2-), 1.29-1.24 (m, 3 H, -CH3). This 
compound was used for the next reaction without further characterization.  
 
General procedure for synthesis of 371-373 and 390-392 
To a Parr flask was added 368-370 and 387-389, 10% palladium on activated carbon (50% 
w/w), and MeOH (100 mL). Hydrogenation was carried out at 55 psi of H2 for 4 h. The 
reaction mixture was filtered through Celite, washed with MeOH (100 mL), and 
concentrated under reduced pressure to give crude mixture containing 371-373 and 390-
392. Without chromatographic separation, these compounds were used for the next 
reaction.  
 
Methyl 4-(3-hydroxypropyl)benzoate (371) 
Compound 371 was prepared using the general method described for the preparation of 
371-373 and 390-392, from 368 (1.45 g, 7.4 mmol) to give 1.2 g (98%) of 371 as a clear 
oil; TLC Rf = 0.16 (EtOAc:Hexane, 1:2);  
1H-NMR (400 MHz) (Me2SO-d6) 7.93 (d, J = 8.0 
Hz, 2 H, Ar), 7.55 (d, J = 7.9 Hz, 2 H, Ar), 5.43 (s, 1 H, exch., -OH), 3.85 (s, 3 H, -OCH3), 
3.29 (t, J = 7.8 Hz, 2 H, -CH2-), 2.67 (t, J = 7.8 Hz, 2 H, -CH2-), 1.72 (dt, J = 41.3, 7.4 Hz, 
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2 H, -CH2-). This compound was used for the next reaction without further 
characterization.  
 
Methyl 4-(4-hydroxybutyl)benzoate (372) 
Compound 372 was prepared using the general method described for the preparation of 
371-373 and 390-392, from 369 (1.45 g, 7.4 mmol) to give 1.1 g (90%) of 372 as a clear 
oil; TLC Rf = 0.16 (EtOAc:Hexane, 1:2); 
1H-NMR (500 MHz) (Me2SO-d6)  δ 7.88 (d, J = 
7.9 Hz, 2 H, Ar), 7.34 (d, J = 7.9 Hz, 2 H, Ar), 4.43 (s, 1 H, exch., -OH), 3.83 (s, 3 H, -
OCH3), 3.35 – 3.25 (m, 2 H, -CH2-), 2.68 (q, J = 10.4, 7.9 Hz, 2 H, -CH2-), 1.72 (dtd, J = 
49.7, 17.2, 15.4, 9.9 Hz, 4 H, -CH2-). This compound was used for the next reaction without 
further characterization.  
 
Methyl 4-(5-hydroxypentyl)benzoate (373) 
Compound 370 was prepared using the general method described for the preparation of 
371-373 and 390-392, from 370 (1.45 g, 7.4 mmol) to give 1.2 g (98%) of 373 as a clear 
oil; TLC Rf = 0.16 (EtOAc:Hexane, 1:2); 
1H-NMR (400 MHz) (Me2SO-d6) δ 7.86 (d, J = 
7.9 Hz, 2 H, Ar), 7.32 (d, J = 7.9 Hz, 2 H, Ar), 4.36 (s, 1 H, exch., -OH), 3.82 (s, 3 H, -
OCH3), 3.37 (t, J = 6.4 Hz, 2 H, -CH2-), 2.62 (t, J = 7.6 Hz, 2 H, -CH2-), 1.57 (p, J = 7.7 
Hz, 2 H, -CH2-), 1.43 (p, J = 6.6 Hz, 2 H, -CH2-), 1.29 (ddt, J = 8.6, 6.5, 3.9 Hz, 2 H, -CH2-
). This compound was used for the next reaction without further characterization.  
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Ethyl 5-(3-hydroxypropyl)thiophene-2-carboxylate (390) 
Compound 390 was prepared using the general method described for the preparation of 
371-373 and 390-392, from 387 (1.1 g, 5.23 mmol) to give 1.0 g (89%) of 390 as a clear 
oil; TLC Rf  0.12 (EtOAc:Hexane, 1:2); 
1H-NMR (400 MHz) (Me2SO-d6) δ 7.63 (t, J = 6.1 
Hz, 1 H, Ar), 6.94 (d, J = 6.1 Hz, 1 H, Ar), 4.44 (t, J = 5.1 Hz, 1 H, exch., -OH), 4.26 (p, J 
= 8.3, 7.1 Hz, 2 H, -OCH2-), 2.83 (t, J = 7.6 Hz, 2 H, -CH2-), 1.66 (p, J = 7.6 Hz, 2 H, -
CH2-), 1.46 (p, J = 6.8 Hz, 2 H, -CH2-), 1.27 (t, J = 7.0 Hz, 3 H, -CH3). This compound 
was used for the next reaction without further characterization.  
 
Ethyl 5-(4-hydroxybutyl)thiophene-2-carboxylate (391) 
 Compound 391 was prepared using the general method described for the preparation of 
371-373 and 390-392, from 388 (1.2 g, 5.35 mmol) to give 1.0 g (82%) of 391 as a clear 
oil; TLC Rf = 0.12 (EtOAc:Hexane, 1:2); 
1H-NMR (400 MHz) (Me2SO-d6)  δ 7.63 (d, J = 
3.7 Hz, 1 H, Ar), 6.95 (d, J = 3.8 Hz, 1 H, Ar), 4.38 (s, 1 H, exch., -OH), 4.23-4.20 (m, 2 
H, -OCH2-), 2.84 (q, J = 9.6, 7.5 Hz, 2 H, -CH2-), 1.63 (p, J = 7.5 Hz, 3 H, -CH3), 1.56 – 
1.39 (m, 2 H, -CH2-), 1.24-1.50 (m, 4 H, -CH2-). The 
1H-NMR matches 1H-NMR of the 
reported compound.246  
 
Ethyl 5-(5-hydroxypentyl)thiophene-2-carboxylate (392) 
Compound 392 was prepared using the general method described for the preparation of 
371-373 and 390-392, from 389 (1.1 g, 4.62 mmol) to give 1.0 g (89%) of 392 as a clear 
oil; TLC Rf = 0.12 (EtOAc:Hexane, 1:2); 
1H-NMR (400 MHz) (Me2SO-d6)  δ 7.63 (d, J = 
3.7 Hz, 1 H, Ar), 6.95 (d, J = 3.8 Hz, 1 H, Ar), 4.36 (s, 1 H, exch., -OH), 4.25 (q, J = 7.0 
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Hz, 2 H, -OCH2-), 3.38 (t, J = 6.3 Hz, 2 H, -CH2-), 2.83 (t, J = 7.4 Hz, 2 H, -CH2-), 1.63 
(p, J = 7.5 Hz, 2 H, -CH2-), 1.44 (p, J = 6.6 Hz, 2 H, -CH2-), 1.39 – 1.30 (m, 2 H, -CH2-), 
1.28 (t, J = 7.0 Hz, 3 H, -CH3). This compound was used for the next reaction without 
further characterization.  
 
General procedure for synthesis of 374-376 and 393-395 
To the alcohols 371-373 and 390-392, was added triethylamine (1 equivalent) and 
dichloromethane (25 mL). The reaction was cooled to 0 ⁰ C and purged with nitrogen gas. 
Under anhydrous conditions, methanesulfonyl chloride (1.05 equivalent) was added 
dropwise over 30 minutes. The reaction was stirred at room temperature for 2 hours and 
the reaction was added into sodium bicarbonate solution (25 mL). The water layer was 
washed thrice with dichloromethane (100 mL). The dichloromethane was evaporated to 
obtain a semi-solid product. To the intermediate in acetone, sodium iodide (1 equivalent) 
was added and refluxed for 8 hours. The reaction mixture was filtered. The filtrate was 
evaporated to obtain 374-376 and 393-395.  
 
Methyl 4-(3-iodopropyl)benzoate (374) 
Compound 374 was prepared using the general method described for the preparation of 
374-376 and 393-395, from 370 (1 g, 4.5 mmol), methanesulfonyl chloride (0.35 mL, 4.5 
mmol) and triethylamine (0.62 mL, 4.5 mmol) to form the intermediate. To this sodium 
iodide was added and the procedure was followed to give 0.9 g (72%) of 374 as a clear oil; 
TLC Rf = 0.63 (EtOAc:Hexane, 1:2); 
1H-NMR (400 MHz) (Me2SO-d6) δ 7.95 – 7.83 (d, J 
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= 8.0 Hz, 2 H, Ar), 7.36 (d, J = 8.0 Hz, 2 H, Ar), 3.84 (s, 3 H, -OCH3), 3.24 (t, J = 6.8 Hz, 
2 H, -CH2-), 2.74 (t, J = 7.5 Hz, 2 H, -CH2-), 2.07 (p, J = 7.0 Hz, 2 H, -CH2-). 
This compound was used for the next reaction without further characterization.  
 
Methyl 4-(4-iodobutyl)benzoate (375) 
 Compound 375 was prepared using the general method described for the preparation of 
374-376 and 393-395, from 372 (1 g, 4.5 mmol), methanesulfonyl chloride (0.35 mL, 4.5 
mmol) and triethylamine (0.62 mL, 4.5 mmol) to form the intermediate. To this sodium 
iodide was added and the procedure was followed to give 1.0 g (80%) of 375 as a clear oil; 
TLC Rf = 0.63 (EtOAc:Hexane, 1:2); 
1H-NMR (500 MHz) (Me2SO-d6) δ 7.86 (d, J = 8.2 
Hz, 2 H, Ar), 7.31 (d, J = 8.3 Hz, 2 H, Ar), 4.55 (t, J = 5.1 Hz, 2 H, -CH2-), 3.82 (s, 3 H, -
OCH3), 3.41 (t, J = 6.4, 2 H, -CH2-), 2.65 (t, J = 6.4, 2 H, -CH2-), 1.78 – 1.66 (m, 2 H, -
CH2-), 1.47-1.40 (m, 2 H, -CH2). This compound was used for the next reaction without 
further characterization.  
 
Methyl 4-(5-iodopentyl)benzoate (376) 
Compound 376 was prepared using the general method described for the preparation of 
374-376 and 393-395, from 373 (1 g, 4.5 mmol), methanesulfonyl chloride (0.35 mL, 4.5 
mmol) and triethylamine (0.62 mL, 4.5 mmol) to form the intermediate. To this sodium 
iodide was added and the procedure was followed to give 1.05 g (85%) of 376 as a clear 
oil; TLC Rf = 0.63 (EtOAc:Hexane, 1:2); 
1H-NMR (400 MHz) (Me2SO-d6) δ 7.87 (d, J = 
8.2 Hz, 2 H, Ar), 7.31 (d, J = 8.3 Hz, 2 H, Ar), 3.82 (s, 3 H, -OCH3), 3.23 (t, J = 6.9 Hz, 2 
H, -CH2-), 2.62 (t, J = 7.7 Hz, 2 H, -CH2-), 1.76 (p, J = 7.0 Hz, 2 H, -CH2-), 1.57 (tt, J = 
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9.2, 6.9 Hz, 2 H, -CH2-), 1.40 – 1.29 (m, 2 H, -CH2-). This compound was used for the next 
reaction without further characterization.  
 
Ethyl 5-(3-iodopropyl)thiophene-2-carboxylate (393) 
Compound 393 was prepared using the general method described for the preparation of 
374-376 and 393-395, from 390 (0/9 g, 4.5 mmol), methanesulfonyl chloride (0.35 mL, 4.5 
mmol) and triethylamine (0.62 mL, 4.5 mmol) to form the intermediate. To this sodium 
iodide was added and the procedure was followed to give 0.85 g (61%) of 393 as a clear 
oil; TLC Rf = 0.63 (EtOAc:Hexane, 1:2); 
1H-NMR (400 MHz) (Me2SO-d6) δ 7.63 (t, J = 
4.6 Hz, 1 H, Ar), 6.97 (d, J = 3.7 Hz, 1 H, Ar), 4.25 (q, J = 7.1 Hz, 2 H, -CH2-), 3.26 (t, J 
= 6.8 Hz, 2 H, -CH2-), 2.93 (q, J = 9.0, 7.4 Hz, 2 H, -CH2-), 2.10 (p, J = 6.9 Hz, 2 H, -CH2-
), 1.28 (t, J = 7.1 Hz, 3 H, -CH3). This compound was used for the next reaction without 
further characterization. 
 
Ethyl 5-(4-iodobutyl)thiophene-2-carboxylate (394) 
Compound 394 was prepared using the general method described for the preparation of 
374-376 and 393-395, from 391 (0.95 g, 4.5 mmol), methanesulfonyl chloride (0.35 mL, 
4.5 mmol) and triethylamine (0.62 mL, 4.5 mmol) to form the intermediate. To this sodium 
iodide was added and the procedure was followed to give 0.9 g (63%) of 394 as a clear oil; 
TLC Rf =  0.63 (EtOAc:Hexane, 1:2); 
1H-NMR (400 MHz) (Me2SO-d6) δ 7.64 (d, J = 3.8 
Hz, 1 H, Ar), 6.97 (d, J = 3.8 Hz, 1 H, Ar), 4.26 (q, J = 7.1 Hz, 2 H, -CH2-), 3.46 – 3.24 
(m, 2 H, -CH2-), 2.87 (t, J = 7.3 Hz, 2 H, -CH2-), 1.93 – 1.64 (m, 4 H, -CH2-), 1.28 (t, J = 
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7.1 Hz, 3 H, -OCH3). This compound was used for the next reaction without further 
characterization. 
 
Ethyl 5-(5-iodopentyl)thiophene-2-carboxylate (395) 
Compound 395 was prepared using the general method described for the preparation of 
374-376 and 393-395, from 392 (1 g, 4.38 mmol), methanesulfonyl chloride (0.35 mL, 4.5 
mmol) and triethylamine (0.62 mL, 4.5 mmol) to form the intermediate. To this sodium 
iodide was added and the procedure was followed to give 0.95 g (64%) of 395 as a clear 
oil; TLC Rf = 0.63 (EtOAc:Hexane, 1:2); 
1H-NMR (400 MHz) (Me2SO-d6) δ 7.60 (t, J = 
4.6 Hz, 1 H, Ar), 7.21 (d, J = 3.7 Hz, 1 H, Ar), 4.22 (q, J = 7.1 Hz, 2 H, -CH2-), 3.35 – 3.27 
(m, 2 H, -CH2-), 3.12 (tt, J = 9.3, 5.2 Hz, 2 H, -CH2-), 2.57 (t, J = 6.8 Hz, 2 H, -CH2-), 1.97 
(q, J = 7.1 Hz, 2 H, -CH2-), 1.29 – 1.12 (m, 5 H, -CH2- and -CH3).  This compound was 
used for the next reaction without further characterization.  
 
General procedure for synthesis of 380-382 and 399-401 
To a solution of ethyl 3-amino-1H-pyrrole-2-carboxylate hydrochloride (0.5 g, 3.24 mmol) 
in dry DMF (10 mL) was added slowly NaH (0.17 g, 7.1 mmol) under nitrogen at room 
temperature. The resulting mixture was stirred for about 15 min when there was no more 
gas produced, and then appropriate iodide (1 equivalent) was added. The reaction mixture 
was stirred at room temperature for 4 h, and DMF was evaporated at elevated temperature 
to offer a gummy residue, which was used for the next step without purification. The 
gummy residue was dissolved in MeOH (10 mL), and 1,3-bis(methoxycarbonyl)-2-methyl-
2- thiopseudourea (0.7 g, 3.3 mmol) was added followed by AcOH (1.0 g, 15 mmol). The 
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mixture was stirred at room temperature overnight and became a thick paste. NaOMe in 
MeOH (25%) (7 mL, 22 mmol) was added, and stirring was continued at room temperature 
overnight. The mixture was neutralized with AcOH, and the methanol was removed under 
reduced pressure. To the residue was added water (20 mL), and the pH value was adjusted 
to 10–11 by adding NH3 · H2O. The solid was collected by filtration and washed well with 
water. The resulting solid was added to 1 N NaOH (2 mL), and the mixture was heated at 
55 °C for 3 h. The mixture was cooled and acidified using 1 N hydrochloric acid. The 
precipitate was collected and dried under reduced pressure overnight to obtain 380-382 and 
399-401 
 
General procedure for synthesis of 383-385 and 402-404 
To a solution of 380-382 and 399-401 in anhydrous DMF (10 mL) was added N-
methylmorpholine (73 mg, 0.72 mmol) and 2-chloro-4,6-dimethoxy-1,3,5-triazine (127 
mg, 0.72 mmol). The resulting mixture was stirred at room temperature for 2 h. To this 
mixture was added N-methylmorpholine (73 mg, 0.72 mmol) and L-glutamate diethyl ester 
hydrochloride (144 mg, 0.6 mmol). The reaction mixture was stirred for an additional 4 h 
at room temperature. Silica gel (400 mg) was then added, and the solvent was evaporated 
under reduced pressure. The resulting plug was loaded on to a silica gel column with 5% 
MeOH in CHCl3 as the eluent. Fractions that showed the desired spot (TLC) were pooled 
and the solvent evaporated to dryness to afford compounds 383-385 and 402-404. 
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General method for synthesis of compounds 269-271 and 280-282 
To a solution of 383-385 and 402-404, was added 4 mL methanol and 2 mL of 1 N sodium 
hydroxide solution. The reaction mixture was stirred for 1 hour at room temperature and 
the disappearance of the starting material was spotted with TLC. The mixture was acidified 
to pH 2-3 using 1 N hydrochloric acid to obtain 269-271 and 280-282 as precipitate on 
filtration.  
 
Diethyl (4-(3-(2-amino-4-oxo-3,4-dihydro-5H-pyrrolo[3,2-d]pyrimidin-5-yl)propyl) 
benzoyl-L-glutamate (0k5) 
Using the general method for synthesis of compounds 380-382 and 399-401, 374 (1.1 g, 
3.62 mmol) was used to obtain 380 (0.3 g, 30%) as a white solid. Using the general method 
for synthesis of compounds 380-382 and 399-401, 380 (0.15 g, 0.48 mmol) was used to 
obtain 383 (0.18 g, 75%) as a greyish brown solid; TLC Rf = 0.23 (MeOH:CHCl3:NH4OH, 
1:10:0.5); 1H-NMR (400 MHz) (Me2SO-d6) δ 10.49 (s, 1 H, exch., -NH), 8.67 (d, J = 7.4 
Hz, 1 H, exch., -NH), 7.80 (d, J = 8.0 Hz, 2 H, Ar), 7.29 (d, J = 8.0 Hz, 2 H, Ar), 7.21 (d, 
J = 2.6 Hz, 1 H, Ar), 5.91 (d, J = 2.7 Hz, 1 H, Ar), 5.81 (s, 2 H, exch., 2-NH2), 4.42 (d, J = 
7.4 Hz, 1 H, -CH), 4.30 – 4.20 (m, 2 H, -CH2-), 4.17 – 3.94 (m, 4 H, -CH2-), 2.65 – 2.54 
(m, 2 H, -CH2-), 2.44 (t, J = 7.4 Hz, 2 H, -CH2-), 2.22 – 1.86 (m, 4 H, -CH2-), 1.35 – 1.09 
(m, 6 H, -CH3). Anal. Calcd.  C25H31N5O6: C, 60.35; H, 6.28; N, 14.08; O, 19.29. Found: 
C, 60.03; H, 6.17; N, 13.76. 
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Diethyl (4-(4-(2-amino-4-oxo-3,4-dihydro-5H-pyrrolo[3,2-d]pyrimidin-5-yl)butyl) 
benzoyl)-L-glutamate (384)  
Using the general method for synthesis of compounds 380-382 and 399-401, 375 (1.1 g, 
3.46 mmol) was used to obtain 381 (0.25 g, 25%) as a white solid; TLC Rf = 0.0 
(MeOH:CHCl3:HCl, 1:5:0.5); 
1H-NMR (400 MHz) (Me2SO-d6) δ 10.50 (s, br, exch., -
COOH), 7.81 (d, J = 7.9 Hz, 2 H, Ar), 7.21 (d, J = 8.0 Hz, 2 H, Ar), 7.18 (d, J = 2.9 Hz, 1 
H, Ar), 5.92 (s, 2 H, exch., 2-NH2), 5.87 (d, J = 2.7 Hz, 1 H, Ar), 4.25 (t, J = 6.8 Hz, 2 H, 
-CH2-), 2.61 (t, J = 7.7 Hz, 2 H, -CH2-), 1.73 (p, J = 7.8 Hz, 2 H, -CH2-), 1.48 (p, J = 7.8 
Hz, 2 H, -CH2-). The melting point assessment suggested impurities and hence this 
compound was used for the next reaction without further characterization. Using the 
general method for synthesis of compounds 380-382 and 399-401, 380 (0.15 g, 0.46 mmol) 
was used to obtain 384 (0.1 g, 43%) as a brown solid; TLC Rf = 0.23 
(MeOH:CHCl3:NH4OH, 1:10:0.5); 
1H-NMR (400 MHz) (Me2SO-d6) δ 10.44 (s, 1 H, 
exch., -NH), 8.64 (d, J = 7.4 Hz, 1 H, exch., -NH), 7.77 (d, J = 8.2 Hz, 2 H, Ar), 7.26 (d, J 
= 8.2 Hz, 2 H, Ar), 7.19 (d, J = 2.9 Hz, 1 H, Ar), 5.88 (s, J = 2.9 Hz, 1 H, Ar), 5.76 (s, 2 H, 
exch., 2-NH2), 4.45-4.41 (m, 1 H, -CH), 4.25 (t, J = 6.8 Hz, 2 H, -CH2-), 4.18 – 4.00 (m, 4 
H, -CH2-), 2.62 (t, J = 7.6 Hz, 2 H, -CH2-), 2.44 (t, J = 7.5 Hz, 2 H, -CH2-), 2.28 – 1.89 (m, 
2 H, -CH2-), 1.87 – 1.62 (m, 2 H, -CH2-), 1.60 – 1.40 (m, 2 H, -CH2-), 1.18 (dt, J = 9.9, 7.0 
Hz, 6 H, -CH3). Anal. Calcd.  C26H33N5O6 0.05 CHCl3: C, 61.04; H, 6.50; N, 13.69; O, 
18.76. Found: C, 60.57; H, 6.44; N, 13.28. 
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Diethyl (4-(5-(2-amino-4-oxo-3,4-dihydro-5H-pyrrolo[3,2-d]pyrimidin-5-yl)pentyl) 
benzoyl)-L-glutamate (385) 
Using the general method for synthesis of compounds 380-382 and 399-401, 376 (1.2 g, 
3.61 mmol) was used to obtain 382 (0.32 g, 29%) as a white solid; TLC Rf = 0.0 
(MeOH:CHCl3:HCl, 1:5:0.5); 
1H-NMR (400 MHz) (Me2SO-d6) δ 12.74 (s, 1 H, exch., -
COOH), 8.14 (s, 2 H, exch., 2-NH2), 7.83 (d, J = 7.9 Hz, 2 H, Ar), 7.45 (d, J = 2.9 Hz, 1 
H, Ar), 7.28 (d, J = 8.0 Hz, 2 H, Ar), 6.13 (d, J = 2.9 Hz, 1 H, Ar), 4.29 (t, J = 6.9 Hz, 2 H, 
-CH2-), 3.37 (t, J = 6.4 Hz, 2 H, -CH2-), 2.64 (t, J = 7.8 Hz, 2 H, -CH2-), 1.79 – 1.70 (m, 2 
H, -CH2-), 1.54 – 1.45 (m, 2 H, -CH2-). The melting point assessment suggested impurities 
and hence this compound was used for the next reaction without further characterization. 
Using the general method for synthesis of compounds 379-381 and 398-400, 382 (0.15 g, 
0.44 mmol) was used to obtain 385 (0.11 g, 47.50%) as a grey solid TLC Rf = 0.23 
(MeOH:CHCl3:NH4OH, 1:10:0.5); 
1H-NMR (400 MHz) (Me2SO-d6) δ 10.45 (s, 1 H, 
exch., -NH), 8.66 (d, J = 7.6 Hz, 1 H, exch., -NH), 7.77 (d, J = 8.0 Hz, 2 H, Ar), 7.27 (d, J 
= 8.0 Hz, 2 H, Ar), 7.16 (d, J = 2.7 Hz, 1 H, Ar), 5.87 (d, J = 2.8 Hz, 1 H, -Ar), 5.75 (s, 2 
H, exch., -NH2), 4.41 (d, J = 13.0 Hz, 1 H, -CH), 4.19 (t, J = 6.9 Hz, 2 H, -CH2-), 4.14 – 
3.96 (m, 4 H, -CH2), 2.59 (t, J = 7.6 Hz, 2 H, -CH2-), 2.43 (t, J = 7.4 Hz, 2 H, -CH2-), 2.20 
– 1.92 (m, 2 H, -CH2-), 1.81 – 1.65 (m, 2 H, -CH2-), 1.63 – 1.51 (m, 2 H, -CH2-), 1.22-1.11 
(m, 8  H, -CH2- and -CH3). Anal. Calcd.  for C27H35N5O6 0.24 H2O: C, 61.70; H, 6.71; N, 
13.32. Found: C, 61.20; H, 6.763; N, 13.13.  
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Diethyl (5-(3-(2-amino-4-oxo-3,4-dihydro-5H-pyrrolo[3,2-d]pyrimidin-5-yl)propyl) 
thiophene-2-carbonyl)-L-glutamate (402) 
Using the general method for synthesis of compounds 380-382 and 399-401, 393 (1.0 g, 
2.97 mmol) was used to obtain 399 (0.18 g, 19%) as a white solid;  TLC Rf = 0.0 
(MeOH:CHCl3:HCl, 1:5:0.5); 
1H-NMR (400 MHz) (Me2SO-d6) δ 11.22 (s, br, 1 H, exch., 
-COOH), 7.49 (d, J = 3.6 Hz, 1 H, Ar), 7.19 (d, J = 3.0 Hz, 1 H, Ar), 6.87 (d, J = 3.8 Hz, 1 
H, Ar), 6.00 (s, 2H, exch., 2-NH2), 5.94 (d, J = 3.0 Hz, 1 H, Ar), 4.25 (t, J = 6.8 Hz, 2 H, -
CH2-), 2.70 (t, J = 7.8 Hz, 2 H, -CH2-), 2.06 (t, J = 7.6 Hz, 2 H, -CH2-). The melting point 
assessment suggested impurities and hence this compound was used for the next reaction 
without further characterization. Using the general method for synthesis of compounds 
380-382 and 399-401, 399 (0.15 g, 0.47 mmol) was used to obtain 402 (0.125 g, 53%) as 
a grey semi-solid; TLC Rf = 0.23 (MeOH:CHCl3:NH4OH, 1:10:0.5); 
1H-NMR (400 MHz) 
(Me2SO-d6) δ 10.44 (s, 1 H, exch., -NH), 8.62 (d, J = 7.5 Hz, 1 H, exch., -NH), 7.69 (d, J 
= 3.8 Hz, 1 H, Ar), 7.20 (d, J = 2.9 Hz, 1 H, Ar), 6.91 (d, J = 3.8 Hz, 1 H, Ar), 5.91 (d, J = 
2.9 Hz, 1 H, Ar), 5.77 (s, 2 H, exch., 2-NH2), 4.38 (dt, J = 9.4, 5.9 Hz, 1 H, -CH), 4.27 (t, 
J = 6.8 Hz, 2 H, -CH2-), 4.08 (dq, J = 23.8, 7.0 Hz, 4 H, -CH2-), 2.72 (t, J = 7.9 Hz, 2 H, -
CH2-), 2.42 (t, J = 7.5 Hz, 2 H, -CH2-), ), 2.10 (q, J = 7.2 Hz, 2 H, -CH2-), 1.97 (ddd, J = 
16.7, 14.0, 7.6 Hz, 2 H, -CH2-), 1.18 (dt, J = 9.0, 7.1 Hz, 6 H, -CH3). This compound was 
used for the next reaction without further characterization.  
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Diethyl (5-(4-(2-amino-4-oxo-3,4-dihydro-5H-pyrrolo[3,2-d]pyrimidin-5-yl)butyl) 
thiophene-2-carbonyl)-L-glutamate (403) 
Using the general method for synthesis of compounds 380-382 and 399-401, 394 (1.0 g, 
2.97 mmol) was used to obtain 400 (0.20 g, 20%) as a white solid. Using the general 
method for synthesis of compounds 379-381 and 398-400, 400 (0.18 g, 0.54 mmol) was 
used to obtain 403 (0.1 g, 37%) as a brown semi- solid; TLC Rf = 0.23 
(MeOH:CHCl3:NH4OH, 1:10:0.5); 
1H-NMR (400 MHz) (Me2SO-d6) δ 10.45 (s, 1 H, 
exch., -NH), 8.63 (d, J = 7.7 Hz, 1 H, exch., -NH), 7.67 (d, J = 3.8 Hz, 1 H, Ar), 7.20 (d, J 
= 2.5 Hz, 1 H, Ar), 6.85 (d, J = 3.9 Hz, 1 H, Ar), 5.88 (d, J = 2.9 Hz, 1 H, Ar), 5.76 (s, 2 H, 
exch., 2-NH2), 4.3-4.45 (m, 1 H, -CH), 4.26 (t, J = 6.8 Hz, 2 H, -CH2-), 4.07 (dq, J = 22.7, 
7.2 Hz, 4 H, -CH2-), 3.46 – 3.24 (m, 2 H, -CH2-), 2.79 (t, J = 7.4 Hz, 2 H, -CH2-), 2.42 (t, 
J = 7.4 Hz, 2 H, -CH2-), 1.76 (t, J = 7.6 Hz, 2 H, -CH2-), 1.51 (t, J = 7.6 Hz, 2 H, -CH2-), 
1.17 (dt, J = 9.5, 7.1 Hz, 6 H, -CH3). This compound was used for the next reaction without 
further characterization.  
 
Diethyl (5-(5-(2-amino-4-oxo-3,4-dihydro-5H-pyrrolo[3,2-d]pyrimidin-5-yl)pentyl) 
thiophene-2-carbonyl)-L-glutamate (404) 
Using the general method for synthesis of compounds 8a-c and 380-382 and 399-401, 395 
(1.0 g, 2.97 mmol) was used to obtain 401 (0.16 g, 16%) as a white solid. Using the general 
method for synthesis of compounds 380-382 and 399-401, 401 (0.1 g, 0.29 mmol) was 
used to obtain 404 (0.11 g, 72 %) as a grey semi-solid; TLC Rf = 0.23 
(MeOH:CHCl3:NH4OH, 1:10:0.5); 
1H-NMR (400 MHz) (Me2SO-d6) δ 10.69 (s, 1H, exch., 
-NH-), 8.65 (d, J = 7.5 Hz, 1 H, exch., -NH), 7.69 (d, J = 3.8 Hz, 1 H, Ar), 7.16 (d, J = 2.9 
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Hz, 1 H, Ar), 6.85 (d, J = 3.7 Hz, 1 H, Ar), 6.12 – 5.71 (m, 3 H, Ar (1 H) and 2-NH2 (2 H, 
exch.)), 4.41 (d, J = 5.6 Hz, 1 H, -CH), 4.21 (t, J = 6.8 Hz, 2 H, -CH2-), 4.11 (q, J = 7.1 Hz, 
2 H, -CH2-), 4.04 (q, J = 7.1 Hz, 2 H, -CH2-), 2.75 (t, J = 7.4 Hz, 2 H, -CH2-), 2.42 (d, J = 
7.5 Hz, 2 H, -CH2-), 2.21 – 1.89 (m, 2 H, -CH2-), 1.73 (t, J = 7.4 Hz, 2 H, -CH2-), 1.60 (t, 
J = 7.6 Hz, 2 H, -CH2-), 1.16 (m, 8 H, -CH2- and -CH3). This compound was used for the 
next reaction without further characterization.  
 
(4-(3-(2-amino-4-oxo-3,4-dihydro-5H-pyrrolo[3,2-d]pyrimidin-5-yl)propyl)benzoyl)-
L-glutamic acid (269) 
Using the general method for synthesis of compounds 269-271 and 280-282, 383 (0.10 g, 
0.2 mmol) was used to obtain 269 (0.06 g, 67%) as a white solid; TLC Rf = 0.0 
(MeOH:CHCl3:HCl, 1:5:0.5); mp, 71.8-80.0 ⁰ C; 1H-NMR (400 MHz) (Me2SO-d6) δ 
12.10-11.20 (s, br, 3 H, exch., -COOH and -NH), 8.59 – 8.25 (m, 1 H, exch., -NH), 7.75 
(d, J = 7.9 Hz, 2 H, Ar), 7.27 (d, J = 7.7 Hz, 2 H, Ar), 7.19 (d, J = 2.6 Hz, 1 H, Ar), 6.44 (s, 
2 H, exch., 2-NH2), 5.89 (d, J = 2.7 Hz, 1 H, Ar), 4.32 – 4.19 (m, 3 H, -CH and -CH2), 2.57 
(t, J = 7.3 Hz, 2 H, -CH2-), 2.34 – 2.11 (m, 2 H, -CH2-), 2.11 – 1.98 (m, 2 H, -CH2-), 2.01 
– 1.83 (m, 2 H, -CH2-). Anal. Calcd.  for C21H23N5O6 0.9 CH3OH 0.8 HCl: C, 52.67; H, 
5.53; N, 14.02; Found: C, 52.53; H, 5.63; N, 14.07. 
 
  
  301 
(4-(4-(2-amino-4-oxo-3,4-dihydro-5H-pyrrolo[3,2-d]pyrimidin-5-yl)butyl)benzoyl)-L-
glutamic acid (270) 
Using the general method for synthesis of compounds 269-271 and 280-282, 384 (0.10 g, 
0.195 mmol) was used to obtain 270 (0.056 g, 63%) as a white solid; TLC Rf = 0.0 
(MeOH:CHCl3:HCl, 1:5:0.5); mp, 82.3-87.0 ⁰ C; 1H-NMR (400 MHz) (Me2SO-d6) δ 
11.80-11.00 (s, br, exch., 3 H, COOH and NH), 8.26 (s, 1 H, exch., -NH), 7.71 (d, J = 7.9 
Hz, 2 H, Ar), 7.33 – 7.09 (m, 3 H, Ar), 6.14 (s, 2 H, exch., 2-NH2), 5.86 (d, J = 2.2 Hz, 1 
H, Ar), 4.23 (m, 3 H, -CH- and -CH2-), 2.77 – 2.56 (m, 2 H, -CH2-), 2.37 – 2.09 (m, 2 H, -
CH2-), 2.04 – 1.84 (m, 2 H, -CH2-), 1.71 (m, 2 H, -CH2-), 1.46 (d, J = 7.4 Hz, 2 H, -CH2). 
Anal. Calcd. for C22H25N5O6 0.77 HCl: C, 54.64; H, 5.37; N, 14.48. Found: C, 54.71; H, 
5.34; N, 14.28. 
 
(4-(5-(2-amino-4-oxo-3,4-dihydro-5H-pyrrolo[3,2-d]pyrimidin-5-yl)pentyl)benzoyl)-
L-glutamic acid (271) 
Using the general method for synthesis of compounds 269-271 and 280-282, 385 (0.10 g, 
0.195 mmol) was used to obtain 271 (0.050 g, 56%) as a white solid; TLC Rf = 0.0 
(MeOH:CHCl3:HCl, 1:5:0.5);  mp, 82.3-84.8 ⁰ C; 1H-NMR (400 MHz) (Me2SO-d6)  δ 
11.95 (s, 2 H, exch., -COOH), 8.54 (d, J = 7.7 Hz, exch., -NH), 7.79 (d, J = 7.8 Hz, 2 H, 
Ar), 7.40 – 7.00 (m, 3 H, Ar), 6.37 (s, 2 H, exch., 2-NH2), 5.94 (d, J = 2.9 Hz, 1 H, Ar), 
4.38 (d, J = 8.2 Hz, 1 H, -CH-), 4.21 (t, J = 7.0 Hz, 2 H, -CH2-), 2.60 (t, J = 7.7 Hz, 2 H, -
CH2-), 2.36 (t, J = 7.4 Hz, 2 H, -CH2-), 2.17 – 1.82 (m, 2 H, -CH2-), 1.80-1.65 (m, 2 H, -
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CH2-), 1.60-1.45 (m, 2 H, -CH2-), 1.26-1.00 (m, 2 H, -CH2-). Anal. Calcd.  C23H27N5O6 
1.08 H2O: C, 56.50; H, 6.01; N, 14.23. Found: C, 56.49; H, 5.83; N, 14.28. 
 
(5-(3-(2-amino-4-oxo-3,4-dihydro-5H-pyrrolo[3,2-d]pyrimidin-5-yl)propyl) 
thiophene-2-carbonyl)-L-glutamic acid (280) 
Using the general method for synthesis of compounds 269-271 and 280-282, 402 (0.10 g, 
0.2 mmol) was used to obtain 280 (0.054 g, 61%) as a white solid; TLC Rf = 0.0 
(MeOH:CHCl3:HCl, 1:5:0.5); mp, 150.3-154.3 ⁰ C;  1H-NMR (400 MHz) (Me2SO-d6) δ 
12.20-11.10 (s, br, exch., 3 H, COOH and NH), 8.49 (d, J = 7.8 Hz, 1 H, exch., -NH), 7.68 
(d, J = 3.8 Hz, 1 H, Ar), 7.20 (d, J = 2.8 Hz, 1 H, Ar), 6.90 (d, J = 3.8 Hz, 1 H, Ar), 5.91 
(d, J = 2.8 Hz, 1 H, Ar), 5.80 (s, 2 H, exch., 2-NH2), 4.31 (dt, J = 28.9, 8.4 Hz, 3 H, -CH 
and -CH2-), 2.72 (t, J = 7.7 Hz, 2 H, -CH2-), 2.33 (t, J = 7.5 Hz, 2 H, -CH2-), 2.08 (dq, J = 
12.7, 6.5, 5.7 Hz, 2 H, -CH2-), 1.91 (m, 2 H, -CH2-). Anal. Calcd.  for C19H21N5O5S 0.8 
H2O: C, 49.41; H, 4.93; N, 15.16; S, 6.94. Found: C, 49.44; H, 4.84; N, 15.13; S, 6.84. 
 
 (5-(4-(2-amino-4-oxo-3,4-dihydro-5H-pyrrolo[3,2-d]pyrimidin-5-yl)butyl)thiophene-
2-carbonyl)-L-glutamic acid (281)  
Using the general method for synthesis of compounds 269-271 and 280-282, 403 (0.10 g, 
0.193 mmol) was used to obtain 281 (0.045 g, 50%) as a white solid; mp, 148.3-150.2 ⁰ C; 
TLC Rf = 0.0 (MeOH:CHCl3:HCl, 1:5:0.5); 
1H-NMR (400 MHz) (Me2SO-d6) δ 11.94 (s, 3 
H, exch., -COOH and NH), 8.54 (d, J = 7.8 Hz, 1 H, exch., -NH), 7.69 (d, J = 7.8 Hz, 1 H, 
Ar), 7.33 (d, J = 3.8 Hz, 1 H, Ar), 6.96 (s, 2 H, exch., 2-NH2), 6.85 (d, J = 3.8 Hz, 1 H, Ar), 
6.01 (d, J = 2.8 Hz, 1 H, Ar), 4.38 – 4.23 (m, 3 H, -CH- and -CH2-), 2.79 (t, J = 7.6 Hz, 2 
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H, -CH2-), 2.34 (t, J = 7.4 Hz, 2 H, -CH2-), 2.14 – 1.92 (m, 2 H, -CH2-), 1.76 (p, J = 6.9 
Hz, 2 H, -CH2-), 1.52 (p, J = 7.6 Hz, 2 H, -CH2-). Anal. Calcd.  for C20H23N5O6S 0.58 HCl: 
C, 49.77; H, 4.92; N, 14.51; S, 6.64. Found: C, 49.80; H, 5.08; N, 14.51; S, 6.74. 
 
(5-(5-(2-amino-4-oxo-3,4-dihydro-5H-pyrrolo[3,2-d]pyrimidin-5-
yl)pentyl)thiophene-2-carbonyl)-L-glutamic acid (282) 
Using the general method for synthesis of compounds 269-271 and 280-282, 404 (0.10 g, 
0.188 mmol) was used to obtain 282 (0.072 g, 81%) as a white solid; mp, 73.4-78.7 ⁰ C; 
TLC Rf = 0.0 (MeOH:CHCl3:HCl, 1:5:0.5); 
1H-NMR (400 MHz) (Me2SO-d6) δ 12.32 (s, 
2H, exch., -COOH), 8.53 (d, J = 7.9 Hz, 1 H, exch., -NH), 7.69 (d, J = 3.8 Hz, 1 H, Ar), 
7.34 (d, J = 7.9 Hz, 1 H, Ar), 7.09 (s, 2H, exch., 2-NH2), 6.87 (d, J = 3.8 Hz, 1 H, Ar), 6.03 
(d, J = 2.8 Hz, 1 H, Ar), 4.34 (d, J = 2.8 Hz, 1 H, -CH), 4.23 (t, J = 7 .0 Hz, 2 H, -CH2-), 
2.77 (t, J = 7.5 Hz, 2 H, -CH2-), 2.34 (t, J = 7.5 Hz, 2 H, -CH2-), 1.92 (d, J = 11.9 Hz, 2 H, 
-CH2-), 1.74 (m, 2 H, -CH2-), 1.61 (m, 2 H, -CH2-), 1.25 (t, J = 7.5 Hz, 2 H, -CH2-). Anal. 
Calcd.  for C21H25N5O6S 0.94 HCl: C, 49.48; H, 5.13; N, 13.74; S, 6.29. Found: C, 49.51; 
H, 5.21; N, 13.53; S, 6.31. 
  
Ethyl 3-Amino-5-methyl-1H-pyrrole-2-carboxylate (407) 
To a suspension of an E/Z mixture of 3-aminobut-2-enenitrile 401 (10 g, 121.79 mmol) in 
MeOH (200 mL) was added diethyl aminomalonate hydrochloride 402 (25.6 g, 146.15 
mmol). The resulting mixture was stirred at room temperature for 5 h. TLC showed the 
disappearance of the starting materials and the formation of one major spot of 406 at Rf  
0.26 (EtOAc:Hexane, 1:2); which was pink in color. The reaction solvent was diluted with 
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ethyl acetate (50 mL), washed with brine (30 mL × 2), and dried over anhydrous Na2SO4. 
The solvent was evaporated to yield 406 as a light pink oil. A 200 mL solution of 20% 
NaOEt in EtOH solution was added slowly to a stirred solution of 406 in 50 mL of EtOH. 
The reaction mixture was stirred for 6 h at 60 °C and cooled to room temperature. The 
solvent was evaporated under reduced pressure. The crude product was purified by column 
chromatography on silica gel with 10% ethyl acetate:Hexane as the eluent to yield 407 
(8.50 g, 42%) as an off-white solid: Rf = 0.36 (ethyl acetate:Hexane, 1:1); mp286, 88 °C; 1H 
NMR (Me2SO-d6) δ 10.21 (s, 1 H, exch., NH), 5.26 (s, 1 H, Ar), 4.91 (s, 2 H, exch., NH2), 
4.12 (q, 2 H, J = 6.4 Hz, -OCH2), 2.03 (s, 3 H, CH3), 1.24 (t, 3 H, J = 6.4 Hz, CH3). 
 
General procedure for synthesis of 411-413 
To a solution of ethyl-5-methyl-3-amino-1H-pyrrole-2-carboxylate (0.5 g, 2.97 mmol) in 
dry DMF (10 mL) was added slowly NaH (0.09 g, 3.6 mmol) under nitrogen at room 
temperature. The resulting mixture was stirred for about 15 min when there was no more 
gas produced, and then appropriate iodide (1 equivalent) was added. The reaction mixture 
was stirred at room temperature for 4 h, and DMF was evaporated at elevated temperature 
to offer a gummy residue, which was used for the next step without purification. The 
gummy residue was dissolved in MeOH (10 mL), and 1,3-bis(methoxycarbonyl)-2-methyl-
2-thiopseudourea (0.7 g, 3.3 mmol) was added followed by AcOH (1.0 g, 15 mmol). The 
mixture was stirred at room temperature overnight and became a thick paste. NaOMe in 
MeOH (25%) (7 mL, 22 mmol) was added, and stirring was continued at room temperature 
overnight. The mixture was neutralized with AcOH, and the methanol was removed under 
reduced pressure. To the residue was added water (20 mL), and the pH value was adjusted 
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to 10–11 by adding NH3 · H2O. The solid was collected by filtration and washed well with 
water. The resulting solid was added to 1 N NaOH (2 mL), and the mixture was heated at 
55 °C for 3 h. The mixture was cooled and acidified using 1 N hydrochloric acid. The 
precipitate was collected and dried under reduced pressure overnight to obtain 411-413. 
 
Diethyl (4-(5-(2-amino-6-methyl-4-oxo-3,4-dihydro-5H-pyrrolo[3,2-d]pyrimidin-5-
yl)pentyl)benzoyl)-L-glutamate (416) 
Using the general method for synthesis of compounds 380-382 and 399-401, 425 (1.2 g, 
3.61 mmol) was used to obtain 413 (0.18 g, 18%) as a white solid; TLC Rf  0.0 
(MeOH:CHCl3:HCl, 1:5:0.5). Using the general method for synthesis of compounds 382-
384 and 402-404, 413 (0.15 g, 0.42 mmol) was used to obtain 416 (0.12 g, 53%) as a brown 
semi-solid; TLC Rf  0.23 (MeOH:CHCl3:NH4OH, 1:10:0.5); 
1H-NMR (400 MHz) (Me2SO-
d6) δ 10.46 (s, 1 H, exch., -NH), 8.65 (d, J = 7.4 Hz, 1 H, -exch., -NH), 7.78 (d, J = 8.0 Hz, 
2 H, Ar), 7.29 (d, J = 8.0 Hz, 2 H, Ar), 5.80 (s, 2 H, exch., 2-NH2), 5.72 (s, 1 H, Ar), 4.43 
(q, J = 7.5 Hz, 1 H, -CH), 4.09 (ddd, J = 30.7, 17.5, 7.1 Hz, 6 H, -CH2-), 2.61 (s, 3 H, -
CH3), 2.44 (t, J = 7.5 Hz, 2 H, -CH2-), 2.15 – 1.98 (m, 2 H, -CH2-), 1.59 (dq, J = 23.8, 8.5, 
8.0 Hz, 4 H, -CH2-), 1.34 – 1.22 (m, 4 H, -CH2-), 1.18 (dt, J = 9.8, 7.2 Hz, 6 H, -CH3). 
Anal. Calcd.  for C28H37N5O6 0.39 CH3OH: C, 61.75; H, 7.04; N, 12.68. Found: C, 61.89; 
H, 7.04; N, 12.68. 
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(4-(3-(2-amino-6-methyl-4-oxo-3,4-dihydro-5H-pyrrolo[3,2-d]pyrimidin-5-
yl)propyl)benzoyl)-L-glutamic acid (284) 
Using the general method for synthesis of compounds 380-382 and 399-401, 374 (1.1 g, 
3.62 mmol) was used to obtain 411 (0.15 g, 16%) as a white solid; TLC Rf = 0.0 
(MeOH:CHCl3:HCl, 1:5:0.5). Using the general method for synthesis of compounds 382-
384 and 402-404, 411 (0.15 g, 0.46 mmol) was used to obtain 414 (0.15 g, 64%) as a light 
brown semi-solid; TLC Rf = 0.23 (MeOH:CHCl3:NH4OH, 1:10:0.5). This compound was 
used for the next reaction without further characterization. Using the general method for 
synthesis of compounds 269-271 and 280-282, 414 (0.10 g, 0.195 mmol) was used to 
obtain 284 (0.072 g, 80%) as a white solid; TLC Rf = 0.0 (MeOH:CHCl3:HCl, 1:5:0.5); mp, 
89.4-92.1 ⁰ C; 1H-NMR (400 MHz) (Me2SO-d6) δ 12.08 (s, 2 H, exch., -COOH), 8.57 (d, 
J = 7.7 Hz, 1 H, exch., -NH), 7.82 (d, J = 7.8 Hz, 2 H, Ar), 7.32 (d, J = 7.9 Hz, 2 H, Ar), 
6.75 (s, 2 H, exch., 2-NH2), 5.85 (s, 1 H, Ar), 4.38 (d, J = 9.3 Hz, 1 H, -CH), 4.24 (t, J = 
7.4 Hz, 2 H, -CH2-), 2.65 (t, J = 8.0 Hz, 2 H, -CH2-), 2.36 (t, J = 7.5 Hz, 2 H, -CH2-), 2.25 
(s, 3 H, -CH3), 2.04-1.80 (m, 4 H, -CH2-). Anal. Calcd.  for C22H25N5O6 1.92 H2O: C, 
53.93; H, 5.93; N, 14.29. Found: C, 53.90; H, 5.63; N, 14.29. 
 
(4-(4-(2-amino-6-methyl-4-oxo-3,4-dihydro-5H-pyrrolo[3,2-d]pyrimidin-5-
yl)butyl)benzoyl)-L-glutamic acid (285) 
Using the general method for synthesis of compounds 380-382 and 399-401, 375 (1.1 g, 
3.46 mmol) was used to obtain 412 (0.2 g, 20%) as a white solid; TLC Rf = 0.0 
(MeOH:CHCl3:HCl, 1:5:0.5). Using the general method for synthesis of compounds 382-
384 and 402-404, 412 (0.15 g, 0.44 mmol) was used to obtain 415 (0.14 g, 60%) as a grey 
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semi-solid; TLC Rf = 0.23 (MeOH:CHCl3:NH4OH, 1:10:0.5); 
1H-NMR (400 MHz) 
(Me2SO-d6) δ 10.32 (s, 1 H, exch., -NH), 8.66 (d, J = 7.5 Hz, 1 H, exch., -NH), 7.78 (d, J 
= 7.9 Hz, 2 H, Ar), 7.28 (d, J = 8.0 Hz, 2 H, Ar), 5.67-5.90 (s, br, 3 H, 2-NH2 (exch.) and 
Ar), 4.36-4.50 (m, 1 H, -CH), 4.23 (t, J = 6.8 Hz, 2 H, -CH2-), 4.08 (dq, J = 22.2, 7.3 Hz, 4 
H, CH2-), 2.71 – 2.58 (m, 2 H, CH2-), 2.51 (s, 3 H, -CH3), 2.44 (t, J = 7.6 Hz, 2 H, CH2), 
2.16 – 1.88 (m, 2 H, CH2-), 1.73 – 1.40 (m, 4 H, CH2-), 1.37 – 0.99 (m, 6 H, CH3). This 
compound was used for the next reaction without further characterization. Using the 
general method for synthesis of compounds 269-271 and 280-282, 415 (0.10 g, 0.190 
mmol) was used to obtain 285 (0.063 g, 73%) as a white solid; TLC Rf = 0.0 
(MeOH:CHCl3:HCl, 1:5:0.5); mp, 159.4-163.4 ⁰ C; 1H-NMR (400 MHz) (Me2SO-d6) δ 
12.00 (s, 2 H, -COOH), 8.56 (d, J = 7.7 Hz, 1 H, exch., -NH), 7.81 (d, J = 7.8 Hz, 2 H, Ar), 
7.32 (d, J = 7.9 Hz, 2 H, Ar), 6.47 (s, 2 H, exch. -NH2), 5.82 (s, 1 H, Ar), 4.39 (s, 1 H, -
CH), 4.24 (t, J = 7.2 Hz, 2 H, -CH2-), 2.65 (t, J = 7.9 Hz, 2 H, -CH2-), 2.57-2.50 (m, 2 H, -
CH2-), 2.34 (d, J = 7.7 Hz, 2 H, -CH2-), 2.24 (s, 3 H, -CH3), 2.04 – 1.87 (m, 4 H, -CH2-). 
Anal. Calcd.  for C23H27N5O6 1.46 H2O:  C, 55.72; H, 6.08; N, 14.13. Found: C, 55.72; H, 
5.69; N, 13.99. 
 
(4-(5-(2-amino-6-methyl-4-oxo-3,4-dihydro-5H-pyrrolo[3,2-d]pyrimidin-5-
yl)pentyl)benzoyl)-L-glutamic acid (286) 
Using the general method for synthesis of compounds 269-271 and 280-282, 416 (0.10 g, 
0.185 mmol) was used to obtain 286 (0.06 g, 67%) as a white solid; TLC Rf = 0.0 
(MeOH:CHCl3:HCl, 1:5:0.5); mp, 143.4-145.3 ⁰ C; 1H-NMR (400 MHz) (Me2SO-d6) δ 
12.25 (s, br, exch., -2 H, -COOH), 8.54 (d, J = 7.7 Hz, 1 H, exch., -NH), 7.79 (d, J = 7.9 
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Hz, 2 H, Ar), 7.28 (d, J = 8.0 Hz, 2 H, Ar), 6.11 (s, 2 H, exch., 2-NH2), 5.76 (s, 1 H, Ar), 
4.44-4.36 (m, 1 H, -CH), 4.18 (t, J = 7.6 Hz, 2 H, -CH2-), 2.61 (t, J = 7.8 Hz, 2 H, -CH2-), 
2.36 (t, J = 7.4 Hz, 2 H, -CH2-), 2.24 (s, 3 H, -CH3), 2.10 (d, J = 14.8 Hz, 2 H, -CH2-), 1.70-
1.54 (m, 4 H, -CH2-), 1.35-1.15 (m, 2 H, -CH2-). Anal. Calcd.  for C24H29N5O6 0.3 HCl 
0.66 CH3OH: C, 57.44; H, 6.24; N, 13.58. Found: C, 57.51; H, 6.00; N, 13.58. 
 
Ethyl 4-(3-hydroxypropoxy)benzoate (418) 
Methyl 4-hydroxybenzoate (6 g, 39.44 mmol), potassium carbonate (8.18 g, 59.15 mmol) 
and 3-bromopropanol (8.22 g, 59.15 mmol) were added to 200 mL acetonitrile and the 
suspension was refluxed at 95 ⁰ C for 16 hours. The solvent was evaporated under reduced 
pressure and to the solids was added water (20 mL) and ethyl acetate (50 mL, three times). 
To the ethyl acetate layer was added anhydrous sodium sulfate and the solution was 
filtered. Silica gel was added to the solvent and a plug was prepared. A flash column 
chromatography was carried out using ethyl acetate-Hexane to afford 418 (6.2 g, 75%) as 
clear liquid; TLC Rf = 0.13 (EtOAc:Hexane, 1:2); 
1H-NMR (400 MHz) (Me2SO-d6) δ 7.90 
(dd, J = 8.8, 2.5 Hz, 2 H, Ar), 7.16 – 6.95 (m, 2 H, Ar), 4.61 (t, 2.2 Hz, 1 H, exch., -OH), 
4.26 (qd, J = 7.2, 2.5 Hz, 2 H, -CH2-), 4.11 (td, J = 6.5, 2.5 Hz, 2 H, -CH2-), 3.58 (qd, J = 
6.0, 2.1 Hz, 2 H, -CH2-), 1.89 (pd, J = 6.3, 2.2 Hz, 2 H, -CH2-), 1.30 (td, J = 7.1, 2.5 Hz, 3 
H, -CH3). This compound was used for the next reaction without further characterization. 
 
Ethyl 4-(3-iodopropoxy)benzoate (419) 
Compound 419 was prepared using the general method described for the preparation of 
374-377 and 393-395, from 418 (2.5 g, 11.15 mmol), methanesulfonyl chloride (1 mL, 
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13.02 mmol) and triethylamine (1.24 g, 12.26 mmol) to form the intermediate. To this 
sodium iodide (1.24 g, 12.26 mmol) was added and the procedure was followed to give 1.8 
g (48%) of 419 as a clear oil; TLC Rf = 0.55 (EtOAc:Hexane, 1:2); 
1H-NMR (500 MHz) 
(Me2SO-d6) δ 7.90 (dd, J = 9.0, 2.5 Hz, 2 H, Ar), 7.02 (dd, J = 9.2, 2.4 Hz, 2 H, Ar), 4.26 
(q, J = 7.0 Hz, 2 H, -CH2-), 4.11 (t, J = 6.4 Hz, 2 H, -CH2-), 3.56 (dt, J = 9.2, 5.4 Hz, 2 H, 
-CH2-), 1.89 (p, J = 6.2 Hz, 2 H, -CH2-), 1.30 (t, J = 7.1 Hz, 3 H, CH3). This compound 
was used for the next reaction without further characterization.  
 
(4-(3-(2-amino-4-oxo-3,4-dihydro-5H-pyrrolo[3,2-d]pyrimidin-5-yl)propoxy) 
benzoyl)-L-glutamic acid (291)  
Using the general method for synthesis of compounds 380-382 and 399-401, 421 (1 g, 3.13 
mmol) was used to obtain 421 (0.30 g, 27%) as a white semi-solid; TLC Rf = 0.0 
(MeOH:CHCl3:HCl, 1:5:0.5). To a solution of 421 (130 mg, 0.41 mmol) in anhydrous 
DMF (10 mL) was added N-methylmorpholine (0.06 mL, 0.62 mmol) and 2-chloro-4,6-
dimethoxy-1,3,5-triazine (1209 mg, 0.62 mmol). The resulting mixture was stirred at room 
temperature for 2 h. To this mixture was added N-methylmorpholine (0.06 mL, 0.62 mmol) 
and L-glutamate diethyl ester hydrochloride (126 mg, 0.62 mmol). The reaction mixture 
was stirred for an additional 4 h at room temperature. Silica gel (400 mg) was then added, 
and the solvent was evaporated under reduced pressure. The resulting plug was loaded on 
to a silica gel column with 5% CHCl3 in MeOH as the eluent. Fractions that showed the 
desired spot (TLC) were pooled and the solvent evaporated to dryness to 422 (110 mg, 
53%) as a grey semi-solid. Using the general method for synthesis of compounds 269-271 
and 280-282, 422 (0.10 g, 0.2 mmol) was used to obtain 291 (0.05 g, 56%) as a white solid; 
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TLC Rf = 0.0 (MeOH:CHCl3:HCl, 1:5:0.5); mp, 147.2-155.9 ⁰ C; 1H-NMR (400 MHz) 
(Me2SO-d6) δ 12.50 (s. 2 H, exch., -COOH), 8.44 (d, J = 7.9 Hz, 1 H, exch., -NH), 7.85 (d, 
J = 8.4 Hz, 2 H, Ar), 7.20 (d, J = 2.9 Hz, 1 H, Ar), 6.96 (d, J = 8.6 Hz, 2 H, Ar), 6.21 (s, 2 
H, exch., 2-NH2), 5.93 (d, J = 2.8 Hz, 1 H, Ar), 4.32-4.22 (m, 3 H, -CH- and -CH2-), 3.94 
(t, 2 H, -CH2-), 2.35 (t, J = 7.5 Hz, 2 H, -CH2-), 2.21 (m, 2 H, -CH2-), 1.95 (m, 2 H, -CH2-
). Anal. Calcd.  for C22H25N5O7 0.78 HCl: C, 52.86; H, 5.20; N, 14.00. Found: C, 52.73; 
H, 5.086; N, 14.40. 
 
Methyl 4-mercaptobenzoate (424) 
To a solution of 4-mercaptobenzoic acid (12 g, 64.86 mmol) in 200 mL methanol, was 
added 4 mL concentrated sulfuric acid. The reaction was refluxed at 65 ⁰ C for 6 hours. 
Silica gel (400 mg) was then added, and the solvent was evaporated under reduced 
pressure. The resulting plug was loaded on to a silica gel column with ethyl acetate-Hexane 
as eluent. Fractions that showed the desired spot (TLC) were pooled and the solvent 
evaporated to dryness to 424 (9.8 g, 70%) as a pale liquid.287 TLC Rf = 0.58 
(EtOAc:Hexane, 1:2); 1H-NMR (400 MHz) (Me2SO-d6) δ 7.86 (dd, J = 8.5, 1.7 Hz, 2 H, 
Ar), 7.39 (dd, J = 8.5, 1.7 Hz, 2 H, Ar), 3.83 (s, 1 H, -OCH3), 3.60 (s, 1 H, exch., -SH). The 
1H-NMR matches the 1H-NMR reported in the literature.288  
 
Methyl 4-((3-hydroxypropyl)thio)benzoate (425) 
Methyl 4-mercaptobenzoate 424 (5 g, 27.44 mmol), cesium carbonate (13.41 g, 41.16 
mmol) and 2-bromopropanol (5.72 g, 41.16 mmol) was added to 200 mL acetonitrile and 
the suspension was refluxed at 95 ⁰ C for 16 hours. The solvent was evaporated under 
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reduced pressure and to the solids was added water (20 mL) and ethyl acetate (50 mL, three 
times). To the ethyl acetate layer was added anhydrous sodium sulfate and the solution was 
filtered. Silica gel was added to the solvent and a plug was prepared. A flash column 
chromatography was carried out using ethyl acetate-Hexane to afford 425 (3.2 g, 55%) as 
clear liquid; TLC Rf = 0.30 (EtOAc:Hexane, 1:2); 
1H-NMR (400 MHz) (Me2SO-d6) δ 7.86 
(dd, J = 8.7, 2.1 Hz, 2 H, Ar), 7.39 (dd, J = 8.5, 1.7 Hz, 2 H, Ar), 4.61 (t, J = 5.2 Hz, 1 H, 
exch., -OH), 3.83 (s, 3 H, -OCH3), 3.52 (q, J = 6.0 Hz, 2 H, -CH2-), 3.09 (t, J = 7.3 Hz, 2 
H, -CH2-), 1.83 – 1.70 (m, 2 H, -CH2-). The 1H-NMR matches the 1H-NMR reported in the 
literature.289  
 
Methyl 4-((3-iodopropyl)thio)benzoate (426) 
Compound 426 was prepared using the general method described for the preparation of 
374-377 and 373-395, from 425 (2.5 g, 10.40 mmol), methanesulfonyl chloride (1 mL, 
13.02 mmol) and triethylamine (1.16 g, 11.44 mmol) to form the intermediate. To this 
sodium iodide (1.72 g, 11.44 mmol) was added and the procedure was followed to give 1.5 
g (41%) of 426 as a clear oil; TLC Rf = 0.80 (EtOAc:Hexane, 1:2); 
1H-NMR (400 MHz) 
(Me2SO-d6) δ 7.87 (d, J = 8.4 Hz, 2 H, Ar), 7.42 (d, J = 8.4 Hz, 2 H, Ar), 3.83 (s, 3 H, -
OCH3), 3.35 (t, J = 6.7 Hz, 2 H, -CH2-), 3.13 (q, J = 7.1, 6.7 Hz, 2 H, -CH2-), 2.08 (p, J = 
6.8 Hz, 2 H, -CH2-).This compound was used for the next reaction without further 
characterization. 
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 (4-((3-(2-amino-4-oxo-3,4-dihydro-5H-pyrrolo[3,2-d]pyrimidin-5-yl)propyl) 
thio)benzoyl)-L-glutamic acid (292) 
Using the general method for synthesis of compounds 380-382 and 399-401, 426 (1 g, 3.57 
mmol) was used to obtain 428 (0.28 g, crude 23%) as a white solid; TLC Rf = 0.0 
(MeOH:CHCl3:HCl, 1:5:0.5); The 
1H NMR assessment suggested impurities and hence 
this compound was used for the next reaction without further characterization. To a 
solution of 428 (150 mg, 0.45 mmol) in anhydrous DMF (10 mL) was added N-
methylmorpholine (0.08 mL, 0.72 mmol) and 2-chloro-4,6-dimethoxy-1,3,5-triazine (120 
mg, 0.69 mmol). The resulting mixture was stirred at room temperature for 2 h. To this 
mixture was added N-methylmorpholine (0.08 mL, 0.72 mmol) and L-glutamate diethyl 
ester hydrochloride (140 mg, 0.69 mmol). The reaction mixture was stirred for an 
additional 4 h at room temperature. Silica gel (400 mg) was then added, and the solvent 
was evaporated under reduced pressure. The resulting plug was loaded on to a silica gel 
column with 5% CHCl3 in MeOH as the eluent. Fractions that showed the desired spot 
(TLC) were pooled and the solvent evaporated to dryness to 429 (100 mg, 43%) as a grey 
semi-solid; TLC Rf = 0.23 (MeOH:CHCl3:NH4OH, 1:10:0.5); The TLC with multiple spots 
and  1H NMR with several aliphatic peaks suggested presented of a polar impurity at Rf  
0.2 (MeOH:CHCl3:NH4OH, 1:5:0.5). To a solution of 429, was added 4 mL of 1 N sodium 
hydroxide solution. The reaction mixture was stirred for 1 hour at room temperature and 
the disappearance of the starting material was spotted with TLC. The resultant solution was 
filtered through a filter paper and the filtrate was collected. The filtrate was acidified to pH 
2-3 using 1N hydrochloric acid to obtain 292 (0.04 g, 50%) as a white solid; TLC Rf = 0.0 
(MeOH:CHCl3:HCl, 1:5:0.5); mp, 63.3-67.9 ⁰ C; 1H-NMR (400 MHz) (Me2SO-d6) δ 
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11.75 (s, br, 2 H, exch., -COOH), 8.60 (d, J = 7.8 Hz, 1 H, exch., -NH), 7.80 (d, J = 8.2 Hz, 
2 H, Ar), 7.30 (d, J = 8.2 Hz, 2 H, Ar), 7.22 (d, J = 2.8 Hz, 1 H, Ar), 6.06 (s, 2 H, exch., 2-
NH2), 5.93 (d, J = 2.8 Hz, 1 H, Ar), 4.34 (m, 3 H, -CH and -CH2-), 2.91 (t, J = 7.5 Hz, 2 H, 
-CH2-), 2.35 (t, J = 7.6 Hz, 2 H, -CH2-), 1.96-2.08 (m, 4 H, -CH2-).  Anal. Calcd.  for 
C21H23N5O6S 0.70 CH3OH 1.6 HCl: C, 47.02; H, 4.98; N, 12.64; S, 5.79. Found: C, 47.05; 
H, 4.86; N, 12.47; S, 5.93. 
 
Methyl 4-((3-hydroxypropyl)amino)benzoate (430) 
To copper iodide (1.02 g, 5.34 mmol) and L-proline (1.23 g, 10.69 mmol) was added 
methyl 4-iodobenzoate (7g, 26.71 mmol) was also introduced at this stage. DMSO (5.0 
mL) was added next and the resulting blue solution was stirred for 5 min before adding the 
amino alcohol (10 g, 133.56 mmol). The resulting mixture was stirred under argon at room 
temperature for 16 h. Upon completion, the reaction mixture was diluted with 30 mL of 
water and extracted twice with 150 mL of ethyl acetate. The combined organic layers were 
successively washed with brine. Silica gel was then added, and the solvent was evaporated 
under reduced pressure. The resulting plug was loaded on to a silica gel column with ethyl 
acetate-Hexane as the eluent. Fractions that showed the desired spot (TLC) were pooled 
and the solvent evaporated to dryness to afford 430 as a clear liquid (4.2 g, 75 %); TLC Rf 
= 0.38 (MeOH:CHCl3:NH4OH, 1:10:0.5); 
1H-NMR (400 MHz) (Me2SO-d6)  δ 7.68 (d, J = 
8.8 Hz, 2 H, Ar), 6.58 (d, J = 8.8 Hz, 2 H, Ar), 6.51 (t, J = 4.0 Hz, 1 H, exch., -NH), 4.51 
(s, 1 H, exch., -OH), 3.74 (s, 3 H, -OCH3), 3.50 (t, J = 6.2 Hz, 2 H, -CH2-), 3.18 – 3.07 (m, 
2 H, -CH2-), 1.70 (p, J = 6.6 Hz, 2 H, -CH2-). This compound was taken for the next reaction 
without further characterization. 
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Methyl 4-((3-iodopropyl)amino)benzoate (432) 
To a solution of triphenylphosphine (2.51 g, 9.56 mmol) in dry methylene chloride (100 
mL) was added iodine (2.43 g, 9.56 mmol) and imidazole (0.65 g, 9.56 mmol) at 0 ºC. The 
resulting solution was stirred for 10 min, before a solution of ethyl 4-((2-
hydroxyethyl)amino)benzoate 430 (2 g, 9.56 mmol) in dry methylene chloride (50 mL) 
was added. The reaction mixture was then quenched with sat. aqueous sodium thiosulfite 
solution after 30 minutes. The organic layer was separated, and washed with brine and 
dried over Na2SO4. Silica gel was then added, and the solvent was evaporated under 
reduced pressure. The resulting plug was loaded on to a silica gel column with ethyl 
acetate-Hexane as the eluent. Fractions that showed the desired spot (TLC) were pooled 
and the solvent evaporated to dryness to 432 (2.5 g, 82%) as a clear liquid; TLC Rf = 0.50 
(MeOH:CHCl3:NH4OH, 1:10:0.5); 
1H-NMR (400 MHz) (Me2SO-d6) δ 7.70 (d, J = 8.4 Hz, 
2 H, Ar), 6.74-6.55 (m, 3 H, Ar and exch. NH), 3.74 (s, 3 H, -OCH3), 3.56 (t, J = 6.0 Hz, 2 
H, -CH2-), 3.16 (q, J = 5.9 Hz, 2 H, -CH2-), 2.03 (p, J = 7.6, 7.2 Hz, 2 H, -CH2-). This 
compound was used for the next reaction without further characterization 
 
 (4-((3-(2-amino-4-oxo-3,4-dihydro-5H-pyrrolo[3,2-d]pyrimidin-5-yl)propyl)amino) 
benzoyl)-L-glutamic acid (293) 
Using the general method for synthesis of compounds 380-382 and 399-401, 432 (1 g, 3.13 
mmol) was used to obtain 434 (0.35 g, 34%) as a white solid; TLC Rf = 0.0 
(MeOH:CHCl3:HCl, 1:5:0.5). To a solution of 434 (120 mg, 0.38 mmol) in anhydrous 
DMF (10 mL) was added N-methylmorpholine (0.06 mL, 0.6 mmol) and 2-chloro-4,6-
dimethoxy-1,3,5-triazine (100 mg, 0.6 mmol). The resulting mixture was stirred at room 
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temperature for 2 h. To this mixture was added N-methylmorpholine 0.06 mL, 0.6 mmol) 
and L-glutamate diethyl ester hydrochloride (120 mg, 0.6 mmol). The reaction mixture was 
stirred for an additional 4 h at room temperature. Silica gel (400 mg) was then added, and 
the solvent was evaporated under reduced pressure. The resulting plug was loaded on to a 
silica gel column with 5% CHCl3 in MeOH as the eluent. Fractions that showed the desired 
spot (TLC) were pooled and the solvent evaporated to dryness to 435 (90 mg, 47%) as a 
grey semi-solid; 1H-NMR showed presence of aliphatic and aromatic impurities and this 
compound was used for the next reaction without characterization. Using the general 
method for synthesis of compounds 269-271 and 280-282, 435 (0.10 g, 0.2 mmol) was 
used to obtain 293 (0.056 g, 34%) as a white solid; TLC Rf = 0.0 (MeOH:CHCl3:HCl, 
1:5:0.5); mp, 76.7-83.9 ⁰ C; 1H-NMR (400 MHz) (Me2SO-d6) δ 12.34 (s, 2 H, -COOH), 
8.14 (d, J = 7.9 Hz, 1 H, exch., -NH), 7.66 (d, J = 8.3 Hz, 2 H, Ar), 7.31 (d, J = 2.6 Hz, 1 
H, Ar), 6.66 (s, 2 H, exch., 2-NH2), 6.52 (d, J = 8.4 Hz, 2 H, Ar), 6.27 (s, 1 H, -exch., -NH-
), 6.00 (d, J = 2.7 Hz, 1 H, Ar), 4.45-4.25 (m, 3 H, -CH and -CH2-), 2.97 (t, J = 6.5 Hz, 2 
H, -CH2-), 2.33 (t, J = 7.5 Hz, 2 H, -CH2-), 2.14 – 1.68 (m, 4 H, -CH2-). Anal. Calcd.  for 
C21H24N6O6 0.5 CH3OH 0.8 HCl: C, 51.47; H, 5.40; N, 16.74. Found: C, 51.50; H, 5.26; 
N, 16.66.  
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 Table 31. Fisher’s randomization test: Cost values for 19 random pharmacophores 
generated using the same parameters as described for the HypoGen hypotheses A1-A10. 
 
 
 
 
 
  
H
yp
o 
C
os
ts 
Random test number 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 
A
1 
73
.9
1 
86.
29 
86.
85 
85
.0
7 
97.
34 
84
.2
2 
87
.5
5 
84
.3
5 
86
.0
5 
89.
38 
82
.6
2 
80
.1
8 
86.
31 
85
.1
9 
86.
59 
90.
73 
91.
32 
85
.5
5 
89
.3
3 
87
.3
9 
A
2 
79
.3
6 
89.
97 
90.
01 
88
.6
3 
98.
28 
86
.8
1 
89
.2
2 
90
.3
7 
87
.3
0 
91.
66 
86
.5
1 
85
.2
2 
88.
01 
90
.8
8 
89.
04 
93.
43 
98.
48 
85
.9
9 
89
.7
2 
88
.0
0 
A
3 
79
.6
3 
90.
48 
91.
22 
88
.8
1 
99.
35 
90
.0
3 
93
.5
5 
92
.9
0 
89
.6
6 
93.
46 
89
.2
5 
85
.9
6 
88.
71 
92
.5
1 
94.
43 
96.
45 
99.
72 
87
.1
0 
90
.0
0 
88
.0
9 
A
4 
79
.7
2 
91.
53 
93.
82 
90
.2
5 
99.
69 
90
.7
0 
95
.5
9 
94
.5
6 
90
.7
2 
96.
35 
90
.5
5 
87
.9
3 
93.
88 
95
.4
5 
96.
88 
98.
92 
10
5.0
0 
88
.2
5 
91
.6
3 
90
.0
2 
A
5 
79
.9
9 
93.
70 
94.
43 
90
.5
0 
99.
83 
91
.0
0 
96
.0
2 
95
.7
6 
90
.9
8 
98.
06 
91
.4
4 
88
.1
9 
94.
69 
95
.7
0 
97.
15 
10
0.0
7 
10
5.2
9 
88
.6
1 
93
.1
1 
90
.0
5 
A
6 
80
.1
7 
95.
46 
97.
08 
90
.6
0 
99.
85 
91
.1
6 
96
.0
3 
96
.3
6 
93
.9
1 
99.
37 
93
.9
3 
88
.6
6 
97.
40 
95
.8
4 
97.
73 
10
0.4
5 
10
8.3
9 
89
.0
1 
93
.6
4 
90
.0
5 
A
7 
80
.8
2 
98.
29 
98.
49 
91
.7
0 
99.
88 
91
.5
7 
96
.9
8 
97
.5
0 
94
.3
1 
10
0.8
0 
94
.8
8 
89
.8
2 
97.
54 
96
.0
7 
98.
63 
10
0.8
2 
10
8.7
4 
89
.3
1 
94
.9
5 
90
.2
6 
A
8 
81
.3
8 
10
0.6
4 
99.
50 
91
.8
1 
99.
92 
92
.0
0 
97
.4
4 
97
.5
8 
94
.5
2 
10
1.1
8 
97
.0
8 
90
.1
0 
97.
78 
96
.0
8 
10
0.6
5 
10
0.8
7 
10
8.8
2 
89
.3
9 
95
.1
9 
92
.4
8 
A
9 
82
.0
6 
10
0.7
2 
99.
66 
92
.7
4 
10
1.0
0 
92
.0
0 
97
.4
8 
97
.6
3 
95
.2
4 
10
2.9
0 
97
.7
9 
90
.1
0 
98.
06 
96
.4
3 
10
0.7
2 
10
1.4
1 
10
9.2
8 
89
.5
3 
96
.0
2 
93
.7
3 
A
10 
83
.2
2 
10
1.3
8 
10
0.3
8 
92
.9
4 
10
1.1
3 
92
.2
8 
98
.4
3 
99
.8
5 
97
.1
1 
10
4.1
1 
97
.8
4 
90
.3
9 
10
0.0
9 
96
.9
5 
10
3.4
1 
10
1.9
1 
10
9.8
7 
91
.4
5 
96
.1
6 
93
.9
0 
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Table 32. Fisher’s randomization test: Correlation values for 19 random pharmacophores 
generated using the same parameters as described for the HypoGen hypotheses A1-A10 
H
yp
o 
Corre
lation 
Random test number 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 
A
1 
0.965 
0.
92
8 
0.
91
9 
0.
95
4 
0.
85
2 
0.
91
7 
0.
93
1 
0.
94
0 
0.
93
8 
0.
92
4 
0.
94
3 
0.
95
9 
0.
91
8 
0.
95
1 
0.
92
1 
0.
91
7 
0.
89
1 
0.
94
1 
0.
91
0 
0.
93
0 
A
2 
0.935 
0.
88
9 
0.
88
9 
0.
90
9 
0.
87
1 
0.
90
1 
0.
92
7 
0.
89
5 
0.
94
6 
0.
88
2 
0.
91
6 
0.
92
2 
0.
91
5 
0.
92
4 
0.
91
0 
0.
87
0 
0.
83
7 
0.
93
7 
0.
93
5 
0.
92
7 
A
3 
0.942 
0.
90
8 
0.
88
9 
0.
92
7 
0.
84
1 
0.
87
6 
0.
88
9 
0.
89
1 
0.
93
1 
0.
87
5 
0.
89
2 
0.
93
9 
0.
92
3 
0.
88
8 
0.
88
0 
0.
89
7 
0.
87
3 
0.
92
5 
0.
90
9 
0.
90
5 
A
4 
0.939 
0.
89
0 
0.
87
6 
0.
92
0 
0.
87
2 
0.
87
2 
0.
85
4 
0.
87
0 
0.
88
9 
0.
85
1 
0.
89
8 
0.
92
2 
0.
86
8 
0.
86
3 
0.
89
5 
0.
83
3 
0.
79
8 
0.
89
8 
0.
90
1 
0.
90
8 
A
5 
0.945 
0.
88
2 
0.
86
8 
0.
89
9 
0.
84
2 
0.
89
8 
0.
89
7 
0.
86
7 
0.
88
5 
0.
84
5 
0.
88
1 
0.
91
4 
0.
87
8 
0.
93
7 
0.
85
0 
0.
82
2 
0.
85
1 
0.
90
2 
0.
90
3 
0.
92
0 
A
6 
0.930 
0.
84
9 
0.
85
2 
0.
92
0 
0.
82
4 
0.
88
0 
0.
87
8 
0.
85
8 
0.
88
5 
0.
83
1 
0.
87
4 
0.
91
1 
0.
85
1 
0.
86
3 
0.
85
7 
0.
83
0 
0.
78
0 
0.
91
3 
0.
88
3 
0.
89
7 
A
7 
0.940 
0.
84
0 
0.
85
9 
0.
90
3 
0.
82
6 
0.
86
8 
0.
84
7 
0.
87
2 
0.
89
5 
0.
84
1 
0.
85
3 
0.
89
7 
0.
85
9 
0.
87
1 
0.
87
4 
0.
82
3 
0.
78
3 
0.
89
9 
0.
87
6 
0.
91
3 
A
8 
0.940 
0.
81
8 
0.
82
8 
0.
89
8 
0.
85
2 
0.
86
4 
0.
86
4 
0.
85
6 
0.
87
3 
0.
84
3 
0.
83
5 
0.
91
9 
0.
85
3 
0.
88
4 
0.
84
2 
0.
82
1 
0.
77
9 
0.
89
4 
0.
87
6 
0.
87
6 
A
9 
0.922 
0.
81
9 
0.
84
4 
0.
87
7 
0.
82
5 
0.
86
1 
0.
84
1 
0.
84
5 
0.
90
2 
0.
81
7 
0.
84
9 
0.
88
2 
0.
84
8 
0.
85
8 
0.
84
8 
0.
82
5 
0.
76
7 
0.
90
7 
0.
85
1 
0.
91
3 
A
10 
0.910 
0.
80
6 
0.
83
1 
0.
89
6 
0.
83
5 
0.
88
0 
0.
86
7 
0.
82
9 
0.
86
3 
0.
86
6 
0.
84
6 
0.
88
8 
0.
82
2 
0.
86
4 
0.
84
1 
0.
83
8 
0.
76
5 
0.
87
5 
0.
86
7 
0.
88
2 
 
Table 33. Fisher’s randomization test: Cost values for 9 random pharmacophores 
generated using the same parameters as described for the HypoGen hypotheses B1-B10. 
Hypo Costs Random test number 
1 2 3 4 5 6 7 8 9 
B1 88.05 124.92 103.57 113.12 105.76 103.99 104.81 116.79 116.84 106.11 
B2 89.89 134.83 106.51 124.80 111.46 105.32 111.42 119.87 125.41 135.56 
B3 92.27 139.89 110.01 128.29 117.69 114.87 116.44 124.28 133.16 138.31 
B4 98.24 143.44 110.98 130.06 120.90 117.22 118.18 128.00 141.87 140.02 
B5 102.82 143.77 115.65 131.40 123.87 118.93 119.18 131.76 142.26 140.99 
B6 105.87 147.46 117.37 135.07 125.21 120.64 123.97 132.40 142.49 141.23 
B7 105.94 148.79 119.01 136.01 127.31 123.87 124.29 133.56 144.05 141.66 
B8 109.14 150.79 119.50 137.27 129.35 123.90 124.38 134.52 144.05 143.12 
B9 109.38 151.31 120.79 139.02 133.07 124.35 125.64 135.20 144.19 143.47 
B10 109.46 151.75 120.80 140.62 134.64 127.06 126.97 135.85 144.50 144.16 
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Table 34. Fisher’s randomization test: Correlation values for 9 random pharmacophores 
generated using the same parameters as described for the HypoGen hypotheses B1-B10. 
Hypo Correlation Random test number 
1 2 3 4 5 6 7 8 9 
B1 0.964 0.869 0.905 0.890 0.912 0.883 0.877 0.797 0.861 0.886 
B2 0.948 0.742 0.887 0.803 0.851 0.871 0.886 0.840 0.782 0.698 
B3 0.932 0.713 0.839 0.763 0.794 0.838 0.818 0.769 0.722 0.723 
B4 0.898 0.675 0.812 0.743 0.828 0.789 0.882 0.730 0.667 0.647 
B5 0.892 0.709 0.782 0.799 0.754 0.769 0.806 0.771 0.653 0.680 
B6 0.867 0.685 0.784 0.734 0.733 0.764 0.782 0.696 0.648 0.685 
B7 0.851 0.749 0.767 0.736 0.725 0.743 0.847 0.672 0.644 0.641 
B8 0.848 0.651 0.767 0.740 0.762 0.743 0.865 0.675 0.636 0.623 
B9 0.851 0.786 0.754 0.701 0.686 0.749 0.772 0.669 0.675 0.614 
B10 0.859 0.648 0.781 0.695 0.869 0.732 0.781 0.644 0.648 0.632 
 
Docking protocol for molecular modeling of selective pjDHFR inhibitors: 
Docking of target compounds was carried out using the published X-ray crystal 
structure of N6-methyl-N6-(3,4,5-trifluorophenyl)pyrido[3,2-d]pyrimidine-2,4,6-triamine 
in hDHFR(PDB: 4QJC, 1.62 Å)36 and in the homology model of pjDHFR35 using LeadIT 
2.1.6.35 The docking in LeadIT was constrained to the active site of the protein. Polar 
hydrogen atoms of amino acids were not constrained, thereby permitting them free rotation. 
Base placement of fragments for docking was carried out using triangle docking. Default 
parameters were used for scoring and clash handling. The maximum number of solutions 
per iteration and maximum number of fragmentation were set to 200. Ten poses were 
obtained per molecule. The docked poses were exported to MOE 2016.08 for 
visualization.40, 290 The validation of LeadIT as a suitable docking system for pjDHFR and 
hDHFR was carried out by re-docking the native ligands in the x-ray crystal structures of 
pcDHFR (PDB: 2FZI)291 and hDHFR (PDB: 4QJC). The ligands were sketched in MOE 
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2016.0840 and docking was carried out with LeadIT 2.1.635 as described above. The best 
docked pose of the ligands had RMSD of 0.7060 Å in pjDHFR and 0.8860 Å in hDHFR. 
Thus, LeadIT 2.1.6 was validated and chosen for the docking studies. 
Table 35. Docked scores of proposed compounds in homology model of pjDHFR and X-
ray crystal structure of hDHFR 
 hDHFR pjDHFR   hDHFR pjDHFR 
141 -29.41 -33.80  177 -28.8 -42.76 
142 -33.12 -35.11  180 -37.36 -42.44 
143 -24.5 -33.1  181 -35.35 -41.40 
144 -23.89 -35.84  182 -31.69 -40.5 
145 -13.67 -15.47  183 -27.11 -43.25 
146 -23.8 -22.33  184 -27.5 -38.21 
147 -22.61 -32.73  185 -27.12 -34.84 
148 -27.1 -35.39  186 -30.05 -40.96 
149 -26.12 -30.28  187 -25.99 -32.72 
150 -29.71 -31.4  188 -30.4 -38.2 
151 -27.42 -40.27  189 -30.8 -39.33 
152 -28.63 -38.35  190 -33.63 -46.57 
153 -28.53 -32.12  191 -30.76 -42.15 
154 -35.98 -38.39  192 -30.25 -41.23 
155 -30.34 -38.04  193 -28.9 -40.85 
156 -26.62 -23.34  194 -30.32 -39.06 
157 -30.81 -27.7  195 -29.19 -41.77 
158 -29.84 -27.55  196 -29.66 -39.31 
159 -29.58 -32.7  197 -31.49 -45.08 
160 -26.45 -24.61  198 -33.13 -42.21 
169 -35.35 -43.99  199 -30.35 -45.3 
170 -29.35 -39.38  201 -34.76 -35.02 
171 -29.74 -40.26  202 -33.12 -26.50 
172 -29.86 -44.89  203 -33.13 -29.26 
173 -35.86 -45.5  204 -33.09 -28.42 
174 -33.23 -43.64  205 -32.9 -28.63 
175 -31.92 -42.11  206 -33.21 -37.88 
176 -27.22 -41.09  207 -27.64 -27.49 
    208 -40.63 -35.96 
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Docking protocol for molecular modeling single agents with combination 
chemotherapy and multiple RTK inhibitory potential: 
Docking of target compounds was carried out in the published X-ray crystal 
structure of colchicine in tubulin (PDB: 4O2B, 2.3 Å),215 axitinib in VEGFR-2 (PDB: 
4AG8, 1.95 Å),222 gefitinib in EGFR (PDB: 4WKQ, 1.85 Å)223 and in the homology 
model292 of PDGFR-β using Molecular Operating Environment (MOE 2016.08).7 The 
crystal structure of tubulin, VEGFR-2 and EGFR were obtained from the protein database 
and imported into MOE 2016.08. The preparation of proteins was done using the 
QuickPrep function and was energy minimized using Amber10:EHT forcefield by default 
settings. The placement was carried out using Triangle Matcher and scores using London 
dG. The refinement was carried out using Induced Fit and scored using GBVI/WSA dG. 
Using the Induced Fit function causes the side chains to be set free. The cut off was set to 
6 Å and radius to 0.4. for tubulin, the side chains C, D, E and F were deleted to reduce the 
time needed for protein preparation and docking. On preparation of protein, Ca+2, Mg+2, 
GDP, GTP and other ligands, except colchicine, were deleted. The docking method was 
validated by performing re-docking of the native ligands colchicine, VEGFR-2 and EGFR, 
respectively, using the set parameters stated above. The rmsd of the best docked pose of 
colchicine in tubulin, axitinib in VEGFR-2 and gefitinib in EGFR were 0.82 Å, 1.27 Å and 
1.63 Å, respectively, which validates our docking using MOE.  
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Table 36. Docked scores of proposed compounds in colchicine site of tubulin, EGFR, 
VEGFR-2 and PDGFR-β 
 tubulin EGFR VEGFR-2 PDGFR- β 
217 -7.37 -6.16 -7.68 -6.44 
218 -7.71 -7.02 -6.92 -6.6 
219 7.95 -6.60 -7.19 -6.77 
222 -7.19 -6.55 -8.44 -7.00 
223 -8.06 -6.22 -8.26 -6.95 
224 -7.22 -6.25 -7.96 -6.68 
225 -7.59 -5.93 -7.91 -6.68 
227 -8.00 -6.56 -8.12 -7.57 
228 -7.98 -6.22 -7.85 -7.38 
231 -6.90 -6.31 7.64 -6.61 
232 -7.63 -6.46 -8.31 -6.88 
233 -7.30 -6.33 -7.9 -6.73 
234 -7.91 -6.05 -8.18 -7.06 
235 -8.13 -7.19 -7.29 -6.68 
236 -8.52 -6.72 -7.06 -7.05 
237 -7.86 -6.43 -8.09 -7.54 
238 -6.76 -6.46 -8.08 -6.40 
239 -8.04 -7.05 -7.14 -6.55 
240 -7.73 -6.26 -7.99 -6.97 
242 -7.11 -6.61 -7.77 -6.55 
243 -7.43 -6.52 -8.04 -6.65 
244 -7.54 -6.67 -8.11 -6.63 
245 -7.04 -6.72 -8.3 -7.00 
247 -6.99 -6.89 -6.98 -7.12 
248 -7.25 -6.45 -6.78 -6.89 
249 -7.32 -6.49 -7.02 -6.58 
250 -7.89 -7.00 -6.83 -6.64 
251 -8.28 -7.17 -7.22 -6.81 
252 -8.14 -7.00 -7.03 -6.73 
253 -7.63 -6.64 -7.73 -7.32 
254 -7.81 -6.58 -7.73 -7.55 
255 -7.51 -6.60 -8.07 -7.49 
256 -7.47 -6.24 -7.81 -6.40 
257 -7.75 -6.59 -7.98 -7.06 
258 -8.02 -7.17 -6.79 -7.39 
259 -8.14 -7.22 -7.13 -6.57 
260 -7.42 -6.70 -7.92 -6.98 
261 -8.12 -7.36 -6.77 -6.72 
262 -7.76 -6.20 -5.55 -6.81 
263 -7.42 -6.05 -7.81 -6.28 
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Docking protocol for molecular modeling of single agents with tumor targeting via 
cellular uptake by Folate Receptors and/or Proton-Coupled Folate Transporter and 
inhibition of de novo purine nucleotide biosynthesis: 
The X-ray crystal structures of human FRα bound to AGF183 (PDB: 5IZQ, 3.60 Å), FRβ 
bound to MTX (PDB: 4KN0, 2.10 Å), human GARFTase bound to AGF150 (PDB: 4ZZ1, 
1.35 Å) and human AICARFTase (PDB: 1P4R, 2.55 Å) were obtained from the protein 
database. Docking studies were performed using LeadIT 2.1.6. Default settings were used 
to calculate the protonation state of the proteins, and the ligands and free rotation of water 
molecules in the active site (defined by amino acids within 6.5 Å from the crystal structure 
ligand) were permitted. Ligands for docking were sketched using MOE 2016.08 and energy 
minimized using the MMF94X force field (limit of 0.05 kcal/mol). Molecules were docked 
in LeadIt 2.1.6 using the triangle matching placement method and scored using default 
settings. The docked poses were visualized using CCP4MG. To validate the docking 
process using LeadIT 2.1.6, the crystallized ligands were sketched using MOE, energy 
minimized, and docked as described. The best pose of AGF183 in FRα had an RMSD of 
0.94 Å. MTX in FRβ had an RMSD of 0.87 Å, AGF150 in the human GARFTase had an 
RMSD of 1.15 Å, and ((S)-(4-((2-amino-4-hydroxyquinazoline)-6-
sulfonamido)phenyl)(hydroxy)methyl)-L-glutamic acid in the human AICARFTase had an 
RMSD of 1.21 Å. Thus, LeadIt 2.1.6 was validated for our docking purposes in FRα, FRβ, 
GARFTase and AICARFTase. 
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Table 37. Docked scores of proposed compounds in crystal structures of FRα, FRβ, 
GARFTase and AICARFTase 
 FRα FRβ GARFTase AICARFTase 
265 -51.77 -53.99 -67.10 -40.17 
269 -44.75 -56.96 -53.34 -34.88 
270 -48.29 -64.54 -60.25 -34.14 
271 -47.6 -50.2 -52.4 -41.23 
280 -45.68 -54.85 -55.42 -36.78 
281 -45.49 -50.74 -58.15 -36.54 
282 -48.6 -43.94 -49.97 -38.75 
284 -44.11 -57.82 -39.28 -28.67 
285 -52.35 -52.27 -60.35 -26.26 
286 -41.01 -26.29 -54.28 -27.21 
291 -52.96 -60.78 -61.93 -37.82 
292 -50.74 -53.38 -63.52 -35.74 
293 -53.27 -53.99 -67.19 -41.33 
The docking scores for all the proposed compounds were similar to the lead 
compound 265, with some exceptions (286 in FRα and FRβ; 282 and 284 in GARFTase 
and 284-286 in AICARFTase). 
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VI. SUMMARY 
 
This dissertation describes the design and synthesis of selective pjDHFR inhibitors, 
single agents with combination chemotherapy and multiple RTK inhibitory potential and 
single agents with tumor targeting via cellular uptake by Folate Receptors and Proton-
Coupled Folate Transporter and inhibition of de novo purine nucleotide biosynthesis. The 
novel compounds synthesized as part of this study are listed below: 
1. 6-((3-methoxyphenyl)thio)-5,7-dimethyl-7H-pyrrolo[2,3-d]pyrimidine-2,4-
diamine (142) 
2. 7-ethyl-6-((3-methoxyphenyl)thio)-5-methyl-7H-pyrrolo[2,3-d]pyrimidine-2,4-
diamine (143) 
3. 6-((3-methoxyphenyl)thio)-5-methyl-7-propyl-7H-pyrrolo[2,3-d]pyrimidine-2,4-
diamine (144) 
4. 7-isopropyl-6-((3-methoxyphenyl)thio)-5-methyl-7H-pyrrolo[2,3-d]pyrimidine-
2,4-diamine (145) 
5. 7-butyl-6-((3-methoxyphenyl)thio)-5-methyl-7H-pyrrolo[2,3-d]pyrimidine-2,4-
diamine (146) 
6. 7-benzyl-6-((3-methoxyphenyl)thio)-5-methyl-7H-pyrrolo[2,3-d]pyrimidine-2,4-
diamine (147) 
7. 6-((3,4-difluorophenyl)thio)-5-methyl-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine 
(152) 
8. 5-methyl-6-((4-(trifluoromethoxy)phenyl)thio)-7H-pyrrolo[2,3-d]pyrimidine-2,4-
diamine (153) 
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9. 5-methyl-6-((4-nitrophenyl)thio)-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine (154) 
10. 6-((2-methoxyphenyl)thio)-5,7-dimethyl-7H-pyrrolo[2,3-d]pyrimidine-2,4-
diamine (155).  
11. 6-((4-methoxyphenyl)thio)-5,7-dimethyl-7H-pyrrolo[2,3-d]pyrimidine-2,4-
diamine (156) 
12. 5,7-dimethyl-6-(naphthalen-2-ylthio)-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine 
(157) 
13. 5,7-dimethyl-6-(naphthalen-1-ylthio)-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine 
(158) 
14. 6-((3,4-difluorophenyl)thio)-5,7-dimethyl-7H-pyrrolo[2,3-d]pyrimidine-2,4-
diamine (159) 
15. 5,7-dimethyl-6-((4-(trifluoromethoxy)phenyl)thio)-7H-pyrrolo[2,3-d]pyrimidine-
2,4-diamine (160) 
16. N6-phenylpyrido[3,2-d]pyrimidine-2,4,6-triamine (169) 
17. N6-(p-tolyl)pyrido[3,2-d]pyrimidine-2,4,6-triamine (170) 
18. N6-(4-methoxyphenyl)pyrido[3,2-d]pyrimidine-2,4,6-triamine (171) 
19. 4-((2,4-diaminopyrido[3,2-d]pyrimidin-6-yl)amino)phenol (172) 
20. N6-(naphthalen-1-yl)pyrido[3,2-d]pyrimidine-2,4,6-triamine (173) 
21. N6-(naphthalen-2-yl)pyrido[3,2-d]pyrimidine-2,4,6-triamine (174) 
22. N6-(3,4-difluorophenyl)pyrido[3,2-d]pyrimidine-2,4,6-triamine (175) 
23. N6-(3,4,5-trifluorophenyl)pyrido[3,2-d]pyrimidine-2,4,6-triamine (176) 
24. N6-(4-(trifluoromethoxy)phenyl)pyrido[3,2-d]pyrimidine-2,4,6-triamine (177) 
25. N6-methyl-N6-phenylpyrido[3,2-d]pyrimidine-2,4,6-triamine (180) 
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26. N6-ethyl-N6-phenylpyrido[3,2-d]pyrimidine-2,4,6-triamine (181) 
27. N6-phenyl N6-propyl-pyrido[3,2-d]pyrimidine-2,4,6-triamine (182) 
28. N6-isopropyl-N6-phenylpyrido[3,2-d]pyrimidine-2,4,6-triamine (183) 
29. N6-butyl-N6-phenylpyrido[3,2-d]pyrimidine-2,4,6-triamine (184) 
30. 6-(3,4-dihydroquinolin-1(2H)-yl)pyrido[3,2-d]pyrimidine-2,4-diamine (185) 
31. 6-(phenylthio)pyrido[3,2-d]pyrimidine-2,4-diamine (186) 
32. 6-phenoxypyrido[3,2-d]pyrimidine-2,4-diamine (187) 
33. 6-((3-methoxyphenyl)thio)pyrido[3,2-d]pyrimidine-2,4-diamine (188) 
34. 6-((3,4-dimethoxyphenyl)thio)pyrido[3,2-d]pyrimidine-2,4-diamine (189) 
35. 6-(naphthalen-1-ylthio)pyrido[3,2-d]pyrimidine-2,4-diamine (190) 
36. 6-(naphthalen-2-ylthio)pyrido[3,2-d]pyrimidine-2,4-diamine (191) 
37. 6-((4-fluorophenyl)thio)pyrido[3,2-d]pyrimidine-2,4-diamine (192) 
38. 6-((3,4-difluorophenyl)thio)pyrido[3,2-d]pyrimidine-2,4-diamine (193) 
39. 6-((3,4,5-trifluorophenyl)thio)pyrido[3,2-d]pyrimidine-2,4-diamine (194) 
40. 6-((2,4-difluorophenyl)thio)pyrido[3,2-d]pyrimidine-2,4-diamine (195) 
41. 6-((4-(trifluoromethoxy)phenyl)thio)pyrido[3,2-d]pyrimidine-2,4-diamine (196) 
42. 6-((4-nitrophenyl)thio)pyrido[3,2-d]pyrimidine-2,4-diamine (197) 
43. 6-(naphthalen-2-ylsulfinyl)pyrido[3,2-d]pyrimidine-2,4-diamine (198) 
44. 6-(naphthalen-2-ylsulfonyl)pyrido[3,2-d]pyrimidine-2,4-diamine (199) 
45. 7-(naphthalen-1-ylthio)pyrido[3,2-d]pyrimidine-2,4-diamine (201) 
46. 7-(naphthalen-2-ylthio)pyrido[3,2-d]pyrimidine-2,4-diamine (202) 
47. 7-((3-methoxyphenyl)thio)pyrido[3,2-d]pyrimidine-2,4-diamine (203) 
48. 7-((3,4-dimethoxyphenyl)thio)pyrido[3,2-d]pyrimidine-2,4-diamine (204) 
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49. 7-((3,4-difluorophenyl)thio)pyrido[3,2-d]pyrimidine-2,4-diamine (205) 
50. 7-((3,4,5-trifluorophenyl)thio)pyrido[3,2-d]pyrimidine-2,4-diamine (206) 
51. 7-((4-(trifluoromethoxy)phenyl)thio)pyrido[3,2-d]pyrimidine-2,4-diamine (207) 
52. 7-((4-nitrophenyl)thio)pyrido[3,2-d]pyrimidine-2,4-diamine (208) 
53. N-(4-methoxyphenyl)-5H-pyrrolo[3,2-d]pyrimidin-4-amine (217) 
54. 6-methoxy-1-(5H-pyrrolo[3,2-d]pyrimidin-4-yl)-1,2,3,4-tetrahydroquinoline (218) 
55. 6-methoxy-1-(5-methyl-5H-pyrrolo[3,2-d]pyrimidin-4-yl)-1,2,3,4-
tetrahydroquinoline (219) 
56. N,2-dimethyl-N-(4-(methylthio)phenyl)-4a,7a-dihydro-5H-pyrrolo[3,2-
d]pyrimidin-4-amine (222) 
57. N,2,5-trimethyl-N-(4-(methylthio)phenyl)-4a,7a-dihydro-5H-pyrrolo[3,2-
d]pyrimidin-4-amine (223) 
58. N-methyl-N-(4-(methylthio)phenyl)-5H-pyrrolo[3,2-d]pyrimidin-4-amine (224) 
59. N,5-dimethyl-N-(4-(methylthio)phenyl)-5H-pyrrolo[3,2-d]pyrimidin-4-amine 
(225) 
60. N-(5-methoxynaphthalen-2-yl)-N,2,5-trimethyl-4a,7a-dihydro-5H-pyrrolo[3,2-
d]pyrimidin-4-amine (227) 
61. N-(5-methoxynaphthalen-2-yl)-N,5-dimethyl-5H-pyrrolo[3,2-d]pyrimidin-4-
amine (228) 
62. 2-chloro-N-(4-methoxyphenyl)-N-methyl-5H-pyrrolo[3,2-d]pyrimidin-4-amine 
(231) 
63. 2-chloro-N-methyl-N-(4-(methylthio)phenyl)-5H-pyrrolo[3,2-d]pyrimidin-4-
amine (232) 
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64. 2-chloro-N-(4-methoxyphenyl)-N,5-dimethyl-5H-pyrrolo[3,2-d]pyrimidin-4-
amine (233) 
65. 2-chloro-N,5-dimethyl-N-(4-(methylthio)phenyl)-5H-pyrrolo[3,2-d]pyrimidin-4-
amine (234) 
66. 1-(2-chloro-5H-pyrrolo[3,2-d]pyrimidin-4-yl)-6-methoxy-1,2,3,4-
tetrahydroquinoline (235) 
67. 1-(2-chloro-5-methyl-5H-pyrrolo[3,2-d]pyrimidin-4-yl)-6-methoxy-1,2,3,4-
tetrahydroquinoline (236) 
68. 2-chloro-I-(5-methoxynaphthalen-2-yl)-I,5-dimethyl-5H-pyrrolo[3,2-d]pyrimidin-
4-amine (237) 
69. N4-(4-methoxyphenyl)-N4-methyl-5H-pyrrolo[3,2-d]pyrimidine-2,4-diamine 
(238) 
70. 4-(6-methoxy-3,4-dihydroquinolin-1(2H)-yl)-5H-pyrrolo[3,2-d]pyrimidin-2-
amine (239) 
71. 2-chloro-N,5-dimethyl-N-(4-(trifluoromethoxy)phenyl)-5H-pyrrolo[3,2-
d]pyrimidin-4-amine (240) 
72. N4-(4-methoxyphenyl)-N4-methylthieno[3,2-d]pyrimidine-2,4-diamine (243) 
73. 2-chloro-N-(4-methoxyphenyl)-N-methylthieno[3,2-d]pyrimidin-4-amine (244) 
74. N-(4-methoxyphenyl)-N-methyl-2-(trifluoromethyl)thieno[3,2-d]pyrimidin-4-
amine (245) 
75. N-methyl-N-(4-(methylthio)phenyl)thieno[3,2-d]pyrimidin-4-amine (247) 
76. 2-chloro-N-methyl-N-(4-(methylthio)phenyl)thieno[3,2-d]pyrimidin-4-amine 
(248) 
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77. N4-methyl-N4-(4-(methylthio)phenyl)thieno[3,2-d]pyrimidine-2,4-diamine (249) 
78. 4-(6-methoxy-3,4-dihydroquinolin-1(2H)-yl)thieno[3,2-d]pyrimidine (250) 
79. 2-chloro-4-(6-methoxy-3,4-dihydroquinolin-1(2H)-yl)thieno[3,2-d]pyrimidine 
(251) 
80. 4-(6-methoxy-3,4-dihydroquinolin-1(2H)-yl)thieno[3,2-d]pyrimidin-2-amine 
(252) 
81. N-(5-methoxynaphthalen-2-yl)-N-methylthieno[3,2-d]pyrimidin-4-amine (253) 
82. 2-chloro-N-(5-methoxynaphthalen-2-yl)-N-methylthieno[3,2-d]pyrimidin-4-amine 
(254) 
83. N4-(5-methoxynaphthalen-2-yl)-N4-methylthieno[3,2-d]pyrimidine-2,4-diamine 
(255) 
84. N-(4-methoxyphenyl)-N,7-dimethylthieno[3,2-d]pyrimidin-4-amine (256) 
85. N,7-dimethyl-N-(4-(methylthio)phenyl)thieno[3,2-d]pyrimidin-4-amine (257) 
86. 4-(6-methoxy-3,4-dihydroquinolin-1(2H)-yl)-7-methylthieno[3,2-d]pyrimidine 
(258) 
87. 6-(methyl(7-methylthieno[3,2-d]pyrimidin-4-yl)amino)naphthalen-1-ol (259) 
88. N4-(4-methoxyphenyl)-N4,7-dimethylthieno[3,2-d]pyrimidine-2,4-diamine (260) 
89. 4-(6-methoxy-3,4-dihydroquinolin-1(2H)-yl)-7-methylthieno[3,2-d]pyrimidin-2-
amine (261) 
90. N-(4-methoxyphenyl)-N,6-dimethylthieno[3,2-d]pyrimidin-4-amine  (262) 
91. N-(4-methoxyphenyl)-N-methyl-2-(trifluoromethyl)thieno[3,2-d]pyrimidin-4-
amine (263) 
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92. (4-(3-(2-amino-4-oxo-3,4-dihydro-5H-pyrrolo[3,2-d]pyrimidin-5-
yl)propyl)benzoyl)-L-glutamic acid (269) 
93. (4-(4-(2-amino-4-oxo-3,4-dihydro-5H-pyrrolo[3,2-d]pyrimidin-5-
yl)butyl)benzoyl)-L-glutamic acid (270) 
94. (4-(5-(2-amino-6-methyl-4-oxo-3,4-dihydro-5H-pyrrolo[3,2-d]pyrimidin-5-
yl)pentyl)benzoyl)-L-glutamic acid (271) 
95. (5-(3-(2-amino-4-oxo-3,4-dihydro-5H-pyrrolo[3,2-d]pyrimidin-5-yl)propyl) 
thiophene-2-carbonyl)-L-glutamic acid (280) 
96. (5-(4-(2-amino-4-oxo-3,4-dihydro-5H-pyrrolo[3,2-d]pyrimidin-5-
yl)butyl)thiophene-2-carbonyl)-L-glutamic acid (281) 
97. (5-(5-(2-amino-4-oxo-3,4-dihydro-5H-pyrrolo[3,2-d]pyrimidin-5-
yl)pentyl)thiophene-2-carbonyl)-L-glutamic acid (282) 
98. (4-(3-(2-amino-6-methyl-4-oxo-3,4-dihydro-5H-pyrrolo[3,2-d]pyrimidin-5-
yl)propyl)benzoyl)-L-glutamic acid (284) 
99. (4-(4-(2-amino-6-methyl-4-oxo-3,4-dihydro-5H-pyrrolo[3,2-d]pyrimidin-5-
yl)butyl)benzoyl)-L-glutamic acid (285) 
100. (4-(5-(2-amino-6-methyl-4-oxo-3,4-dihydro-5H-pyrrolo[3,2-d]pyrimidin-
5-yl)pentyl)benzoyl)-L-glutamic acid (286) 
101.  (4-(3-(2-amino-4-oxo-3,4-dihydro-5H-pyrrolo[3,2-d]pyrimidin-5-
yl)propoxy) benzoyl)-L-glutamic acid (291) 
102.  (4-((3-(2-amino-4-oxo-3,4-dihydro-5H-pyrrolo[3,2-d]pyrimidin-5-
yl)propyl) thio)benzoyl)-L-glutamic acid (292) 
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103.  (4-((3-(2-amino-4-oxo-3,4-dihydro-5H-pyrrolo[3,2-d]pyrimidin-5-
yl)propyl)amino) benzoyl)-L-glutamic acid (293) 
104. 3-nitro-6-((3,4,5-trifluorophenyl)amino)picolinonitrile (297) 
105. 6-(3,4-dihydroquinolin-1(2H)-yl)-3-nitropicolinonitrile (324) 
106. 3-nitro-6-phenoxypicolinonitrile (326) 
107. 6-((2-methyl-4a,7a-dihydro-5H-pyrrolo[3,2-d]pyrimidin-4-
yl)amino)naphthalen-1-ol (336) 
108. 2-chloro-N-(4-(trifluoromethoxy)phenyl)-5H-pyrrolo[3,2-d]pyrimidin-4-
amine (338) 
109. 6-((2-chloro-5H-pyrrolo[3,2-d]pyrimidin-4-yl)amino)naphthalen-1-ol 
(339) 
110. N2,N4-bis(4-methoxyphenyl)-N2,N4-dimethylthieno[3,2-d]pyrimidine-2,4-
diamine (343) 
111. N2,N4-bis(4-(methylthio)phenyl)thieno[3,2-d]pyrimidine-2,4-diamine 
(345) 
112. N2,N4-dimethyl-N2,N4-bis(4-(methylthio)phenyl)thieno[3,2-d]pyrimidine-
2,4-diamine (346) 
113. 2-chloro-N-(4-(methylthio)phenyl)thieno[3,2-d]pyrimidin-4-amine (347) 
114. N-(4-(methylthio)phenyl)thieno[3,2-d]pyrimidin-4-amine (350) 
115. 6-((2-chlorothieno[3,2-d]pyrimidin-4-yl)amino)naphthalen-1-ol  (353) 
116. Diethyl (4-(3-(2-amino-4-oxo-3,4-dihydro-5H-pyrrolo[3,2-d]pyrimidin-5-
yl)propyl) benzoyl)-L-glutamate (383) 
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117. Diethyl (4-(4-(2-amino-4-oxo-3,4-dihydro-5H-pyrrolo[3,2-d]pyrimidin-5-
yl)butyl) benzoyl)-L-glutamate (384)  
118. Diethyl (4-(5-(2-amino-4-oxo-3,4-dihydro-5H-pyrrolo[3,2-d]pyrimidin-5-
yl)pentyl) benzoyl)-L-glutamate (385) 
119. Diethyl (4-(5-(2-amino-6-methyl-4-oxo-3,4-dihydro-5H-pyrrolo[3,2-
d]pyrimidin-5-yl)pentyl)benzoyl)- ate (416) 
 
Proposed compounds from Series I-VIII were evaluated biologically against pjDHFR 
and hDHFR enzymes. The evaluation results and hDHFR crystal structures with some of 
the proposed compounds show the importance of targeting amino acid differences between 
pjDHFR and hDHFR. Our attempts to obtain a compound similar in selectivity of TMP 
and higher in potency than TMP led to 188, 191 and 197. Based on the medicinal chemistry 
approach of carrying out bioisosteric replacement and studying the active site, compounds 
were obtained with significantly increased potency and/or selectivity. It also led to a 
compound which when dosed at 20 mg/kg displays efficacy and survival similar to TMP 
(50 mg/kg)-SMX (250 mg/kg) combination.  
Proposed compounds from the Series X-XXI were evaluated for activity against 
microtubule assembly, EGFR, VEGFR-2 and PDGFR-β. The results revealed an extensive 
SAR for pyrrolo[3,2-d]pyrimidine and thieno[3,2-d]pyrimidines. The SAR for 2- and 5-
position of the scaffold is distinct for pyrrolo[3,2-d]pyrimidine and thieno[3,2-
d]pyrimidines and the effects of a substitution on one scaffold cannot be extrapolated to 
another. Compound 233 was active across all the three angiokinases and was comparable 
to erlotinib and sunitinib in inhibition of EGFR and VEGFR-2, respectively and 20-fold 
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higher than sunitinib in inhibition of PDGFRβ. It shows an excellent inhibition of all the 
four targets (microtubule assembly, EGFR, VEGFR-2 and PDGFR-β) and significant 
improvement in reduction of tumor growth, compared to the positive control-paclitaxel.  
Biological evaluation of proposed compounds from Series XXII-XXIV were 
carried out in engineered CHO cell lines overexpressing RFC, PCFT, FRα and FRβ. One 
of the aims for this study was to obtain compounds with selective uptake through FRα and 
FRβ, compared to RFC. Majority of the proposed compounds showed a selective transport 
through FRα and FRβ over RFC. Hence, we were able to successfully incorporate 
selectivity for FRα and FRβ by performing as scaffold-hopping from the pyrrolo[2,3-
d]pyrimidines. The investigation of the intracellular targets suggests that there is (are) 
additional intracellular target(s) than GARFTase and/or AICARFTase that the compounds 
bind to and inhibit.  
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VIII. APPENDIX 
A. Biological evaluation of Selective pjDHFR inhibitors 
 All the proposed compounds were evaluated as inhibitors of recombinant pjDHFR 
and recombinant hDHFR.1 Selectivity ratios were determined using recombinant hDHFR 
as a mammalian DHFR. TMP and PTX were used as positive controls in the assays.2 
Assays to assess inhibitory concentrations (IC50, in nM) against recombinant DHFR 
from P. jirovecii (pj) and human (h) were carried out at 37 °C under 9 µM dihydrofolic 
acid concentration.2 The assay also contains 117 µM NADPH, 8.9 mM 2-mercaptoethanol, 
150 mM KCl, 41 mM Na phosphate buffer pH 7.4 and sufficient enzyme to cause a change 
in OD340 of 0.005/minute. The standard error of the mean for these values is 12% or less 
than the mean value. 
The biological evaluations were performed by Dr. Sherry Queener (Indiana 
University School of Medicine, Indianapolis, IN 46202), Dr. Vivian Cody (Department of 
Structural Biology, Structural Biology Department, School of Medicine and Biomedical 
Science, Buffalo, NY 14203), Dr. Melanie Cushion (Infectious Diseases, Department of 
Internal Medicine, University of Cincinnati College of Medicine, Cincinnati, Ohio 45267 
and The Cincinnati Veterans Medical Center, Cincinnati, OH) and Dr. David Seybert 
(Chemistry and Biochemistry, Bayer School of Natural and Environmental Sciences, 
Duquesne University, Pittsburgh PA 15282).  
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A1. Biological evaluation of 6- and 7-substituted 5-methyl-pyrrolo[2,3-d]pyrimidine-
2,4-diamines as selective pjDHFR inhibitors 
 
Table 38. Inhibition Concentrations (IC50) against pjDHFR and hDHFR and Selectivity 
Ratios for Series I 
 
#  pjDHFR 
(nM) 
hDHFR 
(nM) 
Selectivity Ratios 
[hDHFR/pjDHFR] 
141 H 213 970 5 
142 CH3 160 1200 8 
143 CH2CH3 35 511 15 
144 CH2CH2CH3 84 2046 24 
145 CH(CH3)2 74 579 8 
146 CH2CH2CH2CH3 73 1130 15 
TMP  92 24500 266 
PTX  41 2 0.05 
 
Table 38 displays the IC50 of 141-146 for pjDHFR and hDHFR. As predicted, 
increasing the alkyl chain on N7 of the pyrrolo[2,3-d]pyrimidine scaffold, the potency for 
pjDHFR increases. Compound 143 with N7-ethyl was found to be 6-fold more potent for 
pjDHFR than 141. Compound 144 showed the most optimum balance for potency and 
selectivity ratio. The increased selectivity for pjDHFR is mainly due to decrease in IC50 of 
144 for hDHFR. This validates our hypothesis that bulk at the 7-position of the pyrrolo[2,3-
d]pyrimidine scaffold could clash with Phe31 in hDHFR and cause decreased binding to 
the hDHFR active site.  
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Table 39. Inhibition Concentrations (IC50) against pjDHFR and hDHFR and Selectivity 
Ratios for Series II 
 
# R pjDHFR 
(nM) 
hDHFR 
(nM) 
Selectivity Ratios 
hDHFR/pjDHFR 
141 3- OCH3 213 970  5 
148 2-OCH3 177 624  4 
149 4- OCH3 252 1410  6 
150 3ˊ4ˊ-(CH)4 101 2100  12 
151 2ˊ3ˊ-(CH)4 167 1216  7 
152 3,4-diF 240 2318  10 
153 4-OCF3 81 811  10 
 
Table 39 displays the IC50 of compounds 141, 148-153 for pjDHFR and hDHFR. 
Among the electron-donating (141, 148-149) electron-withdrawing (150-151) and bulky 
substituents (152-153) on the aryl group, 150 showed the balanced potency and selectivity 
ratio for pjDHFR.  
 
Table 40 displays the IC50 of compounds 142, 155-160 for pjDHFR and hDHFR. 
Comparison of the IC50s of 142, 155-160 with their respective lead compounds in Series II 
(141, 148-153) suggests that N7-methylation did not lead to an improvement in pjDHFR 
potency and/or selectivity ratio. The failure of 142, 155-160 to improve potency and/or 
selectivity, compared to 148-153 could be because the 7-CH3 group might not be large 
enough (a) to cause a clash with Phe31 in hDHFR to reduce binding to hDHFR and/or (b) 
to fit appropriately into a pjDHFR active site and increase binding to pjDHFR.  
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Table 40. Inhibition Concentrations (IC50) against pjDHFR and hDHFR and Selectivity 
Ratios for Series III 
 
# R pjDHFR 
(nM) 
hDHFR 
(nM) 
Selectivity Ratios 
hDHFR/pjDHFR 
142 3- OCH3 160 1200  8 
155 2-OCH3 210 1400  7 
156 4-OCH3 219 1372  6 
157 3ˊ4ˊ-(CH)4 130 970  7 
158 2ˊ3ˊ-(CH)4 177 1104  6 
159 3,4-diF 247 1917  8 
160 4-OCF3 110 1101  10 
 
 
X-ray Crystal Structures (performed by Dr. Vivian Cody): 
Expression and purification of wild type human dihydrofolate reductase (hDHFR) 
were carried out as previously described.3  Recombinant hDHFR was washed in a 
Centricon-10 with 100 mM K2HPO4 buffer pH 6.9 with 30% saturated ammonium sulfate 
and concentrated to 7.9 mg ml-1.  The hDHFR samples were incubated for 1 h on ice with 
a tenfold excess of NADPH and compounds 143 and 156, respectively, prior to 
crystallization using the hanging-drop vapor diffusion method using siliconized glass cover 
slips and storage at 14oC.  Protein droplets of the hDHFR complexes contained K2HPO4 
pH 6.9 with 30% saturated ammonium sulfate equilibrated against a reservoir solution 
consisting of 100 mM K2HPO4 pH 6.9 with 60% saturated ammonium sulfate, 3% (v/v) 
ethanol.  Crystals of hDHFR-143-NADPH and hDHFR-156-NADPH ternary complex 
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were hexagonal and belonged to the space group H3.  Data were collected at 100K to 1.46Å 
resolution for both crystals using the remote access robot on beamline 14.7 at the Stanford 
Synchrotron Radiation Laboratory.3-6  The data were processed using HKL2000 program 
package.7  Both crystal structures were solved by molecular replacement methods using 
the coordinates for hDHFR (1u72)8 in the program Molref.9  Inspection of the resulting 
difference electron density maps made using COOT10 running on an iMac workstation 
revealed density for the ternary complex of both crystals.  The final cycles of refinement 
were carried out using the program Refmac5 in the CCP4 suite of programs.9  The 
Ramachandran conformational parameters from the last cycle of refinement generated by 
RAMPAGE11 showed that more than 96% of the residues refined have the most favored 
conformation and none are in the disallowed regions.  Coordinates for these structures have 
been deposited with the Protein Data Bank. 
 
Structural data were measured for the ternary complexes of NADPH and native 
human DHFR with inhibitors 143 (Table 38) and 156 (Table 40), respectively, to validate 
the binding interactions of these inhibitors in the active site of hDHFR. These data reveal 
that the presence of the N7-CH2CH3 group of 143 causes the conformation of Phe31 to 
differ from that observed in the hDHFR complex with 156; Phe31 adopts alternate 
positions with partial occupancy.  Also, note that the small shift in the binding orientation 
of inhibitors 143 and 156 allows the 3ˊ-OCH3 and the 4ˊ-OCH3 to occupy similar positions 
in the binding site. 
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a          b  
Figure 88. (a) Comparison of the crystal structures of human DHFR as a ternary complex 
with 143 (yellow) and 156 (green) showing the electron density for the complex with 
hDHFR-143 (2Fo-Fc, 1 blue, 3, green) and (b) Comparison of the binding pocket for 
hDHFR-143 (yellow) and 156 (green). Note that Phe31 occupies two alternative 
conformations in these two structures.  This change is in response to the larger N7-ethyl 
substituent of the inhibitor 143 as compared to N7-methyl substituent 156.  
  
The overall structures of hDHFR in complex with 143 and 156 are similar to those 
reported for other hDHFR inhibitor complexes.1-3  As observed in Figure 88, the small shift 
in ligand binding orientation between 143 and 156 permits the 3ˊ-OCH3 and the 4ˊ-OCH3 
substituents to occupy the same binding pocket.   In 143, the amine of the side chain of 
Asn64 is within hydrogen bonding distance to the 3ˊ-OCH3 oxygen (2.9 Å) and the 4ˊ-
OCH3 oxygen is within 3.4 Å of the Asn64 amine in 156.  The interactions of the N7-
CH2CH3 substituent in 143 results in Phe31 having two alternate conformations.  Analysis 
of the intermolecular interactions involving the C5-methyl substituent of 143 and 156 
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shows hydrophobic contacts (4.6 and 4.3Å, respectively) with the C5 of Val115.  The 4-
NH2 of the inhibitors 143 and 156 form a hydrogen bond with the carbonyl of Val115 (3.0 
and 3.3 Å, respectively).   
 
The X-ray crystal structures of 143 and 156 in hDHFR validate our hypothesis that 
bulk at the N7-position of the pyrrolo[2,3-d]pyrimidine scaffold results in a clash with 
Phe31. We have successfully designed, synthesized and evaluated novel series of 
pyrrolo[2,3-d]pyrimidine  analogs to explore active site amino acid residues differences in 
hDHFR and pjDHFR enzymes in our attempt to afford selective inhibitors of pjDHFR over 
hDHFR. This effort led to several compounds exhibiting potency greater than TMP (92 
nM) and selectivity greater than PTX (0.05-fold).  The docking studies and crystal 
structures reveal the importance of targeting differences in amino acid residues in of 
pjDHFR over hDHFR, which was corroborated by the biological evaluation results.  
 
A2. Biological evaluation of N6- substituted pyrido[3,2-d]pyrimidine-2,4,6-triamines 
as selective pjDHFR inhibitors 
Table 41 displays the IC50 of compounds 169-177 for pjDHFR and hDHFR. 
Comparison of activities of pyrido[3,2-d]pyrimidines vs. pyrido[2,3-d]pyrimidines for 
pjDHFR, hDHFR and selectivity ratios, suggested that scaffold replacement strategy was 
favorable. 
 
A considerable improvement in selectivity was exhibited by 169 (vs. 163), 170 (vs. 
164), 171 (vs. 165), 173 (vs. 166), 174 (vs. 167) and 175 (vs. 168). The trifluoro compound 
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175 showed the highest selectivity ratio in the series, which is 560-fold greater than 
selectivity ratio of PTX. Compared to its pyrido[2,3-d]pyrimidine analog 168, it showed a 
11-fold improvement in the potency towards pjDHFR and 5-fold improvement in the 
selectivity ratio.  
 
Table 41. Inhibition Concentrations (IC50) against pjDHFR and hDHFR and Selectivity 
Ratios for Series IV 
 
# 
R pjDHFR 
(nM) 
hDHFR 
(nM) 
Selectivity Ratios 
[hDHFR/pjDHFR] 
163 H 300 190 1 
164 4ˊ-CH3 620 2100 3 
165 4ˊ-OCH3 400 3650 9 
166 2ˊ,3ˊ-(CH)4 250 2100 8 
167 3ˊ,4ˊ-(CH)4 400 2200 5 
168 3ˊ,4ˊ,5ˊ-triF 870 3100 4 
169 H 122 1526 13 
170 4ˊ-CH3 174 2626 15 
171 4ˊ-OCH3 239 2459 10 
172 4ˊ-OH 150 1576 10 
173 2ˊ,3ˊ-(CH)4 112 1098 10 
174 3ˊ,4ˊ-(CH)4 275 3185 12 
175 3ˊ,4ˊ,5ˊ-triF 80 2253 28 
176 3ˊ,4ˊ-diF 155 1808 12 
177 4ˊ-OCF3 194 4125 21 
TMP  92 24500 266 
PTX  41 2 0.05 
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Table 42. Inhibition Concentrations (IC50) against pjDHFR and hDHFR and Selectivity 
Ratios for Series V 
 
# R1 pjDHFR (nM) hDHFR (nM) Selectivity Ratios 
hDHFR/pjDHFR 
169 H 122 1526 13 
180 CH3 96 942 10 
181 CH2CH3 150 1571 10 
182 CH2CH2CH3 123 1338 11 
183 CH(CH3)2 201 1373 7 
184 CH2CH2CH2CH3 66 903 14 
 
 
 Table 42 displays the IC50 of compounds 169, 180-184 for pjDHFR and hDHFR. 
The alkyl analogs in the N6-substituted pyrido[3,2-d]pyrimidine-2,4,6-triamines were 
designed to obtain an improvement in hydrophobic interactions with Ile123 (in pjDHFR) 
vs. Val115 (in hDHFR). The N6-CH3 analog 180 showed no improvement in pjDHFR 
potency and selectivity, compared to the lead compounds with N6-H. This could be due to 
small size of the CH3 group, which is not able to interact with Ile123 in pjDHFR active 
site. Similar to 180, analogs 181-184 also failed to demonstrate a considerable potency and 
selectivity for pjDHFR. This could be due to the flexible nature of alkyl groups and/or the 
possibility that these analogs were not able to interact with Ile123 of pjDHFR. In the N6-
substituted pyrido[3,2-d]pyrimidine-2,4,6-triamine series, 175 remains the best in terms of 
its potency and selectivity for pjDHFR. 
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A3. Biological evaluation of 6-(arylthio)pyrido[3,2-d]pyrimidine-2,4-diamines as 
selective pjDHFR inhibitors 
Table 43. Inhibition Concentrations (IC50) against pjDHFR and hDHFR and Selectivity 
Ratios for Series VI 
 
# R X pjDHFR 
(nM) 
hDHFR 
(nM) 
Selectivity Ratios 
hDHFR/pjDHFR 
173 2ˊ,3ˊ-(CH)4 NH 112 1098 10 
174 3ˊ,4ˊ-(CH)4 NH 275 3185 12 
188 3ˊ-OCH3 S 0.96 450 469 
190 2ˊ,3ˊ-(CH)4 S 0.031 0.526 17 
191 3ˊ,4ˊ-(CH)4 S 0.061 4.12 67 
197 4-NO2 S 2.48 258 104 
TMP   92 24500 266 
PTX   41 2 0.05 
 
Table 43 displays the IC50 of compounds 188, 190, 191 and 197 for pjDHFR and 
hDHFR. The 6-(arylthio)pyrido[3,2-d]pyrimidines 190 and 191 showed a considerable 
improvement than the 6- amine linked 173 and 174, respectively. The sulfur linked analogs 
showed a single digit nanomolar and picomolar potency for pjDHFR. Replacement of -
NH- of 174 with -S- in 191 improved potency for pjDHFR by 4500-fold selectivity ratio 
for pjDHFR by 6-fold. TMP is widely used because of its exceptional selectivity ratio for 
pjDHFR but has a low potency for pjDHFR. Compounds with picomolar potency for 
pjDHFR have not been reported in the literature, in our opinion. All the compounds tested 
in this series so far have a single digit nM or a pM IC50 for pjDHFR.  
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a b  
c  
Figure 89. (a) Superimposition of docked pose of 191 (magenta, docked score = 28.32 
kJ/mol) and 174 (cyan, docked score = 30.76 kJ/mol) in the homology model of pjDHFR 
(b) Superimposition of docked pose of 191 (magenta, docked score = 43.64 kJ/mol) and 
174 (cyan, docked score = 41.18 kJ/mol)  in the crystal structure of hDHFR (PDB: 4QJC, 
1.62 Å)1 and (c) Docked pose of 191  (cyan) in the crystal structure of hDHFR (PDB: 
4QJC, 1.62 Å)1 with space filled model of side chain aryl 191 and Phe31 side chain. 
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With an improvement in IC50 for pjDHFR 188, 191 and 197, no increase in potency 
for hDHFR was observed. This gain in selectivity ratio could be explained by studying the 
active sites of hDHFR and pjDHFR. The binding site where the side chain aryl group binds 
contains the Met33 in pjDHFR and the Phe31 in hDHFR. The Met33/Phe31 in 
pjDHFR/hDHFR can affect binding due to their distinct steric and electronic effects. 
Compared to the lead compound 174, sulfur linked analog 191 could change the bond 
angle, distance and electronics of the naphthyl group and cause a clash with Phe31 in 
hDHFR, whereas appropriately fit with Met33 in pjDHFR (Figure 89). The increased C-S 
bond length and reduced C-S-C bond angle poses an increase in probability of a clash 
between the side chain aryl ring and the Phe31 in hDHFR, and thus decrease binding of 
such compounds with hDHFR. Such a clash is avoided in binding of 6-substituted sulfur 
linked pyrido[3,2-d]pyrimidines to pjDHFR active site due to the flexible nature of the 
Met33 side chain.  
 
Cell based assay of 191 (performed by Dr. Melanie Cushion): 
 Compound 191 was evaluated in P. carinii cell-culture assay for its efficacy and 
toxicity.  
(a) Efficacy assay using P. carinii  
Compound Preparation.  The compound 191 was solubilized in 100% DMSO for 20mg/ml 
stock solutions and unused portions were stored at 4 ̊C. Results of a quench control assay 
indicated that neither compound interfered with the luciferin/luciferase reaction at 
100µg/ml concentration. Serial dilutions of 100, 10, 1, and 0.1µg/ml were made in RPMI-
1640 containing 20% horse serum, 1% MEM vitamin solution, 1% MEM NEAA, and 
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2,000 units/ml Pen-Strep. Negative controls were media alone, 1% DMSO, and 10µg/ml 
ampicillin. Positive control was 1µg/ml pentamidine isethionate. 
P. carinii ATP assays. Cryopreserved and characterized P. carinii (Pc) isolated from lung 
tissue of two rats was distributed into triplicate wells of 48-well plates with a final volume 
of 500µl and a final concentration of 5x107 nuclei/ml Pc. Controls and compound dilutions 
were added and incubated at 36 ̊C, 5% CO2.   At 24, 48, and 72 hours, 10% of the well 
volume was removed and the ATP content was measured using Perkin Elmer ATP-liteM 
luciferin-luciferase assay. The luminescence generated by the ATP content of the samples 
was measured by a BMG PolarStar optima spectrophotometer. A sample of each group 
was examined microscopically on the final assay day to rule out the presence of bacteria.  
Calculations. Background luminescence was subtracted and triplicate well readings of 
duplicate assays were averaged. For each day’s readings, % reduction in ATP for all groups 
was calculated: media control - experimental/media control x100. 50% inhibitory 
concentration (IC50) was calculated using INSTAT linear regression program. 
Results. Compound 191 markedly reduced the in vitro ATP activity of P. carinii in a time 
and dose dependent manner. The 72-hour IC50 for 191 was 0.961µg/ml, which rates as 
marked activity against P. carinii in vitro 
 
(b) Toxicity assay using L2 and A549 cells 
Compound Preparation.  The compound 191 was solubilized in 100% DMSO for a 
20mg/ml stock solution and unused portions were stored at 4°C. A quench control assay 
indicated no interference with the luciferin/luciferase reaction at 100µg/ml concentration.  
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L2 and A549 Toxicity assay. For mammalian cell toxicity testing, A549 cells were provided 
with DMEM media and L2 cells with F12 media. Both were supplemented with 10% fetal 
calf sera, 1x MEM vitamins, and 1X NEAA. Cultured cells were plated at 2x105/ml and 
grown to confluent monolayers. Media was removed and replaced with fresh media 
containing controls and test compound dilutions.  Assays of 3 time points (24, 48, 72 hours) 
with duplicate wells were tested for viability. Media was aspirated from the wells, adherent 
cells were lysed with 0.1M NaOH, and a portion of the lysate was assayed for ATP using 
the Perkin Elmer ATP-liteM luciferin-luciferase assay as described above. 
Calculations. Background luminescence was subtracted and replicate well readings of 
were averaged. For each day’s readings, % reduction in ATP for all groups was calculated: 
media control - experimental/media control x100. The 50% inhibitory concentration (IC50) 
was calculated using GraphPad PRIZM linear regression program. 
Results. Compound 191 was found to be mildly toxic in both cultured A459 and L2 cells 
at 72 hours of exposure with IC50 values of 34.83µg/ml and 67.0µg/ml. This compares 
favorably to our previous finding of 0.961µg/ml IC50 in Pneumocystis carinii.  
 
In vivo assay for efficacy and toxicity of 191 (performed by Dr. Melanie Cushion): 
As a prelude to clinical trials it was necessary to evaluate 191 in animals. Since 
there is no Pj culture or animal model available, the efficacy study was carried out in P. 
murina (mice) model. Compound 191 was thus evaluated in the mouse model of PCP for 
efficacy and whether it was more potent than TMP alone. Results for Pneumocystis murina 
burden, expressed as total nuclei counts and asci (cyst) counts after 14- and 21 days of 
treatment are shown in Figure 90. As was evident at both time points, 191 significantly 
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reduced the total organism burden and the asci burdens at 20 mg/kg and were more 
effective than the parent compound TMP.  
 
 
 
Figure 90. Efficacy of 191.  Groups of 6 mice each received vehicle control (C/S), 20- or 
2 mg/kg/d of 191; 50 mg/kg TMP; 50/250 mg/kg/d of TMP/SMX and sacrificed at 14- and 
21 days, post treatment (dosed i.p.).  Microscopic enumeration of nuclei (total burden) and 
asci were performed after histological staining.  One-way ANOVA with Tukey’s post- test 
was used to assign significance of P<0.05 
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  More striking was the advantage offered in survival (Figure 91), where 191 had 
statistically significant better survival than the TMP-treated group vs non-treated group.  
The survival of groups 191 and the TMP-SMX were not significantly different, suggesting 
further evaluation of 191 as a monotherapy at higher doses or in combinations with other 
agents are warranted.  The lack of toxicity for 191 correlated with that in the mouse model. 
 
Figure 91.   Kaplan-Meier Survival Curve.  Untreated mice were compared to TMP, 
TMP/SMX, and 191 (20 g/kg) for survival, over 21 days.  Both 191 and TMP/SMX had 
significantly better survival than the other groups.  P<0.05 
  
Our attempts to obtain a compound similar in selectivity of TMP and higher in 
potency than TMP led to compounds 188, 191 and 197. Based on the medicinal chemistry 
approach of carrying out bioisosteric replacement and studying the active site, compounds 
were obtained with increased potency and/or selectivity. It also led to a compound which 
when dosed at 20 mg/kg exhibits efficacy and survival similar to TMP (50 mg/kg)-SMX 
(250 mg/kg). Evaluations of other compounds in this series are underway. 
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B. Biological evaluation of Single agents with combination chemotherapy and 
multiple RTK inhibitory potential  
The biological evaluations reported in this section were performed by Dr. Michael 
Ihnat (Department of Pharmaceutical Sciences, University of Oklahoma College of 
Pharmacy, Oklahoma City, OK 73117), Dr. Ernest Hamel (Screening Technologies 
Branch, Developmental Therapeutics Program, Division of Cancer Treatment and 
Diagnosis, Frederick National Laboratory for Cancer Research, National Cancer Institute, 
Frederick, MD 21702), Dr. Susan Mooberry (Department of Pharmacology, University of 
Texas Health Science Center at San Antonio, San Antonio, TX 78229) and National Cancer 
Institute (Developmental Therapeutics Program).  
 
B1. Biological evaluation of 2-, 4- and 5- substituted pyrrolo[3,2-d]pyrimidines 
(a) Activity as MTAs 
The EC50 (concentration required to cause 50% loss of cellular microtubules) was 
determined in A-10 cells.12 The effects of the compounds on interphase and mitotic 
microtubules were evaluated using indirect immunofluorescence techniques, and the EC50 
values were calculated from a minimum of three experiments.13 Antiproliferative effects 
were evaluated against the drug sensitive MDA-MB-435 melanoma cells using 
sulforhodamine B assay and the IC50 values (concentration required to cause 50% 
inhibition of proliferation) were calculated.13 
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Table 44. Effects in cellular assays and on purified tubulin for Series X-XV (ND= not 
determined) 
 
 R1 R2 IC50 ± SD in MDA-
435 Cells (nM) 
EC50 for Microtubule Depolymerization 
in A·10 Cells (nM) 
216 H H 193 ± 39  5700 
212 CH3 H 96.6 ± 5.3  1200 
231 Cl H 18.3 ± 5.0  309  
238 NH2 H ND >10000 
217 H CH3 13.4 ± 0.5 27.5 
213 CH3 CH3 4.3 ± 0.3 7.4 
233 Cl CH3 1.3 ± 0.0 1.48 
224 H H ND >10000 
222 CH3 H 76.9 ± 0.8  2400 
232 Cl H 17.2 ± 3.4 576  
225 H CH3 >500 >5000 
223 CH3 CH3 6.2 ± 1.0  23  
234 Cl CH3 3.6 ± 0.3 2.7 
218 H H ND >10000 
214 CH3 H 42.7 ± 3.2 233.1 
235 Cl H 9.2 ± 1.8 78 
239 NH2 H ND >10000 
219 H CH3 30.5 ± 0.8 76.5 
215 CH3 CH3 21.0 ± 3.6 39.2 
236 Cl CH3 4.1 ± 0.1 3.31 
228 H  ND >10000 
227 CH3  2000  >10000 
237 Cl  22.6 50 
240   49.3 ± 1.1 138.7 
CA-4 - - 4.4 ± 0.3 9.8 
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 Biological evaluation of 212-219, 222-225, 227, 228 and 231-239 enabled a SAR 
on the pyrrolo[3,2-d]pyrimidine scaffold. An electron withdrawing substituent at the 2-
position showed an improvement in inhibition of tubulin depolymerization (Table 44). The 
activity trend for 2-postion was Cl>CH3>H>NH2. Varying aryl group at the 4-position on 
the pyrrolo[3,2-d]pyrimidine scaffold did not create a significant impact on the inhibition 
of tubulin assembly, without an exception of naphthyl group. The bulky naphthyl group of 
227, 228 and 236 could be creating a steric hindrance to attain the binding in the colchicine-
binding site of tubulin. The most striking effect was seen on comparison of 5-H and 5-CH3 
compounds. Comparing the IC50s of 216 (2-H, 5N-H) vs. 217 (2-H, 5N-CH3); 212 (2-CH3, 
5N-H) vs. 213 (2-CH3, 5N-CH3) and 231 (2-Cl, 5N-H) vs. 233 (2-Cl, 5N-CH3), the 5N-
CH3 substitution exhibits an increase in IC50 values from 14- to 23-fold.  
 
Figure 92. Possible steric clash between N4-CH3 and 5-CH3 in 233 
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The improvement in the microtubule depolymerization activity of the 5-CH3 can be 
explained by studying the stable solution conformations of 231 and 233, using 1H-NMR. 
The 4-methoxyphenyl group causes an anisotropic effect on 5-H and 5-CH3 of 231 and 233 
respectively (Figure 84). This solution conformation of 231 is possibly due to steric clash 
between 5-H and N4-CH3. This clash is further reinforced in 233 by steric clash between 5-
CH3 and N
4-CH3 (Figure 92). 
The 4-OCF3 replacement of 4-OCH3 group of 233 was not conducive to 
microtubule depolymerization activity. The biological evaluation of 240 (Table 44) 
suggested that replacement of 4-OCH3 with 4-OCF3 causes 38-fold decrease in 
antiproliferative activity against MDA-MB-435 cells and 44-fold decrease in inhibition of 
microtubule depolymerization and thus suggest the significance of the methoxy group and 
its conformation, for anti-tubulin activity. 
(b) Activity as angiokinase inhibitors   
Cells used were tumor cell lines naturally expressing high levels of VEGFR-2 
(U251), PDGFR-b (SF-539) and EGFR (A431).13 Expression levels at the RNA level were 
derived from the NCI Developmental Therapeutics Program (NCI-DTP) web site 
describing molecular target information. Briefly, cells at 60–75% confluence were placed 
in serum-free medium for 18 h to reduce background phosphorylation. Cells were always 
>98% viable by trypan blue exclusion. Cells were then pretreated for 60 min to obtain 
dose–response data, using concentrations of 1.4–100 µM compound, followed in ⅓log 
increments by 100 ng/mL VEGF, PDGF-BB or EGF for 10 min. The reaction was stopped, 
and cells permeabilized by quickly removing the media from the cells and adding ice-cold 
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Tris-buffered saline (TBS) containing 0.05% Triton X-100, protease inhibitor cocktail and 
tyrosine phosphatase inhibitor cocktail. The TBS solution was then removed and cells fixed 
to the plate for 30 min at 60 ⁰ C with a further incubation in 70% ethanol for 30 min. Cells 
were exposed to a blocking solution (TBS with 1% BSA) for 1 h, washed, and then a 
horseradish peroxidase (HRP)-conjugated phosphotyrosine (PY) antibody was added 
overnight. The antibody was removed, and the cells were washed again in TBS, exposed 
to an enhanced luminol ELISA substrate (Pierce Chemical EMD, Rockford, IL), and light 
emission was measured using a UV Products (Upland, CA) BioChemi digital darkroom. 
Data were graphed as a percent of cells receiving growth factor alone and IC50 values were 
determined from two to three separate experiments (n = 8–24) using non-linear regression 
dose–response analysis with Prism 5.0 software (GraphPad, San Diego, CA). In each case, 
the activity of a positive control inhibitor did not deviate more than 10% from the IC50 
values listed in the table. 
The most active anti-tubulin compounds (Table 45) were evaluated for activity 
against VEGFR-2 (U251), PDGFR-b (SF-539) and EGFR (A431) using cellular assays 
(Table 45). Since only a few compounds were evaluated, a comprehensive SAR is not 
possible. The replacement of CH3 of 213 at 2-position with the 2-Cl in compound 233 
displayed an increased the potency towards all the three kinases.  Comparison of 231 (2-
Cl, 5-H) vs. 233 (2-Cl, 5-CH3) suggests that methylation at the 5-position of the 
pyrrolo[3,2-d]pyrimidine scaffold increases potency for all the EGFR (by 15-fold), 
VEGFR-2 (by 19-fold) and PDGFR-β (by 49-fold). Thus, the conformation forced due to 
clash between 5-CH3 and N
4-CH3 was conducive for binding to the active site of kinases. 
It also corroborates with the results of molecular modeling studies carried out for these 
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compounds in the colchicine site of tubulin and ATP-binding sites of EGFR, VEGFR-s 
and PDGFR-β 
Table 45. Inhibition (IC50) of cellular VEGFR-2, EGFR and PDGFRβ- RTKs. (ND= not 
determined) 
 
 
 
 
 
 .  
  
 
 
 
The trend of activity in inhibition of microtubule assembly and kinases at the 2-
position was: Cl>CH3>H>NH2 and Cl>CH3 respectively. This could be due to an increase 
in cLogP (measure of lipophilicity) for Cl>CH3>H>NH2, which enables a higher passive 
diffusion of compounds into cancer cells. Compound 233 was active across all the three 
angiokinases and was comparable to erlotinib and sunitinib in inhibition of EGFR and 
VEGFR-2, respectively and 20-fold higher than sunitinib in inhibition of PDGFRβ. It 
 EGFR (nM) VEGFR-2 (nM) PDGFRβ (nM) 
212∙HCl 29.5 ± 3.1 182.3 ± 20.6  250.2 ± 43.0 
213.HCl 25.2 ± 0.41 30.5 ± 5.3 67.0 ± 10.2 
214.HCl 49.2 ± 5.1 80.6 ± 8.2 140.9 ± 19.2 
215.HCl 10.8 ± 1.7 35.7 ± 6.2 29.3 ± 4.8 
216.HCl 132.6 ± 22.1 132.6 ± 22.1 223.2 ± 4.8 
222 478.3 ± 67.3 1040.0 ± 200.1 1420.4 ± 207.4 
231 91.5 ± 5.1 241.5 ± 51.2 204.4 ± 9.8 
232 89.3 ± 9.2 52.0 ± 6.7 >200 
233 6.3 ± 0.9 12.4 ± 1.2 4.2 ± 0.9 
234 9.0 ± 0.9 15.2 ± 2.0 8.4 ± 0.8 
236 16.4 ± 2.6 33.9 ± 3.9 10.8 ± 1.6 
sunitinib ND 18.9 ± 2.7 83.1 ± 10.1 
erlotinib 1.2 ± 0.2 ND ND 
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shows an excellent inhibition of all the four targets (microtubule assembly, EGFR, 
VEGFR-2 and PDGFR-β). 
a b  
Figure 93. in vivo study of 233 in mice: (a) Tumor volumes during the trial on treatment 
with 233 (10 mg/kg), Paclitaxel (PTX) and control, dosed i.p. Arrows indicate treatment 
days for compound 7 and PTX (dosed days 1, 3, 5, 8, 10, 12). n = 7-10 tumors and data 
points represent mean ± SEM. (b) Change in weight of the animal on treatment with 233 
(10 mg/kg), Paclitaxel (PTX) and control. 
 The most active compound from the pyrrolo[3,2-d]pyrimidine series (233) was 
evaluated in vivo using MDA-MB-435 model (Figure 93). The MDA-MB-435 cells were 
implanted subcutaneously into both flanks of nude mice. Mice were treated with MTD and 
schedule using IP injections. Tumor volume was determined using tumor length, width, 
and height measured with calipers. Two-way repeated measures ANOVA with post hoc 
testing was used to analyze the datasets. Compared to paclitaxel, 233 showed a significant 
improvement in reduction of tumor growth. It also showed a weight loss of only 5%. 
Further evaluation for this compound in other preclinical models is underway. 
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B2. Biological evaluation of  2-, 4-, 6- and 7- substituted thieno[3,2-d]pyrimidines 
a) Activity as MTAs 
Table 46. Effects in cellular assays and on purified tubulin for Series XVI and XVII  
 
 R IC50 ± SD in MDA-435 
Cells (nM) 
EC50 for Microtubule 
Depolymerization in A·10 Cells (nM) 
242 H 36.9 200 
244 Cl 5.0 ± 1.2 23 
243 NH2 60.4 319 
245 CF3 22.5 ± 1.1 70 
247 H 28.2 ± 5.5 nM 707 
248 Cl 4.4 ± 0.7 20 
249 NH2 91.1 687 
250 H 3.8 ± 0.3 nM 22 nM 
251 Cl 2.2 nM ND 
252 NH2 ND ND 
253 H 15.7 ± 2.2 61 
254 Cl 1.3 ± 0.2 ND 
255 NH2 7.3 ± 0.7 ND 
  
Biological evaluation of 243-255 enabled a SAR around 2- and 4-position of 
thieno[3,2-d]pyrimidine scaffold. The trend observed at the 2-postion was: 
Cl>CF3>H>NH2 (Table 46). This suggests that electron withdrawing group at 2-position is 
conducive to the activity towards tubulin. It could also indicate that improved cLogP 
(lipophilicity) increases inhibition of tubulin depolymerization (due to increased passive 
diffusion). Compared to the pyrrolo[3,2-d]pyrimidine scaffold, 2-NH2 showed an 
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improved activity as MTA. This suggests that similar substitutions on different scaffolds 
can create varying effects on the targets. It is not therefore advisable to postulate the effect 
of a substituent form one scaffold to another. Varying the aryl group at the 4-position on 
the thieno[3,2-d]pyrimidine scaffold did not create a significant impact on the inhibition of 
tubulin assembly.  
 
 
Table 47. Effects in cellular assays and on purified tubulin for Series XVIII-XXI  
 
 R IC50 ± SD in MDA-
435 Cells (nM) 
EC50 for Microtubule Depolymerization 
in A·10 Cells (nM) 
256 H ND >10000 
257 H ND >10000 
258 H 126.1 ± 6.4 4000 
259 H 106.9 ± 14.8 513  
260 NH2 303.6 ± 24.0 631 
261 NH2 10.9 ± 0.9 66  
262  111.1 853.4  
263  >1000 nM 2500  
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Biological evaluation of 256-263 enabled a SAR around 5- and 6-position of 
thieno[3,2-d]pyrimidine scaffold (Table 47). The replacement of H at 5- and 6-position on 
the thieno[3,2-d]pyrimidine scaffold led to a decreased activity as MTAs. Similar to the 
activity seen for similar pyrrolo[3,2-d]pyrimidine compound 240 (with 4ˋ-OCF3), 
compound 263 also showed a decreased activity against tubulin assembly compared to its 
4ˋ-OCH3 analog 242, further suggesting the importance of 4ˋ-OCH3 on the aryl ring 
substituted at the 4-position of the scaffold.  
 
(b) Activity as angiokinase inhibitors   
Table 48. Inhibition (IC50) of cellular VEGFR-2, EGFR and PDGFRβ- RTKs. 
 
 
 
 
 
The most active anti-tubulin compounds (Table 48) were evaluated for activity 
against VEGFR-2 (U251), PDGFR-b (SF-539) and EGFR (A431) using cellular assays 
(Table 48). Since only a few compounds were evaluated, a comprehensive SAR is not 
possible. Evaluation of other compounds in this series in underway. 
 EGFR (nM) VEGFR-2 (nM) PDGFR (nM) 
244 25.4 ± 4.6 39.6 ± 10.1 4.4 ± 0.6 
250 34.4 ± 6.1 633 ± 89.2 300 ± 41.3 
253 88.8 ± 16.2 211.6 ± 28.8 131.4 ± 16.7 
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a b  
Figure 94. in vivo study of 244 in mice: (a) Tumor volumes during the trial on treatment 
with 244 (50 mg/kg), Paclitaxel (PTX) and control, dosed i.p. Arrows indicate treatment 
days for compound 2 and PTX (dosed days 1, 3, 5, 8, 10, 12). n = 7-10 tumors and data 
points represent mean ± SEM. (b) Change in weight of the animal on treatment with 244 
(50 mg/kg), Paclitaxel (PTX) and control. 
 Based on the solubility studies of the most active compounds from the thieno[3,2-
d]pyrimidine series, 244 was selected for evaluation in vivo using MDA-MB-435 model 
(Figure 94). The MDA-MB-435 cells were implanted subcutaneously into both flanks of 
nude mice. Mice were treated with MTD and schedule using IP injections. Tumor volume 
was determined using tumor length, width, and height measured with calipers. Two-way 
repeated measures ANOVA with post hoc testing was used to analyze the datasets. 
Compared to paclitaxel, 244 showed a significant improvement in reduction of tumor 
growth. It also showed a weight loss of less than 5%. Further evaluation for his compound 
in other preclinical models is underway. 
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C Biological evaluation of single agents with tumor targeting via cellular uptake by 
Folate Receptors and/or Proton-Coupled Folate Transporter and inhibition of de 
novo purine nucleotide biosynthesis 
Cell lines and assays of antitumor drug activities:14 The engineered CHO sublines 
including RFC-, PCFT- and FRα-null MTXRIIOuaR2-4 (R2), and RFC- (PC43-10), 
PCFT- (R2/PCFT4), or FRα- (RT16) and FRβ- (D4) expressing CHO sublines were 
previously described. The CHO cells were cultured in α-minimal essential medium (MEM) 
supplemented with 10% bovine calf serum (Invitrogen, Carlsbad, CA), penicillin (1000 
U/mL) streptomycin (1000 μg/mL) and 2 mM L-glutamine at 37° C with 5% CO2. All the 
R2 transfected cells (PC43-10, RT16, R2/hPCFT4) were cultured in complete α-MEM 
media plus 1 mg/mL G418. Prior to the cytotoxicity assays (see below), RT16 and D4 cells 
were cultured for 3 days in complete folate free RPMI 1640 (without added folate), plus 
dialyzed fetal bovine serum (FBS) (Sigma-Aldrich) and penicillin/streptomycin. KB 
human nasopharengeal carcinoma cells were purchased from the American Type Culture 
Collection (Manassas, VA). KB cells were routinely cultured in folate-free RPMI 1640 
medium, supplemented with 10% FBS (Sigma-Aldrich), penicillin-streptomycin solution, 
and 2 mM L-glutamine. For growth inhibition studies, cells (CHO, KB) were plated in 96 
well dishes (~2500-5000 cells/well; total volume of 200 μl medium) with a range of 
antifolate concentrations (0-1000 nM). The experiments with RT16, D4, and KB cells used 
folate-free RPMI medium with 10% dialyzed FBS, antibiotics and L-glutamine; the 
medium was supplemented with 2 nM LCV. To confirm FR-mediated drug uptake, 200 
nM folic acid was added to parallel incubations. For experiments with R2, PC43-10, and 
R2/PCFT4 cells, cells were routinely cultured in folate free RPMI 1640 (pH 7.2)/10% 
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dialyzed FBS with antibiotics and L-glutamine, supplemented with 25 nM LCV. Cells were 
incubated up to 96 h and viable cells were assayed with Cell-Titer BlueTM reagent 
(Promega, Madison, WI), with fluorescence measured with a fluorescence plate reader. 
Fluorescence data were analyzed for calculations of IC50s, corresponding to the drug 
concentrations that resulted in 50% loss of cell proliferation. 
FR binding assay:14 To measure relative binding affinities for antifolate drugs, RT16 
(expresses FRα) and D4 (FRβ) CHO cells were cultured in 60 mm dishes until they were 
~80% confluent. Cells (2-4 x 106 cells) were sequentially rinsed at 4 ⁰ C with Dulbecco’s 
phosphatebuffered saline (DPBS) (3x), followed by acidic buffer (10 mM sodium acetate, 
150 mM NaCl, pH 3.5) (2x) (removes FR-bound folates), and finally HEPES-buffered 
saline (20 mM HEPES, 140 mM NaCl, 5 mM KCl, 2 mM MgCl2, 5 mM glucose, pH 7.4) 
(HBS). Cells were incubated with [3H]folic acid (50 nM, specific activity 0.5 Ci/mmol) in 
HBS in the presence and absence of unlabeled folic acid, MTX (negative control), or the 
synthesized antifolates (range of concentrations up to 1000 nM) for 15 min at 0 ⁰ C. Dishes 
were rinsed with HBS (0-4 ⁰ C, 3x). Cells were solubilized with 0.5 N NaOH, and aliquots 
were measured for radioactivity and protein contents. Protein concentrations were 
quantified with Folin-phenol reagent. FR-bound [3H]folic acid was calculated as pmol/mg 
protein and binding affinities were calculated as the inverse molar ratios of unlabeled 
ligands required to inhibit [3H]folic acid binding by 50%. The relative affinity of folic acid 
was assigned a value of 1. 
Transport assays:14  R2 and R2/hPCFT4 CHO sublines were grown in suspension as 
spinner cultures at densities of 2-5 x 105 cells/mL. Cells were collected by centrifugation, 
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washed with DPBS, and the cell pellets (~2 x 107 cells) were suspended in transport buffer 
(2 mL) for cellular uptake assays. PCFT-dependent uptake of 0.5 µM [3H]MTX was 
assayed in cell suspensions over 2 min at 37° C in HBS at pH 6.8, or in 4-
morpholinopropane sulfonic (MES)-buffered saline (20 mM MES, 140 mM NaCl, 5 mM 
KCl, 2 mM MgCl2, and 5 mM glucose) at pH 5.5 in the presence of 1 or 10 µM inhibitor. 
At the end of the incubations, transport was quenched with ice cold DPBS, cells were 
washed three times with ice-cold DPBS, and cellular proteins were solubilized with 0.5 N 
NaOH. Levels of drug uptake were expressed as pmol/mg protein, calculated from direct 
measurements of radioactivity and protein contents of the cell homogenates. Proteins were 
quantified using Folin-phenol reagent. Transport results were normalized to levels in 
untreated controls. Data were analyzed by Dixon plots. 
 
C1. 5-substituted 2-amino-3,5-dihydro-4H-pyrrolo[3,2-d]pyrimidin-4-ones 
 
The pyrrolo[3,2-d]pyrimidine compounds 269-271 were designed based on 5-
substituted pyrrolo[2,3-d]pyrimidines 264-266 (Table 49). The synthesized analogs 
showed a considerable improvement in FRα and PCFT assays, across all chain lengths. 
They also had a decreased uptake through RFC for 4 (270) and 5 (271) atom linkers. Hence, 
they display a higher selectivity for uptake for both FRα and PCFT uptake. These 
compounds also exhibited an uptake through FRβ. Among the three pyrrolo[3,2-
d]pyrimidine compounds, the RFC and PCFT uptake decreases as chain length increases, 
suggesting an increase in chain length of the linker is detrimental to uptake through PCFT 
and RFC.  
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Table 49. IC50s (in nM) in RFC-, PCFT- and FR-expressing cell lines and KB human tumor 
cells (express RFC, FRα, and PCFT) for Series XXII 
 
 
hRFC hFRα hFRβ hPCFT hRFC/ hFRα/hPCFT 
 
PC43-10 R2 RT16 D4 R2/hPCFT4 KB 
264 68.8 ± 21.2 >1000 72 ± 27.1 ND 49.5 ± 13.2 49.5 ± 13.2 
265 56.6 ± 5.8 >1000 8.6 ± 2.1 ND 12.7 ± 5.4 12.7 ± 5.4 
266 196.4 ± 55 >1000 33.5 ± 2.5 ND 17.3 ± 8.9 17.3 ± 8.9 
269 43 >1000 50 1.59 25.2 6.7 
270 516 >1000 2.13 1.29 309 6.8 
271 >1000 >1000 26.6 6.3 327 6.3 
 
Although the RFC/PCFT uptake ratio is not desirable, the RFC/FRα ratio and RFC/FRβ 
ratio shows a considerable improvement than pyrrolo[2,3-d]pyrimidines 264-266. One of 
the aims for this study was to obtain compounds with selective uptake through FRα and 
FRβ, compared to RFC. Compounds 270 and 271 show a favorable uptake though both the 
FRs. For 271, no RFC uptake is observed, suggesting that the selectivity of transport 
through FRα and FRβ was greater 270-fold and 159-fold, respectively. Hence, we have 
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been able to incorporate selectivity for FRα and FRβ by performing a scaffold-hopping 
from the pyrrolo[2,3-d]pyrimidines 264-266. 
 
Figure 95. Cell proliferation assays in MIA-PaCa-2 cells to identify intracellular targets of 
269. 
The intracellular targets for 264 and 265 were GARFTase and AICARFTase. To 
investigate the intracellular targets, 269 was subjected to growth inhibition studies of KB 
cells along with protection by excess folic acid, AICA, adenine and thymidine. To identify 
the targeted pathways and the folate-dependent intracellular enzymes in KB cells treated 
with 269 (1−1000 nM), cell proliferation assays were performed in the presence of 10 μM 
thymidine, 60 μM adenosine, or 320 μM AICA. The results were normalized to those for 
untreated cells (no drug) and for 269. The results shown are representative of triplicate 
experiments (Figure 95). From the protection studies performed, the inhibition of 
proliferation of KB cells was not protected by thymidine suggesting it is not a TS inhibitor. 
The inhibition of proliferation of KB cells was not protected by AICA alone; suggesting it 
is might be GARFTase inhibitor, along with another intracellular target. The inhibition of 
proliferation of KB cells was protected by adenosine at low concentrations (up to 10 nM), 
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suggesting it could be GARFTase and/or AICARFTase inhibitor at that low concentration. 
At higher concentrations (> 31.6 nM), the inhibition of proliferation of KB cells was not 
protected by adenosine, suggesting that there is (are) additional intracellular target(s) that 
the compounds bind and inhibit. Further studies to investigate the possible targets are 
underway. 
 
The pyrrolo[3,2-d]pyrimidine compounds with thiophene regioisomers of 273-275  
were designed by scaffold hopping from their pyrrolo[2,3-d]pyrimidine counterparts 269-
271. Compared to their pyrrolo[2,3-d]pyrimidine analogs, the synthesized analogs improve 
binding to FRs across all chain lengths (Table 50). They also have a decreased uptake 
through RFC and PCFT, compared to the lead compounds 273-275. It was striking to 
discover that these pyrrolo[3,2-d]pyrimidine compounds display no RFC uptake compared 
to their pyrrolo[2,3-d]pyrimidine analogs. Compounds 280-282 also show improved KB 
activity, compared to 273-275. Except for loss in PCFT activity of 280-282, these 
compounds display the desired improvement in antiproliferative activity and transporter 
selectivity. The pyrrolo[3,2-d]pyrimidine compounds with thiophene 280-282  were also 
an improvement from the pyrrolo[3,2-d]pyrimidine compounds with phenyl 269-271 in 
transporter selectivity for FRs over RFC. To study the intracellular targets, detailed 
protection studies of all the synthesized compounds are currently underway.  
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Table 50. IC50s (in nM) in RFC-, PCFT- and FR-expressing cell lines and KB human tumor 
cells (express RFC, FRα, and PCFT) for Series XXIII. 
  
 
hRFC hFRα hFRβ hPCFT hRFC/FRα/hPCFT 
 
PC43-10  R2 RT16 D4 R2/hPCFT4 KB 
273 38.3±6.6 >1000 49.3±11.5 ND 141 ± 40 66.0 ± 14.4 
274 243.2±49.9 >1000 45.5±22.8 ND 57.4 ± 21.4 41.7 ± 10.1 
275 >1000 >1000 >1000 ND >1000 >1000 
269 43 >1000 50 1.59 25.2 6.7 
270 516 >1000 2.13 1.29 309 6.8 
271 >1000 >1000 26.6 6.3 327 6.3 
280 >1000 >1000 33 1.94 245 24 
281 >1000 >1000 2.82 1.13 >1000 2.58 
282 >1000 >1000 14.62 7.89 >1000 7.47 
 
C2. 5-substituted 2-amino-6-methyl-3,5-dihydro-4H-pyrrolo[3,2-d]pyrimidin-4-ones 
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Table 51. IC50s (in nM) in RFC-, PCFT- and FR-expressing cell lines and KB human tumor 
cells (express RFC, FRα, and PCFT) for Series XXIV 
 
 
hRFC hFRα hFRβ hPCFT hRFC/hFRα/hPCFT 
 
PC43-10  R2 RT16 D4 R2/hPCFT4 KB 
269 43 >1000 50 1.59 25.2 6.7 
270 516 >1000 2.13 1.29 309 6.8 
271 >1000 >1000 26.6 6.3 327 6.3 
284  >1000 >1000 9.16 3.14 >1000  188  
285 >1000 >1000 2.97 3.06 >1000 9.61 
286 >1000 >1000 4.44 3.17 >1000 5.53 
 
The 6-methyl-pyrrolo[3,2-d]pyrimidine compounds 284-286 were designed based 
on 6-desmethyl-pyrrolo[3,2-d]pyrimidines 269-271 (Table 51). The synthesized analogs 
maintain binding to FRα across all chain lengths. They also have a decreased uptake 
through RFC and PCFT, compared to their 6-desmethyl analogs 269-271. Hence, they 
show a higher selectivity for uptake for both FRs uptake. For all the three pyrrolo[3,2-
d]pyrimidine analogs 269-271, the RFC uptake decreases by placing 6-methyl on the 
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scaffold (284-286). This proves our hypothesis that 6-methyl on the 5-substituted 
pyrrolo[2,3-d]pyrimidine scaffold can impose a conformation which has selectivity in 
binding for some targets over another. In 284-286, the conformation induced by the 6-
methyl group was not conducive for binding to RFC and PCFT, but maintained activity for 
FRs. Although the RFC/PCFT uptake ratio is not as expected for compounds 284-286, the 
RFC/ FRα ratio is desirable compared to the lead compounds 269-271. 
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